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ANATOMY OF THE HUMAN EYE
Light enters the eye through the cornea, pupil and lens to ultimately focus on the central retina 
at the back of the eye. The retina is the neural portion of the eye with the ability to convert light 
entering the eye into biochemical signals. The retina is comprised of various cell layers including 
the ganglion cell layer, inner nuclear layer (containing the cell bodies of the amacrine, bipolar 
and horizontal cells), and outer nuclear layer (containing the cell bodies of the photoreceptors) 
which together are involved in processing light signals (Figure 1). The actual conversion of light 
into biochemical signals occurs in the outer segments of the photoreceptors, through a series 
of reactions known as the phototransduction cascade. The signals are then transferred to the 
optic nerve to be translated into visual perception by the brain.1,2 
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Figure 1: Anatomy of the human eye. Cross section of the retinal cell layers from anterior to posterior: 
vitreous, nerve fiber layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear 
layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptors (PR), retinal pigment 
epithelium (RPE), Bruch’s membrane (BM) and choroid. Adapted from 3,4.
There are two types of photoreceptors in the retina, namely rod and cone cells. Rods are 
extremely sensitive and are activated under low luminance conditions. With increased 
illumination, cones participate more dominantly than rods in determining vision enabling color 
detection and high resolution vision. On average, the human retina contains 20 times more 
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rods than cones, however modern-day vision is predominantly regulated by the cone system, 
mediating high visual acuity under bright light conditions.
The macula is a region located centrally in the retina. The macula is a pigmented area, appearing 
yellow, due to the presence of lutein, zeaxanthin and xanthophyll pigments. The macular 
pigments absorb the harmful short wavelengths of visible light, acting as natural sunglasses. 
In addition, lutein and zeaxanthin function as antioxidants, which is particularly helpful in an 
oxygen-rich region like the macula, as it is extremely vulnerable to oxidative damage.5 The 
center of the macula, known as the fovea, is a highly specialized region packed with cones.2 
The retinal pigment epithelium (RPE) is a melanin-containing cell layer which performs 
essential roles in maintaining and supporting photoreceptors. The main functions of the RPE 
include recycling of the photopigment chromophore 11 cis-retinal for the phototransduction 
cascade, protection against photo-oxidation by absorbing light, and phagocytosing the outer 
segment discs.2 The RPE and Bruch’s membrane (BM) complex form the outer blood-
retina barrier, which regulates the rapid exchange of waste products, oxygen and nutrients 
between photoreceptors and the choroidal vasculature, functioning as a protective barrier and 
maintaining retinal homeostasis.6
AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among 
elderly individuals, accounting for 8.7% of blindness worldwide. The disease is most prevalent 
in populations of European ancestry with approximately 1-3% of the total population suffering 
from an advanced form of AMD.7-9 Globally, the total number of patients with any type of AMD is 
expected to increase to 288 million affected individuals in 2040.9 Patients experience blurring 
of their central visual field or images may appear as distorted (metamorphopsia), in addition 
to difficulties with seeing colors and fine details. Over time, the central field may become 
obscured and central vision loss is experienced (scotoma) as the disease progresses.10
Clinical presentation
The early clinical signs of AMD are the appearance of yellowish deposits, called drusen, between 
the RPE and BM. Drusen can be classified according to type, morphology and size. Soft drusen 
range in size from small (≤63µm in diameter) to large (≥125µm) with diffuse borders. The 
increase in size and number of soft drusen is a sign of progressing AMD. Hard drusen are 
smaller in diameter and have more defined borders. Hard drusen are a common sign of aging 
and an independent risk factor for vision loss in AMD.11 When soft and hard drusen undergo 
calcification they are referred to as crystalline drusen, due to their glistening appearance.12,13 
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Cuticular drusen (also known as basal laminar drusen) refer to a specific drusen phenotype 
characterized by a large number of small (hard) drusen scattered throughout the retina.14
Presentation on funduscopy
An ophthalmologist can examine the retina to evaluate the nature of the disease, for example 
by capturing a photograph of the inner lining of the eye through the pupil. A fundus photograph 
visualizes the main structures of the retina like the central (macula) and peripheral retina, the 
optic nerve head (or the optic disc), and the retinal vessels (Figure 2). In patients with an early 
form of AMD the yellowish drusen, clustering around the macula, are clearly visible on fundus 
photographs.15 
 A  B
 C  D
Figure 2: Fundus photograph of a healthy retina (A) and different stages of AMD (B-D). The darker patch 
in the center of the image is the macula, and the optic disk is located on the left. B) Intermediate AMD 
with extensive intermediate to large drusen primarily located in the macula. C) Advanced AMD with central 
geographic atrophy surrounded by soft drusen. D) Advanced AMD with choroidal neovascularization with 
central hemorrhage. 
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Figure 3: Graphical representation of the retinal anatomy in normal and various AMD stages. (A) Normal 
retinal architecture focused at the macula comprised of various cell layers from anterior (top) to posterior 
(bottom). (B) As the disease progresses Bruch’s membrane (BM) thickens and drusen form between the 
BM and the retinal pigment epithelium (RPE), attracting immune cells like macrophages and microglia 
cells. Eventually, the disease can progress in one of two late forms: wet (C) and dry (D) AMD. Wet AMD is 
characterized by the invasion of abnormal and leaky blood vessels and an accumulation of macrophages. In 
dry AMD general degeneration of the RPE and photoreceptors is observed.
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Drusen composition
Drusen contain a high variety of components, including proteins, lipids, cholesterol, and 
cellular fragments of the RPE. The main proteins found in drusen include: immunoglobulin 
and components of the complement pathway (complement receptor 1, C3, C5, membrane 
cofactor protein, and terminal complex C5b-9), acute inflammation response (amyloid beta) 
and immune response modulating proteins such as vitronectin, clusterin, apolipoprotein E, 
fibrinogen, HLA-DR and enzymes like factor X and prothrombin.16-22
AMD PATHOLOGY AND STAGING
In early stages of the disease drusen number is limited and does not affect visual function. 
As the number of drusen increases, or pigmentary changes are apparent in the retina due 
to the degeneration of RPE cells, the disease progresses from early to intermediate AMD23,24 
(Figure 3B). Eventually the disease can progress to late AMD, which exists in two distinguished 
forms: neovascular AMD, known as wet AMD, or geographic atrophy, known as advanced dry 
AMD. The neovascular form is characterized by infiltration of abnormal blood vessels from the 
choroidal vasculature into the retina. These newly formed vessels are fragile and break easily, 
leaking blood in the retina and leading to sudden vision loss (Figure 3C). The second form, 
geographic atrophy, is the result of gradual degeneration of RPE and photoreceptors cells as 
well as the constriction of choroidal blood vessels.23,24 (Figure 3D). 
Although neovascularization occurs in only 15-20% of cases, it is responsible for the vast 
majority of vision loss caused by AMD. Intraocular injections of drugs targeting vascular 
endothelial growth factor, one of the central molecules in neovascularization, have proven 
to be very successful in neovascular AMD.25 However, no treatment is available for patients 
who have early, intermediate or geographic atrophy AMD. Furthermore there are currently no 
effective means of preventing progression of early to advanced stages.26,27
AMD IS A MULTIFACTORIAL DISORDER
Multifactorial and ‘complex’ are commonly used synonyms, meaning that the disease clearly 
has a heritable component, but is also partially influenced by environmental and lifestyle 
factors. A variety of non-genetic factors has been identified, of which aging, ethnicity, dietary 
habits and cigarette smoke are consistently associated with AMD.7,9,15,28
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Environmental factors
Age is the most dominant risk factor for AMD; as individuals age the risk for developing AMD 
increases as well. Within the age group 55 to 64 years of age, advanced AMD is present in 0.2% 
of the population, while this number rises to 13% in the group of 85 years and older.29
Cigarette smoke is the most important modifiable risk factor and has been associated with 
a two-to-three fold risk of developing AMD. A clear dose-response effect is observed, where 
increased cigarette consumption leads to an increased risk of developing AMD. Moreover, 
former smokers still have modest risk of developing AMD compared to non-smokers.7,30 
Cigarettes contain numerous toxins which act through different biochemical mechanisms and 
may result in oxidative damage, vascular changes, and inflammation.
Oxidative stress affects the RPE and especially the macula. The macula is extremely vulnerable 
for oxidative stress due to its high metabolic activity, high oxygen demand and polyunsaturated 
fatty acid content which is prone to oxidation.30 Dietary intake of antioxidants and zinc reduce 
the risk of developing AMD in elderly individuals.31,32 High doses of oral antioxidants (vitamin C, 
vitamin E, and carotenoids lutein and zeaxanthin), in addition to zinc, reduce AMD progression. 
It was shown that these supplements were able to reduce AMD progression by approximately 
25% over 5 years.27,31,33,34
Heritability
Evidence for a strong genetic component in AMD was established using twin and family studies. 
Twin studies observed a high concordance of AMD between monozygotic pairs, even double 
compared to dizygotic pairs, and estimated the heritability of AMD to be as high as 46-71%.35-
37 Family studies noted a higher prevalence of AMD characteristics and an earlier onset of 
disease symptoms among relatives of patients compared to control families.38-41 
GENETIC ANALYSES
AMD is a very heterogeneous disorder with a variety of genes and pathways implicated in the 
disease pathogenesis. Identification of disease-causing variants can be done using techniques 
like genome-wide association study (GWAS) and next-generation sequencing (NGS). 
Genome-wide association studies
GWASes are hypothesis-free approaches that use genetic variation across the genomes of 
thousands of individuals to search for genetic influences on traits. The success of GWASes 
is based on the common-disease common-variant hypothesis that postulates that common 
diseases, like AMD, can largely be explained by common variants found in more than 1-5% 
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of the population.42,43 Using an array-based platform, on which several hundred thousands of 
single nucleotide changes can be captured, common variants with small to large effect sizes 
can be detected. In AMD, GWASes and subsequent meta-analyses have been exceptionally 
successful, which is due to the relatively large effect sizes of common variants at two AMD loci 
(CFH and ARMS2/HTRA1). However, the majority of variants have an odds ratio (OR) between 
0.7 and 1.5.44-48 These variants collectively account for 15-65% of the genomic heritability, 
suggesting that other genetic factors must be involved in the disease etiology.47 
The common-disease rare-variant hypothesis proposes that rare variants, or specifically 
multiple risk alleles each of which is individually rare, may explain the heritability.49,50 Rare 
variants, found in <1% of the population, are by definition found in only a minority of individuals. 
Compared to common variants, these rare variants may have more obvious functional 
consequences as they are enriched in genomic regions that are evolutionary conserved, and 
are often predicted to affect protein function.51,52 GWAS arrays are inefficient in tagging rare 
variants due to the low correlation between the variants, as rare variants are often private 
and in low linkage disequilibrium. However, arrays can be designed to capture rare genetic 
variants directly. The most recent GWAS in AMD used an array enriched with rare variants to 
uncover 52 variants, of which 45 were common, that could be grouped into four main pathways: 
(1) complement system, (2) high-density lipoprotein metabolism (3), angiogenesis, and (4) 
extracellular matrix remodeling. In addition, seven rare variants were identified which had an 
OR between 1.5 and 47.6, and were all located in or near genes of the complement system. In 
addition, a burden of rare genotyped variants was found for the CFH, CFI, SLC16A8 and TIMP3 
genes, meaning that rare variants in these genes were collectively observed more frequently 
in AMD cases than in controls.47,48 It should be noted that the rare variants in these genes 
were manually enriched on the array. Extremely rare or novel rare variants will normally not 
be detected using GWAS but will require a broader detection of the gene as provided in next-
generation sequencing (NGS).
Next-generation sequencing
In 1977, a method to sequence DNA by using chain termination was published by Fred Sanger.53 
Sanger sequencing allows for the sequential analysis of individual DNA sequences, limiting 
the ability to rapidly and affordably reading large parts of the genome. In 2005, however, a 
new sequencing approach was introduced in which the sequencing process was performed 
in a massive parallel fashion.54 This nascence of massive parallel sequencing, also termed 
next generation sequencing, has dramatically changed our ability to read DNA, and nowadays 
we can reliably, rapidly and affordably sequence many or even all genes of a genome, or even 
the entire genome of a human being. The total amount of sequencing data is growing on a 
logarithmic scale, as it has been estimated that the amount of sequencing data is doubling 
approximately every seven months beyond the capacity to process and store the data.55,56
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Figure 4: Example of a whole exome sequencing pipeline. The DNA is cut into smaller pieces and 
equipped with adapter sequences. Exome capture selects specific regions of the genome and redundant 
fragments are washed away. Index tags are added for recognition and the fragments are amplified. The 
fragments bind to a flow cell for paired-end clustered bridge amplification. The fragments are read using 
sequencing by synthesis: a step-by-step incorporation of fluorescent nucleotides. The fluorescent signal is 
read at each cluster and recorded until the reaction is complete.59,60 Adapted from 61. 
Whole-exome sequencing (WES) captures and sequences the entire coding part of our 
genome, all of the exons of all of our genes. This exome comprises approximately 1% of the 
entire human genome. Whole-genome sequencing (WGS) encompasses the complete genome, 
including intronic and intergenic regions.57,58 WES relies on the principle of simultaneously 
capturing thousands of fluorescent signals. In short, DNA samples are subjected to several 
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preparatory steps in a process called library preparation. The DNA is randomly fragmented 
into smaller pieces followed by end-repair and ligation of adapter sequences. Specific regions 
of the DNA are captured, amplified by polymerase chain reaction and clustered together with 
unique barcodes. Sequencing is performed by repeating cycles, in which fluorescently labeled 
nucleotides terminate the sequence, and the signal is captured (Figure 4).59,60
Output of a NGS reaction is an uninterrupted series of nucleotides (‘sequencing reads’), and 
after aligning each of these reads to the reference genome we can calculate how often a specific 
nucleotide is sequenced (termed ‘sequence coverage’). Depending on the used capture kit, 
WES identifies between 20 and 50 thousand variants per sequenced exome. To reduce false-
positives the data is filtered for standard quality criteria like minimum coverage per region or 
consistent call rate in more than 5% of the samples. Vigorous filtering of the data or comparing 
the variant load between case and control groups is required to uncover variants playing a 
potential role in disease pathogenesis. 
Analysis of NGS data assuming Mendelian inheritance
Mendelian traits are caused by variation in a single gene and recognizable by a classic 
inheritance pattern. Sometimes multifactorial diseases can behave as Mendelian traits, 
showing clustering in families and presenting with a more severe phenotype or an earlier 
age of onset. Assuming monogenic inheritance in such families, it is a matter of reducing the 
number of variants identified by NGS until a limit set of variants remains. First, variants can 
be selected that are shared among all affected individual family members. Next, variants can 
be selected that alter protein function, as these are potential disease-causing variants (splice 
site or non-synonymous variants). Subsequently, public databases like 1000genomes,62 The 
Exome Aggregation Consortium (ExAC),63 or Exome Variant Server64 can be consulted to filter 
out common variants.58 The remaining variants can be prioritized based on specific genes of 
interest (in a candidate gene study) or predicted to be pathogenic by in-silico prediction.65-67 A 
number of studies used this approach to identify rare variants in families affected by AMD.68-74 
Rare genetic variants reported in AMD families are reviewed in more detail in Chapter 1B: The 
complement system in age-related macular degeneration.
Analysis of NGS data using association analyses
Complex traits, like AMD, often do not follow the predictable patterns of Mendelian inheritance 
and other approaches are required for the analysis of NGS data. NGS strategies have only 
recently been adopted to identify rare genetic variants in complex diseases.75,76 The first 
successful report of WGS in AMD was in 2013 in a large population-based cohort77 from Iceland. 
Two more studies used WES to identify risk variants in an AMD case-control cohort.78,79 Genetic 
variants reported in AMD are reviewed in more detail in Chapter 1B: The complement system 
in age-related macular degeneration.
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NGS can be applied to case-control cohorts, followed by association analyses to identify rare 
variants that are associated with the disease. The initial analysis that can be performed is a 
single-variant analysis, in which the association of individual rare variants with the disease 
is tested. However, the bottleneck with rare variants detection is the large sample size 
required compared to common variants, especially if the effect size of the rare variants is 
small. Therefore, case-control studies are often underpowered to detect single rare variant 
associations.80 Instead of single variant analyses, aggregation tests (also called burden tests) 
evaluate the cumulative effect of multiple genetic variants in a single gene, region or pathway. 
Variant data is grouped and association analyses in cases and controls is performed. 
There are two types of burden tests, (1) variants in a region are assumed to have the same 
direction of effect (damaging or protective), or (2) variants in a region are allowed to have 
opposite effects.81 The first test is simpler as it collapses variants, scores them, and tests for 
the association between the score and a trait. Examples include the Combined Multivariate 
and Collapsing (CMC) or Variable Threshold (VT) burden tests.82,83 The second test, known as 
a variance component test, assesses variants distribution also when the consequences are in 
opposite directions, like the Sequence Kernel Association Test (SKAT)84.
THE COMPLEMENT SYSTEM IN AMD 
Before any specific gene or biological pathway had been conclusively linked to AMD, studies 
into the molecular constituents of drusen suggested that AMD may have an immunological 
component. These theories were based on proteins found in drusen which are involved in 
inflammation and/or other immune-associated responses, including components of the 
complement system.17,19,21,22 
The alternative pathway of the complement system became a major focus in AMD research 
after the identification of risk variant in CFH p.Tyr402His in 2005.85 Ever since, genetic variants 
have been identified in the alternative pathway of the complement system, which plays an 
important role in AMD pathogenesis.47,48,86-94 In the most recent GWAS, twelve of the 45 identified 
common variants and all rare variants (all seven) resided in or near a gene of the complement 
system: CFH, CFI, C3, C2/CFB, C9 and VTN.48 
There are several theories on how complement activation contributes to retinal damage. 
Some theories focus on functional loss of RPE triggered by external factors (like smoking 
and aging), which accelerate complement activation. Others focus on local activation of the 
complement system by drusen. Genetic variations add to these scenarios as they may lead 
to hyperactivation of the complement system or obstruct proteins from properly preventing 
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unwanted complement attack.95-97 Continuous low levels of complement activation are 
beneficial for the removal of cellular debris. However, decades of low-grade inflammation 
may lead to tissue damage.98 In AMD, increased levels of systemic complement activation are 
observed in serum or plasma. The activation markers Ba, Bb, C3a C3d, C5a and regulators 
FB and FD are higher in patients with AMD compared to (age-matched) controls in addition to 
decreased FH levels.99-103 Complement activation products were also found locally in aqueous 
humor, vitreous and BM in (postmortem) eyes of AMD patients 104-106. Furthermore, genetic 
variants in complement genes linked to AMD have a direct effect of systemic complement 
activation.99-102,107 In addition, AMD disease stage, age, BMI and smoking individually influence 
complement levels as well.99-102,107-109
The common AMD-associated variant CFH p.Tyr402His, located in SCR7, results in reduced 
binding of FH to the BM and inner choroid which could explain the AMD phenotype.110 Moreover, 
the CCP6-8 mediates recruitment of FH on the RPE and BM in the eye, while the CCP19-
20 region is involved in tissue-specific binding with the glomerular basement membrane in 
the kidney.110 For CFI, rare AMD-associated genetic variants in the CFI gene result in reduced 
systemic FI levels and consequently lower the regulatory activity of the alternative pathway.91,92 
Knowledge is lacking regarding the effects of genetic alterations on complement protein C9 
and MAC formation, in relation to AMD. However, MAC deposits have been identified within 
drusen and in BM,28 and sublytic MAC induces an inflammatory response in cultured RPE cells, 
suggesting local inflammation.111 
THE COMPLEMENT SYSTEM: THE ALTERNATIVE PATHWAY
The complement system is part of the innate immune system and tight regulation of this 
system is needed to protect the body’s own cells from tissue damage. The complement system 
accomplishes its goal, self-defense against invading pathogens, by (1) attacking the microbial 
membrane by generating convertases, (2) generating millions of defense molecules at great 
speed and bulk, and (3) creating local inflammatory sites.21,112-114 
There are three activation pathways of the complement system. The lectin pathway, activated 
by mannose-binding lectin, the classical pathway activated by antibody-antigen complexes, 
and the alternative pathway which is activated by spontaneous hydrolysis. Auto-activation of 
the alternative pathway is unique as it relies on the hydrolyzing of labile C3 thioester bonds, in 
a process known as tickover. Upon activation C3a is cleaved off C3 forming C3b whereby the 
exposed thioester bonds have the ability to form covalent bonds. These covalent bonds bind 
freely to the surfaces of cells and of microbes.115
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The C3 and C5 convertases catalyze further steps in the cascade by (1) initializing a feedback 
loop, and (2) starting the breakdown cycle. In the breakdown cycle, surface-bound C3b can be 
inactivated by serine protease factor I (FI) into its inactive form iC3b, which requires the help of 
cofactors (details provided below in Chapter 1.6.3. Factor I). Further steps of the breakdown 
cycle are illustrated and explained in Figure 5. In the feedback loop, stabilized C3 convertase 
(C3bBb) can generate numerous C3b molecules. The additionally generated C3b aid in formation 
of the C5 convertase and continued activation of the alternative pathway.112-114,116 (Figure 5). 
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Figure 5: The alternative pathway of the complement system. 1. The alternative pathway is activated the 
moment C3 is spontaneously hydrolysed. 2. C3 can swiftly amplify by employing proteases factor B (FB) 3. 
Factor D (FD) together with stabilizing protein properdin (FP) forms the C3 convertase (C3bBb). 4. The C3-
convertase can, through an efficient feedback loop, generate large amounts of C3b to opsonize pathogens 
or can bind to additional C3b to form the C5-convertase (C3bBbC3b). 5. The C5-covertase cleaves C5 into 
C5a and C5b. 6. C5b initiates the membrane attack complex (MAC; C5b-9), by binding sequentially to C6, 
C7, C8 and multiple C9 molecules. *Inhibition of the C3-convertase is achieved by regulators like Factor H 
(FH) and decay accelerating factor (DAF). **Factor I (FI) can digest C3b through cofactor mediated cleavage 
with FH or Membrane Cofactor of Proteolysis (MCP; CD46). Figure adapted from 117. 
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C3
C3 is the central component of the complement system. C3 interacts with a wide range of 
complement factors, including proteases, receptors and regulators but also viral and bacterial 
proteins through distinct binding sites. Anaphylatoxin C3a modulates inflammation and 
possesses antimicrobial activity. C3b has the ability to bind to the cell surface of invading 
pathogens via the exposed thioester bond.118
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Figure 6: Structure of C3. (A) Schematic structure of C3 divided in the β and α-chain with amino acid 
numbering corresponding to the mature protein. (B) A graphical representation of the domain arrangement 
relative orientations in the crystal structure as shown in C. (C) Superposition of C3 with individual domains, 
based on crystallized structure submitted in the protein data bank (PDB) accession number 2A73.118
Structurally, C3 consists of an α-chain and β-chain linked by a disulfide bridge. The β-chain 
starts the formation of a ring-like structure with macroglobulin (MG) domains and a hydrophobic 
linker (LNK). The anaphylatoxin (ANA) domain, released as the C3a fragment. The remaining 
domains, piled on the ring, are CUB (complement C1r/C1s, Uegf, Bmp1) domain framing and 
holding the globular thioester-containing domain (TED; C3d), and an anchored C-terminal 
complement domain (CTC)(Figure 6).118,119 In the formation of C3 to C3b, the β-chain remains 
largely unchanged whereas the α-chain is rearranged with the TED located at the other side of 
the MG ring. The repositioned CUB is involved in binding FB and FI cofactors.120,121
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Factor H
Factor H (FH) is the main inhibitor of complement through binding to C3b and aiding FI in 
cofactor mediated cleavage. The FH protein is made up of 20 short consensus repeats (SCRs) 
connected by short linkers which fold into distinct three-dimensional structures named 
complement control protein (CCP) modules (Figure 7). While the 20 modules seem highly 
similar in appearance, there are several distinct functional regions. The first four CCPs (CCP1-
4) form a C3b binding site by competing with FB, and in addition make C3b susceptible for 
cleavage by FI.122 Regions CCP6-8 and CCP19-20 are similar in function, and can interact with 
glycans (like glycosaminoglycans (GAGs)), lipid peroxidation products, extracellular matrix 
proteins, apoptotic or necrotic cells and foreign bacteria.123
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Figure 7: Structure of FH and interaction with C3b. (A) Schematic structure of FH with amino acid 
numbering corresponding to the mature protein with signaling peptide. The two major functional regions 
are colored green are functioning as binding sites for C3b/C3d, heparin/glycosaminoglycans and cell 
surfaces. There are no crystallized structures available for SCR5-18. (B) A representation of the domain 
arrangement partial FH ‘miniFH’ in interaction with C3b. MiniFH consists of CCP domains 1–4 and 19–20, 
connected by 12 glycine residues. (C) superposition of C3b-miniFH with C3b in gold (α-domain) and silver 
(β-domain) and miniFH consisting of CCP1-4 and 19-20 binding to C3b and C3d, respectively. Based on 
PDB 5O35.122
Factor I
Factor I (FI) is a serine protease critical for regulation of the complement system by cleaving 
C3b in the presence of one the cofactors. Known FI cofactors are membrane bound membrane 
cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35), next to plasma 
components FH and C4b-binding protein (C4BP).113 FI can degrade C3b and C4b in fluid phase 
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or when deposited on the cell surface. The FI protein circulates in the blood and is unique is its 
inhibitory function as it has no natural blocker.113
FI consists of a heavy and a light chain linked by a disulfide bridge. The heavy chain contains a 
FI membrane attack complex (FIMAC) domain, a SRCR domain (scavenger receptor cysteine-
rich domain, also called CD5), low-density lipoprotein receptor 1 and 2 domains (LDLr1 and 2) 
and a small undefined region. The light chain of FI comprises a serine protease (SP) domain 
(Figure 8).124-126 The working theory is that a cofactor binds C3b and forms a stable platform 
for FI to adhere to. Once the heavy chain of FI is fastened, remodeling of the protein promotes 
allosteric activation whereby activation sites become exposed.127
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Figure 8: Structure of FI in interaction with FH and C3b. (A) Schematic structure of FI with amino acid 
numbering corresponding to the mature protein with signaling peptide. (B) A graphical representation 
C3b-miniFH-FI domain arrangement as their relative orientations in the crystal structure. MiniFH consists 
of CCP domains 1–4 and 19–20, connected by 12 glycine residues without the unknown structure of CCP5-
18. (C) superposition of the C3b-miniFH-FI protein complex. FI binds in cofactor activity with C3b-miniFH 
at the CTC, MG2 and CUB domain of C3b in addition to CCP2-3 of FH. Based on crystallized structure PDB 
5O32 122, adapted in PyMOL. 
Regulators of complement activation 
The regulators of complement activation (RCA) protein/gene cluster controls complement 
activation. The family consists of decay-accelerating factor (DAF; DD55), CD46, CR1, FH and 
C4BP. The RCA members can act either through cofactor mediated cleavage or by decay-
accelerating activity. Decay-accelerating activity disassociates the catalytic domain of C3 or C5 
convertases, but only temporary as the convertases can reassemble.95,114 Down-regulation of 
complement activation takes place on the cell surface and in fluid phase. 
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Complement regulators CR1, CD46, and DAF are expressed on cell membranes, on which they 
provide immediate protection to host cells. Soluble regulator FH stops complement activation 
in the fluid phase and differentiates between “self” or “non‐self” cells and matrix material by 
binding host molecular patterns.110,128
Table 1: specification of regulators of complement activation proteins. 
Protein Function Interaction Pathway
CD46 CA Surface (via transmembrane domain) CP, LP and AP
CD55 DAA Surface (via glycolipid anchor) CP, LP and AP
CR1 CA/DAA Surface (via transmembrane domain) CP, LP and AP
FH CA/DAA Fluid (binds to C3b) AP
C4BP CA/DAA Fluid (binds to C4b) CP and LP
CA = cofactor activity; DAA = decay acceleration activity; CP = classical pathway; LP = lipid pathway; AP = 
alternative pathway.
C9 and the membrane attack complex 
Cleavage of C5 into C5a and C5b is the first step of the formation of the terminal complement 
complex. C5b sequentially binds to C6, C7 and C8. Subsequently 22 copies of C9 (four in the 
tilt and 18 in the circular structure) are incorporated to form the membrane attack complex 
(MAC). This split-washer (open ring) formation can disrupt membrane integrity by penetrating 
the cell membrane (Figure 9). Vitronectin and clusterin can bind to the complex and yield a 
soluble complex which prevents C9 from penetrating the membrane. In addition, the complex 
will be unable to binding more C9 thereby effectively preventing pore formation. Furthermore, 
MAC-inhibitory protein (MAC-IP; CD59) located on host membranes can prevent C9 from 
polymerizing and MAC forming.129-134 
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Figure 9: Structure of C9 and the membrane attack complex. (A) Schematic structure of C9 with amino 
acid numbering corresponding to the mature protein with signaling peptide. The protein consist of four 
domains: an N-terminal thrombospondin type-1 TSP domain (TSP1), a low-density lipoprotein receptor 
class A (LDLRA), MAC Perforin (MACPF) and a C-terminal epidermal growth factor (EGF-like) domain.135 
(B) Pseudo-atomic model of the membrane attack complex rim including the individually labeled 
complement proteins C5b to C9. Note: there is no crystallized structure available. (C) One C9 ribbon fitted 
into the reconstruction and the unmodeled β-helices below. (D) A graphical representation of the C9 ribbon 
with corresponding C9 domains. Adapted from 130 as submitted in Electron Microscopy Data Bank under 
accession numbers EMD 3134.
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AIMS OF THIS THESIS AND CHAPTER INTRODUCTION
It was previously hypothesized that a common disease, like AMD, should be caused by common 
genetic variants. However, at the start of this thesis project, after large GWASes uncovered 
19 loci, a large fraction of the heritability still remained unexplained.47 Rare genetic variants, 
defined as genetic changes with a minor allele frequency below 1% in the population, can have 
large effects on disease and may account for the ‘missing’ heritability.
The aim of this thesis is to further elucidate the role of rare genetic variants in AMD pathogenesis. 
We hypothesize that a proportion of the missing heritability in AMD can be explained by rare 
highly penetrant variants. We aimed to identify novel genetic causes of AMD, and to understand 
their role in the disease mechanisms.
Chapter 1A: Introduction
This chapter provides the basic information needed to understand the current genetic en 
biochemical research in the ophthalmology field regarding AMD. An introduction is given on 
AMD, performing genetic analyses, and on the complement system.
Chapter 1B: The complement system in age-related macular degeneration
This chapter goes into depth on the common and rare genetic variants found in genes of the 
complement pathway, which have been found to play a role in the pathogenesis of AMD. It reviews 
all rare variants identified in AMD patients, and summarizes the functional consequences of 
rare genetic variation in complement genes. 
Chapter 2: Rare genetic variants associated with development of age-related macular 
degeneration
Chapter 2 determines the contribution and segregation of rare genetic variants in the 
complement system in large families with AMD. Furthermore, clinical characteristics in 
carriers versus non-carriers of rare genetic variants in large families and in a case-control 
cohort are described.
Chapter 3: Rare variants in CFH and CFI result in decreased C3b degradation in patients 
with age-related macular degeneration
Chapter 3 uncovers novel rare genetic variants in complement genes previously found to be 
associated with AMD by using WES in AMD families. The chapter assesses the functional effect 
of rare genetic variants on levels of complement components in serum. C3b degradation ability 
was used as a marker of complement activation to assess the effect of different rare variants.
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Chapter 4: Functional analysis of rare genetic variants in complement C9
In chapter 4 we go into detail on the functional analyses performed on serum samples of 
individuals carrying rare variants in C9, and HEK293F cells in which the same C9 mutations 
were introduced.
Chapter 5: Geographic distribution of rare genetic variants previously associated with age-
related macular degeneration
For chapter 5 we describe the geographical distribution of seven independently associated rare 
variants for ~40.000 individuals. 
Chapter 6: Phenotype characteristics of patients with age-related macular degeneration 
carrying a rare variant in the CFH gene
Chapter 6 assesses the distinctive phenotypical characteristics of AMD patients carrying a rare 
genetic variant in CFH compared to AMD patients who do not carry such rare variants.
Chapter 7: Genetic screening for macular dystrophies in patients clinically diagnosed with 
dry age-related macular degeneration 
In chapter 7 we evaluate the occurrence of AMD-mimicking dystrophies in an AMD cohort. We 
screened individuals with intermediate and advanced geographic AMD for genes associated 
with autosomal dominant and autosomal recessive macular degeneration mimicking AMD.
Chapter 8: Genotype-phenotype correlations of low frequency genetic variants in the 
complement system in renal disease and age-related macular degeneration 
Genetic variation in the complement system have been linked to renal diseases atypical 
hemolytic uremic syndrome and C3 glomerulopathy. In chapter 8, we systematically compare 
low frequency genetic variants found in CFH, CFI, and C3 for renal diseases patients, AMD 
patients and control individuals. In addition, we provide a comprehensive genotype-phenotype 
correlation analyses between these disease groups
Chapter 9: Whole-exome sequencing in age-related macular degeneration identifies rare 
protein-altering variants in COL8A1, a component of Bruch’s membrane 
In chapter 9 we used whole-exome sequencing to detect a disease burden of rare protein-
altering variants in a large European cohort consisting of 1125 AMD cases and 1361 controls 
individuals.
Chapter 10: General discussion
The discussion paragraph elaborates on the primary findings of this thesis, places these 
findings in a broader perspective, and discusses the clinical and scientific relevance.
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CLINICAL CHARACTERISTICS OF AGE-RELATED MACULAR 
DEGENERATION
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among 
the elderly, accounting for 8.7% of blindness worldwide. AMD is most prevalent in populations of 
European ancestry with approximately 1-3% of the total population suffering from an advanced 
form of AMD.1-3 Globally, the total number of patients with any type of AMD is expected to 
increase over the next 25 years to 288 million affected individuals.3 
The disease is characterized by a gradual loss of central vision due to photoreceptor 
cell degeneration in the centre of the retina at the back of the eye, known as the macula. 
Photoreceptors are in close contact with a layer of cells called the retinal pigment epithelium 
(RPE). RPE cells support the function of the photoreceptors and play an important role in 
maintaining retinal homeostasis. In AMD, this natural function of the RPE is disturbed, resulting 
in the accumulation of retinal waste products called drusen underneath the RPE. Drusen are 
the tell tale sign of AMD and are easily recognized by ophthalmologists.
AMD is a progressive retinal disease is which the early stage is characterized by relatively few 
small drusen within the macula. When AMD progresses, drusen size and number increase, 
eventually leading towards more advanced stages of AMD. Two forms of advanced AMD are 
distinguished. The first form, neovascular AMD, is characterized by infiltration of abnormal 
blood vessels into the retina. These newly formed vessels are fragile and when they break, 
the leakage of blood constituents in the retina leads to sudden vision loss. The second form 
of advanced AMD, geographic atrophy, is the result of gradual degeneration of the RPE and 
photoreceptors cells. Although neovascularization occurs in only 15-20% of AMD cases, it 
is responsible for the vast majority of vision loss caused by AMD. Drugs targeting vascular 
endothelial growth factor (VEGF), one of the central molecules in neovascularization, have 
proven to be very successful in neovascular AMD. However, no treatment is available for the 
remaining majority of early, intermediate or geographic atrophy AMD cases, and furthermore 
there are no effective means of preventing progression of early to advanced stages.4,5
THE COMPLEMENT SYSTEM PLAYS A CENTRAL ROLE IN THE ETIOLOGY 
OF AMD
Research on the etiology of AMD: a historical perspective
Today it is known that AMD is the result of a complex interaction of environmental and genetic 
risk factors. Pooled evidence from numerous studies has demonstrated that environmental 
factors like aging itself, smoking behavior, and body mass index (BMI) are strong risk factors 
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for AMD. In addition, cataract surgery, cardiovascular disease and family history are also 
strongly associated.1 Before any specific gene or biological pathway had been conclusively 
linked to AMD, studies into the molecular constituents of drusen had already suggested that 
AMD may have an immunological component. This suggestion arose after proteins involved 
in inflammation and/or other immune-associated responses, including components of the 
complement system, were found within drusen.6-8
Evidence for a strong genetic component in AMD arose from twin and family studies. Twin 
studies observed a high concordance of AMD between monozygotic pairs, even double 
compared to dizygotic pairs, and estimated that the heritability of AMD may be as high as 45 to 
70%.9-11 These findings were in line with familial aggregation analyses that observed a higher 
prevalence of AMD characteristics and an earlier onset of disease symptoms among relatives 
of patients compared to control families.12,13
Genetic evidence for a role of the complement system in AMD
In search for genomic regions implicated in AMD, genetic linkage analyses were done in large 
family-based studies.14-18 Among a few other regions, the findings from these studies strongly 
and consistently implicated a region on chromosome 1 in the disease. When the first genome-
wide association study (GWAS) for AMD was performed in 2005, it identified that same genomic 
region, which lead to the discovery of a highly associated genetic variant in complement factor 
H (CFH; p.Tyr402His).19 These findings were corroborated by three additional studies.20-22
Table 1: Genes in the complement system associated with AMD 
Gene/Locus Approach Reference#
C2/CFB Candidate gene 23
C3 Candidate gene/WGS 24,25/26-28
C9 Candidate gene 27,29
CFH Candidate gene/ Linkage/ GWAS 19-22/30
CFHR1-CFHR3 Candidate gene 31
CFI Candidate gene 32/33
VTN GWAS 34
# Reference of first cited association based on common and/or rare genetic variant.  
WGS = whole-genome sequencing; GWAS = genome-wide association study
Through genetic studies that followed over the next decade, the understanding of the genetic 
basis of AMD increased dramatically with the identification of disease-associated variants 
across several biological systems.35 The genetic link between AMD and the complement system 
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was further expanded when genetic variants in or near complement factor I (CFI), complement 
component 3 (C3), complement component 2 (C2), complement component 9 (C9), complement 
factor B (CFB) and vitronectin (VTN) were also found to be associated with the disease.23-25,32,34,35 
(Table 1). In addition, a common haplotype carrying a deletion of complement factor H related 
genes CFHR1 and CFHR3 was found to be protective for AMD.31 
The role of rare genetic variants in AMD
Common genetic variants (with a minor allele frequency (MAF) of >5% in the population) near 
the complement genes CFH, C2/CFB, C3 and CFI together explain 40-60% of the heritability of 
AMD.36 However, a large fraction of the heritability still remains unknown and is referred to as 
missing heritability. One hypothesis states that low frequency and rare genetic variants (with 
a MAF of <1-5% and <1%, respectively) may explain the remaining fraction of the heritability.37 
During the past years, genetic studies in AMD have therefore shifted towards the identification 
of rare genetic variants. However, a practical problem arises when analyzing rare variants. The 
number of patients and controls needed for the identification of novel variants increases when 
variants are more rare, since the sample size requirements increase roughly linearly with the 
inverse of the allele frequency. Therefore, analyses of very large cohorts are required for a 
comprehensive understanding of the role of rare genetic variants in AMD. 
Genetic approaches to identify rare genetic variants in AMD 
In order to discover rare variants investigators resort to other methods of analyses than those 
methods yielding insight into common variation. An effective approach that can be used to detect 
rare disease-associated variants is through a GWAS using exome chips. An exome chip is an array 
containing both common genetic variants as well as rare exonic variants, and is cost-effective in 
capturing a specific set of variants in large case-control studies. These chips can be customized 
and enriched for specific variants of interest. The approach is limited in the sense that it cannot 
discover new genetic variants other than the ones that the chip captures, but after imputation 
the chip covers over 12 million variants across the genome.34 A recent large GWAS using exome 
chips detected 52 (45 common and 7 rare) variants at 34 genomic regions that are independently 
associated with AMD. More than one third (19/52) of these variants reside in or near a gene of 
the complement system: C2/CFB, C3, C9, CFH, CFI, and VTN (table 1). Besides evaluating the 
association of single genetic variants with the disease, the cumulative number of rare variants 
detected across an entire gene can be compared between patients and control individuals using 
burden tests. Interestingly, a significant burden of rare variants in the CFH and CFI genes, in 
addition to two other genes (TIMP3 and SLC16A8), was observed in AMD.34
Another approach that is widely used to detect rare variants is sequence analysis of candidate 
genes in cases and controls. An advantage of this approach above the use of exome chips is 
that it can discover new genetic variants, thereby allowing a comprehensive analysis of all 
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genetic variation in a candidate gene or a set of candidate genes. With the development of next-
generation sequencing technologies, tens to hundreds of genes can effectively be analyzed in 
large cohorts consisting of thousands of individuals. The candidate gene approach has been 
successfully employed in AMD in several studies, which have mainly focused on sequencing 
of genes of the complement system and other genes previously associated with AMD. These 
studies lead to the discovery of rare variants in the CFH, CFI, C3 and C9 genes in AMD.27,28,33,38,39
Whereas candidate gene sequencing is a very targeted approach, whole exome sequencing 
(WES) or whole genome sequencing (WGS) can interrogate genetic variants in all coding regions 
of the genome (WES) or even the entire genome (WGS). Since WES and WGS are expensive to 
perform in large cohorts, approaches can be used to enrich for rare variants, for example by 
analyzing large AMD families. Recent studies in AMD using WES and WGS have successfully 
identified novel genetic variants in AMD using a case-control cohort26 or by analyzing multiple 
affected individuals of large AMD families.40-46 New genetic variants were detected in CFH, CFI, 
C3 and C9, in addition to other genes (FBN2 and HMCN1). Although rare variants segregated 
with AMD in some of these families,41,43,44 several variants did not perfectly segregate with 
the disease, but were enriched in cases compared to control individuals.40,42,45 This is in line 
with the complex etiology of AMD, to which both common and rare genetic variants, and also 
environmental factors contribute.
RARE GENETIC VARIANTS IN THE COMPLEMENT SYSTEM 
Multiple rare genetic variants in the complement system have been associated with AMD. The 
following paragraphs summarize these variants, focusing on the ones that were found in more 
than a single AMD patient. A complete list of rare variants described in literature is presented 
in Supplementary Table 1 and visualized in Figure 1. 
Complement factor H 
An important rare variant associated with AMD, CFH p.Arg1210Cys, was discovered after re-
sequencing a rare risk haplotype in CFH.30 The authors demonstrated that the p.Arg1210Cys 
variant was highly associated with AMD, independently of the common variant p.Tyr402His. 
Moreover, carriers of this variant were significantly younger when the first symptoms of AMD 
appeared. The p.Arg1210Cys variant conferred a 47 times higher risk of developing AMD.34
Earlier, nonsense variant p.Gln408Ter and missense variant p.Arg1078Ser in CFH had already been 
identified in families that presented with a particular subtype of AMD known as cuticular drusen. 
Here it was argued that the rare variant, in addition to the common variant CFH p.Tyr402His, may 
underlie the phenotype.47 In addition, in other families with cuticular drusen, frameshift variants 
p.Ile184Leufs*33 and p.Lys204Thrfs*26 were identified, also independently of CFH p.Tyr402His.48
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Splice site variant CFH c.790+1G>A and coding variants CFH p.Arg53Cys, p.Asp90Gly, 
p.Arg127His, p.Arg175Pro, p.Arg175Gln, p.Cys192Phe, and p.Ser193Leu were identified by 
WES of AMD families in which known genetic risk factors could not explain the high burden 
of disease.43,45,49 Variant CFH p.Pro503Ala was identified using WES in an Amish family after 
exclusion of the other main risk variants for AMD, and was significantly associated with AMD in 
an Amish AMD case-control cohort (Table 2).40 Next-generation sequencing was performed for 
CFH in a cohort of 2417 individuals, demonstrating an enrichment of rare variants in functional 
domains of factor H in AMD. In this study, 65 coding CFH variants were identified of which only 
15 rare variants were found in more than one affected individual; the other variants were found 
only in single cases (Table 3, Supplementary Table 1).38 
Overall, three different splice site variants, ten different nonsense, four different frameshift 
and 106 different rare missense variants in CFH were detected in AMD case-control and family 
studies (Supplementary Table 1). Functional variants seem to cluster in SCR 1-4 domains 
which mediate complement regulation of the protein, and SCR 19-20 which allow attachment 
of FH to the host cell. In total, 10 of 15 identified functional variants affect amino acid residues 
in one of these domains. In total, 124 variants were found of which 14 were significantly (p 
<0.05) associated with AMD (Table 2). The majority of the coding variants (68/124) were found 
in only in one study cohort and were not significantly associated with AMD.   
Complement factor I 
After sequencing the entire CFI gene in a subset of patients, and subsequent replication in a 
number of large case-control cohorts, the variant p.Gly119Arg was shown to be strongly associated 
with AMD.33 The p.Gly119Arg variant conferred a 5 times higher risk of developing AMD.34 
Additional variants in CFI have been identified in AMD families, including p.Gly188Ala,33 
p.Leu131Arg,45 and p.Val412Met.44 It has been demonstrated that the CFI gene is enriched for 
rare variants four-fold in AMD cases compared to controls, and that these variants largely 
reside in the catalytic domain (residing in the serine protease domain) of the protein.27 Of 
the 70 variants identified in this study,39 eight coding variants were confirmed in five or more 
individuals, while the majority of variants were found only once (Supplementary Table 1). 
None of the variants were individually associated with AMD, although three variants showed a 
nominal association (CFI p.Pro553Ser, p.Arg406His and p.Ala240Gly)(Table 2).
Overall, one splice site variant, seven different nonsense, and 86 different rare missense 
variants in CFI were detected in AMD case-control and family studies (Supplementary Table 1). 
The variants appear to cluster in the serine protease domain, with 42 of 94 identified variants 
affecting amino acid residues in this domain, which is in accordance with a previous report.27 
Of these variants, 14 were significantly associated with AMD (Table 2). 
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Table 2: Rare variants in complement genes associated with AMD and accompanying OR/LOD scores.
Gene Variant (p.) Effect (Odds Ratio) Significance (P-value and/or LOD score) Study
CFH Arg2Thr Risk (14.1) P = 0.0158** 34
CFH Arg53Cys Risk (22.5) LOD score 5.07, P = 6.7x10-7, P = 0.00118** 34,43
CFH Arg53His Risk (13.4) P = 0.01** 34
CFH Ser58Ala Risk (2.58) P = 0.00702** 34
CFH Asp90Gly Risk (NA) LOD score 1.22, P = 0.009 43
CFH Arg175Gln Risk (1.50) P = 0.04 51
CFH Ser193Leu Risk (NA) P = 0.01 51
CFH Ile221Val Risk (11.8) P = 0.0314** 34
CFH Arg303Trp Risk (12.2) P = 0.0378** 34
CFH Pro503Ala Risk (NA) P = 9.27×10−13 40
CFH Gln950His Protective (0.72) P = 0.00258** 34
CFH Asn1050Tyr Protective (0.36) P = 5.92x10-44** 34
CFH Asn1056Lys Protective (0.08) P = 0.024** 34
CFH Arg1210Cys Risk (31.8) P = 3.2x10–31* 34
CFI Gly119Arg Risk (3.87) P = 8.6x10–11* 34
CFI Leu131Arg Risk (NA) P = 0.02 51
CFI Val152Met Risk (7.57) P = 4.65x10-4** 34
CFI Gly162Asp Risk (20.3) P = 0.00231** 34
CFI Arg187Ter Risk (1.30) P = 0.0175** 34
CFI Thr203Ile Risk (2.46) P = 0.0344** 34
CFI Ala240Gly Risk (OR 7.43) P = 0.02 39
CFI Ala258Thr Risk (3.88) P = 6.25x10-5** 34
CFI Gly287Arg Risk (4.61) P = 0.00761** 34
CFI Thr300Ala Protective (NA) P = 0.0144** 34
CFI Arg317Trp Risk (12.2) P = 1.97x10-4** 34
CFI Arg339Gln Risk (11.8) P = 0.0312** 34
CFI Arg406His Protective (0.10) P = 0.02 39
CFI Val412Met Risk (NA) LOD score 2.51 44
CFI Pro553Ser Risk (3.7; 2.69) P = 0.04; P = 0.03 39,51
C3 Lys155Gln Risk (3.12) P = 1.5x10–32* 34
C3 Arg161Trp Risk (1.5) P = 0.01 51
C3 Val619Met Risk (2.66) P = 2.38x10-4** 34
C3 Arg1532Trp Risk (12.3) P = 0.0379** 34
C9 Arg116Ter Protective (0.20) P = 0.021 29
C9 Arg118Trp Risk (1.12) OR = 0.04 51
C9 Pro167Ser Risk (1.79) P = 1.6x10–14* 34
*IAMDGC Locus-wide conditioned analysis (adjusting for the identified index variant(s) in the locus) ** Not 
conditioned for index variant(s) in the locus. NA = not available.
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Complement component 3 
The p.Lys155Gln variant in C3 was described to be associated with AMD independently by three 
studies.26-28 The p.Lys155Gln variant confers a 3 times higher risk of developing AMD.34 
In a sequencing study of all coding exons of the C3 gene, four other C3 variants were identified: 
p.Lys65Gln, p.Arg161Trp, p.Arg735Trp and p.Ser1619Arg.50 All but p.Arg161Trp were found to be 
associated in the index cohort, but none of the rare variant associations were replicated in an 
independent cohort. The p.Arg735Trp and p.Ser1619Arg variants and two additional variants, 
p.Val619Met and p.Lys633Arg, were identified by next-generation sequencing of the C3 gene in 
1676 cases and 745 controls, but none of the variants were found to be significantly associated 
with AMD.27
Overall, 71 different rare missense variants in C3 were detected in AMD case-control and 
family studies (Supplementary Table 1). The variants that effect protein function are located at 
the first and second MG domains. Of these variants, four variants were significantly associated 
with AMD (Table 2). The majority (39/71) of variants were found in only one in one study cohort 
and were not significantly associated with AMD.
Complement component 9 
Sequence analysis of the C9 gene in 1676 cases and 745 controls demonstrated that the 
p.Pro167Ser variant confers an increased risk of developing AMD.27 The p.Pro167Ser variant 
was confirmed to confer risk of AMD in other cohorts as well,42 with a 1.7 times increased risk 
of developing AMD.34
Sequence analysis of C9 also identified 2 other variants, p.Met45Leu and p.Ile203Val, but these 
were not found to be significantly associated with AMD.27 In addition, variant p.Arg118Trp was 
identified in an AMD family with three affected siblings.45 The nonsense variant p.Arg95Ter has 
been associated with a reduced risk for advanced AMD but is a founder mutation of East Asian 
origin and extremely rare in European populations.29
Overall, four nonsense, one frameshift and 15 different rare missense variants in C9 were 
detected in AMD case-control and family studies (Supplementary Table 1). Of these variants, 
three were significantly associated with AMD (Table 2). The majority (16/20) of variants were 
found in one study cohort and were not significantly associated with AMD.
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FUNCTIONAL IMPLICATION OF RARE GENETIC VARIANTS
A genetic association provides statistical evidence that a particular variant is implicated in the 
disease, but if offers no insight into the molecular mechanisms that underlie and lead to the 
disease. To better understand this, the functional consequences of genetic variants on the 
complement system need to be investigated. Although the complement system acts locally, 
complement components or activation products can be detected systemically, for example in 
serum or plasma. In literature, several studies have described the expression of complement 
regulators and measurements of both complement components and activation products in 
AMD patients compared to controls. In addition, for some variants in vitro studies have been 
performed to examine their effect. In the next paragraphs we summarize the rare variants 
described in AMD literature, and detail their functional effects (Table 3).
Complement factor H
Complement factor H (FH) is an inhibitor and plays a key role in the alternative pathway of the 
complement system. FH protects tissues by inhibiting the formation of excess C3 convertase 
through competition with factor B (FB) in the binding of C3b, and in addition promoting the 
decay of surplus C3 convertase. 
The p.Arg1210Cys variant showed reduced binding to C3b, C3d and heparin but normal cofactor 
activity to factor I (FI).52,53 Through the introduction of a cysteine residue, p.Arg1210Cys forms 
covalent interactions with human serum albumin.52 It has been postulated that it is the albumin 
bound to FH rather than any functional defect of the protein itself that eventually disrupts FH 
function.54 Variants p.Arg53Cys and p.Asp90Gly are both located within the first four domains of 
FH which are known to bind C3b, however only p.Arg53Cys showed minor decreased affinity to 
bind C3b.43 Independent of the C3b affinity, the variants strongly affected co-factor activity of FI. 
In addition, p.Arg53Cys disrupted decay accelerating activity and was shown to correlate to low 
C3 levels.43,55,56 Later, variants c.790+1G>A, p.Arg127His, p.Arg175Pro and p.Cys192Phe were 
analyzed for levels of serum concentration, and all variants, except p.Arg127His, had reduced 
FH serum levels compared to a control group. The coding variants all shown impaired protein 
secretion.49,57 
Variants can be grouped according to effect on the protein function. Type 1 mutations cause 
lower protein expression levels as a result of misfolding or degradation of the protein, in 
contrast to type 2 mutations that result in reduced functionality which is not necessarily 
reflected in protein levels. This distinction is also observed for variants found in CFH. Serum 
concentration of FH and C3 were measured in plasma samples of carriers of 5 CFH variants 
(p.Cys192Phe, p.Tyr277Ter, p.Cys431Ser, and two splice-site variants). For these variants, 
lower FH concentrations were observed in each of the carriers compared to a non-carrier 
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control set,38 and can thus be classified as type 1 mutations. For two other variants, p.Arg175Gln 
and p.Ser193Leu, serum levels were normal but these variants exhibited a reduced ability to 
degrade C3b,45 suggesting that they are type 2 mutations.
Complement factor I
Complement factor I (FI) is a serum serine protease that converts C3b and C4b to their inactive 
form to reduce the formation of the C3 and C5 convertases. Unbound C3b would otherwise 
result in increased C3 convertase formation and feedback amplification of the alternative 
pathway.
Overall, many rare variants in CFI result in lower FI levels in serum and consequently lower 
the regulatory activity of the alternative pathway.27,39 Serum measurements found low FI levels 
for pathogenic variants p.Ala240Gly and p.Gly119Arg compared to non-carriers, while serum 
levels were normal for p.Pro553Ser and p.Arg406His.39 
In an independent study, CFI p.Gly119Arg and p.Gly188Ala resulted in reduced FI levels in 
plasma, which was supported by in vitro analysis of recombinant FI in human cells, showing 
that mutant FI is expressed and secreted at lower levels than wild-type FI.33 Overall plasma 
samples of carriers of the p.Gly119Arg variant showed a lower ability to degrade C3b compared 
to non-carriers, but the ability of recombinant p.Gly119Arg mutant protein to cleave C3b and 
C4b was intact. This suggests that this variant is a type 1 mutation and that low expression 
levels underlie the observed functional effect.33 Similarly, variant p.Leu131Arg in CFI showed 
both impaired FI levels and an inability to properly cleave C3b,45 supporting that is also a 
type 1 mutation. A difficult variant to classify is CFI p.Pro553Ser, which confers risk for AMD 
in multiple studies.39,45 The variant however does not alter system FI levels, is classified by 
prediction software as benign, and showed a lower ability to degrade C3b compared to non-
carriers controls but not non-carriers cases.
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Table 3: Described functional effects of rare variants in the complement system 
Gene Variant (p.) Functional implication Sources
CFH Arg53Cys Reported to possibly affect the local conformation of FH. This 
variant did not affect levels of FH in serum of 22 individuals, 
but showed slightly reduced binding affinity to C3b compared 
to wild type. Marked loss of decay accelerating activity. Trend 
towards lower cofactor activity for FI. 
43
Arg53His Like the 53Cys variant, the 53His variant showed minor 
decreased affinity to bind C3b. Independent of the C3b affinity, 
the variant strongly affected co-factor activity of FI. In addition, 
the variant disrupted decay accelerating activity and was shown 
to correlate to low C3 levels. 
58,59
Asp90Gly No reported effect on FH levels in serum from 22 individuals. 
No effect on C3b binding affinity and decay accelerating activity. 
Significantly reduced cofactor activity for FI
43
Arg127His Reduced FH serum levels in heterozygous and homozygous 
carriers and no secretion of the protein.
49,57,60
Arg175Pro Reduced FH serum levels and no secretion of the recombinant 
protein.
49
Arg175Gln No reported effect on FH levels. Reduced C3b degradation 
ability.
45
Cys192Phe Lower expression of FH and reduced secretion of the protein. 
Normal C3 in plasma of one carrier
38,49
Ser193Leu No reported effect on FH levels. Reduced C3b degradation 
ability.
45
Tyr277Ter Lower expression of FH and normal C3 in plasma of one carrier 38
Arg303Gln Normal plasma levels for FH, FI and C3 61
Gln400Lys Lower FH levels, but no effect on plasma concentrations of C3 
and FB
62
Cys431Ser Lower expression of FH and normal C3 in plasma of one carrier 38
Val609Asp Affects FH expression and resulted in decreased alternative 
pathway activity and C3 level in remission
63
Ser890Ile The variant did not result is differences in FH co-activity with 
FI. The C3b binding was not affected and FH concentration in 
plasma were normal. In addition a hemolytic assay showed 
that the capacity to regulate the alternative pathway on cellular 
surfaces was normal. 
64
Gln950His This variant demonstrated reduced erythrocyte binding and, 
consequently, increased lysis after serum addition to sheep 
erythrocytes. Patient plasma levels of FH were not different 
compared to controls, but transient expression levels of mutant 
lagged behind that of the wild type. No impaired cofactor 
binding for FI was observed and normal complementary 
inhibitory functions were observed.
63,65
Thr956Met No effect on C3 or FH levels in plasma. The lysis of erythrocytes 
was not increased and no effect on protein expression was 
shown.
63,66
Val1007Leu No differences in FH co-activity nor C3b binding; normal 
hemolytic assay (capacity to regulate the alternative pathway 
on cellular surfaces); normal FH in plasma
64
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Asn1050Tyr Abnormal C3 and normal FH levels in serum 67
Gln1076Glu Normal C3 and FH levels in serum 68
Gly1194Asp Slightly increased complement regulatory function of mutant 
FH on cell surfaces (sheep erythrocyte lysis); normal C3 FH and 
FI levels in serum
69,70
Val1197Ala Normal lysis of sheep erythrocytes, low FH and C3 levels, and 
shows low binding to surface bound C3b.
52,71
Arg1203Trp Hemolytic test showed no lysis 63
Arg1210Cys This variant results in a covalent binding to human serum 
albumin which hampers all FH functional domains. It also 
shows reduced binding to heparin and endothelial cells and 
binding to C3b and C3d is also decreased. No effects on 
cofactor activity for FI was reported and no effect on erythrocyte 
lysis was shown.
52-54,72,73 
c.244+2T>C 
splice site
Normal expression of FH and high C3 in plasma of one carrier 38
c.790+1G>A; 
splice site
Lower expression of FH in three carriers and low C3 in plasma 
of one carrier
38,49
CFI Pro50Ala
(Pro32Ala)*
Elevated FB in plasma; normal C3 and FI in plasma; impaired 
function towards degradation of the alpha-chains of C4b and 
C3b in solution when FH was used as cofactor
74
Gly119Arg
(Gly101Arg)*
This variant resulted in reduced FI levels in human serum as 
well as in transient in vitro expression studies. The variant 
resulted in a lower ability to degrade C3b due to impaired 
expression and secretion of the mutant protein.
33,39,45
Leu131Arg
(Gly113Arg)
 The variant resulted in a lower ability to degrade C3b which 
could be due to impaired expression and secretion of the 
mutant protein.
45
Gly188Ala
(Gly170Ala)*
This variant resulted in lower FI levels in human serum as 
well as in transient in vitro expression studies. The variant 
resulted in impaired degradation of C3b.
33
Arg202Ile 
(Arg184Ile)*
This variant had no effect on FI levels in human serum 39
Ala240Gly 
(Ala222Gly)*
This variant resulted in lower or normal FI levels in human 
serum/plasma. The degradation of fluid phase C4b and C3b 
was normal, although the ability to cleave surface-bound C3b 
was impaired. 
39,75,76
Gly261Asp 
(Gly243Asp)*
No effect on FI levels in human serum; slightly different 
migration pattern; normal degradation of C3b and C4b. 
39,77,78
Thr300Ala 
(Thr282Ala)*
No effect on FI levels in human serum 39
Arg317Trp 
(Arg299Trp)*
Normal FI plasma level and normal functioning on hemolytic 
assay; only impaired secretion compared to wildtype FI.
75,76,78
Arg339Gln 
(Arg321Gln)*
Reduced C3, FH, and FB levels, but normal FI levels in serum 63
Ile340Thr 
(Ile323Thr)*
Normal FI and C3 levels in serum 70
Tyr369Ser 
(Ile351Thr)*
Normal FH and C4 levels; low C3 levels in serum 79
Arg406His 
(Arg388His)*
No effect on FI levels in human serum 39
THE COMPLEMENT SYSTEM IN AMD: A REVIEW
57
Ile416Leu 
(Ile398Leu)*
Low FI and C3 serum levels; normal FB levels 74,80
His418Leu 
(His400Leu)*
Homozygous variation results in FI deficiency (low or 
undetectable FI and C3 levels)
81
Lys441Arg 
(Lys423Arg)*
This variant had no effect on FI levels in human serum
 
39,82
Tyr459Ser 
(Tyr441Ser)*
Normal FI and C3 levels in serum 74
Arg474Gln 
(Arg456Gln)*
Normal FI protein level. 63
Arg474Ter 
(Arg456Ter)*
Low FI and C3 serum levels; normal FB levels 74,76,83
Pro553Ser
(Pro535Ser)*
This variant had no effect on FI levels in human serum and 
slightly lower ability to degrade C3b.
39,45
C3 Lys65Gln
(Lys43Gln)*
This variants weakened the interaction of C3b and FH and 
showed reduced MCP binding affinity
84,85
Lys155Gln
(Lys131Gln)*
This variant resulted in significantly reduced cleavage of C3b 
in fluid phase cofactor assays as well as reduced binding to 
FH. MCP cofactor activity was not changed.
26-28,34
Arg161Trp
(Arg139Trp)*
Reduced binding activity of C3b to FH in one study and no 
effect on binding and cleavage of C3 in other studies. MCP 
binding was reduced, FB binding was increased. This variant 
is discussed to be a gain-of-function variant of the convertase 
complex and C3a, C5a, C5b-9 formation was shown to be 
increased.
26-28,34
Arg735Trp
(Arg713Trp)*
This variant showed no functional effects on MCP binding, FI 
cofactor activity, FB binding, CR1 binding and FH binding.
88,89
Leu1549Met 
(Leu1527Met)*
No influence on FH, MCP, or CR1 binding 85
C9 Arg95Ter C9 serum concentration was below the level of detection 90,91
Pro167Ser Median C9 serum concentration was elevated in carriers 
compared to non-carriers
45
Only variants on which functional analysis were done are shown * described in literature without signaling 
peptide Bold: genetic association with AMD through case-control analysis or found in multiple cases of 
within an AMD family
Complement component 3 
Complement factor 3 (C3) is the central player in the activation of the complement system and 
several rare variants in C3 have been investigated functionally (Table 3). 
The C3 p.Lys155Gln variant is located close to the binding site for FH, and its interaction was 
analyzed both in silico and in vitro with matching results. The p.Lys155Gln variant causes 
inefficient binding of C3 with FH and consequently reduces cofactor mediated cleavage of 
C3b.27,92 Variant p.Lys65Gln leads to a decreased binding of FH to C3b and a slightly lowered 
affinity to the membrane cofactor protein (MCP; also known as CD46). The p.Arg161Trp 
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variant increases the affinity to bind to FB and thereby creates an overactive C3 convertase 
accompanied by increased formation of C3a, C5a and C5b-C9. In addition, p.Arg161Trp also 
has reduced binding affinities for MCP and FH, which would otherwise both inactivate C3b/
C4b through co-factor activity with FI.84-86 Variant p.Arg735Trp demonstrated normal MCP, FB, 
sCR1 and FH binding and proper cleavage by FI.88 
Complement component 9
Complement factor 9 (C9) takes part in the formation of the terminal complement complex 
(TCC) comprised of several C5b-9 elements. The TCC can be soluble or it can form a scaffold 
on the surface of the membrane together with multiple (up to 16) C9 proteins to assemble a 
pore-like structure known as the membrane attack complex (MAC) promoting cell lysis.
Recently it was shown that carriers of the C9 p.Pro167Ser variant, associated with an increased 
risk for AMD, have elevated C9 concentrations in serum compared to non-carriers. It was 
hypothesized that increased C9 levels could result in elevated complement activation which, 
through lysis of the cells, may contribute to the degenerative process observed in AMD.45 Asian 
Founder mutation C9 p.Arg95Ter is responsible for most Japanese C9 deficiency cases but is 
simultaneously protective for AMD. It is shown that C9 serum concentrations are low, even 
below detection level,90,91 suggesting that less MAC can be formed which could otherwise 
contribute to retinal damage. 
COMPLEMENT THERAPIES IN AMD
The treatment of neovascular AMD has highly improved with the introduction of anti-
neovascularization therapy with VEGF as the principle target. However, VEGF-based treatment 
is not effective or even not applicable in most AMD patients since only a minority of patients 
suffer from the neovascular form of AMD. Currently, no available treatment is available for the 
majority of AMD patients that suffer from early or intermediate AMD or geographic atrophy. 
Moreover, no effective means other than a modest effect of AREDS supplements to reduce the 
risk of AMD progression is available.93-95 Because of the central role of the complement system 
in AMD, complement inhibition has been considered a potential therapeutic option and several 
clinical trials have been initiated to investigate this possibility (Table 4).96-98 
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Table 4: Clinical trials for AMD targeting the complement system
Drug, trade name 
(company)
Target Status Source
Eculizumab, Soliris  
(Alexion)
Complement 
component 5 
Phase II has been completed 97
Lampalizumab  
(Genentech, Roche)
Complement  
factor D
Phase II has been 
completed; recruitment for 
phase III clinical trial has 
started
96,98
Avacincaptad pegol  
(ARC-1905) 
Zimura (Ophthotech)
Complement 
component 5
Recruitment for II/III clinical 
trial has started.
Clinicaltrials.gov
Tesidolumab , LFG316  
(Novartis)
Complement 
component 5
Recruitment for II/III clinical 
trial has started
Clinicaltrials.gov
CLG561 (Novartis) Properdin Recruitment for phase II 
clinical trial has started
Clinicaltrials.gov
POT4, (Potentia  
Pharmaceuticals and Alcon)
Complement 
component 3
Phase I has been completed. Clinicaltrials.gov
Of the studies that published the outcomes, the COMPLETE study was a phase II clinical trial 
with systemic eculizumab, an humanized IgG antibody that inhibits complement component 5 
(C5). The trial results showed that eculizumab was not effective in the treatment of geographic 
AMD, as the growth of atrophic lesions did not decrease after 6 months of treatment.97 The 
MAHALO study was a phase II clinical trial with lampalizumab, an antibody directed against 
complement factor D. MAHALO showed promising preliminary results: progression of the 
geographic atrophy lesion showed a 20% reduction after 18 months of treatment and it was 
suggested that lampalizumab is most effective in a subpopulation of patients, since an even 
higher reduction rate was seen in patients carrying a specific CFI genotype.96,98 A phase III 
trial with lampalizumab is currently ongoing, which will further investigate the role of the CFI 
genotype on treatment response. 
In summary, a number of clinical trials using complement inhibitors in AMD have been 
performed, or are currently still running. Eculizumab seemed not to be effective, while 
lampalizumab may have a (limited) beneficial effect in reducing AMD progression.
CHAPTER 1B
60
DISCUSSION AND CONCLUSION
Just over a decade after the initial discovery of the involvement of CFH in AMD,19 basic science 
has been translated to experimental approaches where complement inhibitors against AMD 
are now tested in clinical trials. Although the involvement of the complement system in AMD 
has been firmly established, the limited success of these clinical trials seem to suggest that the 
drugs currently tested are not entirely effective in the overall study populations.96 In part this may 
be explained by the fact that, besides the complement system, also other biological systems 
like the extracellular matrix, lipid homeostasis or oxidative stress may contribute substantially 
to AMD pathogenesis.34,94,99 At this time, it is not well understood how these pathways interact 
with each other in the development of the disease. Therefore the complement system is not 
necessarily the only, or even an appropriate target for any given AMD patient.
It is conceivable that a subset of patients would benefit more from anti-complement therapy 
than others, in particular those that have a genetic defect in genes of the complement system. 
It has now been shown that rare genetic variants in complement genes that are genetically 
associated with AMD often negatively impact the functioning of this system.33,38,39,43,45 However, 
does this mean that all AMD patients carrying a rare variant in the complement system will 
benefit from complement inhibitors?
Several issues arise when considering the role of rare variants in AMD. To date only few rare 
variants have been consistently replicated across multiple cohorts.26-28,30,33,34 While some rare 
variants are present relatively abundantly in one population, they are virtually absent in other 
populations, for example p.Arg1210Cys in CFH28,30,100,101 and p.Gly119Arg in CFI.33,39,102,103
Many other potentially interesting variants have been found, illustrated by this review, but very 
large cohorts are required to detect a significant genetic association with AMD.37,104 The question 
arises whether a rare variant is or is not relevant in the context of the disease if it cannot be 
genetically associated with AMD. Functional assays could help clarify if a genetic variant has 
an impact on protein stability or systemic levels. This may provide functional evidence that a 
variant could be involved in the pathogenesis of the disease in the cases where statistical tests 
are underpowered to detect any association.
At this time, patients who carry AMD-associated rare variants proven to have a negative impact 
on function, could be prioritized in clinical trials with complement inhibitors. Across multiple 
cohorts, numerous of such patients have now been identified. Such focused studies would 
offer a proof of principle that could later benefit many more patients that have a defective 
complement system based on functional tests, but carry genetic variants that are too rare to 
be statistically associated with AMD. 
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AMD patients should therefore be screened using a functional complement assay in addition 
to genetic analyses. An exciting future lies ahead in the field of AMD where, for each individual 
patient, genetic evidence and functional tests come together in a treatment plan that is 
personalized and tailored to the specific needs and requirements of that patient.
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CHAPTER 2
ABSTRACT
Importance: Rare variants in the complement genes CFH, CFI, C9 and C3 were found to be 
highly associated with age-related macular degeneration (AMD); however, the effect on clinical 
characteristics and familial segregation by these variants is lacking.
Objectives: To determine the contribution of rare CFH p.Arg1210Cys, CFI p.Gly119Arg, C9 
p.Pro167Ser, and C3 p.Lys155Gln variants in the development of AMD in 22 multiplex families 
and to describe clinical differences in carriers versus non-carriers in these families and a large 
case-control cohort.
Design, setting and participants: This retrospective case-control study included 114 affected 
and 60 unaffected members of 22 multiplex families with AMD as well as 1589 unrelated 
patients with AMD and 1386 unrelated control individuals enrolled in the European Genetic 
Database (EUGENDA). Patients were recruited from March 29, 2006, to April 26, 2013, 
and data were collected from April 20, 2012, to May 7, 2014. All participants underwent an 
extensive ophthalmic examination and completed a questionnaire. Venous blood samples were 
obtained from all participants for genetic analysis, including whole-exome sequencing and 
measurements of complement activation. Data were analyzed from September 23, 2014, to 
November 4, 2015.
Main Outcome Measures: Differences between carriers and noncarriers of rare variants in age 
at onset of symptoms, the family history of AMD, complement activation levels (C3d/C3 ratio), 
the presence of reticular pseudodrusen, and AMD phenotype.
Results: Among the 114 affected and 60 unaffected members of 22 multiplex families with 
AMD and the 1598 unrelated patients with AMD and 1386 controls in the EUGENDA cohort who 
underwent analysis, the presence of the CFI p.Gly119Arg, C9 p.Pro167Ser, or C3 p.Lys155Gln 
variant was confirmed in 18 individuals in 5 families but did not completely segregate with the 
disease. In the case-control cohort, the 91 affected carriers of these variants were younger 
at symptom onset (mean [SD] age, 67.4 [8.5] versus 71.3 [8.9] years; P = .01) and more often 
reported a positive family history (35 of 79 [44.3%] versus 367 of 1201 [30.6%]; P = .008) 
compared with the 1498 noncarriers. Patients with advanced atrophic AMD carried these rare 
variants more frequently than patients with neovascular AMD (11 of 93 [11.8%] versus 40 of 835 
[4.8%]; P = .04).
Conclusions and relevance: Previously reported rare variants do not completely segregate 
within families with AMD. However, patients carrying these rare variants differ clinically from 
non-carriers by an earlier age at symptom onset, higher prevalence of a positive family history, 
and by AMD phenotype. These results suggest that genetic tests for AMD might be designed 
to detect common and rare genetic variants, especially in families, because rare variants 
contribute to the age at onset and progression of the disease. 
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of irreversible, central visual 
loss in the elderly population in developed countries.1 A combination of genetic and non-
genetic factors plays a role in the development and progression of this multifactorial disease.2,3 
Genome-wide association studies have identified common genetic risk variants that are 
strongly associated with AMD, such the p.Tyr402His (rs1061170) variant in the complement 
factor H (CFH) gene (HGNC 4483), and the p.Ala69Ser (rs10490924) variant in the age-related 
maculopathy susceptibility 2 (ARMS2) gene (HGNC 32685).2,4,5
Previous family- and twin-studies have demonstrated a strong genetic component and 
aggregation of AMD within families.6-9 Approximately 20-30% of the patients have a positive 
family history for AMD,7,10-12 which has been reported as a significant risk factor for AMD. A 
positive family history also has been associated with an earlier age at onset of disease.13-17 
Clustering of known common genetic risk factors does not fully explain the number of affected 
family members in large, densely affected families.7 Several recent studies have identified rare 
genetic variants, that strongly increase the risk for AMD, including CFH p.Arg1210Cys, CFI 
(HGNC 5394) p.Gly119Arg, C9 p.Pro167Ser (HGNC 1358), and C3 (HGNC 1318) p.Lys155Gln.15,18-21 
These rare variants are located in genes of the complement system, which plays a major role 
in the pathogenesis of AMD.2,22 Owing to their strong effect size, these rare, highly penetrant 
genetic variants may account for clustering of AMD in families and lead to more severe 
disease. Highly penetrant variants have been identified in families with AMD, thus confirming 
the hypothesis that rare variants cluster in families.15-17 Understanding the contributions of 
these rare variants to the clinical characteristics of AMD is important because carriying these 
variants may have diagnostic, predictive and therapeutic consequences for carriers.
The aim of the present study was to determine the contribution of known rare genetic variants 
in the development of AMD in large, multiplex families with AMD. In addition, we aimed to 
describe differences in clinical characteristics in carriers compared with non-carriers of these 
rare genetic variants, in families and a large case-control cohort.
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METHODS
Participants
In this retrospective study, we evaluated 114 affected and 60 unaffected members of 22 
multiplex families with AMD. In addition, we analyzed a case-control cohort of 1589 unrelated 
patients with AMD and 1386 unrelated control individuals from the European Genetic 
Database (EUGENDA). This study was approved by the local ethics committees of Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen and University Hospital Cologne on 
research involving human participants, and met the criteria of the Declaration of Helsinki.23 
Before enrollment in EUGENDA, all participants provided written informed consent and 
completed a detailed questionnaire on their medical history, age at onset of first symptoms, 
family history of AMD, and lifestyle factors. For the case-control cohort, a family history positive 
for AMD was defined as at least two first-degree relatives (parents and/or siblings) with AMD 
or possible AMD. 
Patients were recruited from March 29, 2006, to April 26, 2013, and data were collected from 
April 20, 2012, to May 7, 2014. Each participant of the EUGENDA cohort, and all members 
of the 22 families, underwent digital color fundus photography and spectral-domain optical 
coherence tomography (OCT, Spectralis; Heidelberg Engineering, Heidelberg, Germany) after 
pupillary dilation. Digital non-stereoscopic 30° color fundus photography centered on the 
fovea was performed (TRC 50IX camera; Topcon Corporation, Tokyo, Japan). Spectral-domain 
OCT volume scans consisted of 19 or 37 parallel OCT B-scans for analysis, which covered a 
macular area of 6x4 mm. For each OCT B-scan, 20 images were averaged using the automated 
real-time function.24_ENREF_21 Color fundus photographs and OCT scans of both eyes of 
all individuals were evaluated by two independent certified reading center graders, including 
one of us (T.S.), according to the standard protocol of the Cologne Image Reading Center 
and Laboratory (CIRCL).24 We classified AMD by the presence of pigmentary changes with at 
least 10 small drusen (diameter, <63 µm) or the presence of intermediate (diameter, 63-124 
µm) or large (diameter, ≥125 µm) drusen in the Early Treatment Diabetic Retinopathy Study 
grid. Advanced AMD was defined as AMD with subfoveal geographic atrophy (GA) or choroidal 
neovascularization (CNV) in at least one eye. Age at onset of AMD was defined as the age at 
which the first visual symptoms occurred. Controls were classified as having no abnormalities 
or only small drusen or pigmentary abnormalities, and were 60 years or older. In addition, 
in 479 individuals, infrared images and spectral domain OCT images were evaluated for the 
presence of reticular pseudodrusen by one of us (TS). 
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Genotyping
Whole exome sequencing was used to genotype 85 affected members of 22 multiplex families 
with AMD. The samples were sequenced at the Erasmus Medical Center using DNA obtained 
from venous blood after extraction using standard procedures. The DNA was fragmented using 
shearing according to the manufacturer’s instructions (Adaptive Focused Acoustics; Covaris, 
Inc., Woburn, MA), and a DNA library preparation kit (Kapa Biosystems, Inc., Wilmington, 
MA) was used on sequencer workstation (Sciclone NGs; Caliper Life Sciences, Hopkinton, 
MA). Exome capture was achieved using an exome solution kit (Nimblegen SeqCap EZ V2; 
Roche Nimblegen, Inc., Madison, WI), designed to capture more than 44 Mb of exonic regions. 
Paired-end 2 ×100 sequencing was performed on a device (HiSeq2000; Illumina, Inc) using 
a reagent kit (TruSeq V3; Illumina, Inc.). Downstream analyses included demultiplexing 
(CASAVA software, Illumina) and alignment to the hg19 reference genome (Genome Reference 
Consortium Human Reference25 [http://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.25/]) 
by Burrows-Wheeler alignment tool.26 Alignments were sorted by Picard (http://broadinstitute.
github.io/picard) and subsequently processed using the Genome Analysis Toolkit (GATK)(indel 
realignment and Base-Quality Score Recalibration).27 Finally, polymerase chain reaction 
duplicates were marked by Picard, mean depth of coverage was determined using GATK, and 
Freemix values were estimated through verifyBAMid.28 Samples that passed technical quality 
control metrics were genotyped to genomic variant format level through the GATK haplotype 
caller. Insertions, deletions, and single nucleotide variants were filtered separately using the 
GATK Variant-Quality Score Recalibration, and annotated using the ANNOVAR tool.29 
We used filtering steps to select the previously associated variants in the CFH (p.Arg1210Cys; 
rs121913059), CFI (p.Gly119Arg; rs141853578), C9 (p.Pro167Ser; rs34882957) genes and 
C3 (Lys155Gln; rs147859257) from the exome files of the 85 affected family members. The 
annotation of the identified variants was confirmed by Sanger sequencing using primers 
designed with Primer3 software (http://primer3.ut.ee) (eTable 1). The variants were also 
analyzed in the patients of the index families of whom exome sequencing was not available 
(n=15) using Sanger sequencing.
Genotyping of the rare CFH p.Arg1210Cys, CFI p.Gly119Arg, C9 p.Pro167Ser, and C3 p.Lys155Gln 
genetic variants was performed in all 2975 included participants of the EUGENDA case-control 
cohort. Genotyping of the CFI p.Gly119Arg variant was performed using a custom-made assay 
(TaqMan; Life Technologies), as described previously.18 Genotyping of the CFH p.Arg1210Cys, 
C9 p.Pro167Ser and C3 p.Lys155Gln variants was performed by competitive, allele-specific, 
polymerase chain reaction assays (KASP SNP Genotyping System; LGC Group) for CFH as 
previously described30 and C9, C3, according to the manufacturers’ recommendations (eTable 2).
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Complement measurements
Levels of complement component C3 and the activation fragment C3d were measured in 
serum samples as described previously.31 The C3d/C3 ratio was calculated as a measure of 
complement activation,32 and is a strong marker for AMD.29 For the statistical analysis the C3d/
C3 ratio underwent natural logarithm transformation.
Statistical analysis
Data were analyzed from September 23, 2014, to November 4, 2015. The odds ratio (OR) of 
the presence of a rare variant for AMD was calculated by binary logistic regression analysis. 
Statistical analyses were performed to study differences in age at symptom onset, complement 
activation levels, family history of AMD, and AMD subtype between carriers and non-carriers 
of the rare CFI p.Gly119Arg, C9 p.Pro167Ser or C3 p.Lys155Gln variants. We analyzed the mean 
values of the continuous traits, complement activation levels, and age at first symptoms using 
independent sample t-tests and compared the mean value using the Pearson’s chi-square 
test for the other variables. Data were analyzed using SPSS Software version 20.0 (SPSS Inc., 
Chicago, IL).
RESULTS
The rare variants CFI p.Gly119Arg, C9 p.Pro167Ser and C3 p.Lys155Gln were observed in 18 
individuals in five of the 22 multiplex families with AMD. Although these variants aggregated 
within these families, they did not segregate completely with the disease (Figure 1). The CFH 
p.Arg1210Cys variant was not observed in any of the 22 families. 
The CFI p.Gly119Arg variant was detected in one family (Figure 1, family A). Of the four affected 
individuals, three were carriers of the CFI p.Gly119Arg variant. Affected individual II:4 lacked 
the CFI p.Gly119Arg variant but carried the CFH p.Tyr402His risk allele homozygously. The 
youngest unaffected individual (64 years) carried the risk conferring CFI variant. In family B 
(Figure 1, family B), two rare variants, C9 p.Pro167Ser and C3 p.Lys155Gln, were identified 
heterozygously. Although both variants were found only in affected individuals, neither variant 
segregated fully with the disease phenotype. The C3 p.Lys155Gln variant was found to cluster 
in two additional families (Figure 1, families C and D). In family C, the C3 p.Lys155Gln variant 
was detected in two affected individuals (II:2 and II:4), who also carried the ARMS2 p.Ala69Ser 
and CFH p.Tyr402His risk alleles homozygously. Individuals II:1 and II:3 were had intermediate 
AMD without carrying the rare variant in C3, and were heterozygous for the common ARMS2 
p.Ala69Ser and CFH p.Tyr402His risk alleles. In family D, five individuals carried the C3 
p.Lys155Gln variant, of whom four had AMD and one did not (II:8). Individuals II:6 and II:7 
carried the C3 variant and were diagnosed as having intermediate AMD. Their older siblings 
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II:4 and II:5 who did not carry the rare variant did not develop AMD, although they had a higher 
genotypic load of the two common variants. In addition to family B, the C9 p.Pro167Ser variant 
was also identified in family E (Figure 1, family E). Two affected individuals carrying the variant 
had a more advanced AMD stage than the affected non-carrier family members.
Within the five families, rare variants were detected in 16 affected individuals and 2 unaffected 
individuals (Table 1). Carrying one of the variants in CFI, C9 or C3 resulted in an OR of 7.11 for 
AMD (95% CI 1.23-40.98; P = 0.03). 
The age at symptom onset was earlier in affected family members who carried the rare CFI 
p.Gly119Arg, C9 p.Pro167Ser, or C3 p.Lys155Gln variants, compared with affected non-carriers 
(64 versus 69 years; P = 0.25)(Figure 2). The complement activation level (C3d/C3 ratio) was 
higher in affected family members who carried a rare variant in a complement gene compared 
to non-carriers (1.43 and 1.18, respectively; P = 0.05)(Figure 2). Most patients graded as 
advanced AMD carried a rare variant. This finding holds true for the single patient with GA and 
five of the patients with CNV (P = 0.17).
Five of 25 affected family members showed an AMD phenotype with reticular pseudodrusen, 
and all 5 patients carried the rare CFI p.Gly119Arg, C9 p.Pro167Ser, or C3 p.Lys155Gln variant. 
Carrying one of these variants was associated with developing reticular pseudodrusen (P = 0.02). 
The p.Pro167Ser variant in the C9 gene appeared to segregate with the reticular pseudodrusen 
phenotype in the family E, because individuals II:2 and II:3, who carried the rare variant, showed 
reticular pseudodrusen, whereas II:1 and II:4 did not. However, the rare variants in the CFI and 
C3 genes did not segregate with the reticular drusen phenotype. Individual II:1 of family A, and 
individuals II:2 and II:6 of family D, showed the reticular pseudodrusen phenotype, but this 
phenotype was not observed in their siblings who carried the same rare variant.
Next, the analyses were replicated in a large case-control EUGENDA cohort, which was 
genotyped for the rare variants CFH p.Arg1210Cys, CFI p.Gly119Arg, C9 p.Pro167Ser, and C3 
p.Lys155Gln. Of the 1589 patients and 1386 controls in the case-control cohort, we identified 91 
carriers (5.7%) in the AMD cohort and 43 carriers (3.1%) in the control cohort of the (Table 1). 
The CFH p.Arg1210Cys variant was not present in our case-control cohort.
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Figure 1: Pedigrees of 5 families with age-related macular degeneration. Pedigrees depict results of 
segregation analysis of rare and common CFH p.Tyr402His and ARMS2 p.Ala69Ser variants in patients with 
the rare CFI p.Gly119Arg, C9 p.Pro167Ser, or C3 p.Lys155Gln variants of complement factor genes. Risk 
alleles are indicated in red. Affected individuals are assigned grades representing AMD stage (1 indicates 
early; 2, intermediate; 3, advanced with subfoveal geographic atrophy; and 4, advanced with choroidal 
neovascularization). Outer circles mark the individuals who underwent whole-exome sequencing.
99
RARE GENETIC VARIANTS ASSOCIATED WITH DEVELOPMENT OF AMD
3.0
2.5
2.0
1.5
1.0
0.5
90
80
70
60
50
40 Noncarriers
Ag
e 
at
 O
ns
et
, y
Carriers
Five families with AMDA P =.25
P =.05 P =.85
P =.01
0 NoncarriersC
om
pl
em
en
t 
A
cti
va
ti
on
, I
n 
(C
3d
/C
3)
Carriers
NoncarriersCarriers
EUGENDA cohortB
NoncarriersCarriers
90
80
70
60
50
40
Ag
e 
at
 O
ns
et
, y
3.0
2.5
2.0
1.5
1.0
0.5
0Co
m
pl
em
en
t 
A
cti
va
ti
on
, I
n 
(C
3d
/C
3)
Figure 2: Age at onset and complement activation in carriers versus noncarriers of rare genetic variants. 
Analysis was performed in the members of 5 families with age-related macular degeneration (AMD) and 
in AMD cases and controls from the European Genetic Database (EUGENDA) cohort. The difference in 
age at onset between carriers and noncarriers was not significant in the families (mean [SD] age, 63.9 
[10.3] versus 69.4 [7.1] years) but was significant in the EUGENDA cohort (67.4 [8.5] vs 71.3 [8.9] years). 
The complement activation ratio between carriers and noncarriers in the families (1.43 versus 1.18) and 
EUGENDA cohort (1.463 vs 1.455) was not significant. Lines indicate mean values. Ln = natural logarithm.
The presence of a rare genetic variant was associated with AMD and conferred an OR of 1.90 
(95% CI 1.31-2.75; P = 0.001). This association was comparable with the OR for advanced AMD 
(OR 1.90; 95% CI 1.27-2.85; P = 0.002). Separate analyses for each rare variant showed large 
effect sizes for the CFI p.Gly119Arg variant (OR 11.38; 95% CI 1.49-87.06; P = 0.003), whereas 
the effect sizes for the C9 p.Pro167Ser variant (OR 1.54; 95% CI 0.96-2.45; P = 0.07) and the 
C3 p.Lys155Gln variant (OR 1.81; 95% CI 0.96-3.44; P = 0.06) were smaller (Table 2). Patients 
with AMD who carried the rare CFI p.Gly119Arg, C9 p.Pro167Ser or C3 p.Lys155Gln variant 
reported a positive family history for AMD more often than patients with AMD who did not carry 
these rare variants (35 of 79 [44.9%] versus 367 of 1201 [30.6%], respectively P = 0.008). This 
difference in positive family history was the largest for carriers of the CFI p.Gly119Arg variant 
(58.3% vs 30.6%, P = 0.04), followed by variant p.Pro167Ser in C9 (44.7% vs 30.6%, P = 0.04)
(eTable 3). 
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In addition, an earlier age at symptom onset was found in patients with AMD with the rare 
CFI p.Gly119Arg, C9 p.Pro167Ser, or C3 p.Lys155Gln variant than in patients who did not carry 
these rare variants (mean [SD] age, 67.4 [8.5] versus 71.3 [8.9] years, respectively; P = .01) 
(Table 1 and Figure 2). In individuals carrying a rare variant, the mean complement activation 
level (ln C3d/C3) was higher in cases compared with controls (P < 0.001). In contrast, the mean 
C3d/C3 ratio in patients with AMD who carried one of the rare variants was not different from 
that of non-carriers of these variants (P = 0.85)(Figure 2). In patients with advanced AMD, the 
rare CFI p.Gly119Arg, C9 p.Pro167Ser, and C3 p.Lys155Gln variants were present more often 
in patients with GA (11 of 93 [11.8%]) than in patients with CNV (40 of 835 [4.8%]; P = .04). A 
reticular pseudodrusen phenotype was present in 59 of 202 AMD patients and none of the 183 
controls (Table 1). No association was found between the presence of reticular pseudodrusen 
and the presence of one of these rare variants in the large AMD cohort (P = 0.80).
Table 2. Frequencies and effect sizes of the rare variants in the EUGENDA cohort.
Rare variant of 
Complement Gene
No. (%) of Participants OR (95% CI) P-value
Patients Carriers 
 (n = 1589)
Control Carriers  
(n = 1386)
CFI p.Gly119Arg 13 (0.8) 1 (0.1) 11.38 (1.49 - 87.06) 0.003
C9 p.Pro167Ser 49 (3.1) 28 (2.0) 1.353 (0.96 - 2.45) 0.07
C3 p.Lys155Gln 29 (1.8) 14 (1.0) 1.841 (0.96 - 3.44) 0.06
CFH p.Arg1210Cys 0 (0) 0 (0) - -
Abbreviations: EUGENDA = European Genetic Database; OR = odds ratio.
DISCUSSION
The development of AMD in densely affected families can be influenced by rare genetic variants, 
of which four (CFH p.Arg1210Cys, CFI p.Gly119Arg, C9 p.Pro167Ser, and C3 p.Lys155Gln) were 
previously associated with AMD.15,18-21 In our EUGENDA case-control cohort, the presence of a 
variant resulted in an OR of 1.90 for AMD, which is comparable with previously reported effect 
sizes for the C9 p.Pro167Ser and C3 p.Lys155Gln variants.15,18-21 However, the effect size of 
the p.Gly119Arg variant in the CFI gene was much stronger, with an OR of 11.38, which is in 
line with those of previous reports (ORs 8.5 and 22.2).18,33 The CFH p.Arg1210Cys variant was 
previously associated with AMD in North-American cohorts,15,20 but not in Icelandic19 and Han 
Chinese cohorts.34 The absence of this variant in our AMD case-control cohort may reflect the 
different distribution of low-frequency alleles among populations.30
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Almost half of the patients who carried one of the rare CFI p.Gly119Arg, C9 p.Pro167Ser variants 
or C3 p.Lys155Gln a positive family history reported for AMD, which has important implications 
for counseling of these patients and their family members, and underlines the importance of 
including these rare variants in genetic tests for AMD. 
Despite their strong association with AMD in case-control cohorts,18-21 the CFI p.Gly119Arg, 
C9 p.Pro167Ser and C3 p.Lys155Gln variants did not segregate with the disease in the five 
families in this study. This could point to the contribution of other genetic risk alleles and 
environmental factors in such multiplex families. Further research is warranted to determine 
whether additional rare variants aggregate in the remaining 17 families with AMD in this study. 
Patients who carry a known rare genetic variant differ clinically from patients who do not. We 
demonstrated that carriers of the rare CFI p.Gly119Arg, C9 p.Pro167Ser or C3 p.Lys155Gln 
variants have an onset of symptoms 4-year-earlier, of which the CFI p.Gly119Arg variant shows 
the strongest effect. This finding is comparable to the earlier onset previously described in 
patients carrying the rare p.Arg1210Cys variant in the CFH gene15 and is in line with the ealier 
age at symptom onset in patients with familial AMD.14 
Many of the common genetic variants associated with AMD reside in genes encoding 
components of the complement cascade,2,4,35-37 some of which have been associated with 
increased systemic levels of complement activation and complement components.25,31,38 Nearly 
all the recently identified rare variants are located in complement genes,15,17-21, 39-41 enphasizing 
the important role of the complement system in the pathophysiology of AMD. Mean complement 
activation levels were slightly higher in patients with AMD who carry rare variants CFI, C9, 
or C3 gene compared to non-carriers, but this difference in complement activation levels 
cannot be explained by the presence of the rare variants evaluated in this study. Preventive and 
therapeutic options inhibiting the complement cascade have been suggested to be effective in 
treating AMD,42 but our current results do not support the hypothesis that subjects who carry a 
rare variant in a complement gene will benefit more from such treatments than non-carriers. 
However, complement inhibition is a promising target for treatment of GA in AMD,43 which is 
more prevalent in affected carriers than non-carriers.
In this study rare variants were more frequently identified in patients with advanced AMD and 
GA than advanced AMD with CNV. This finding is in line with that of a recent study,44 which 
observed higher prevalence of GA among patients carrying the CFH p.Arg1210Cys variant. 
A previously investigation,14 suggested that additional genetic factors may contribute to the 
development of GA in familial patients, because a higher prevalence of GA was found in familial 
than sporadic AMD cases, and siblings are more likely to develop the same advanced AMD 
subtype as their family proband.32 The findings of the current study are thus consistent with our 
suggestion that additional genetic factors play a role in GA development.14
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From these findings we recommend that patients of European descent, in densely affected 
families with AMD, undergo screening for rare CFI p.Gly119Arg, C9 p.Pro167Ser and C3 
p.Lys155Gln variants, because these rare variants play a role in more than 20 percent of our 
screened families. However, these associations may not hold true within populations of other 
antecedents, because different rare variants in these populations, may play a more important 
role, such as for example CFH p.Arg1210Cys in the North American population.19 
We observed a higher familial occurrence and an earlier age at onset in the carriers of the 
rare genetic CFI p.Gly119Arg, C9 p.Pro167Ser and C3 p.Lys155Gln variants. These findings 
emphasize the importance of counseling of patients and family members to increase awareness 
and enable early detection of the disease. Genetic tests for AMD should therefore be designed 
to detect, in addition to the common variants, the described rare genetic variants, especially 
in families, because these rare variants contribute to the age at onset and progression of the 
disease. 
Earlier presentation: this study was presented orally during the ‘Molecular biology of 
AMD’ session at: the 2015 Annual Meeting of the Association for Research in Vision and 
Ophthalmology, May 3–7, 2015, Denver, Colorado.
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SUPPLEMENTARY INFORMATION
eTable 1. Primer sets used to amplify and Sanger sequence the rare variants in five AMD families
Primer Primer sequence Annealing 
temperature (°C)
Product length 
(basepairs)
CFI Gly119Arg forward CGTAAAATGATTGCTTACTATTACTTG 57.1 431
CFI Gly119Arg reverse TGATGCACATAGTTAATTTTCTTAGG 58.0
C9 Pro167Ser forward ACGGTGACATGAACTGAAGC 58.7 388
C9 Pro167Ser reverse CCAAACTACATCGCCTCTTC 57.4
C3Lys155Gln forward AGATCCGGAAGCTGGACC 60.2 444
C3Lys155Gln reverse TTGCCTCTCCTAAGCCTGTG 60.5
CFH Tyr402His forward TCTTTTTGTGCAAACCTTTGTTAG 59.7 469
CFH Tyr402His reverse CCATTGGTAAAACAAGGTGACA 59.8
ARMS2 Ala69Ser forward ATGCCACCCACAACAACTTT 60.3 403
ARMS2 Ala69Ser reverse GGTTCTCTCGCTGAGATTCG 60.1
eTable 2. KASPAR assays used for genotyping the rare variants in EUGENDA case-control cohort
ID C9_rs34882957 C3_rs147859257
Primer_AlleleFAM CATTGTCAAAAGGTGTGCTTAGGGA GGATCTTCACCGTCAACCACC
Primer_AlleleHEX GTCAAAAGGTGTGCTTAGGGG CGGATCTTCACCGTCAACCACA
Primer_Common TTCTCAGGATCAACATTTTAGGGATGGAT ACCGTCCGGCCCACGGGTA
eTable 3. Quantitative traits for each of the rare variants in the EUGENDA case-control cohort
Rare variant Mean age 
at onset in 
carriers vs 
non-carriers 
(years)
P-value Familial 
occurance in 
carriers vs 
non-carriers  
(%)
P-value Mean 
complement 
ratio in carriers 
vs non-carriers
P-value
CFI p.Gly119Arg 58.7 vs 71.3 0.005 58.3 vs 30.6 0.038 1.670 vs 1.463 0.125
C9 p.Pro167Ser 69.1 vs 71.3 0.225 44.7 vs 30.6 0.040 1.442 vs 1.463 0.325
C3 p.Lys155Gln 66.5 vs 71.3 0.127 36.6 vs 30.6 0.556 1.486 vs 1.463 0.745
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ABSTRACT
Importance: In age-related macular degeneration (AMD), rare variants in the complement 
system have been described, but their functional consequences remain largely unexplored.
Objectives: To identify new rare variants in complement genes and determine the functional 
effect of identified variants on complement levels and complement regulation in serum 
samples from carriers and noncarriers.
Design, setting and participants: This study evaluated affected (n = 114) and unaffected (n = 
60) members of 22 families with AMD and a case-control cohort consisting of 1831 unrelated 
patients with AMD and 1367 control individuals from the European Genetic Database from 
March 29, 2006, to April 26, 2013, in Nijmegen, the Netherlands, and Cologne, Germany. 
Exome sequencing data of families were filtered for rare variants in the complement factor H 
(CFH), complement factor I (CFI), complement C9 (C9), and complement C3 (C3) genes. The 
case-control cohort was genotyped with allele-specific assays. Serum samples were obtained 
from carriers of identified variants (n = 177) and age-matched noncarriers (n = 157). Serum 
concentrations of factor H (FH), factor I (FI), C9, and C3 were measured, and C3b degradation 
ability was determined.
Main Outcome Measures: Association of rare variants in the CFH, CFI, C9, and C3 genes with 
AMD, serum levels of corresponding proteins, and C3b degradation ability of CFH and CFI 
variant carriers.
Results: The 1831 unrelated patients with AMD had a mean (SD) age of 75.0 (9.4) years, and 
60.5% were female. The 1367 unrelated control participants had a mean (SD) age of 70.4 (7.0), 
and 58.7% were female. All individuals were of European descent. Rare variants in CFH, CFI, 
C9, and C3 contributed to an increased risk of developing AMD (odds ratio, 2.04; 95% CI, 1.47-
2.82; P < .001). CFI carriers had decreased median FI serum levels (18.2 µg/mL in p.Gly119Arg 
carriers and 16.2 µg/mL in p.Leu131Arg carriers versus 27.2 and 30.4 µg/mL in noncarrier 
cases and controls, respectively; both P < .001). Elevated C9 levels were observed in p.Pro167Ser 
carriers (10.7 µg/mL versus 6.6 and 6.1 µg/mL in noncarrier cases and controls, respectively; 
P < .001). The median FH serum levels were 299.4 µg/mL for CFH p.Arg175Gln and 266.3 µg/
mL for CFH p.Ser193Leu carriers versus 302.4 and 283.0 µg/mL for noncarrier cases and 
controls, respectively. The median C3 serum levels were 943.2 µg/mL for C3 p.Arg161Trp and 
946.7 µg/mL for C3 p.Lys155Gln carriers versus 874.0 and 946.7 µg/mL for noncarrier cases 
and controls, respectively. The FH and FI levels correlated with C3b degradation in noncarriers 
(R2 = 0.35 and R2 = 0.31, respectively; both P < .001).
Conclusions and relevance: Reduced serum levels were associated with C3b degradation in 
carriers of CFI but not CFH variants, suggesting that CFH variants affect functional activity of FH 
rather than serum levels. Carriers of CFH (p.Arg175Gln and p.Ser193Leu) and CFI (p.Gly119Arg 
and p.Leu131Arg) variants have an impaired ability to regulate complement activation and may 
benefit more from complement-inhibiting therapy than patients with AMD in general.
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INTRODUCTION
Age-related macular degeneration (AMD) is caused by a combination of environmental and 
genetic factors. Although aging and smoking confer the strongest non-genetic risk, genetic 
alterations account for 45% to 70% of the variability in disease risk.1 Genetically, AMD is 
heterogeneous, with 34 genomic loci implicated in disease pathogenesis. Susceptibility genes 
that reside in these loci are grouped into 4 main pathways: (1) complement system, (2) high- 
density lipoprotein metabolism, (3) angiogenesis, and (4) extracellular matrix remodeling.2,3
The complement system is part of the innate immune system, and tight regulation of this 
system is needed to protect the body’s own cells from tissue damage. The central component 
of the system is C3, which is cleaved into C3b and C3a. C3b is a crucial component of C3 and 
C5 convertases that catalyze further steps in the cascade. The final step is the formation of 
the membrane attack complex, which includes several copies of C9. Factor H (FH) is one of 
the main inhibitors of complement through binding of C3b and aiding its degradation by serine 
protease factor I (FI).4,5
In AMD, the complement system is highly burdened by genetic variations.6 Most of these 
genetic variants are relatively common in the population and have a modest to low effect on 
AMD development.3 Recently, rare genetic variants (defined by a minor allele frequency <1%) 
in the complement system were also described to play an important role in AMD. Such rare 
variants were described in the complement factor H (CFH) (NM_000186),7-10 complement factor 
I (CFI) (NM_000204),11,12 complement factor 9 (C9) (NM_001737),12 and complement factor 3 (C3) 
(NM_000064) genes.12-15 Carriers of these rare genetic variants presented with a younger age at 
disease onset and more often progressed to end-stage AMD compared with noncarriers.10,16-19
Only a limited number of studies10-12,18-21 have investigated functional effects of rare variants 
on activity of the affected protein and the complement system overall. The reported effects of 
rare CFH variants on FH levels are inconsistent. Although one study19 reported reduced serum 
FH levels in rare variants carriers, others10,20 did not observe this effect. Lower FI serum and 
plasma levels were found in carriers of CFI variants compared with controls.11,18 In addition, 
the CFI variant p.Gly119Arg resulted in a lower ability to degrade C3b.11 Similarly, carriers of 
the rare variant p.Lys155Gln in C3 had reduced C3b cleavage.12 The C3 variant p.Arg161Trp 
was reported to affect the ability of FH to inhibit C3 convertase.21 C9 variants were previously 
associated with AMD12,22; however, the functional effect of these variants has not been studied.
In this study, we aimed to identify novel rare genetic variants in complement genes previously 
associated with AMD. We intended to determine the effect of rare genetic variants on levels of 
complement components in serum and analyze the ability to degrade C3b in serum samples 
from rare variant carriers compared with noncarriers.
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METHODS
Participants
We evaluated 22 severely affected AMD families with at least 4 affected siblings, resulting in 114 
affected and 60 unaffected family members, from March 29, 2006, to April 26, 2013, in Nijmegen, 
the Netherlands, and Cologne, Germany. In addition, 1831 unrelated patients with AMD and 
1367 unrelated control individuals from the European Genetic Database (EUGENDA) were 
studied. Control individuals were 60 years or older. All patients underwent clinical evaluation 
and were graded for AMD according to the Cologne Image Reading Center protocol.17,23 Serum 
samples were obtained by a standard coagulation and centrifugation protocol, after which they 
were stored at −80°C within 1 hour after collection. Genomic DNA was isolated from peripheral 
blood samples according to standard procedures. This study was approved by local ethics 
committees on research involving human subjects, namely, the Commissie Mensgebonden 
Onderzoek Regio Arnhem- Nijmegen and the local committee of University Hospital Cologne, 
and met the criteria of the Declaration of Helsinki.24 Before enrollment in EUGENDA, all 
participants provided written informed consent and were assigned a database identifier code 
for anonymization.
Genetic Analysis
Whole exome sequencing analysis was implemented to uncover the coding regions (the 
Supplementary information) of selected complement genes previously reported to harbor rare 
variants associated with AMD, namely, CFH, CFI, C9, and C3.7-15 From the candidate genes, we 
selected variants that would induce an amino acid change. Frequency filters from the public 
databases 1000 Genomes Project and Exome Variant Server database ensured selection of 
rare variants only. Variants with a minor allele frequency less than 1% were considered rare. 
Variants found in multiple individuals were selected for Sanger sequencing as confirmation 
and segregation. Primer sets used for Sanger sequencing were designed manually using 
Primer3Plus.25 Predicted effect of each variation was examined using PolyPhen2 and SIFT 
(Sorting Intolerant From Tolerant).26,27
Genotyping
Genotyping of rare genetic variants CFH p.Ser193Leu, CFH p.Arg175Gln, CFI p.Pro553Ser, 
CFI p.Leu131Arg, C9 p.Arg118Trp, and C3 p.Arg161Trp was performed for participants of the 
EUGENDA case-control cohort by custom-made competitive allele-specific polymerase chain 
reaction assays (Kompetitive Allele Specific Single-Nucleotide Polymorphism Genotyping 
System; LGC Ltd) according to the manufacturer’s recommendations.
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Selection of Serum Samples
We collected serum samples of rare variant carriers (n = 157) and available family members 
(n = 93). Two comparison groups with similar mean age had available serum samples: (1) 77 
patients with AMD who did not carry any of the selected variants and (2) 80 control individuals 
who did not have any of the selected variants. The total number of serum samples encompassed 
407, of whom 201 individuals carry a rare variant.
Functional Analysis
The concentrations of FH, FI, C9, and C3 in serum samples were measured by enzyme-linked 
immunosorbent assay in triplicate.28 In addition, the degradation of C3b in fluid phase was 
analyzed to assess how CFH and CFI variants affect the proteins’ ability to degrade C3b in the 
fluid phase. Details are in the supplementary information.
Statistical Analysis
Because of the low frequency of rare variants, asymptotic statistics can be inaccurate. 
Therefore, we used exact statistics to test association for individual variants. This analysis 
in- cluded an aggregate meta-analysis, which included close family members. To include the 
first-degree siblings (second- degree siblings for families A and E), we calculated statistical 
significance using a binominal distribution. When family members were included, the chance 
for siblings to inherit similar rare genetic variation was 50%. The calculation of this statistical 
aggregation score has been replicated as described in detail by Raychaudhuri et al7 and a 
previously rare variant analysis.12
Serum levels and carrier status were analyzed using Kruskal-Wallis with the Dunn post 
hoc comparison adjustment. Within figures, median values with interquartile ranges are 
depicted, and differences at P < .05 were considered statistically significant. For correlations, 
the covariates AMD status and rare variant status were included. Spearman ρ correlation 
coefficient was used for nonparametric correlations, and P values were evaluated using 
Bonferroni correction (P < .007 was considered significant).
RESULTS
The 1831 unrelated patients with AMD had a mean (SD) age of 75.0 (9.4) years, and 60.5% were 
female. The 1367 unrelated controls had a mean (SD) age of 70.4 (7.0), and 58.7% were female. 
All individuals were from European descent. We found CFI p.Gly119Arg, C9 p.Pro167Ser, and 
C3 p.Lys155Gln, which have been previously associated with AMD,7,11-14 and we described 
their familial segregation in detail previously.17 We identified 6 additional rare genetic 
variants, namely, CFH p.Ser193Leu, CFH p.Arg175Gln, CFI p.Pro553Ser, CFI p.Leu131Arg, 
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C9 p.Arg118Trp, and C3 p.Arg161Trp (Table 1). Although the identified variants were highly 
prevalent within these families, a perfect segregation with disease phenotype was not observed 
(eFigure in the Supplement).
The 6 new variants clustered in 5 AMD families (families A, B, D, E, and F). Furthermore, we 
identified 2 smaller families, both consisting of 3 siblings, carrying the same variants (families 
C [CFH p.Ser193Leu] and G [C3 p.Arg161Trp]). Newly identified rare variants were present 
more frequently in affected members compared with unaffected individuals (28 of 37 [75.7%] 
and 4 of 10 [40.0%], respectively; P = .07).
Next, we investigated whether the rare variants identified in our families were associated 
with AMD in a case-control cohort of 1831 patients with AMD and 1367 control individuals. We 
identified 194 carriers of novel and previously identified variants in complement genes CFH, 
CFI, C9, or C3. Carrying one of these rare variants was significantly associated with AMD status 
because 139 carriers (72.4%) were AMD case patients and 53 (27.6%) were control individuals 
(odds ratio, 2.04; 95% CI, 1.47-2.82; P < .001). In the meta-analysis, which combined results of 
the family and case-control cohorts, all variants had a nominal association with AMD (Table 2 
and eTable 1 in the Supplement).
To determine the effect of newly identified rare variants (CFH p.Ser193Leu, CFH p.Arg175Gln, CFI 
p.Pro553Ser, CFI p.Leu131Arg, C9 p.Arg118Trp, and C3 p.Arg161Trp) and of previously identified 
variants (CFI p.Gly119Arg, C9 p.Pro167Ser, and C3 p.Lys155Gln)17 on protein expression, we 
performed serum measurements. Levels of FH, FI, C3, and C9 were determined by enzyme-
linked immunosorbent assay in serum samples of 314 individuals, of which 157 carried a rare 
variant. Carriers of different variants were grouped per gene and included both patients with 
AMD and controls. To assess differences between cases and con- trols, noncarriers were split 
based on AMD status (Figure 1). Significant differences in serum levels of FI and C9 were 
observed (eTable 2 in the Supplement). 
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Carriers of CFI p.Gly119Arg had a significantly decreased median serum FI level (18.2 µg/mL) 
compared with noncarrier cases and controls (27.2 and 30.4 µg/mL, both P < .001), as did 
carriers of CFI p.Leu131Arg (16.2 µg/mL) versus noncarrier cases (27.2 µg/mL, P = .005) and 
controls (30.4 µg/mL, P = .001) (Figure 1B). Carriers of C9 p.Pro167Ser had an elevated C9 
serum level (10.7 µg/mL) compared with noncarriers (6.6 µg/mL in cases and 6.1 µg/mL in 
controls, P < .001) (Figure 1C). Median FI serum levels for non- carriers were 27.2 and 30.4 µg/
mL (cases and controls, respectively). Median C9 serum levels for noncarriers were 6.6 and 6.1 
µg/mL (cases and controls, respectively). The median FH serum levels were 299.4 µg/mL for 
CFH p.Arg175Gln and 266.3 µg/mL for CFH p.Ser193Leu carriers versus 302.4 and 283.0 µg/
mL for noncarrier cases and controls, respectively. The median C3 serum levels were 943.2 
µg/mL for C3 p.Arg161Trp and 946.7 µg/mL for C3 p.Lys155Gln carriers versus 874.0 and 946.7 
µg/mL for noncarrier cases and controls, respectively (Figure 1A and D and eTable 2 in the 
Supplement).
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Figure 1: Serum levels of factor H (FH), factor I (FI), C9, and C3 in carriers and noncarriers. Serum 
levels of FH (A), FI (B), C9 (C), and C3 (D) measured in carriers and noncarriers in corresponding genes. 
Significance values are on the left (versus noncarrier cases) and right (versus noncarrier controls). Lines 
indicate median; error bars, interquartile range. C3 indicates complement 3 gene; C9, complement 9 gene; 
CFH, complement factor H gene; and CFI, complement factor I gene. a P < .001.
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Next, we assessed C3b degradation in serum samples from individuals carrying CFH or CFI 
mutations and compared them with noncarriers. As illustrated in Figure 2, carriers of rare 
variants in CFH and CFI had a lower capacity to degrade C3b when compared with noncarriers, 
except for CFI p.Pro553Ser carriers (eTable 3 in the Supplement). 
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Figure 2: C3b Degradation Assay in Serum Samples of Complement Factor H (CFH) and Complement 
Factor I (CFI) Gene Variant Carriers. C3b degradation depicted as ratio of 43-kDa degradation product 
over the α′ chain. Significance values are on the left (versus noncarrier cases) and right (versus noncarrier 
controls). Lines indicate median; error bars, interquartile range. a P < .001 b P < .01. c P = .39.
Finally, we determined whether FH and FI levels affect an individual’s ability to degrade C3b 
irrespective of rare variant status (Figure 3). Linear regression revealed a positive correlation 
between both FH and FI serum levels with C3b degradation ratios in noncarrier cases and 
controls (r2 = 0.34 for FH serum levels and r2 = 0.31 for F1 serum levels; P < .001). Carriers of 
CFH and CFI variants were plotted in these graphs, revealing lower serum concentrations and/
or a reduced ability to degrade C3b.
DISCUSSION
We identified 6 new rare variants in complement genes in 5 of 22 densely affected families 
with AMD. Serum measurements revealed altered serum levels for individuals carrying some 
of these variants compared with controls. In addition, serum samples from carriers of rare 
variants in CFH and CFI revealed a diminished ability to degrade C3b, suggesting that the 
variants result in impaired complement regulation.
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To our knowledge, this is the first description of variants CFI p.Leu131Arg and C9 p.Arg118Trp 
in the literature. Variants p.Ser193Leu and p.Arg175Gln in CFH were both previously identified 
by our group.8 CFI p.Pro553Ser has been described earlier in atypical hemolytic uremic 
syndrome (aHUS), a severe rare renal disease, but was also noted as a possible risk variant for 
AMD.12,18,29,30 The p.Arg161Trp variant in C3, another aHUS variant,31 was previously reported.15
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Figure 3. Correlation Between Factor H (FH) and Factor I (FI) Serum Levels With the Ability to Degrade 
C3b. Correlation between the FH (A) and FI (B) serum levels and the ability to degrade C3b. Complement 
factor H (CFH) gene carriers had normal serum levels but functional defect. Complement factor I (CFI) 
gene variants had reduced serum levels.
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In our case-control cohort, the newly and previously described rare variants were predominantly 
found in cases and contributed to an increased risk of developing AMD. Similarly, the carrier 
status within the families was higher in cases compared with unaffected family members. 
Even though the variants did not perfectly segregate with the AMD phenotype, the combined 
P value of the case-control and family cohorts supports an association of these rare variants 
with AMD. Our findings further strengthen the notion that rare variants in complement genes 
play an important role in AMD development and that family studies are a useful approach to 
identify rare variants.3,10,32
By analyzing the effect of rare variants on protein expression, we found that carriers of CFH 
mutations have normal serum FH concentration. Although no functional analysis has been 
described for either of these variants, a previous study19 measured FH levels in five patients 
with AMD carrying other rare variants in CFH (p.Cys192Phe, p.Tyr277*, p.Cys431Ser, two 
splice site variants). Lower median FH concentrations were observed in carriers compared 
with noncarriers. In another study, ten carriers of CFH variants p.Arg53Cys and p.Asp90Gly 
were found to have normal FH concentrations. Similarly, measurement of serum levels of CFH 
p.Gln950His carriers revealed FH levels within the reference range.20 These results indicate 
that not all rare variants in CFH lead to lower FH levels. Variants group into two major mutation 
types. Type 1 mutations cause low protein levels as a result of misfolding or degradation, 
whereas type 2 mutations result in reduced functionality with normal protein levels. The CFH 
variants identified in our study (CFH p.Ser193Leu and p.Arg175Gln) are most likely type 2.
The FI levels were measured in the serum of carriers of CFI p.Gly119Arg, p.Leu131Arg, and 
p.Pro553Ser. It was previously reported that individuals with advanced AMD carrying CFI 
variants have reduced FI concentration.18 In particular, p.Gly119Arg had high odds ratios for 
AMD and significantly reduced FI levels in plasma.11 We confirm this finding and report that 
novel variant p.Leu131Arg in CFI also leads to a strong reduction of FI serum levels. The third 
variant, CFI p.Pro553Ser (ten cases and two controls), did not alter FI levels compared with 
noncarriers, which is consistent with previous studies.12,18
C3 levels of carriers of C3 p.Lys155Gln or p.Arg161Trp variants were normal compared with 
noncarriers, in line with a previous report.33 Another study12 found that carriers of rare variant 
p.Lys155Gln failed to degrade C3b properly and hypothesized that this was caused by reduced 
binding to FH. Although C3 p.Lys155Glnis was highly associated with AMD, median serum 
level of C3 Lys155Gln did not differ from that of noncarriers, supporting that the variant 
influences protein functionality rather than level. In aHUS, p.Arg161Trp has been described 
to be pathogenic because of a hyperactive C3 convertase formation attributable to increased 
binding to factor B, accompanied by increased C3a, C5a, and membrane attack complex. The 
p.Arg161Trp variant leads to reduced binding to FI cofactors, such as FH.21,31,34,35 Although C3 
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variants result in a lower C3 level in most aHUS and AMD patients (70%-80%), very low C3 
levels are observed only in patients with homozygous CFH or gain-of-function mutations in 
CFB or C3.21,33,36 One individual in family E carrying the p.Arg161Trp (indicated by an asterisk) 
reported reduced renal function attributable to hypertension and urolithiasis.
To our knowledge, we are the first to report significantly elevated C9 serum levels in carriers 
of C9 p.Pro167Ser in AMD. We hypothesize this increased C9 level results from elevated 
complement activation in patients with AMD, which, through lysis of the target cells, may 
directly contribute to retinal destruction observed in the disease pathogenesis. For C9 only 
two variants have been described in AMD: C9 p.Pro167Ser12 and p.Arg95*,22 the latter being 
inherent to Asian populations. Our study indicates that other rare variants in the C9 gene, such 
as p.Arg118Trp, are also associated with AMD, although this variant did not affect C9 serum 
concentration.
In this study, all carriers of rare variants in CFH and CFI had reduced ability to degrade C3b 
compared with noncarriers. Furthermore, carriers of CFI variants (p.Gly119Arg and p.Leu131Arg) 
had decreased FI serum level. A previous study,11 using recombinant FI (p.Gly119Arg), reported 
that both expression and secretion of mutant protein were reduced compared with wild-type 
protein. Consequently, impaired levels led to reduced C3b degradation. The FH levels remained 
stable, suggesting that CFH variants affect complement activation independent of FH serum 
levels by its inability to properly serve as a cofactor in the cleavage of C3b to inactive C3b. This 
finding might be explained by the variants’ location at the N-terminus, where a C3b-binding 
site is located.37
We detected a natural correlation of FH and FI levels with the ability to degrade C3b in 
noncarrier individuals. Carriers of rare variants in CFH and CFI group outside the linear curve 
of noncarriers. This finding suggests that carriers of rare variants in the CFH and CFI genes 
have a decreased ability to degrade C3b and thus higher levels of complement activation 
compared with noncarriers and may benefit more from complement-inhibiting therapy than 
patients with AMD in general.
Several clinical trials are currently evaluating complement- inhibiting treatments in AMD,38 
and two clinical trials have been completed. The Complement Inhibition with Eculizumab 
for the Treatment of Nonexudative Age-Related Macular Degeneration (COMPLETE) study 
involved eculizumab, an anti- body that binds to C5 and inhibits cleavage of C5 to C5a.39 The 
trial results suggested eculizumab was not effective in treating AMD because the growth of 
geographic atrophy (advanced AMD) did not decrease after 6 months of treatment. The Safety, 
Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month 
to Patients With Geographic Atrophy (MAHALO) study with lampalizumab, an antibody directed 
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against complement factor D, which is a rate- limiting enzyme involved in the activation of the 
alternative pathway,40 had promising results because progression of the geographic atrophy 
lesion had a 20% reduction after 18 months of treatment. Lampalizumab has been suggested 
to be most effective in a subpopulation of patients because an even higher reduction rate was 
seen in patients with a specific CFI genotype.40 Selection of such patients would lead to more 
effective clinical trials, requiring smaller patient groups to re- veal an effect of the drug being 
tested. Screening of individuals for genetic (eg, rare variants in CFH and CFI) or serum (eg, 
reduced FI levels) biomarkers will enable treatment in an early phase of the disease, before 
substantial tissue damage has occurred. Personalized treatment could be provided for patients 
with rare genetic variants in the CFH and CFI genes or reduced FI levels, linked to the functional 
inability to degrade C3b efficiently, and act on this effect by using complement inhibitors.
Limitations
A limitation of the study is that functional effects of variants were only assessed for those 
variants that were significantly associated with AMD. Private variants were not included in this 
study. Enlarging the study cohort would improve the power to detect rare variants.
CONCLUSIONS
We identified multiple rare variants in complement genes encoding FH, FI, C9, or C3. Carriers 
of CFI (p.Gly119Arg; p.Leu131Arg) had decreased FI levels, whereas individuals with the C9 
p.Pro167Ser variant had elevated serum concentrations compared with noncarriers. Carrying 
a CFH or C3 variant did not change FH or C3 levels. Carriers of rare variants in CFH and CFI 
had a reduced ability to degrade C3b compared with noncarriers. For CFI, this effect was linked 
to reduced serum FI levels, but CFH affects C3b degradation independent of FH serum levels. 
Carriers of rare variants in CFI and CFH are less able to inhibit complement activation and 
may benefit more from complement-inhibiting therapy than patients with AMD in general. Our 
results suggest that patients with AMD should be screened using a functional complement 
assay and should be tested for rare genetic variants and corresponding serum levels to apply 
the most proper therapeutic regimen for disease treatment.
Earlier presentation: this study was presented as a poster during the ‘Complex traits and 
Polygenic Disorders’ session at: the 2016 American Society of Human Genetics annual meeting, 
October 18–22, 2016, Vancouver, Canada.
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SUPPLEMENTARY INFORMATION
Genetic analysis and genotyping: Exome capture was achieved using the Nimblegen SeqCap 
EZ V2 kit (Roche Nimblegen, Inc., Madison, WI), on Illumina HiSeq2000 sequencer using 
Illumina TruSeq V3 chemistry (Illumina, Inc., San Diego, CA). Downstream analyses included 
demultiplexing (CASAVA software, Illumina) and alignment to the hg19 reference genome 
(Genome Reference Consortium Human Reference 37) by Burrows-Wheeler alignment tool. 
Alignments were sorted by Picard (http://broadinstitute.github.io/picard) and subsequently 
processed by GATK (Indel Realignment and Base-Quality Score Recalibration). PCR duplicates 
were marked by Picard, Mean Depth of Coverage was determined using GATK, and Freemix 
values were estimated through verifyBAMid. Samples that passed technical QC metrics were 
genotyped to gVCF level through GATKs HaplotypeCaller. Insertions, deletions, and single 
nucleotide variants were filtered separately using GATKs Variant-Quality Score Recalibration, 
and annotated using ANNOVAR. Quality filters established high quality annotation with 
sufficient reads (number or reads ≥10, and percentage of variation ≥20%).
ELISA: Maxisorp Nunc Immunoplates (Nunc) were coated overnight either with 5 µg/mL 
anti-human FH (Abcam), or 10 µg/mL anti-human FI (generated in house), or anti-human C3 
(1:1000 dilution, Dako) or 5 µg/mL anti-human C9 (Hycult Biotech) in 50 mM sodium carbonate 
(pH 9.6) at 4 °C. After blocking with Quench solution (50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 
2 mM CaCl2, 0.1% Tween 20 and 3% fish gelatin), plates were incubated with serum samples 
for 1h at 370C in the following dilutions: FH (1:3000), FI (1:1000), C3 (1:30.000) and C9 (1:100). As 
standards, recombinant wild-type proteins were used. After incubation, bound proteins were 
detected using goat anti-human FH (Abcam, 1 µg/mL), or anti-human FI (Quidel, 1:2000), or 
anti-human C3 (Quidel, 1:1000), or anti-human C9 (Complement Technologies, 1:4000) followed 
by rabbit antibody to goat immunoglobulin conjugated with horseradish peroxidase (Dako; 
1:2000 dilution for FI, C3 and C9 or 1:5000 dilution for FH). As substrate, 1,2-phenylenediamine 
dihydrochloride (Dako) was used.
Degradation of C3b in fluid phase: serum samples were diluted 50X in 50 mM Tris-HCl and 
150 mM NaCl, pH 8.0, and mixed with trace amounts of AlexaFluor 647-labeled C3b (C3b 
was purchased from Complement Technologies and labeled according to the manufacturer’s 
instructions; Pierce). A mixture of 20 µg/ml plasma-purified FI, 20 µg/ml plasma-purified 
FH and trace amount of C3b-AlexaFluor 647 was used as a positive control. As a negative 
control, AlexaFluor647-labeled C3b was used alone. The samples were incubated at 37 °C for 
90 min, and reactions were terminated by adding reducing (DTT) sample buffer and boiling 
for 3 min. Proteins were separated on 10% SDS-PAGE and visualized using a Typhon scanner 
(GE Healthcare). Images of the gels were analyzed using ImageQuant Tl 8.1 software. The 
degradation of C3b in serum samples was calculated across triplicate measurements by 
taking the ratio of the 43-kDa degradation product and the 101-kDa α′chain in triplicate. Data 
were analyzed using SPSS Software version 22.0 and figures were generated using Graphpad 
Prism 5.03.
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eFigure 1: Pedigrees of 7 AMD families in which rare variants were identified. Risk alleles are indicated 
in red. Affected individuals are numbered representing AMD-stage (1 early; 2 intermediate; 3 GA; 4 CNV) 
and age at examination is given. Individual * of family E reported kidney failure. Arrows point to family 
probands.
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eTable 1: Number and percentage of carriers of rare variants in the case-control cohort
Variant AMD cases (n=1831)* % AMD controls (n=1367) % 
CFI p.Gly119Arg 15 0.819% 1 0.073%
C9 p.Pro167Ser 61 3.332% 31 2.268%
C3 p.Lys155Gln 42 2.294% 16 1.170%
CFH p.Ser193Leu 5 0.273% 0 -
CFH p.Arg175Gln 2 0.109% 1 0.073%
CFI p.Pro553Ser 10 0.546% 2 0.146%
CFI p.Leu131Arg 4 0.218% 0 -
C9 p.Arg118Trp 3 0.164% 2 0.146%
C3 p.Arg161Trp 4 0.218% 0 -
Total* 139 7.794% 53 3.877%
* Some AMD cases carry multiple rare variants
eTable 2: Median serum levels of FH, FI, C9 and C3 in carriers and non-carriers of rare variants
Median FH  
(µg/ml)
Median FI  
(µg/ml)
Median C9  
(µg/ml)
Median C3  
(µg/ml)
Cases (non-carrier) 283.0 27.2 6.6 874.0
Controls (non-carrier) 302.4 30.4 6.1 966.6
CFH p.Arg175Gln 299.4
CFH p.Ser193Leu 266.3
CFI p.Gly119Arg 18.2
CFI p. Leu131Arg 16.2
CFI p.Pro553Ser 28.4
C9 p.Pro167Ser 10.7
C9 p.Arg118Trp 7.4
C3 p.Arg161Trp 943.2
C3 p.Lys155Gln 946.7
Underlined: significantly different compared to non-carrier cases and controls
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eTable 3. Median C3b Degradation (43-kDA product over the alpha-chain) and quartiles.
Median Ratio (Q1-Q3)
Cases (non-carrier) 0.724 (0.621-0.839)
Controls (non-carrier) 0.845 (0.676-0.913)
CFH p.Arg175Gln 0.387 (0.282-0.447)
CFH p.Ser193Leu 0.421 (0.315-0.454)
CFI p.Gly119Arg 0.395 (0.324-0.445)
CFI p.Leu131Arg 0.373 (0.330-0.393)
CFI p.Pro553Ser 0.532 (0.466-0.616)
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ABSTRACT
Age-related macular degeneration (AMD) is a progressive disease of the central retina and 
the leading cause of irreversible vision loss in the western world. The involvement of abnormal 
complement activation in AMD has been suggested by association of genetic variants in genes 
encoding complement proteins with disease development. A low-frequency variant (p.Pro167Ser) 
in the complement component C9 (C9) gene was recently shown to be highly associated with 
AMD, however, the functional outcome of this variant remains largely unexplored. In this study, 
we reveal five novel rare genetic variants (p.Met45Leu, p.Phe62Ser, p.Gly126Arg, p.Thr170Ile 
and p.Ala529Thr) in C9 in AMD patients, and evaluate their functional effects in vitro together 
with previously identified C9 variants in AMD (p.Arg118Trp and p.Pro167Ser).
Our results demonstrate that the concentration of C9 is significantly elevated in patients’ sera 
carrying the p.Met45Leu, p.Phe62Ser, p.Pro167Ser and p.Ala529Thr variants compared to non-
carrier controls. However, no difference was observed in soluble terminal complement complex 
(sTCC) levels between the carrier and non-carrier groups. Comparing the polymerization 
tendency of the C9 variants, we demonstrate that the p.Pro167Ser mutant spontaneously 
aggregates. Other C9 mutant proteins fail to polymerize in the presence of zinc ions. Altered 
polymerization of the p.Phe62Ser and p.Pro167Ser variants associated with decreased lysis of 
sheep erythrocytes and ARPE-19 cells by carriers’ sera. However, assays using recombinant 
proteins did not detect any alteration between lytic activity of the wild-type and mutant C9 
proteins. 
Our data suggest that the analyzed C9 variants affect only the secretion and polymerization of 
C9 without influencing its classical lytic activity. Future experiments need to be performed to 
understand the implications of the altered polymerization of C9 in AMD pathogenesis. 
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INTRODUCTION
Age-related macular degeneration (AMD; MIM# 603075), a progressive eye disorder, is the 
major cause of irreversible vision loss in the western world.1 AMD is a multifactorial disease in 
which both environmental and genetic factors contribute to pathogenesis.2 Genetic alterations 
are estimated to account for 46-71% of variability in disease risk.3 A large component of the 
heritability of AMD can be explained by genetic variants in the alternative pathway of the 
complement system. A recently published genome-wide association study4 detected 52 (45 
common and 7 rare) variants at 34 genomic regions that are independently associated with 
AMD. More than one third of these variants reside in or near a gene of the complement system.4
Activation of the complement cascade results in enzymatic-cleavage of the central component 
C3 into C3b and C3a. C3b is a crucial component of C3 and C5 convertases, allowing further 
propagation of the cascade into the terminal pathway where C5b-8 complexes incorporate into 
the membrane. After binding several copies of C9, the pre-formed C5b-8 complexes merge 
into the membrane and generate the pore-forming membrane attack complex (MAC), also 
known as the terminal complement complex (TCC).5,6 Once constructed, MAC kills the target 
cell by inducing cell lysis, or at a reduced sublytic concentration MAC can provoke a wide array 
of physiologic responses ranging from apoptosis to pro-inflammatory cytokine secretion.7-10. 
MAC has been identified in the retina of AMD patients and there is a correlation between the 
amount of MAC deposition and the loss of RPE cells.11,12 In addition, sublytic MAC deposition 
on RPE cells induces secretion of pro-inflammatory cytokines and vascular endothelial growth 
factor, contributing to the development of advanced AMD.13,14 
Recently, three rare genetic variants in C9 were reported in association with AMD,15-17 namely 
p.Arg95*, p.Arg118Trp and p.Pro167Ser. The C9 p.Pro167Ser was reported to be highly 
associated with AMD risk in multiple studies. 4,15,18,19 More recently, a genetic burden of C9 
variants was described in two separate AMD cohorts. The first study identified 13 rare variants 
(p-value 2.4x10−08)18 and the second study (Corominas, manuscript submitted) identified 17 
rare variants (p-value 5.01x10−03) in C9, however in both studies the burden did not remain 
significant after correction for multiple comparisons. 
In a recent study we demonstrated that the p.Pro167Ser variant leads to increased serum 
concentration of the protein.17 However, the exact functional consequences of the p.Pro167Ser 
variant and of other genetic alterations in C9 remain unclear. In this study, we aimed to further 
elucidate the functional effects of C9 variants in vitro in order to understand the role of C9 in 
AMD pathogenesis. 
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RESULTS
Genetic alterations identified in C9
Through whole-exome sequencing in 793 unrelated individuals (662 AMD cases and 131 
controls) we identified five novel rare variants in C9, namely p.Met45Leu, p.Phe62Ser, 
p.Gly126Arg, p.Thr170Ile and p.Ala529Thr, in addition to previously reported C9 p.Arg118Trp 
and p.Pro167Ser (Fig. 1). Genotyping of these seven variants in 1896 unrelated AMD cases and 
1499 unrelated control individuals identified 132 rare variant carriers (Supplementary Table 
1). In our case-control cohort, none of the rare C9 variants were individually associated with 
AMD pathogenesis (Supplementary Table 2). However, the p.Pro167Ser variant was previously 
shown to be highly associated with AMD in large case-control studies,4,15,18,19 and a burden of 
rare variants was recently suggested for C9.18(Corominas, manuscript submitted) Therefore, 
we set out to identify the functional effect of these variants on the C9 protein, in order to place 
them into context of AMD pathogenesis. 
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Figure 1. Overview of rare genetic variants in C9 identified in AMD case-control cohort. *Higher PhyloP 
[range -14;6.4] and Grantham [range 0-215] scores correlate with a higher conservation. ** Sorting 
Intolerant from Tolerant (SIFT) and PolyPhen2 classification: (T, tolerated; B, benign; D, damaging; P, 
pathogenic). NA: non available
The identified variants are present in different domains of the protein: the thrombospondin type 
1 (TSP1), the low-density lipoprotein receptor type A (LDLRA), the MAC/perforin (MACPF) and 
the epidermal growth factor-like (EGF) domains (Fig. 1A). All the identified variants are non-
synonymous point mutations resulting in amino acid changes in the mature protein.
To study the effect of these variants in vitro, 128 serum and 95 plasma samples of the identified 
carriers were included in functional assays and compared to 156 sera (78 with AMD and 78 
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without the disease) and 155 plasma samples (77 with AMD and 78 without AMD) of age-
matched non-carrier individuals (Supplementary Table 2).
Serum C9 and plasma terminal complement complex level of C9 carriers
To analyze whether the identified genetic variants affect secretion of the mature proteins, the 
concentration of C9 was measured in sera of 127 AMD patients carrying rare genetic variants 
in C9 and compared to 78 non-carriers with (n=78) or without (n=78) AMD. We found that 
the p.Met45Leu, p.Phe62Ser, p.Pro167Ser and p.Ala529Thr variants lead to a significantly 
increased C9 level compared to non-carrier controls (Fig. 2A). Sera carrying the p.Arg118Trp 
and p.Gly126Arg variants did not significantly differ in C9 levels between carriers and non-
carriers (Fig 2A).
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Figure 2. Measurement of serum C9 and plasma sTCC levels in C9 carriers. Concentrations of C9 in sera 
(A) and sTCC level in plasma (B) of patients carrying rare genetic variants in C9 were measured by ELISA 
and compared to non-carriers with or without AMD. Differences with p<0.05 were considered statistically 
significant and marked with dark (carriers versus non-carriers with AMD) or with light grey asterisks 
(carriers versus non-carriers without AMD) (Kruskal-Wallis test with Dunn’s correction, nsp>0.05, *p<0.05, 
**p<0.0021, *** p<0.0002, ****p <0.0001). Data are shown as median mg/ml secreted C9 or AU/ml sTCC 
level (the latter on log10 scale) with interquartile range of four (C9 ELISA) or three (TCC ELISA) independent 
experiments.
Binding of C9 to soluble C5b-8 complexes results in formation of soluble terminal complement 
complex (sTCC), which is a sign of ongoing complement activation. Therefore, we measured 
sTCC levels in patient and control sera of carriers and non-carriers of rare C9 variants. 
Measurement of sTCC levels in patient and control plasma showed no differences in variant 
carriers compared to the control groups, even though elevated C9 concentrations are present 
(Fig. 2B)
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Secretion of C9 mutants by HEK293F cells
In order to explore the impact of the identified variants on the protein function, independent of 
other serum components, Freestyle HEK293F cells were transfected with either wild type or 
mutant C9 constructs. The isolated proteins were visualized by both silver staining (data not 
shown) and Western blotting under non-reducing conditions (Fig. 3A), confirming the presence 
of pure, monomeric C9.
Using a similar experimental approach we compared the expression and secretion of the wild 
type and mutant C9 proteins. To this end, HEK293F cells were transfected with either the 
wild type or mutant C9 constructs, and the concentration of secreted C9 in the supernatants 
was analyzed by ELISA. As shown in Figure 3B, secretion of the p.Phe62Ser and p.Gly126Arg 
mutant proteins was significantly elevated compared to the wild type protein. The secretion of 
the p.Met45Leu, p.Arg118Trp, p.Pro167Ser, p.Thr170Ile and p.Ala529Thr mutant proteins did 
not significantly differ from the wild type C9 protein.
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Figure 3. Expression and secretion of recombinant WT and mutant C9 variants in HEK293F cells. 
(A) Wild type and mutant C9 proteins were expressed in HEK293F cells and purified by Ni2+-affinity 
chromatography and gel filtration. Purified proteins were separated under reducing conditions by 10% 
SDS-PAGE (0.5 mg/lane) and transferred onto PVDF membrane. The presence and purity of recombinant 
proteins were investigated using goat anti-human C9. Results of one representative purification out of ten 
is shown. (B) HEK293F cells were transiently transfected with 5 mg WT or mutant C9-pCEP4 constructs. 
Concentration of C9 mutant proteins in the secreted supernatants was measured by ELISA. Graphs show 
mean ± SD mg/ml secreted C9 of four independent experiments. Differences with p<0.05 were considered 
statistically significant (one-way ANOVA with Dunnett’s multiple comparison, nsp>0.05, *p<0.05, **p<0.002, 
***p<0.0002).
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Lytic activity of recombinant C9 variants
To investigate whether the identified variants have a functional impact, the recombinant, 
purified wild type and mutant C9 proteins were compared in their ability to lyse erythrocytes. 
To this end, sensitized sheep erythrocytes were treated with C9-depleted serum which was 
reconstituted with the wild type or mutant C9 proteins. As demonstrated in Figure 4A, we 
observed that the lytic activity of the mutant C9 proteins did not differ from that of the wild 
type protein, with the exception of the p.Pro167Ser mutant protein, which showed a slight, but 
significant reduction in lysis of the erythrocytes.
To further investigate the effects in a more relevant model for disease development, we 
compared the lytic activity of the wild type and mutant C9 proteins on the retinal pigment 
epithelial cell line, ARPE-19. To induce MAC deposition, ARPE-19 cells were pre-incubated 
with a function-blocking anti-CD59 antibody and C9-depleted serum supplemented with either 
the wild type or mutant recombinant C9 proteins. We did not observe any differences between 
the wild type and mutant C9 proteins in their cytotoxic activity on ARPE-19 cells (Fig. 4B).
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Figure 4. Lytic activity of recombinant C9 variants. Sheep red blood cells (SRBCs)(A) or ARPE-19 
cells (B) were treated with C9-depleted serum supplemented with the recombinant WT or mutant C9 
proteins. (A) Lysis of SRBCs was analyzed via measurement of released hemoglobin at 405 nm. Data are 
expressed as median with interquartile range of water-induced maximum lysis and are results of three 
independent experiments carried out in duplicate. (B) MAC-induced cytotoxicity was measured via lactate 
dehydrogenase (LDH) release from ARPE-19 cells. Data expressed are mean ± SD of lysis buffer-induced 
maximum lysis and are results of three independent experiments measured in duplicate. Differences with 
p<0.05 were considered statistically significant (one-way ANOVA with Dunnett’s multiple comparison, 
nsp>0.05, **p<0.0021).
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Lysis of SRBCs
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Figure 5. C9-dependent lytic activity of sera of carriers and non-carriers of rare genetic variants in C9. 
Lytic activity of sera was measured by incubation of SRBCs (A) or ARPE-19 cells (B and C) with C9-depleted 
serum supplemented with EDTA-GVB diluted sera of carriers and non-carriers. (A) Lysis of SRBCs was 
analyzed via measurement of released hemoglobin at 405 nm. Data are expressed as median with 
interquartile range of water-induced maximum lysis and are results of four independent experiments. (B 
and C) MAC-induced cytotoxicity of ARPE-19 cells was measured via LDH release (B) and by analysis of 
Annexin V+ZombieAqua+ (late apoptotic) cells by flow cytometry (C). Data are expressed as median with 
interquartile range of lysis buffer-induced maximum LDH release (B) and % of late apoptotic cells (C) of 
two independent experiments measured in duplicate. Differences with p<0.05 were considered statistically 
significant and marked with dark (carriers versus non-carriers with AMD) or with light grey asterisks 
(carriers versus non-carriers without AMD) (Kruskal-Wallis test with Dunn’s multiple comparison, nsp>0.05, 
*p<0.05, **p<0.0021, ****p <0.0001).
Lytic activity of sera of C9 carriers
A modified hemolytic assay was designed to measure the C9-dependent lytic activity 
independent of other complement components. Sensitized erythrocytes or ARPE-19 cells were 
incubated with C9-depleted serum in DGVB++ (dextrose gelatin veronal buffer), which allows 
complement activation and deposition of C5b-8 complexes on the cell membrane. Thereafter 
the cells were incubated with sera of carriers or non-carrier controls diluted in EDTA-
GVB (ethylenediaminetetraacetic acid - gelatin veronal buffer), which blocks complement 
activation and novel C5b-8 complex formation, but allows integration of C9 in the pre-formed 
C5b-8 complexes and induces lysis dependent on both the protein function and C9 serum 
concentration.
In spite of the significantly increased C9 concentration in sera of the p.Met45Leu, p.Phe62Ser, 
p.Pro167Ser and p.Ala529Thr carriers, the elevated C9 level did not cause increased lysis of 
erythrocytes (Fig. 5A) or ARPE-19 cells (Fig. 5B and 5C). On the contrary, we observed a slight 
but significant decrease in lytic activity for C9 p.Phe62Ser on both erythrocytes and ARPE-19 
cells compared to non-carrier controls without AMD. Furthermore, the C9 p.Pro167Ser variant 
showed decrease in lytic activity on erythrocytes compared to non-carriers with or without 
AMD (Fig. 5A and Fig. 5C).
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Figure 6. Polymerization of WT and mutant C9 proteins in the presence or absence of Zn2+ ions. 
Recombinant WT or mutant C9 (5 mM) were allowed to polymerize in the presence or absence of 15 
mM Zn2+ ions at 37oC for 4h. The proteins were separated by electrophoresis on a 5-10% polyacrylamide 
gradient gel and polymers were visualized by silver staining. (A) One representative experiment of three 
is shown. (B) Densitometric analysis of polymer and monomer ratios of WT and mutant C9 proteins were 
calculated by ImageLab software. Results shown are the densitometric ratios of polymer and monomer C9 
bands and illustrated as median with interquartile range of three independent experiments. Differences 
between WT and mutant C9 proteins with p<0.05 were considered statistically significant and marked with 
dark (spontaneous polymerization) or with light grey asterisks (Zn2+-induced polymerization) (one-way 
ANOVA with Dunnett’s multiple comparison, nsp>0.05, **p<0.021, ****p<0.0001).
Polymerization of recombinant C9 mutant proteins
During purification of recombinant C9 proteins we observed that the p.Pro167Ser mutant 
protein tends to aggregate and form high molecular weight aggregates (Fig. 3A). To evaluate the 
polymerization tendency of the C9 mutant proteins, purified C9 was incubated in the presence 
or absence of zinc ions, which accelerate C9 polymerization and are used as dietary supplement 
to reduce AMD progression20. We observed that the p.Pro167Ser mutant protein spontaneously 
aggregates (Fig. 6). In the absence of zinc, the other mutant proteins polymerized normally. 
However, the p.Met45Leu, p.Phe62Ser, p.Arg118Trp, p.Gly126Arg and p.Thr170Ile mutant 
proteins showed impaired polymerization in the presence of zinc in contrast to the p.Pro167Ser 
mutant protein, which showed higher polymerization than the wild type protein. Polymerization 
ability of the p.Ala529Thr mutant protein was unaltered.
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DISCUSSION
In this study, we studied the functional effect of the p.Pro167Ser variant in C9, which was in 
multiple recent studies found to be highly associated with AMD.4,15,18,19 In addition, a burden of 
rare genetic variants in C9 was recently suggested by two independent studies.18(Corominas, 
manuscript submitted) In this study we identified five novel, non-synonymous rare genetic 
variants in C9 (p.Met45Leu, p.Phe62Ser, p.Gly126Arg, p.Thr170Ile and p.Ala529Thr), in addition 
to the previously identified C9 p.Arg118Trp17 and p.Pro167Ser variants.15 The identified C9 
variants (except for C9 p.Met45Leu variant) were more prevalent in individuals affected by 
AMD compared to control individuals (Suppl. Table 2). However, due to the limited number of 
individuals analyzed in the current study, in combination with the low allele frequency of the 
C9 variants, the association to AMD was statistically inconclusive. Functional characterization 
of the identified variants on the C9 protein may provide insight in the role of C9 in AMD 
pathogenesis.
For C9, only three genetic variants have previously been described in AMD. A non-sense 
variant (p.Arg95*) leads to complete or partial C9 deficiency.21 This variant is protective for 
AMD, conferring a 4.7-fold reduction in disease risk, and is correlated to decreased vascular 
endothelial growth factor levels.16 The p.Arg118Trp C9 variant was identified with a relatively 
low allelic odds-ratio (1.12) and did not alter the C9 level in carriers compared to non-carriers.17 
C9 p.Pro167Ser confers risk for AMD4,15,17-19 and results in elevated serum C9 levels in carriers 
compared to non-carriers.17 
We did not detect any significant alteration in systemic complement activation levels, measured 
in the form of plasma sTCC between the carrier, non-carrier, affected and unaffected 
individuals in serum (Fig. 2B). This is in accordance with previous studies, reporting no 
significant difference in systemic sTCC level between AMD patients and non-carrier control 
groups.22-24 Increased MAC (soluble C5b-9 MAC and immunohistochemistry staining) was 
previously observed in Bruch’s membrane and the choriocapillaris of human eyes, gradually 
increasing with age. The elevated MAC was especially evident in eyes affected by AMD, even 
more so in carriers of the CFH risk allele.11,12 These findings suggest that changes in MAC are 
associated with AMD but can only be detected locally.
We found that carriers of the p.Met45Leu, p.Phe62Ser, p.Pro167Ser and p.Ala529Thr variants 
have increased serum C9 levels compared to non-carrier controls (Fig. 2A). However, carriers 
of the p.Arg118Trp and p.Gly126Arg variants did not have altered C9 serum concentrations 
compared to sera of non-carrier controls. Unfortunately, no serum was available for 
p.Thr170Ile. These data confirm our earlier results reporting normal C9 levels in sera carrying 
the C9 p.Arg118Trp variant and elevated C9 levels in carriers of the p.Pro167Ser variant.17 
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Interestingly, in HEK293F cells secretion of the recombinant C9 proteins was higher for the C9 
p.Phe62Ser and p.Gly126Arg mutant proteins (Fig. 3B), but not for the p.Met45Leu, p.Pro167Ser 
and p.Ala529Thr mutant proteins. The discrepancy between results of C9 ELISA from serum 
and cell culture supernatants may be due to the fact that in vivo C9 is secreted by various cell 
types which express the protein at distinct level in contrast to our in vitro system, where C9 was 
produced by a single cell type.
Despite the significantly elevated C9 levels in carriers of the p.Met45Leu, p.Phe62Ser, 
p.Pro167Ser and p.Ala529Thr variants (Fig. 2A), we did not detect an increase in C9-
dependent lytic activity of patients´ sera carrying these rare genetic variants in C9 (Fig. 4). 
More surprisingly, the sera of carriers of the p.Phe62Ser and p.Pro167Ser C9 variants caused 
decreased lysis of sheep erythrocytes or ARPE 19 cells. The lytic activity of the sera of carriers 
of p.Met45Leu and p.Ala529Thr C9 variants was not altered, despite increased serum levels 
(Fig 5A and Fig. 5C). One would assume that an increased C9 concentration would result in 
enhanced MAC formation and thus, increased killing of the target cells. Nevertheless, it should 
be considered that the stochiometry of C5b-8 and C9 within MAC is strictly regulated. One 
C5b-8 complex can bind only a limited number of C9 molecules 25, therefore, even when more 
C9 is available, it does not necessarily lead to more C5b-9 complex and hence, enhanced pore 
formation and lysis. 
Hemolytic assays performed with the recombinant C9 proteins purified on a nickel column 
(containing both monomeric and polymeric proteins) displayed a significantly reduced lytic 
activity of the C9 p.Phe62Ser and p.Pro167Ser mutant proteins (data not shown). We confirmed 
these observations using serum samples (Fig. 5A). To exclude the functionally inactive polymers 
from our analysis, the recombinant C9 proteins were further purified by gel filtration (Fig. 3A). 
Notably, applying the pure, monomer forms of C9, we did not detect any differences in lytic 
activity of the wild type and mutant proteins (Fig. 4), suggesting that the genetic alterations do 
not alter the classical, lytic function of C9. 
C9 has a tendency to polymerize, leading to formation of poly(C9) and a rapid loss of hemolytic 
activity26. Although we could not detect the presence of poly(C9) in sera of the p.Pro167Ser 
carriers, our in vitro data suggest that the C9 p.Pro167Ser mutant protein has an increased 
tendency to aggregate. Formation of polymers of C9 p.Pro167Ser mutant proteins could already 
be observed during expression and purification of the recombinant protein. In contrast, the C9 
p.Phe62Ser mutant protein had a decreased capacity to polymerize in the presence of zinc ions 
(Fig. 6). Despite the almost complete lack of zinc-induced polymerization, the hemolytic activity 
of the C9 p.Phe62Ser mutant protein was only slightly reduced (Fig. 5). This suggests that the 
C9 p.Phe62Ser variant only slightly impairs the capacity of C9 to bind C5b-8.
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In our experiments, zinc was used to induce polymerization since formation of poly(C9) is 
accelerated by the metal ion.27 However, zinc is also used in dietary supplements to reduce AMD 
progression.20,28 The zinc concentrations we used are within the same range as recommended 
for supplementation. Zinc treated C9 mutant (p.Pro167Ser) polymerizes and is thus not able 
to bind to C5b-8 and unable to cause lysis. However, the polymerization tendency of almost all 
other C9 mutants is reduced in the presence of zinc compared to wildtype C9. This suggests 
that zinc supplementation may be ineffective at reducing MAC associated lysis in patients 
carrying the C9 mutations.
Previously, C9 polymerization was reported to occur rapidly in the presence of C5b-8 complexes, 
while spontaneous poly(C9) formation takes several days at 37oC 26. The rapid polymerization 
of the C9 p.Pro167Ser mutant protein even in the absence of C5b-8 complexes or zinc ions 
(Fig. 6) indicate that functionally inactive aggregates can already be formed during the assay, 
leading to reduced lysis of the target cells even when applying the protein in monomer form 
(Fig. 4A). In contrary, polymerization of the C9 p.Phe62Ser mutant protein was only observed in 
the presence of C5b-8 complexes (Fig.4) or during longer incubation time, for example during 
production and purification of the protein. This may explain the discrepancy between decreased 
lytic activity of patients’ sera carrying the p.Phe62Ser C9 variant (Fig. 5) and of mixed polymer-
monomer solution of purified C9 p.Phe62Ser mutant protein (data not shown) in contrast to 
normal lytic activity of the purified, monomer protein (Fig. 4). The decreased lysis we observed 
could be explained by altered polymerization tendency of C9 p.Phe62Ser and by spontaneous 
aggregation of the p. P167S mutant protein (Fig. 5A; Fig 6).
The in vitro assays showed altered polymerization and decreased lytic activity of C9 p.Phe62Ser 
and p.Pro167Ser mutant proteins, while this was not seen for the other C9 mutant proteins. 
This may be explained by the localization of the variants in the mature protein (Fig. 1): the TSP1 
and MACPF domains have been reported as main drivers of C9 polymerization during MAC 
formation.29 Thus, the p.Phe62Ser variant and in particular the p.Pro167Ser variant (due to the 
substitution of a proline residue) may alter the structure of C9 in a way that results in impaired 
pore formation and lysis.
Taken together, we have shown that several identified C9 variants, including the p.Pro167Ser 
variant highly associated with AMD, affect the serum level and polymerization of C9 without 
influencing its classical lytic activity. These results, alongside with normal sTCC level of the 
carriers’ plasma and the lack of correlation between C9 concentration and lytic activity of 
patients’ sera, suggest that the variants influence disease pathology locally in the eye but not 
by increased lytic activity. Future experiments are needed to understand the implications of the 
altered polymerization on AMD pathogenesis. We hypothesize that accumulation of aggregated 
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protein within the cell induces (endoplasmatic reticulum) stress, which could eventually lead 
to apoptosis of the cells.
MATERIALS AND METHODS
Genetic analysis and patient selection
We performed whole-exome sequencing for 793 unrelated individuals (662 cases and 131 
controls), as described in detail previously17. Filtering steps were implemented to uncover the 
coding non-synonymous variants of C9 (NM_001737.3). Frequency filters, using public database 
ExAC 30 were implemented to ensure selection of rare variants (minor allele frequency <1%). 
We identified seven unique rare variants in C9 which were screened in an additional cohort 
consisting of 1234 unrelated case and 1368 unrelated control individuals using custom-made 
competitive allele-specific PCR assays according to manufacturers’ recommendations (KASP 
SNP Genotyping System, LGC). Furthermore, family members of 8 different families (n=17) of 
which the proband carried a C9 variant were screened using Sanger sequencing.
All individuals included in the study underwent clinical evaluation and were graded for ‘AMD’ or 
‘no AMD’ according to the Cologne Image Reading Center protocol. Control individuals without 
AMD were 60 years or older 31. 
Collection of serum and plasma samples
Serum and plasma samples were obtained by a standard coagulation/centrifugation protocol 
and frozen at −80°C within 1 hour after collection. Genomic DNA was isolated from peripheral 
blood samples according to standard procedures. This study was approved by local ethics 
committees on Research Involving Human Subjects and met the criteria of the Declaration of 
Helsinki.
To analyze the functional effect of rare genetic variants in C9, 128 serum and 95 plasma samples 
of 132 carriers were collected. Furthermore, we obtained serum (n=156) and plasma (n=155) of 
157 individuals that did not carry a rare genetic variant in C9 (Supplementary Table 2).
Cell lines
Freestyle HEK293F cells (Invitrogen) were cultured in Freestyle Expression medium (Invitrogen) 
according to the manufacturer’s instructions. Cells were passaged every third day and 
transfected at passage 10. The retinal pigment epithelial cell line ARPE-19 (ATCC) was cultured 
in DME/F12 medium (Hyclone) supplemented with 10% heat-inactivated FCS (Hyclone). Cells 
used for functional assays were between passage 10 and 20. The cells were mycoplasma free 
and tested regularly with the VenorGEM Classic kit (Minerva Biolabs).
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ELISA for measurement of C9 concentration
C9 concentrations in serum samples or supernatants of HEK293F cells secreting C9 
recombinant proteins were determined by ELISA. Maxisorp microtiter plates (96-well, Thermo 
Scientific) were coated with 1 µg/mL mouse anti-human C9 (Hycult Biotech) in 50 mM 
sodium carbonate (pH 9.6) overnight, at 4 °C. Between each of the following steps, the plates 
were washed four times with Immunowash (50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM 
CaCl2, 0.1% Tween 20). After coating, plates were blocked in Quench solution (Immunowash 
supplemented with 3% fish gelatin, Nordic) for 1h at room temperature (RT) and incubated 
with serum samples (diluted 1:200 in Quench) or with supernatants of HEK293F cells for 1h 
at RT. As standard, serum-purified C9 (prepared in our lab) was applied. After incubation, 
bound proteins were detected using goat anti-human C9 (1:4000 in Quench, Complement 
Technologies) followed by HRP-conjugated rabbit anti-goat Ig (1:2000 in Quench, Dako). As 
substrate, 1,2-phenylenediamine dihydrochloride (OPD, Dako) was used and absorbance at 
490 nm was measured using a Cary50 MPR microplate reader (Varian).
ELISA for measurement of sTCC concentration
Maxisorp immunoplates (96-well) were coated with 0.5 µg/mL mouse anti-human TCC (aE11, 
Hycult) in PBS (pH7) (GE Healthcare) at RT, overnight. Between each of the following steps, 
plates were washed four times with PBST (PBS + 0.2% Tween 20). After coating, the plates 
were incubated with plasma samples diluted 5X in AG buffer (PBS + 0.02% NaN3 + 0.2% Tween 
20 + 0.02 M Na2EDTA) for 1h at RT. As standard, zymosan activated serum (ZAS-93, 1000AU/ml, 
Hycult) was used. Plasma sTCC was detected using biotinylated mouse anti-human C6 (1:2000 
in PBST, Quidel) followed by HRP-conjugated streptavidin (1:1000 in PBST, R&D Sytems). As 
chromogen, OPD was used.
C9 cDNA clones for recombinant proteins
To determine if the genetic variants affect the function of the protein, both the wild type (WT) 
and mutant C9 proteins were expressed in vitro. To this end, full-length cDNA encoding 
human C9 with an N-terminal His-tag was purchased from Invitrogen in pMA-T vector. The 
identified variants in C9, i.e. p.Met45Leu, p.Phe62Ser, p.Arg118Trp, p.Gly126Arg, p.Pro167Ser, 
p.Thr170Ile and p.Ala529Thr were introduced using the QuikChange site-directed mutagenesis 
kit (Agilent Technologies), according to manufacturer’s instructions. The primers used are 
listed in Supplementary Table 1. The variants were confirmed by automated Sanger DNA 
sequencing (GATC Biotec). Wild type and mutant C9 cDNA sequences were then subcloned into 
the eukaryotic pCEP4 expression vector (Invitrogen), suitable for transfection of HEK293F cells.
Expression and purification of recombinant C9 proteins
HEK293F cells were transiently transfected with the wild type or mutant C9-pCEP4 constructs 
using FreeStyle Max Reagent according to manufacturer’s instructions (Invitrogen). Secreted 
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supernatants were collected after 2, 4, 6, 8 days, pooled and stored at -20oC. Recombinant wild 
type and mutant C9 proteins were isolated from the collected media using a column of Ni-NTA 
Superflow resin (Qiagen) equilibrated with 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 
pH8 (binding buffer). After extensive washing with binding buffer, bound proteins were eluted 
with 50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, pH8 (elution buffer). The presence 
of C9 in the eluted fractions was verified by 7.5% SDS-PAGE and silver staining. To separate 
monomer and polymer C9 proteins by gel filtration, C9-containing fractions of Ni2+-affinity 
chromatography were pooled, concentrated using an Amicon Filter unit with 50kDa cut-off 
(Millipore) and loaded onto Sephacryl-100 column (GE healthcare) to separate monomer and 
polymer C9 proteins. All preparative works were done at 4oC. The purity of monomer wild type 
and mutant C9 proteins was analyzed by SDS-PAGE and Western blot. 
SDS-PAGE and Western blot
The purified recombinant C9 proteins were separated by gel electrophoresis under reducing 
(25 mM DTT) conditions and transferred to a PVDF membrane using semi-dry blotting apparatus 
(BioRad). The membranes were blocked with Quench solution and C9 was visualized using a 
polyclonal, goat anti-human C9 antibody from Complement Technologies (1:20.000 dilution in 
Quench) followed by incubation with HRP-conjugated rabbit anti-goat Ig (diluted 1:10.000 in 
Quench). Bound antibodies were visualized by the enhanced chemiluminescence (ECL) method 
(Millipore) and analyzed with the ImageLab software (BioRad).
Lysis of erythrocytes by recombinant wild type and mutant C9 proteins
Sheep erythrocytes (Håtunalab) were washed with dextrose gelatin veronal (DGVB++) buffer 
(2.5 mM veronal buffer, pH 7.3, 72 mM NaCl, 140 mM glucose, 0.1% gelatin, 1 mM MgCl2, and 
0.15 mM CaCl2), pelleted and incubated with 1 ml of DGVB++ containing amboceptor (Behring) 
diluted 1:1000 for 20 min at 37oC. Sensitized erythrocytes were washed three times, pelleted 
and resuspended in DGVB++ to obtain a cell suspension of which 10 µl lysed by 90 µl of water 
gives 1.2-1.4 absorbance at 405 nm. The suspension (10 µl) was incubated with 50µl of 2% C9-
depleted serum (Complement Technologies) reconstituted with 50 ng/ml wild type or mutant 
C9 proteins (preliminary titrated concentration of recombinant wild type C9 causing lysis of 
50% of erythrocytes). After incubation for 30 min at 37oC, cells were overlayed with another 50 
µl of DGVB++ and centrifuged. Released hemoglobin levels of the collected supernatants (80 
µl) were measured at 405 nm using Cary50 MPR microplate reader.
Lysis of erythrocytes by sera of C9 carriers and non-carrier controls
To analyse C9-dependent lysis of erythrocytes by sera of carriers and non-carriers, erythrocytes 
were prepared and sensitized as described above. To induce deposition of C5b-8 complexes, 10 µl 
of the erythrocyte suspension was incubated with 50 µl of 2% C9-depleted serum (Complement 
Technologies) diluted in DGVB++ at 37oC for 30 min, shaking at 650 rpm. After incubation, cells 
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were washed three times with 40 mM EDTA-GVB buffer (2.5 mM veronal buffer, pH 7.3, 72 mM 
NaCl, 140 mM glucose and 40mM EDTA) and MAC assembly was induced by serum samples, 
diluted 1:2000 in 40 mM EDTA-GVB (the buffer blocks complement activation and thus prevents 
formation of novel C5b-8/9 complexes from the applied sera). After incubation for 30 min at 
37oC, cells were overlayed with another 50 µl of 40mM EDTA-GVB and centrifuged. Released 
hemoglobin level of the collected supernatants (80 µl) was measured at 405 nm using a Cary50 
MPR microplate reader.
Treatment of ARPE-19 cells using recombinant wildtype and mutant C9 proteins
ARPE-19 cells were plated at 106 cells/ml concentration on 96-well plates (Nunc) in DME/
F12 medium supplemented with 10% FCS. After 1 day, cells were washed and medium was 
changed to DME/F12 without FCS. The next day, cells were centrifuged and treated with 3 
µg/well function-blocking anti-CD59 antibody (IBGRL) for 45 min at 4oC to enhance MAC 
formation. After incubation, cells were treated with 10% C9-depleted serum reconstituted with 
10 µg/ml of purified wild type or mutant C9 proteins in DGVB++ for 2h at 37oC, shaking at 150 
rpm. After 2h, cells were centrifuged at 1500 g for 3min, and supernatants were collected to 
measure lactate dehydrogenase (LDH) release using the Pierce LDH cytotoxicity detection kit 
(ThermoScientific). 
Treatment of ARPE-19 cells by sera of C9 carriers and non-carrier controls
ARPE-19 cells were plated and primed for MAC deposition as described above. To induce C5b-8 
deposition, anti-CD59 sensitized cell were treated with 20% C9-depleted serum in DGVB++ for 
45 min at 37oC, shaking at 150 rpm. After incubation, cells were washed three times in EDTA-
GVB and treated with diluted serum samples. Serum samples were diluted 2.5 times in 40 
mM EDTA-GVB. After 2h, supernatants were collected to measure LDH release and cells were 
analyzed for MAC deposition by flow cytometry.
Lactate-dehydrogenase (LDH) assay
LDH release was measured in 80µl volume using the Pierce LDH cytotoxicity detection kit 
(ThermoScientific) according to the manufacturer’s instruction. LDH release was calculated 
by subtracting the background LDH activity of individual sera and medium treated cells 
(spontaneous LDH release control) from the sera/purified C9-treated cell culture supernatants 
and divided by the total LDH activity (maximum LDH Release induced by 1X lysis buffer), 
multiplied by 100.
Flow cytometry
To detect MAC deposition and viability of ARPE-19 cells after induction of MAC assembly, cells 
were washed twice in PBS and incubated with a neoantigen specific rabbit anti-human C5b-9 
antibody (Complement Technologies, 1:400) for 30min at 4 °C. The cells were washed twice in 
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binding buffer (10mM HEPES, 140 mM NaCl, 2.5 mM CaCl2) and incubated with AlexaFluor647-
conjugated goat anti-rabbit Ab (ThermoScientific, 1:2000), Annexin V-FITC (Immunotools, 
2µl/sample) and ZombieAqua fixable viability dye (BioLegend, 1:2000) for 30 min at RT in the 
dark. The stained cells were washed twice and analyzed by CytoFlex flow cytometer (Beckman 
Coulter). Data were analysed with FlowJo software (Tree Star) and expressed as geometric 
mean fluorescence intensity (gMFI) of C5b-9 signal or % of ZombieAqua and Annexin V double 
positive, late apoptotic cells.
C9 polymerization
Purified C9 protein (5 µM) was allowed to polymerize in TBS in the presence or absence of 15 
µM Zn2+ ions at 37oC for 4h, shaking at 350 rpm. After incubation, samples were separated by 
5-10% gradient gel electrophoresis and visualized by silver staining. 
Statistical analysis
Results investigating the relationship between serum C9 concentration, plasma sTCC level 
and lytic activity of serum samples and the carrier status were analyzed using the Kruskal-
Wallis test with Dunn’s multiple comparison. Data comparing the functional activity and 
polymerization of recombinant wild type and mutant C9 proteins were analysed by one-way 
ANOVA with Dunnett’s multiple comparison. Data were analyzed and figures prepared using 
Prism Software version 7.
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Supplementary Figure 1: Lytic MAC deposition on ARPE-19 cells. ARPE-19 cells were incubated with 
C9-depleted serum supplemented with EDTA-GVB diluted sera of carriers of C9 variants and non-carrier 
controls. MAC assembly on the cell surface was analyzed using a neoantigen specific anti-C5b-9 antibody 
by flow cytometry. Data expressed are median with interquartile range of geometric mean fluorescence 
intensity (gMFI) of two independent experiments measured in duplicate. Differences with p<0.05 were 
considered statistically significant (Kruskal-Wallis test with Dunn’s multiple comparison, nsp>0.05).
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Supplementary Table 1 Number of patients included in this study. 
Whole exome sequencing
Allele-specific PCR assay
Sanger-sequencing
Plasma collected
Serum collected
AMD (n) Control (n) Total (n) Carriers identified (n)
662
1234
13
160
139
131
1368
4
124
111
793
2602
17
284
250
43
84
13*
128
95
*excluding 8 probands carrying a rare variant in the case-control analysis 
Supplementary Table 2 Case-control frequency of rare genetic variants in C9 and number of sera and 
plasma included in functional assays. 
AMD (n)
Allelic
odds-ratio
Fisher two-tailed
p value
Met45Leu
Phe62Ser
Gly126Arg
Pro167Ser
Thr170Ile
Ala529Thr
Arg118Trp
1.554 1.000
1.943 0.478
1.203 1.000
ND 1.000
1.606 0.092
1.572 0.701
ND 0.491
Heterozygous carriers
Control (n)
10 9
2 5
2 3
0 1
33 60
2 4
0 1
AMD (n)
 Noncarriers
Control (n)
684 654
1381 1778
1466 1828
685 662
1484 1843
1457 1854
685 662
Noncarriers with AMD
Noncarriers without AMD
Serum (n) Plasma (n)
Analyzed
13 14
8 8
7 5
1 1
91 59
7 8
0 0
78 78
78 77
ND: not determinable
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Supplementary Table 3 Forward primers used in site-directed mutagenesis to generate C9 variants. 
Mutation Forward primers (5’ to 3’)*
M45L
F62S
G126R
P167S
T170I
A529T
R118W
CACACATAGACTGCAGATTGAGCCCCTGGAGTGAATG
CATAAAGATGCGACTTTGGTGTAATGGTGACAATG
CTTGTCTCAGACAAATGTCTCGTTCAAGAAGCATTG
GGTGACAATGACTGCAGAGACTTTTCAGATGAGG
CATTTTAGGGATGGATTCCCTAAGCACACCTTTTG
GGGATGGATCCCCTAAGCATACCTTTTGACAATGAGTTC
GATGGAAAGTGTTTGTGTACCTGCCCATTCAAATTTGAG
* Mutations are marked in boldface and underlined.
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ABSTRACT
Purpose: A recent genome-wide association study by the International Age-related Macular 
Degeneration Genomics Consortium (IAMDGC) identified seven rare variants that are 
individually associated with age-related macular degeneration (AMD), the most common 
cause of vision loss in elderly. In literature, several of these rare variants have been reported 
with different frequencies and odds ratios across populations of Europe and North America. 
Here, we aim to describe the representation of these seven AMD-associated rare variants in 
different geographical regions based on 24 AMD studies. 
Methods: We explored the occurrence of seven rare variants independently associated 
with AMD, namely (CFH rs121913059 (p.Arg1210Cys), CFI rs141853578 (p.Gly119Arg), C3 
rs147859257 (p.Lys155Gln), and C9 rs34882957 (p.Pro167Ser) and three non-coding variants 
in or near the CFH gene (rs148553336, rs35292876, rs191281603), in 24 AMD case-control 
studies. We studied the difference in distribution, interaction and effect size for each of the rare 
variants based on the minor allele frequency within the different geographical regions.
Results: We demonstrate that two rare AMD-associated variants in the CFH gene (rs121913059 
[p.Arg1210Cys] and rs35292876) deviate in frequency among different geographical regions 
(p=0.004 and p=0.001, respectively). The risk estimates of each of the seven rare variants were 
comparable across the geographical regions.
Conclusion: Our results emphasize the importance of identifying population-specific rare 
variants, for example by performing sequencing studies in case-control studies of various 
populations, because their identification may have implications for diagnostic screening and 
personalized treatment.
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INTRODUCTION
Genetic diversity is observed among populations of different ancestries. Allele frequencies can 
exhibit large diversity among populations due to forces like genetic drift and natural selection. 
While most common variants are shared worldwide, rare variants (minor allele frequency [MAF] 
<1%) have the tendency to cluster in specific populations. Particularly population-specific rare 
variants tend to have a strong functional effect1. 
In age-related macular degeneration (AMD), large variability in rare variant frequency has been 
reported in case-control studies of various populations, for instance for variant rs121913059 
(p.Arg1210Cys) in complement factor H (CFH). CFH rs121913059 was first reported in a case-
control study from the United States2. While some studies could replicate the finding3-5, other 
Caucasian studies 6-9 and Asian studies 10,11 were unable to replicate its strong association 
(Table 1). Another example, variant rs141853578 (p.Gly119Arg) in complement factor I (CFI) 
first reported in a European cohort7, was screened both in a British12 and American13 cohort 
(OR = 22.2; 8.5 and 2.6, respectively). However, while the variant was associated with AMD, its 
risk effect size was much weaker when compared to the first report. 
Table 1. Minor allele frequencies of the CFH rs121913059 (p.Arg1210Cys) variant among different 
geographical regions reported in literature.
 Source Carriers 
(n)
Total 
Cases 
(n)
Total 
Controls 
(n)
MAF 
Cases 
(%)‡
MAF Odds-
Ratio
P-value
Controls 
(%)‡ 
World Fritsche2016 3 108 16144 17832 0.319 0.014 20.3 8.9 x 10-24
Eastern USA
Raychaudhuri2011 2# 34 2414 1120 0.684 0.045 NA 8.0 × 10-5
Zhan2013 5 24 2268 2268 0.507 0.022 23.1 2.9 × 10-6
European
Helgason2013 8 0 1143 51435 0 0 NA NA
Saksens2016 9* 0 1589 1386 0 0 NA NA
Recalde2016 4 5 259 330 0.965 0 NA NA
Asian
Shen2012 11 0 258 426 0 0 NA NA
Miyake2015 10 1 1364 1208 0.037 0 NA NA
Additional publications from: the Boston study#13,15 and EUGENDA study*6,7. ‡ major allele C, minor allele 
T. NA = Not available or not reported.
In a recent genome-wide association study of the International Age-related Macular Degeneration 
Genomics Consortium (IAMDGC)3 seven rare variants were observed to independently confer 
risk for AMD. All seven rare variants are localized in or near genes encoding components of 
the complement system, namely CFH, CFI, and complement components 3 and 9 (C3 and C9).
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The difference in association for rare variants among different AMD case-control studies may 
reflect the difference in distribution of such rare alleles across geographical regions. This 
observation raises the question if these variants identified by the IAMDGC are represented 
in all case-control studies or whether the association is driven by one or more studies from 
a specific geographical region. Therefore, we sought to evaluate the representation of these 
seven AMD-associated rare variants in 24 AMD case-control studies of different geographical 
regions. 
MATERIALS AND METHODS
Data for this study were provided by the IAMDGC. The genotypes are in part available via 
dbGaP under accession number phs001039.v1.p1. The original dataset contained data from 
40,633 individuals of European ancestry as described by Fritsche et al.3 For analyses of the 
current study, participants from the Utah case-control study were excluded due to their 
mixed regions of origin. Also, the Jerusalem case-control study was excluded due to its small 
sample size compared to the other geographical regions. Final analyses were performed on 
39,582 participants deriving from 24 of 26 studies3. The included studies were grouped in five 
geographical regions: eastern USA, western Europe, Britain, western USA and Australia (S1 
Table). Data were collected by all study groups in accordance with the tenets of the Declaration 
of Helsinki; participants provided informed consent and study protocols were approved by local 
ethical committees3. 
The MAF in each region was calculated and compared independently of AMD status. For 
comparison of effect sizes and interaction analyses, individuals were assigned “AMD” 
when exhibiting signs of (1) advanced AMD defined as geographic atrophy and/or choroidal 
neovascularization in at least one eye, or (2) non-advanced AMD defined as pigmentary changes 
in the macula and/or more than five macular drusen with a diameter ≥63 µm. Individuals 
without any reported signs of AMD were assigned “No AMD”. 
Genotype data of seven rare genetic variants were selected from array based data generated by 
the IAMDGC3. Fritsche et al.3 showed these seven rare variants to be independently associated 
with AMD: CFH rs121913059 (p.Arg1210Cys), CFI rs141853578 (p.Gly119Arg), C3 rs147859257 
(p.Lys155Gln), and C9 rs34882957 (p.Pro167Ser) and three non-coding variants in or near CFH 
(rs148553336, rs35292876, rs191281603). 
The software package SAS, (Statistical Analysis System Institute, V9.2) was used to compare MAFs 
between the different geographical regions in a logistic regression analysis with Firth correction 
(S1 Supporting information)14. Furthermore, we estimated the mean allele frequency of each rare 
159
GEOGRAPHICAL DISTRIBUTION OF AMD ASSOCIATED RARE VARIANTS
genetic variant in each of the geographical regions including a 95% confidence interval (details 
provided in S1 Supporting information). To study a potential difference in effect size of each 
variant between the geographical regions, interaction analyses were performed using binary 
logistic regression models with SPSS statistics software (IBM SPSS Statistics, V22.0). 
RESULTS 
Demographic characteristics for each of the five geographical regions are shown in supporting 
information S1 Table. The characteristics of participants from the different regions were 
comparable, although the British study samples were slightly younger than the others, and the 
western European study samples included relatively more female participants compared to the 
remainder . These differences were comparable in both cases and controls. 
1.53% 1.84%
1.22%
1.33%
1.35%
B
0.23% 0.17%
0.08%
0.08%
0.13%
A
Figure 1. The two rare variants in CFH that are differently distributed variants among different 
geographical regions. Minor allele frequencies (in percentage) for CFH rs121913059 (A) and CFH 
rs35292876 (B). Variants mapped to geographical location (from left to right): western USA, eastern USA, 
Britain, western Europe, and Australia.
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We analyzed the difference in distribution of the seven rare variants among case-control studies 
from eastern USA, western Europe, Britain, western USA and Australia using logistic regression 
analysis with Firth correction (Table 2; Figure 1), and observed a difference in distribution of 
variants CFH rs121913059 (p.Arg1210Cys, p=0.004) and CFH rs35292876 (p=0.001) across the 
different geographical regions. CFH rs121913059 was found at a higher frequency in eastern 
USA, especially compared to Britain and Australia (p=0.011 and p=0.003, respectively). CFH 
rs35292876 was found at a higher frequency in western Europe, compared to all other regions 
(ranging from p<0.001 in Britain to p=0.012 in Eastern USA). The other five variants were found 
to have similar allele frequencies among all geographical regions. 
Table 2. Distribution and interaction analysis of seven rare AMD-associated genetic variants across 
five geographical regions. 
 Difference in distribution 
between geographical 
regions#
Interaction 
Analysis*
Overall effect 
size‡
p-value p-value OR (95%CI)
CFH rs121913059 (p.Arg1210Cys) 0.004 0.665 24.2 (8.9-65.6)
CFI rs141853578 (p.Gly119Arg) 0.707 0.563 3.7 (2.5-5.7)
 C3 rs147859257 (p.Lys155Gln) 0.665 0.680 2.8 (2.3-3.4)
 C9 rs34882957 (p.Pro167Ser) 0.315 0.572 1.7 (1.5-2.0)
 CFH rs148553336 0.053 0.015 0.5 (0.4-0.6)
 CFH rs35292876 0.001 0.709 2.3 (2.0-2.6)
 CFH rs191281603 0.735 0.980 0.9 (0.7-1.1)
#Logistic Regression with Firth correction. Individual Wald Chi-Square from likelihood ratio test for each 
of the variants across the geographical regions. *Interaction Analysis: Effect sizes in entire study and 
interaction analysis to study potential differences in effect size between cohorts. ‡Overall effect size 
adjusted for geographical region. Bold values: p-value considered significant after Bonferroni correction 
(p<0.007).
The difference in distribution is also reflected by the estimated MAFs of each variant in the 
different geographical regions (S2 Table). The allele frequency of CFH rs121913059 is nearly 
three times higher in eastern USA than in Britain and Australia. Noteworthy is the near 
absence of this risk variant in control individuals without AMD, indicating that the difference in 
distribution appears to be driven solely by AMD individuals (S3 Table). 
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To determine if the effect size was influenced by geographical region we performed interaction 
analyses for each variant. We observed that the risk associated with each specific rare variant 
is independent of geographical region (Table 2). Overall effect sizes of the rare variants are 
comparable to the effect sizes reported in the IAMDGC study3.
DISCUSSION
The distribution of rare CFH variants rs121913059 (p.Arg1210Cys) and rs35292876 was 
significantly different between several of the studied geographical regions. This confirms 
differences reported in previous studies for the CFH rs121913059 variant2-11,13,15 (Table 1). CFH 
rs121913059 was first associated with AMD in study from the USA2, however the association 
was not consistently replicated in Dutch/German7, Icelandic8, Japanese10 and Chinese11 studies. 
In this study we confirmed the hypothesis that rare variants can be differently distributed 
among geographical regions but, as expected, the risk estimates are comparable across the 
geographical regions.
In AMD, a difference in geographical distribution has already been described for common risk 
haplotypes of CFH and ARMS2 genes, which are the most prominent common genetic AMD risk 
factors3. While Asian populations report a lower frequency of CFH risk haplotypes, the opposite 
holds true for the ARMS2/HTRA1 risk haplotype which is more prevalent in Asians compared to 
Caucasian populations16,17. These patient and population specific variations have implications 
for genetic counseling and carrier screening in both diagnostic and research settings. 
Besides single variant associations, a significant burden of rare variants in the CFH and CFI 
genes has been reported for AMD3,15. The disease burden in these genes is attributed to the 
cumulative effect of rare coding variants, some of which are identified in multiple studies, 
while others are restricted to a single population or even a single patient18. Carriers of specific 
rare genetic variants in the complement genes that increase complement activation may 
benefit more from complement inhibiting therapy than those who do not carry such variants18. 
Personalized treatment aiming at complement activating rare variants in clinical trials may 
only be applicable to specific populations where these variants are sufficiently common.
It is likely that additional rare variants, other than CFH Arg1210Cys and rs35292876, fluctuate in 
frequency among geographical regions. To identify these variants, additional large sequencing 
studies will need to be performed in populations originating from diverse geographic regions. 
Up to now, large sequencing initiatives are predominantly of North American or European 
origin, and sample sizes for non-European-descent population are limited3,19. Recruiting case-
control studies from other geographical regions and ancestries could allow for identification of 
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novel highly penetrant rare variants implicated in AMD pathogenesis. These variants may be 
located in known AMD pathways, such as the complement system, or novel pathways20. 
In conclusion, we demonstrated that rare AMD-associated variants CFH rs121913059 and 
rs35292876 are differently distributed among different geographical regions. These results 
emphasize the importance of identifying population-specific rare variants in AMD.
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SUPPLEMENTARY INFORMATION
S1 Supporting information: Code for the software package SAS for a logistic regression analysis and 
Firth’s bias correction.
*Load raw dataset and implement filter criteria;
*The following commands will analyze only variant CFH_Arg1210Cys;
libname ‘name’;
data geographic;
set lees.’name’;
if include=1;
run;
proc print data=geographic;
run;
*Create variables to summarize data per geographical region;
data Add;
length samplename $27;
samplename = ‘fake’;
continent=1;
output;
samplename = ‘fake’;
continent=3;
output;
samplename = ‘fake’;
continent=4;
output;
samplename = ‘fake’;
continent=5;
output;
samplename = ‘fake’;
continent=6;
output;run;
proc print data=Add;
run;
data geographic2;
set geographic Add;
run;
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*Logistic regression with Firth correction for each of the regions as reference;
*Using Proc logistic to suppresses the display of results;
*For more information check http://support.sas.com/en/support-home.html ; 
proc logistic descending data =geographic2;
class continent (param=ref ref=’1’) CFH_Arg1210Cys ;
model CFH_Arg1210Cys = continent/cl firth;
output out=geographic_out predicted=pred lower=pred_low upper=pred_up;
run;
proc logistic descending data =geographic2;
class continent (param=ref ref=’3’) CFH_Arg1210Cys ;
model CFH_Arg1210Cys = continent/cl firth;
run;
proc logistic descending data =geographic2;
class continent (param=ref ref=’4’) CFH_Arg1210Cys ;
model CFH_Arg1210Cys = continent/cl firth;
run;
proc logistic descending data =geographic2;
class continent (param=ref ref=’5’) CFH_Arg1210Cys ;
model CFH_Arg1210Cys = continent/cl firth;
run;
proc logistic descending data =geographic2;
class continent (param=ref ref=’6’) CFH_Arg1210Cys ;
model CFH_Arg1210Cys = continent/cl firth;
run;
* Calculate estimated allele frequency per geographical region;
data geographic_out2;
set geographic_out;
if samplename=’fake’;
pred_low=pred_low*100;
pred_up=pred_up*100;
pred=pred*100;
keep continent pred pred_up pred_low;
run;
proc print data=geographic_out2;
var continent pred_low pred pred_up; 
run;
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S1 Table. Demographic characteristics of AMD cohorts grouped in five geographical regions. 
Eastern USA1 Western 
Europe2
Britain3 Western 
USA4
Australia5
Participants 
(n)
18454 6590 4329 4226 5983
Mean Age 
(years ± SD)
74.0 ± 9.2 74.1 ± 8.2 69.6 ± 10.4 74.8 ± 10.0 74.3 ± 9.7
Gender Male (%) 7934 (43.0%) 2512 (38.1%) 1743 (40.3%) 1875 (44.4%) 2531 (42.3%)
Female (%) 10520 (57.0%) 4078 (61.9%) 2586 (59.7%) 2351 (55.6%) 3452 (57.7%)
AMD status AMD (%) 11564 (62.7%) 3865 (58.6%) 2125 (49.1%) 2061 (48.8%) 2449 (40.9%)
No AMD (%) 6890 (37.3%) 2725 (41.4%) 2204 (50.9%) 2165 (51.2%) 3534 (59.1%)
1)Eastern USA: AREDS, BDES, CWRU, Marshfield, Vanderbilt, Miami, Michigan, Pittsburgh, Pennsylvania, 
Baltimore. 2)Western Europe: Regensburg, Rotterdam, Creteil, Paris, Bonn, Cologne, UMCN. 3)Britain: 
Cambridge, Southampton, NHS_HPF, Edinburgh. 4)Western USA: University California, UCSD, Oregon. 5)
Australia: Westmead, UWA/LEI/ Flinders and Melbourne.
S2 Table. Overall estimated mean MAF of seven rare AMD-associated genetic variants across five 
geographical regions. 
 Eastern USA Western Europe Britain Western USA Australia
CFH rs121913059
0.229 
(0.185-0.283)
0.178 
(0.119-0.267)
0.087 
(0.042-0.177)
0.136 
(0.076-0.242)
0.088 
(0.048-0.161)
CFI rs141853578
0.197 
(0.156-0.247)
0.163 
(0.107-0.249)
0.249 
(0.163-0.379)
0.184 
(0.112-0.302)
0.213 
(0.145-0.314)
C3 rs147859257
0.803 
(0.717-0.900)
0.907 
(0.758-1.084)
0.918 
(0.738-1.143)
0.917 
(0.734-1.144)
0.840 
(0.691-1.020)
C9 rs34882957
1.196 
(1.090-1.312)
1.286 
(1.107-1.493)
1.276 
(1.060-1.536)
1.366 
(1.140-1.637)
1.065 
(0.896-1.266)
CFH rs148553336
0.630 
(0.554-0.716)
0.573 
(0.457-0.717)
0.815 
(0.645-1.027)
0.503 
(0.373-0.679)
0.740 
(0.601-0.910)
CFH rs35292876
1.535 
(1.414-1.665)
1.840 
(1.624-2.084)
1.230 
(1.018-1.485)
1.331 
(1.107-1.599)
1.350 
(1.158-1.573)
CFH rs191281603
0.321 
(0.268-0.384)
0.391 
(0.297-0.513)
0.295 
(0.200-0.434)
0.337 
(0.234-0.486)
0.313 
(0.228-0.431)
Calculated by SAS for each variant in percentage separated by geographical region including 95% 
confidence interval
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S3 Table: Minor allele frequencies (%) of seven rare AMD-associated genetic variants across five 
geographical regions stratified by AMD status.
  Eastern 
USA
Western 
Europe
Britain Western 
USA
Australia
CFH rs121913059
AMD 0.359 0.272 0.165 0.243 0.204
No AMD 0.007 0.037 0.000 0.023 0.000
CFI rs141853578
AMD 0.259 0.259 0.353 0.291 0.388
No AMD 0.087 0.018 0.136 0.069 0.085
C3 rs147859257
AMD 1.020 1.216 1.365 1.431 1.450
No AMD 0.435 0.459 0.476 0.416 0.410
C9 rs34882957
AMD 1.397 1.630 1.647 1.698 1.307
No AMD 0.856 0.789 0.907 1.039 0.891
C3 rs147859257
AMD 1.020 1.216 1.365 1.431 1.450
No AMD 0.435 0.459 0.476 0.416 0.410
CFH rs148553336
AMD 0.519 0.349 0.376 0.291 0.286
No AMD 0.813 0.881 1.225 0.693 1.047
CFH rs35292876
AMD 1.889 2.393 1.765 1.868 2.103
No AMD 0.936 1.046 0.703 0.808 0.821
CFH rs191281603
AMD 0.307 0.336 0.259 0.315 0.286
No AMD 0.341 0.459 0.318 0.346 0.325
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ABSTRACT
Importance: Rare variants in the complement factor H (CFH) gene and their association with 
age-related macular degeneration (AMD) have been described. However, there is limited 
literature on the phenotypes accompanying these rare variants. Phenotypical characteristics 
could help ophthalmologists select patients for additional genetic testing.
Objective: To describe the phenotypical characteristics of patients with AMD carrying a rare 
variant in the CFH gene.
Design, setting and participants: In this cross-sectional study, we searched the genetic 
database of the department of ophthalmology at the Radboudumc (tertiary ophthalmologic 
referral center) and the European Genetic Database for patients with AMD with a rare genetic 
variant in the CFH gene. Patient recruitment took place from March 30, 2006, to February 18, 
2013, and data were analyzed from November 30, 2015, to May 8, 2017. Phenotypical features 
on fundus photographs of both eyes of patients were graded by two independent reading center 
graders masked for carrier status.
Main Outcomes and Measures: Differences in phenotypical characteristics between rare 
variant carriers and noncarriers were analyzed using univariable generalized estimated 
equations logistic regression models accounting for intereye correlation. 
Results: Analyses included 100 eyes of 51 patients with AMD carrying a CFH variant (mean [SD] 
age, 66.7 [12.1] years; 64.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] 
age, 67.1 [11.8] years; 54.9% female). Carrying a rare pathogenic CFH variant was associated 
with larger drusen area (odds ratio range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-
155.99]; P = 0.002), presence of drusen with crystalline appearance (odds ratio, 3.24; 95% CI, 
1.24-8.50; P = 0.02), and drusen nasal to the optic disc (odds ratio range, 4.03 [95% CI, 1.70-
9.56] to 7.42 [95% CI, 0.65-84.84]; P = 0.003).
Conclusions and Relevance: Identification of rare CFH variant carriers may be important 
for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, 
drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to have 
a rare variant in the CFH gene. However, it is not likely that carriers can be discriminated 
from noncarriers based solely on phenotypical characteristics from color fundus images. 
Therefore, ophthalmologists should consider genetic testing in patients with these phenotypic 
characteristics in combination with other patient characteristics, such as early onset, cuticular 
drusen on fluorescein angiography, and family history of AMD. 
173
PHENOTYPE CHARACTERISTICS OF AMD PATIENTS WITH RARE CFH VARIANTS
INTRODUCTION
Age-related macular degeneration (AMD) is a common multifactorial eye disease in Western 
countries,1 however the exact pathophysiology of the disease is not yet completely understood. 
Environmental factors, such as age and smoking,2,3 and both common and rare genetic 
variants have been identified as risk factors for AMD.4 A large number of these genetic variants 
are located in genes encoding components of the complement system. Additionally, higher 
local and systemic complement activity has been reported in patients with AMD compared 
with control individuals.5-7 Together, these findings implicate a pivotal role of the complement 
system in AMD.
Rare genetic variants located in the complement factor H (CFH) gene are among the variants 
that confer the highest risk for AMD.4,8,9 The CFH gene encodes factor H (FH), a regulator of the 
alternative pathway of the complement system. Factor H inhibits the C3-convertase (C3bBb) 
and also acts as cofactor for factor I-mediated inactivation of C3b,10 leading to decreased 
activity and thereby preventing overactivation of the complement system. Several studies 
showed lower systemic FH levels in patients carrying a rare CFH variant.10,11 Furthermore, 
functional studies have reported an altered function of FH in patients carrying a rare variant 
in CFH resulting in increased complement activation despite normal systemic FH levels.9,12,13 
While antivascular endothelial growth factor treatment is available for neovascular AMD, there 
is currently no effective treatment available for the early and atrophic stages of AMD. Because 
the complement system plays an important role in AMD pathogenesis, therapies targeting 
different components of the complement system are being developed. Currently, a number 
of phase 2/3 clinical trials are in progress, and so far two phase 2 trials have been completed 
with mixed results.9,14,15 The Complement Inhibition With Eculizumab for the Treatment of Non-
Exudative Age-Related Macular Degeneration (COMPLETE) study did not show decreased 
atrophy progression after administration of eculizumab,16 while the MAHALO study showed 
beneficial effect of lampalizumab treatment on reducing atrophy progression.17 
With upcoming therapies targeting the complement system, it may be important to identify 
the patients who will most likely benefit from these therapies. Patients carrying a rare variant 
in the CFH gene seem to be a very suitable patient group for complement inhibiting therapies 
because of the associated functional consequences on complement activation.12 However, it 
is expensive to genetically screen every patient with AMD in a diagnostic setting; therefore, 
it is desirable to preselect cases for genotyping based on phenotype. Unfortunately, there is 
limited literature on the phenotypes accompanying these CFH variants. Previously, a higher 
burden of extramacular drusen was reported in families carrying rare CFH variants compared 
with unrelated AMD cases; however, other distinct phenotypical characteristics were not 
described.11 Another study described phenotypical characteristics in a more detailed manner, 
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but only included individuals carrying the rare p.Arg1210Cys variant in CFH.18 We hypothesize 
that all pathogenic CFH variants share phenotypical characteristics owing to their functional 
influences on FH. Detailed characterization of phenotypes caused by a broad spectrum of 
rare CFH variants is lacking. Therefore, we aim to describe the phenotypical characteristics 
of patients with AMD carrying a rare variant in the CFH gene. A distinct phenotype description 
of these CFH carriers will enable ophthalmologists to select patients for additional genetic 
testing and complement-inhibiting therapies more efficiently. 
METHODS
Study Population
In this retrospective cross-sectional study, we searched the genetic database of the department 
of ophthalmology at the Radboud university medical center, Nijmegen, the Netherlands 
(Radboudumc) and the European Genetic Database (EUGENDA), a multicenter database for 
clinical and molecular analysis of AMD, for individuals with a rare genetic variant in the CFH 
gene. Patient recruitment took place from March 30, 2006, to February 18, 2013. We selected 
AMD cases carrying protein-altering variants with a population frequency of less than 1%. We 
defined AMD as the presence of at least 10 small drusen (<63 µm) and pigmentary changes, 
intermediate or large drusen (≥63 µm), or late AMD, including subfoveal geographic atrophy 
(GA) and/or choroidal neovascularization (CNV) in at least one eye on color fundus images. 
Details of this classification are described elsewhere.19
 In total, 51 patients, with 33 different CFH variants, were identified and included in this study, 
hereafter referred to as carriers. Additionally, for each carrier, we selected from the European 
Genetic Database two similarly aged AMD cases (±2 years) without a rare genetic variant 
associated with AMD; these cases were defined as noncarriers (n = 102). For two carriers color 
fundus images of only one eye were available; therefore, final analyses included 100 eyes of 51 
carriers and 204 eyes of 102 noncarriers. All participants indicated to be of European descent. 
Written informed consent was provided by all participants. The study was approved by the 
local ethics committee on research involving human participants, Commissie Mensgebonden 
Onderzoek Regio Arnhem-Nijmegen, and the local committee of University Hospital Cologne 
and was performed in accordance with the tenets of the Declaration of Helsinki. 
Genotyping
Whole-exome sequencing (WES) and/or Sanger sequencing was previously performed. For 
both approaches, DNA was extracted from venous blood using standard procedures. Most CFH 
carriers (n = 42) were identified through WES. Preparation and sequencing of the DNA samples 
were done as previously described.12 In short, exome capture Nimblegen SeqCap EZ V2 kit 
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(Roche) paired-end sequencing was performed on an Illumina HiSeq2000 sequencer using 
TruSeq V3 chemistry (Illumina) followed by downstream quality control and genotyping of the 
samples. For this study, WES data were filtered specifically for the CFH gene (HUGO Gene 
Nomenclature Committee ID: 4883; NM_000186). Additional filtering steps on the data were 
implemented to select genetic variants that result in a splice-site or protein change (non-
synonymous) as these variants are more likely to be pathogenic. We focused on rare genetic 
variants only (minor allele frequency ≤ 1%) as based on the Exome Aggregation Consortium 
(ExAC) database, specifically the non-Finnish European population.20 Individual variants 
were confirmed with Sanger sequencing using primers designed by Primer3 software.21 The 
remainder of CFH carriers (n = 9) was identified through conventional Sanger sequencing of 
the entire CFH gene as described in detail previously.22 We excluded rare CFH variants with 
a described protective effect in case-control analyses (c.2850G>T p.Gln950His) or a likely 
benign effect in functional studies (c.2669G>T p.Ser890Ile, c.2867C>T p.Thr956Met, c.3019G>T 
p.Val1007Leu).9 All CFH variants included in this study are described in the eTable in the in the 
Supplement
For all noncarriers, WES data were available and screened for rare genetic variants in the CFH, 
CFI, C3 and C9 genes associated with AMD. Only individuals without any rare variant in the CFH 
gene or a described pathogenic rare variant in the other AMD-associated genes9 were included 
in this study as noncarriers.
Image Assessment
Digital 35° or 40° field of view color fundus photographs centered on the fovea were performed 
with a Topcon TRC 50IX camera (Topcon Corporation) or Canon 60 UVi fundus camera (Canon), 
respectively. Color fundus photographs were analyzed for this study by two senior graders from 
an independent reading center (Moorfields Eye Hospital, London, England, UK) according to 
a standardized grading protocol. The following fundus features were assessed: predominant 
type of drusen, largest type of drusen in the central field, percentage of the area of the 
Early Treatment Diabetic Retinopathy Study (ETDRS) grid covered with drusen, presence of 
extramacular drusen (defined as drusen outside the ETDRS grid), drusen nasal to the optic 
disc, reticular drusen, drusen with crystalline appearance, serogranular/serous drusen 
pigment epithelium detachment, pigmentary abnormalities, geographic atrophy, or signs of 
neovascularization. 
Statistical analysis
Data were analyzed from November 30, 2015 to May 8, 2017. Demographic characteristics of the 
two study groups were compared using one-way analysis of variance or the χ2 test. Phenotypical 
characteristics were individually assessed using binary logistic regression models. Generalized 
estimating equations procedures were used to correct for the fellow eye. To compare the 
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frequencies of late AMD subtypes between carriers and noncarriers, we performed a χ2 test 
based on the more severely affected eye of each patient. In case both geographic atrophy and 
choroidal neovascularization were present in an individual, it was classified as mixed late AMD. 
A phenotypic risk score for each eye was calculated as the sum of regression coefficients of 
all individual phenotypical characteristics resulting from univariable generalized estimating 
equations logistic regression analyses. A receiver operating characteristic curve was obtained 
and the area under the curve was measured for this risk score. Finally, symmetry between eyes 
was calculated as follows: number of equal phenotypical characteristics between right and left 
eye divided by the number of phenotypical characteristics graded times 100%. All statistical 
analyses were performed using SPSS statistics software (released 2013; IBM SPSS Statistics 
for Windows, Version 22.0; IBM Corp).
RESULTS
In total, 100 eyes of 51 carriers and 204 eyes of 102 noncarriers were included for analyses. 
Demographic and environmental characteristics were comparable between carriers and 
noncarriers (Table 1). The frequency of common genetic variants in CFH, ARMS2, and C3 
seems to be slightly higher in noncarriers compared with carriers. However, the minor allele 
frequencies of these common variants in noncarriers are comparable with the general AMD 
population.23 This may imply that carriers of rare CFH variants are less burdened by common 
AMD risk variants and that their AMD risk is rather attributable to the rare variants.
When comparing the fundus features by carrier status, the odds of carrying any rare CFH 
variant increases with increasing drusen area within the ETDRS grid (odds ratio [OR] up to 
6.85 when more than 50% of the ETDRS grid is covered with drusen, P = 0.004), and with 
the presence of serogranular/serous drusen pigment epithelium detachment (OR, 4.74; 95% 
CI, 1.30-17.31; P = 0.02). Additionally, drusen deposition in rare variant carriers is often not 
limited to the central retina; these carriers tend to have extramacular drusen (80.8%) and 
drusen nasal to the optic disc (43.8%) more frequently than noncarriers (73.4% and 35.1%, 
respectively), although these differences were not significant. The association of all assessed 
fundus features of carriers and noncarriers are shown in Table 2.
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Table 1: General Characteristics of the Study Groups.
Characteristic
No. (%)
Noncarriers 
(n = 102; 204 eyes)
Carriers 
(n = 51; 100 eyes)
Age at participation, mean (SD), y 67.1 (11.8) 66.7 (12.1)
Sex
- Male 46 (45.1) 18 (35.3)
- Female 56 (54.9) 33 (64.7)
Smoking status
- Never 21 (22.3) 16 (39.0)
- Past 53 (56.4) 17 (41.5)
- Current 20 (21.3) 8 (19.5)
BMI, mean (SD) 26.1 (4.1) 26.5 (4.2)
Family history for AMD
- Yes 52 (58.4) 27 (67.5)
- No 37 (41.6) 13 (32.5)
Common genetic variants, 
No. of minor allels/total No. of alleles (MAF %)
- ARMS2, rs10490923, T 75/176 (42.6) 17/74 (23.0)
- CFH, rs1061170, C 99/176 (56.3) 29/76 (38.2)
- C3, rs2230199, G 49/174 (28.2) 10/76 (13.2)
Abbreviations: ARMS2, age-related maculopathy susceptibility 2; BMI, body mass index (calculated as 
weight in kilograms divided by height in meters squared); C3, complement component 3; CFH, complement 
factor H; MAF, minor allele frequency.
Because the carrier group contains both rare variants known to be associated with AMD and 
rare variants of unknown clinical significance, we repeated the analyses with stricter inclusion 
criteria comparing only cases carrying a known pathogenic variant (n = 25) with noncarriers 
(Table 3). Known pathogenic variants included rare CFH variants associated with AMD in case-
control or segregation analyses or with a described functional effect. This subanalysis showed 
an even higher association between drusen area within the ETDRS grid and rare pathogenic 
CFH variant carriers (OR range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-155.99]; P = 
0.002). Additionally, intermediate and large drusen located nasal to the optic disc (OR range, 
4.03 [95% CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = 0.003) and the presence drusen with 
crystalline appearance (OR, 3.24; 95% CI, 1.24-8.50; P = 0.02) were significantly associated with 
carrying a rare pathogenic CFH variant. Subanalysis of late AMD cases only (n = 71) showed 
a higher frequency of late atrophic AMD in rare pathogenic variant carriers (57.1%) compared 
with noncarriers (28.1%), although this was not significantly different (P = 0.12). Notably, the 
association between serogranular/serous drusen pigment epithelium detachment and carrier 
status did not remain significant but still tended to increase the odds of carrying a rare CFH 
variant. Examples of color fundus photographs of carriers of rare CFH variants with the 
associated fundus features are displayed in Figure 1.
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Table 2: Phenotypical Characteristics of Carriers and Noncarriers of Rare CFH Variants.
Phenotypic characteristic
No. of Eyes (%)
Odds ratio 
(95% CI)a P-value
Noncarrier 
(n = 204)
Carrier 
(n = 100)
Predominant drusen type within ETDRS grid
None or small drusen (<63 µm) 32 (15.7) 12 (12.0) Reference 0.31
Intermediate drusen (63-125 µm) 107 (52.5) 45 (45.0) 1.12 (0.47-2.68)
Large drusen (>125 µm) 65 (31.9) 43 (43.0) 1.76 (0.71-4.38)
Largest drusen type within central field
None or small drusen (<63 µm) 106 (52.5) 44 (44.9) Reference 0.58
Intermediate drusen (63-125 µm) 77 (38.1) 44 (44.9) 1.38 (0.75-2.52)
Large drusen (>125 µm) 19 (9.4) 10 (10.2) 1.27 (0.46-3.48)
Proportion of grid area covered by drusen, %
0-10 111 (54.4) 27 (27.3) Reference 0.004b
10-25 61 (29.9) 41 (41.4) 2.76 (1.36-5.63)
25-50 29 (14.2) 26 (26.3) 3.69 (1.58-8.58)
>50 3 (1.5) 5 (5.1) 6.85 (1.37-34.37)
Extramacular drusen
Absent 54 (26.6) 19 (19.2) Reference 0.27
Present 149 (73.4) 80 (80.8) 1.53 (0.72-3.24)
Drusen nasal to the optic disc
None or small drusen (<63 µm) 89 (65.0) 45 (56.3) Reference 0.47
Intermediate drusen (63-125 µm) 46 (33.6) 32 (40.0) 1.38 (0.69-2.74)
Large drusen (>125 µm) 2 (1.5) 3 (3.8) 2.97 (0.30-29.51)
Reticular drusen
Absent 163 (86.7) 83 (93.3) Reference 0.14
Present 25 (13.3) 6 (6.7) 0.47 (0.18-1.27)
Drusen with crystalline appearance
Absent 178 (89.4) 76 (81.7) Reference 0.15
Present 21 (10.6) 17 (18.3) 1.90 (0.80-4.48)
SPED
Absent 199 (97.5) 84 (89.4) Reference 0.02
Present 5 (2.5) 10 (10.6) 4.74 (1.30-17.31)
RPE pigmentation
Absent 84 (45.4) 31 (32.3) Reference 0.08
Present 101 (54.6) 65 (67.7) 1.74 (0.93-3.27)
Geographic atrophy
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Absent 154 (76.2) 65 (70.7) Reference 0.42
Present 48 (23.8) 27 (29.3) 1.33 (0.66-2.69)
Neovascular AMD
Absent 144 (72.4) 79 (82.3) Reference 0.12
Present 55 (27.6) 17 (17.7) 0.56 (0.28-1.15)
Abbreviations: AMD, age-related macular degeneration; CFH, complement factor H; ETDRS, Early 
Treatment Diabetic Retinopathy Study; RPE, retinal pigment epithelium; SPED, serogranular/serous 
drusen pigment epithelium detachment. a The presented odds ratios result from univariable generalized 
estimating equations logistic regression analyses. b P-value remained significant after Bonferroni 
correction for multiple testing.
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Patient with symmetric appearance of drusen and drusen nasal to optic discA
B
D
C
Patient with extensive bilateral drusen and drusen with crystalline appearance
Patient with primary geographic atrophy and extramacular drusen
Patient with hyperpigmentations and large soft drusen
A) A woman in her 50s 
(CFHc.2537A>G, p.Gln846Arg) 
with a symmetric appearance of 
extensive drusen deposition within 
the Early Treatment Diabetic 
Retinopathy Study grid extending 
beyond the inferior and superior 
retinal arcades and nasal to the 
optic disc in both eyes. 
B) A man in his 60s (CFHc.550delA, 
p.Ile184Leufs*33) with extensive 
bilateral drusen deposition 
inside and outside the Early 
Treatment Diabetic Retinopathy 
Study grid and nasal to the 
optic disc, presence of drusen 
with crystalline appearance, 
and hypopigmentations and 
hyperpigmentations. 
C) Woman in her 70s (CFH 
c.524G>A, p.Arg175Gln) with 
primary geographic atrophy 
surrounded by predominantly large 
drusen, some with crystalline 
appearance, beyond the retinal 
arcades and the optic disc.
D) A man in his 40s (CFH 
c.1198C>A, p.Gln400Lys) with 
hyperpigmentations and mainly 
centrally located large soft 
drusen but also extending to the 
peripheral retina.
Figure 1. Color Fundus Photographs of Carriers of Rare Variants in the Complement Factor H (CFH) 
Gene.
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Table 3. Associations of phenotypical characteristics with confirmed pathogenic rare CFH variants.
Phenotypic characteristic
No. of Eyes (%)
Odds ratio 
(95% CI)a
P-valueNoncarrier 
(n = 204)
Carrier 
(n = 48)
Predominant drusen type within ETDRS grid
None or small drusen (<63 µm) 32 (15.7) 4 (8.3) Reference 0.06
Intermediate drusen (63-125 µm) 107 (52.5) 18 (37.5) 1.35 (0.34-5.38)
Large drusen (>125 µm) 65 (31.9) 26 (54.2) 3.20 (0.80-12.75)
Largest drusen type within central field
None or small drusen (<63 µm) 106 (52.5) 24 (50.0) Reference 0.97
Intermediate drusen (63-125 µm) 77 (38.1) 19 (39.6) 1.16 (0.29-4.66)
Large drusen (>125 µm) 19 (9.4) 5 (10.4) 1.09 (0.50-2.39)
Proportion of grid area covered by drusen, %
0-10 111 (54.4) 6 (12.5) Reference 0.002b
10-25 61 (29.9) 23 (47.9) 6.98 (2.04-23.89)
25-50 29 (14.2) 16 (33.3) 10.21 (2.85-36.59)
>50 3 (1.5) 3 (6.3) 18.50 (2.19-155.99)
Extramacular drusen
Absent 54 (26.6) 6 (12.5) Reference 0.11
Present 149 (73.4) 42 (87.5) 2.54 (0.80-8.04)
Drusen nasal to the optic disc
None or small drusen (<63 µm) 89 (65.0) 12 (30.8) Reference 0.003b
Intermediate drusen (63-125 µm) 46 (33.6) 25 (64.1) 4.03 (1.70-9.56)
Large drusen (>125 µm) 2 (1.5) 2 (5.1) 7.42 (0.65-84.84)
Reticular drusen
Absent 163 (86.7) 43 (93.5) Reference 0.23
Present 25 (13.3) 3 (6.5) 0.46 (0.13-1.64)
Drusen with crystalline appearance
Absent 178 (89.4) 34 (72.3) Reference 0.02
Present 21 (10.6) 13 (27.7) 3.24 (1.24-8.50)
SPED
Absent 199 (97.5) 43 (91.5) Reference 0.11
Present 5 (2.5) 4 (8.5) 3.70 (0.74-18.63)
RPE pigmentation
Absent 84 (45.4) 13 (28.3) Reference 0.10
Present 101 (54.6) 33 (71.7) 2.11 (0.87-5.14)
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Geographic atrophy
Absent 154 (76.2) 28 (65.1) Reference 0.23
Present 48 (23.8) 15 (34.9) 1.72 (0.71-4.14)
Neovascular AMD
Absent 144 (72.4) 38 (82.6) Reference 0.23
Present 55 (27.6) 8 (17.4) 0.55 (0.21-1.47)
Abbreviations: AMD, age-related macular degeneration; CFH, complement factor H; ETDRS, Early 
Treatment Diabetic Retinopathy Study; RPE, retinal pigment epithelium; SPED, serogranular/serous 
drusen pigment epithelium detachment. a The presented odds ratios result from univariable generalized 
estimating equations logistic regression analyses. b P-value remained significant after Bonferroni 
correction for multiple testing.
Overall, rare CFH variant carriers tend to have more and larger drusen, and drusen are 
more often located outside the ETDRS grid. However, not all of these analyzed phenotypical 
characteristics individually reach statistical significance. Based on the findings in Table 
3, we calculated a phenotypic risk score for each eye including all assessed phenotypical 
characteristics (eFigure 1 in the Supplement). The mean (SD) phenotypic risk score in carriers 
(4.35 [2.0]) was significantly higher compared with noncarriers (2.32 [2.5]), although the ability 
to accurately discriminate between eyes of carriers of pathogenic CFH variants and noncarriers 
based on the phenotypic risk score was limited (area under the curve, 0.75; 95% CI, 0.65-0.85; 
eFigure 2 in the Supplement). Similar results were obtained when including only the highest 
phenotypic risk score for each patient (area under the curve, 0.75; 95% CI, 0.61-0.88). 
Finally, for every patient, the grade of symmetry between eyes was determined based on the 
number of equal characteristics. Each study group showed a high grade of symmetry between 
the eyes (79.9% in noncarriers vs 79.1% in carriers of pathogenic variants) and the groups were 
not significantly different (P = 0.85).
DISCUSSION
In this study, we aimed to describe the phenotypical characteristics of patients with AMD 
carrying a rare variant in the CFH gene. Overall, rare CFH variant carriers have a more severe 
phenotype with more and larger drusen, often extending to the peripheral retina. Larger 
drusen area within the ETDRS grid and drusen located nasal to the optic disc were significantly 
associated with patients with AMD carrying a rare pathogenic CFH variant. These findings are 
in line with previous studies reporting extensive macular drusen accumulation and presence of 
extramacular drusen in patients with AMD carrying the CFH p.Arg1210Cys variant18 and other 
rare CFH variants.11 
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In addition, we report an association between the presence of drusen with crystalline 
appearance and carrying a rare variant in CFH. Drusen with crystalline appearance, also known 
as refractile or calcified drusen, have a characteristic glistening appearance on color fundus 
imaging and have been associated with the development of geographic atrophy.24,25 Thus, these 
patients might be at higher risk for developing geographic atrophy compared with noncarriers. 
In the current study, rare CFH variant carriers seem to develop geographic atrophy more 
often than choroidal neovascularization, as was already observed in rare variant carriers of 
other complement genes (CFI, C3, and C9).26 However, probably owing to the small number of 
patients with late AMD, this difference was not significant. 
From literature, it is known that CFH carriers usually have an earlier age at onset.8,11,13,22,26,27 
Owing to our study design a lower age at onset in rare variant carriers could not be analyzed. 
Our study was merely designed to analyze phenotypical differences between rare CFH carriers 
and noncarriers; therefore, age-matched noncarriers were selected. As a consequence, no 
difference in age at onset could be observed. However, assessing the age at onset remains 
an important clue for ophthalmologists when considering (rare) genetic variants in a patient. 
Familial burden is also known to be associated with rare CFH variant carriers.11,13,18,26,28 Although 
the number of carriers with a family history of AMD (64.7%) was not significantly different 
from noncarriers (53.9%), it must be emphasized that family history was obtained through 
interviewer-assisted questionnaires. From previous studies, it is known that CFH carriers often 
have asymptomatic family members29,30 and, therefore, it is plausible that the percentage of 
carriers with a family history of AMD is underestimated.
Assuming that rare protein-altering variants located in the CFH gene lead to similar phenotype, 
this study was not restricted to one or more specific CFH variants but included a wide variety 
of rare protein-altering CFH variants identified by WES or Sanger sequencing in our cohort. 
Therefore, our analyses also included some variants that were not described before in the 
literature. However, when limiting the analyses to confirmed pathogenic variants only, the 
associations between rare variant carriers and phenotypical characteristics become more 
pronounced. More information on pathogenicity of variants is therefore desirable. As prediction 
tools do not always correctly predict a genetic variant to be functionally impaired,31,32 other 
large sequencing or functional studies are needed to confirm the clinical significance of these 
variants. 
Limitations
Because of an overlap in phenotypical characteristics between carriers and noncarriers, even 
when including only confirmed pathogenic variants, the sample size of our study might be 
insufficient to detect small to moderate associations or associations with relatively infrequent 
features, such as serogranular/serous drusen pigment epithelium detachment and the 
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presence of geographic atrophy. Additionally, when correcting for multiple comparisons, only 
drusen area remained significantly associated with rare variant carriers, which is most likely 
the result of our small sample size. 
Our study was also restricted by its retrospective design, therefore, for the analyses, we were 
limited to the images that were captured in the past. Peripheral fundus images and other image 
modalities were often lacking and therefore not taken into account in the current study. To 
assess to what extent drusen are located outside the central retina, imaging should preferably 
be extended to the peripheral retina. Additionally, certain phenotypical characteristics are better 
visualized with other imaging techniques (eg, cuticular drusen). Previously, CFH variants were 
identified in patients with the cuticular drusen subtype of AMD, and fluorescein angiography 
is considered the best modality to diagnose these type of drusen.22,29,30 Furthermore, optical 
coherence tomography enables detailed visualization of the different retinal layer structures 
that are not visible on color fundus images, and has the advantage of three-dimensional image 
assessment. Future prospective studies could therefore benefit from assessing multiple image 
modalities and imaging of the peripheral retina. 
CONCLUSION
Because patients with AMD carrying a rare CFH variant seem a very suitable group for upcoming 
complement-inhibiting therapies, identification of this subpopulation may be very important 
to direct choice of treatment. Our results indicate that patients with an extensive drusen 
area, drusen with crystalline appearance, and drusen nasal to the optic disc are more likely 
to have a rare genetic variant in the CFH gene. These phenotypical characteristics could aid 
ophthalmologists to select patients for genetic screening. However, it is unlikely that carriers 
can be discriminated from noncarriers based solely on phenotypical characteristics. Therefore, 
ophthalmologists should consider genetic testing in patients with extensive drusen deposition, 
drusen with crystalline appearance and/or drusen nasal to the optic disc in combination with 
other patient characteristics, such as an early age at onset, cuticular drusen on fluorescein 
angiography, and a positive family history for AMD. 
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	eFigure 1. Distribution of Phenotypic Risk Scores in Eyes of Rare Pathogenic CFH Variant Carriers 
(green) and Noncarriers (blue). The x-axis represents the phenotypic risk score and the y-axis frequency 
as percentages within each study group. 
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	eFigure 2. Receiver Operating Characteristic Curve of the Phenotypic Risk Score. The optimal cut-off for 
this phenotypic risk score is 3 with a sensitivity of 0.86 and specificity of 0.63. 
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CHAPTER 7
ABSTRACT
Purpose: It can be clinically challenging to distinguish dry age-related macular degeneration 
(AMD) from AMD-mimicking dystrophies, and sometimes misdiagnosis occurs. With upcoming 
therapies for dry AMD it is important to exclude patients with a different retinal disease from 
clinical trials. Here, we aim to evaluate the occurrence of AMD-mimicking dystrophies in an 
AMD cohort. 
Methods: Whole-exome sequencing (WES) was performed in patients with intermediate AMD 
or geographic atrophy secondary to AMD (n=218), selected from the European Genetic Database 
(EUGENDA). Additionally, WES was performed in 133 EUGENDA controls. We analyzed WES 
data for variants in 19 genes associated with autosomal dominant and recessive macular 
dystrophies mimicking AMD.
Results: In three cases we identified a pathogenic heterozygous variant (PRPH2 c.424C>T; 
p.Arg142Trp) causal for autosomal dominant central areolar choroidal dystrophy (CACD). 
Phenotypically, these patients all presented with geographic atrophy. In 12 cases we identified 
a heterozygous variant of unknown clinical significance, but predicted to be highly deleterious, 
in genes previously associated with autosomal dominant macular dystrophies. One case 
carried two heterozygous variants in the IMPG1 gene of unknown clinical significance.
Conclusions: For inclusion in clinical trials it is crucial to select patients who will most likely 
benefit from these therapies. In our AMD cohort we identified three cases with CACD. The 
distinction between AMD and AMD-mimicking dystrophies, such as CACD, can be challenging 
based on phenotype alone. Genetic screening for genes associated with macular dystrophies, 
especially PRPH2, might be beneficial to help identify AMD-mimicking dystrophies. 
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INTRODUCTION
Age-related macular degeneration (AMD) is a common progressive retinal disorder affecting 
the elderly.1 The early stages of AMD are characterized by drusen accumulation in the macula, 
and as disease progresses two types of advanced AMD can be distinguished: geographic atrophy 
(GA) and choroidal neovascularization (CNV).2 Currently, no curative treatment exists for the 
early and atrophic stages of AMD, which affect the majority of patients (80-90%).3,4 However, 
therapies targeting AMD disease pathways are in development and are being evaluated in 
clinical trials.3,4 A number of these trials are targeted against components of the complement 
system. From genetic, physiological and histopathological studies we know that increased 
activation of the complement system seems to play a major role in AMD pathogenesis.5-9 To 
date, results of two phase 2 trials with complement inhibiting agents have been published. 
Administration of eculizumab did not show a beneficial effect on atrophy progression in the 
COMPLETE study,10 while the MAHALO study reported promising results for lampalizumab 
in reducing atrophy progression.11 Therapeutic agents targeting other pathways, such as the 
visual cycle and oxidative stress, are also being evaluated in clinical trials, but thus far without 
promising results.4 
In order for clinical trials to be successful, it is crucial to select patients that will most likely 
benefit from the treatment. Currently, in- and exclusion criteria of clinical trials are based on a 
clinical diagnosis and are often described in terms of “well demarcated area of GA secondary to 
AMD” and “exclude GA due to other diseases”. Sometimes it is, however, clinically challenging 
to distinguish AMD from macular dystrophies that are characterized by drusen-like yellowish 
spots in the macula and geographic atrophy.12 For example, the early stages of central areolar 
choroidal dystrophy (CACD) are characterized by pigmentary changes mimicking early AMD,13 
and late-onset Stargardt disease is characterized by the appearance of yellowish flecks in 
the macula.14 Both diseases eventually progress to chorioretinal atrophy similar to advanced 
atrophic AMD. Additionally, several other monogenic macular disorders can be labeled as 
so-called AMD-mimicking dystrophies.12 Especially when a patient presents at older age and 
GA has already developed, it can be challenging to distinguish AMD from GA secondary to 
other retinal diseases and potentially patients might be misdiagnosed. Before inclusion of 
patients in clinical trials for dry AMD, it may therefore be useful to perform genetic testing 
to exclude AMD-mimicking dystrophies. In this study, we aim to evaluate the occurrence of 
genetic variants associated with autosomal dominant or autosomal recessive AMD-mimicking 
dystrophies in 218 cases diagnosed with dry AMD.
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METHODS
Study population
For this study we selected participants enrolled in the European Genetic Database (EUGENDA), 
a large multicenter database for clinical and molecular analyses of AMD. Patients selected 
for this study were classified with intermediate AMD or advanced atrophic AMD. Color fundus 
photographs of both eyes, and if available spectral domain optical coherence tomograms and 
fluorescein angiograms, were evaluated by two independent reading center graders according 
to the Cologne Image Reading Center and Laboratory (CIRCL) protocol.15 Classification of AMD 
was based on grading of the worst affected eye. Intermediate AMD was defined as the presence 
of at least one large druse (diameter ≥ 125µm) or 15 intermediate drusen (diameter 63-125µm) 
in the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. A sharply demarcated round 
or oval area of RPE depigmentation (diameter ≥ 175µm) with increased visibility of choroidal 
vessels within the central circle of the ETDRS grid secondary to AMD without signs of CNV was 
defined as advanced atrophic AMD. In total, 218 AMD cases were included for analysis. For 33 
cases one of more family members were included. In total 62 family members were included, 
of which 40 were diagnosed with AMD, and 22 did not have signs of AMD . Additionally, 133 
control individuals aged 65 years and older without signs of AMD were included in this study. 
All individuals provided written informed consent for enrollment in EUGENDA. This research 
was approved by the local ethical committees at the Radboud university medical center and 
the University Hospital of Cologne and the study adhered to the tenets of the Declaration of 
Helsinki. 
Whole-exome sequencing
Genomic DNA was extracted from venous blood samples using standard procedures. Whole-
exome sequencing (WES) was performed for 218 patients classified with intermediate AMD or 
advanced atrophic AMD, 62 of their family members, and 133 control individuals. WES capture 
and variant calling was obtained though the Nimblegen SeqCap EZ Exome v2 kit by paired-
end sequencing on an Illumina HiSeq sequencer using TruSeq V3 chemistry (Corominas et 
al, manuscript submitted). For this study, we analyzed WES data for variants in 19 genes 
associated with autosomal dominant and recessive macular dystrophies mimicking AMD (Table 
1). Filtering of the data was performed to select protein-altering (nonsynonymous), nonsense, 
frameshift or splice-site variants with a minor allele frequency (MAF) ≤1% in the non-Finnish 
European population reference panel of the Exome Aggregation Consortium (ExAC),16 and in the 
Dutch population reference panel of the Genome of the Netherlands (GoNL) consortium.17 To 
minimize the number of false positive variants, additional filter criteria included coverage depth 
of at least 20 reads, 10 variant reads and 20% variation of reads. A variation of reads between 
20% and 80% was defined as heterozygous, and all variants with a variation of reads ≥90% 
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were named homozygous. Thereafter, we searched literature and public archives (ClinVar18 
and LOVD19) to determine if a variant is described to be pathogenic or is of unknown clinical 
significance (including variants with conflicting interpretations of pathogenicity). We explored 
the deleteriousness of nonsynonymous missense variants of unknown clinical significance 
using scaled Combined Annotation Dependent Depletion (CADD phred) prediction scores.20 
RESULTS
In this study, 126 intermediate AMD cases and 90 advanced AMD cases with GA were included. 
Of these, 80 AMD cases were male (36.7%) and 138 female (63.3%). Their mean age was 72.7 
years (SD 10.4). Gender distribution was comparable to the control individuals with 37.8% male 
individuals. The mean age of the control individuals was higher (79.3±11.5 years), but this is 
explained by the inclusion criteria for control individuals (≥65 years of age), while there were 
no age criteria for AMD cases. 
In the next sections, we first describe the occurrence of variants associated with autosomal 
dominant macular dystrophies, and thereafter variants associated with autosomal recessive 
macular dystrophies in our AMD cohort.
Variants in genes associated with autosomal dominant macular dystrophies
In our case-control cohort, we identified one heterozygous variant previously described as 
pathogenic in literature or in public archives. It concerns a missense variant in the PRPH2 
gene in three individuals (c.424C>T, p.Arg142Trp), which is reported to be causal for CACD.21 All 
three cases presented with geographic atrophy (Figure 1). No other known pathogenic variants 
were identified in the PRPH2 gene or other genes associated with autosomal dominant AMD-
mimicking dystrophies.
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Table 1. Genes associated with AMD-mimicking diseases. 
Gene Chr. Associated disease
Autosomal Dominant
BEST1 1 Adult-onset foveomacular vitelliform dystrophy (AFVD)
Best vitelliform macular dystrophy (BVMD)
C1QTNF5/MFRP 1 Late onset retinal degeneration (LORD)
CTNNA1 5 Butterfly-shaped pigment dystrophy
EFEMP1 2 Malattia Leventinese (ML)/Doyne honeycomb retinal dystrophy
ELOVL4 6 Stargardt-like macular dystrophy (STGD3)
Autosomal dominant macular dystrophy
FSCN2 17 Autosomal dominant macular degeneration
Autosomal dominant retinitis pigmentosa 
GUCA1B 6 Autosomal dominant retinal degeneration
OTX2 14 Autosomal dominant pattern dystrophy
PRDM13 6 North-Carolina macular dystrophy (NCMD)
PRPH2 6 Central areolar choroidal dystrophy
Adult-onset foveomacular vitelliform dystrophy
Autosomal dominant pattern dystrophy
Pseudo-Stargardt pattern dystrophy
RP1L1 8 Autosomal dominant occult macular dystrophy
TIMP3 22 Sorsby fundus dystrophy
Autosomal Recessive
ABCA4 1 (late-onset) Stargardt disease
ABCC6 16 Pseudoxanthoma elasticum related dystrophy (angioid streaks) 
DRAM2 1 Autosomal recessive macular dystrophy
MFSD8 4 Nonsyndromic autosomal recessive macular dystrophy
Autosomal Dominant or Autosomal Recessive
IMPG1 6 Autosomal dominant benign concentric annular macular dystrophy
Autosomal dominant and autosomal recessive vitelliform macular 
dystrophies
PROM1 4 Autosomal dominant bull’s-eye macular dystrophy
Autosomal dominant stargardt-like dystrophy
Autosomal recessive cone-rod dystrophy
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Additionally, 28 variants of unknown clinical significance were identified, which were not 
identified in the 133 control individuals (eTable1). Because of their uncertain significance 
further evaluation included only those variants leading to a premature nonsense codon, 
leading to a shift in the open reading frame, or affecting the invariable splice donor or acceptor 
sites (-1, -2, +1, +2), and nonsynonymous missense variants predicted to be the 1% most 
deleterious variants in the human genome (CADD score ≥ 20). In 18 cases we identified a 
variant of unknown clinical significance predicted to be highly deleterious. For 4 of these 
cases WES data of family members were available. In all four cases, the variants of unknown 
clinical significance did not segregate with the disease, and were therefore not considered to 
be pathogenic. The 12 remaining cases carried a variant of unknown clinical significance in the 
BEST1, ELOVL4, FSCN2, IMPG1, OTX2, PRDM13, PROM1 or RP1L1 gene (Table 2). All 12 cases 
had typical characteristics of intermediate AMD or GA (Table 2).
Variants in genes associated with autosomal recessive retinal dystrophies
None of our cases carried homozygous coding variants in genes associated with autosomal 
recessive macular dystrophies. We identified one case with two heterozygous variants in IMPG1 
(c.336TC>C; p.Ile112Ile*, c.173G>A; p.Arg58Lys) of unknown clinical significance. Additionally, 
13 out of 218 cases (6.0%) carried a single heterozygous variant, previously described to be 
pathogenic in literature or in public archives, in the ABCA4, ABCC6, MFSD8 or PROM1 gene 
(Table 3). The allele frequencies of these 8 variants were comparable to MAFs in population 
reference panels, however, 7 variants were not detected in the 133 control individuals. 
DISCUSSION
Phenotypic similarities between macular dystrophies and AMD have been described in 
literature.22,12,13 In this study, we evaluated the occurrence of genetic variants associated with 
autosomal dominant and autosomal recessive AMD-mimicking dystrophies in cases clinically 
diagnosed with dry AMD. 
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Table 2. Variants of unknown clinical significance in autosomal dominant macular dystrophy genes 
identified in cases diagnosed with dry AMD .
ExAC
MAF (%)
Cases 
n (MAF[%])
Characteristics on retinal imaging of cases 
carrying a variant of unknown clinical significance
BEST 1
c.1193C>T; p.Ser398Phe 0.08 1 (0.23%) Central geographic atrophy (GA) surrounded by small hard drusen extending to the periphery
ELOVL4
c.145A>G; p.Thr49Ala - 1 (0.23%) Large soft drusen throughout the macula
FSCN2
c.1057G>A; p.Val353Met 0.04 1 (0.23%) Reticular pseudodrusen and some soft drusen
IMPG1
c.1982G>A; p.Arg661His - 1 (0.23%) Multifocal GA and some intermediate drusen
c.1945C>T; p.Leu649Phe 0.40 1 (0.23%) Few intermediate to large soft macular drusen
c.1738C>T; p.Arg580Cys 0.02 1 (0.23%) Intermediate to large soft macular drusen
c.336TC>C; p.Ile112Ile* - 1 (0.23%) Intermediate to large soft macular drusen
OTX2
c.844T>A; p.Cys282Ser 0.003 1 (0.23%)
Extensive large soft drusen and calcified drusen 
throughout the macula and reticular pseudodrusen 
around the retinal arcades 
PRDM13
c.113C>T; p.Ser38Leu 0.07 1 (0.23%) Numerous small hard (cuticular) drusen throughout the macula extending beyond the vascular arches
PROM1
c.1345G>A; p.Val449Met 0.20 1 (0.23%) Central GA surrounded by intermediate to large drusen and some peripheral drusen
c.155T>C; p.Ile52Thr 0.003 1 (0.23%) Drusen deposition throughout the macula
RP1L1
c.553G>T; p.Ala185Ser - 1 (0.23%) Multifocal GA surrounded by large soft drusen
Variants leading to a premature nonsense codon, frameshift, affecting the splice donor or acceptor sites 
(-1, -2, +1, +2), and nonsynonymous missense variants predicted to be the 1% most deleterious variants in 
the human genome (CADD score ≥ 20).
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A B
C
D
E F
G H
Figure 1. Retinal images of three patients with geographic atrophy secondary to autosomal dominant 
central areolar choroidal dystrophy (CACD) caused by a heterozygous variant in PRPH2 (c.424C>T, 
p.Arg142Trp). Patient 1 (A-D). Color fundus photographs of right (A) and left (B) eye of a 67-year-old 
female with geographic atrophy and foveal sparing surrounded by drusen secondary to CACD. On the 
Optical Coherence Tomography (OCT) images of both eyes (C+D) drusen are visible near the edges of the 
central atrophy. Drusen are indicated by arrows, atrophy is indicated by a continuous line with dashes just 
below the atrophic area. Patient 2 (E-F). A 64-year-old male with central atrophy in both eyes secondary 
to CACD. Patient 3 (G-H). A 76-year-old male with extensive geographic atrophy and peripapillary atrophy 
in both eyes. 
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Table 3. Variants in autosomal recessive macular dystrophy genes previously described as 
pathogenic.
ExAC
MAF (%)
GoNL
MAF (%)
Cases
total n=218
n(MAF[%])
Controls
total n=133
n(MAF[%])
Disease association
ABCA4
c.6089G>A; p.Arg2030Gln 0.06% 0.10% 1 (0.23%) - Stargardt disease58
c.3113C>T; p.Ala1038Val 0.20% 0.30% 1 (0.23%) - Stargardt disease58
c.2947A>G; p.Thr983Ala - - 1 (0.23%) - Stargardt disease58
c.2588G>C; p.Gly863Ala 0.81% 0.80% 4 (0.92%) 1 (0.38%) Stargardt disease58
c.2546T>C; p.Val849Ala 0.01% - 1 (0.23%) - Stargardt disease58
ABCC6
c.2787+1G>T; p.? 0.02% - 2 (0.46%) - Pseudoxanthoma 
elasticum59,60
MSFD8
c.1006G>C; p.Glu336Gln 0.33% 0.30% 2 (0.46%) - Nonsyndromic 
autosomal recessive 
macular dystrophy61
PROM1
c.1355A>TA; p.Tyr452Tyr* 0.03% - 1 (0.23%) - Autosomal recessive 
cone-rod dystrophy42
Age-related macular degeneration and central areolar choroidal dystrophy
We identified three patients carrying a heterozygous variant in the PRPH2 gene (p.Arg142Trp). 
This variant causes a central cone dystrophy phenotype associated with autosomal dominant 
CACD.23,21. There are strong phenotypic similarities between CACD and AMD.13 Stage 1 and 2 
of CACD are characterized by focal parafoveal RPE changes and a mottled autofluorescence 
pattern.24,13 Additionally, CACD has been described in combination with the presence of drusen 
in some families.25 These phenotypes can very much resemble the RPE alterations and drusen 
as present in early AMD, and like in early AMD, patients often do not have visual complaints 
at this stage.24 As CACD progresses, parafoveal atrophy of the retinal pigment epithelium 
and choriocapillaris develops (stage 3), eventually also involving the fovea (stage 4).24,13 Most 
patients with advanced stage CACD are aged between 40 and 70 years old and present with 
vision loss and central scotomas.24 An overlap in age of onset of CACD with atrophic AMD 
was also described by Boon and colleagues.23 Furthermore, CACD can be easily overlooked 
and misdiagnosed with AMD based on ophthalmological examination alone, especially in 
families with incomplete penetrance, which may mask the autosomal dominant inheritance of 
CACD. Additional imaging, such as spectral-domain optical coherence tomography and fundus 
autofluorescence imaging, or genetic analyses could help distinguishing between these two 
diseases.13 
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Different heterozygous variants in the PRPH2 gene have been described to be causal for 
autosomal dominant CACD.23,26,21,27,28 In this study, we detected the p.Arg142Trp variant while 
no other variants in the PRPH2 gene were found. Family studies strongly suggest that this 
variant represents a founder mutation with its origin in the southeast of the Netherlands.23 This 
could explain why we detected this specific PRPH2 variant and no other variants in PRPH2. 
In different regions however, other variants could be more prevalent. For example, a higher 
frequency of the p.Arg172Trp variant has been described in British patients, also due to a 
founder effect.29 Additionally, a splice-site variant in PRPH2 (c.828+3A>T) is also considered 
a founder mutation and has been associated with diverse retinal phenotypes besides CACD.30 
Considering the fact that variant frequencies differ between populations, it is to be advised to 
sequence the entire coding region of the PRPH2 gene for variants, rather than screening for a 
specific variant. 
Autosomal dominant macular dystrophies mimicking AMD
In this study we also report several variants in genes associated with autosomal dominant 
and recessive macular dystrophies of unknown clinical significance. We describe 12 variants 
that are predicted to be deleterious in genes associated with autosomal dominant macular 
dystrophies (BEST1, ELOVL4, FSCN2, IMPG1, OTX2, PRDM13, PROM1 and RP1L1).
To date, several variants in the ELOVL4 gene, most frequently a 5-bp deletion in exon 6, 
have been associated with Stargardt-like macular dystrophy (STGD3). This study describes 
a missense variant in exon 2, in contrast to previously described variants, which are located 
at the 3’ end of the gene. Therefore, it is unlikely that the p.Thr49Ala variant in ELOVL4 gene 
identified in one AMD patient in this study is disease-causing. Also, evaluation of the ELOVL4 
gene in AMD patients showed no association with AMD in previous studies.31,32 
The FSCN2 gene is described to be a candidate gene for autosomal dominant macular 
degeneration (RetNet, the Retinal Information Network). One variant (c.208delG) is reported 
to be associated with the disease in Japanese patients,33 but this could not be confirmed in 
Chinese and Spanish studies.34,35 Other variants in FSCN2 have been described, but lacked 
co-segregation.34 The association of this gene with autosomal dominant macular dystrophy 
is therefore unclear. It is therefore unlikely that the missense variant p.Val353Met in FSCN2 
identified in one AMD patient in this study is disease-causing. 
In autosomal dominant North-Carolina Macular Dystrophy the disease-causing variants are 
located in the PRDM13 gene. A few missense variants and tandem duplications have been 
described.36,37 We can therefore not exclude that the p.Pro38Leu in PRDM13 identified in one 
AMD patient in this study is disease-causing. 
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Variants in the IMPG1 gene can cause both autosomal dominant and recessive vitelliform 
macular dystrophies, and one heterozygous missense variant in IMPG1 has been described 
in dominant benign concentric annular macular dystrophy.38,39 Four AMD patients in this study 
were found to carry a potentially pathogenic variant in the IMPG1 gene, and we cannot exclude 
that these variants may be disease-causing. 
Variants in PROM1 have mainly been associated with autosomal recessive cone-rod dystrophies, 
a severe retinal phenotype with early onset.40,41 However, associations between this locus and 
autosomal dominant macular dystrophies have also been described.42,43 We cannot therefore 
not exclude that the PROM1 p.Ile52Thr and p.Val449Met variants identified in two AMD patients 
in this study may be disease-causing. 
OTX2 variants can cause severe ocular disorders, such as developmental ocular malformations 
or Leber congenital amourosis, but a heterozygous missense variant (p.Glu79Lys) was reported 
in two families with autosomal dominant pattern dystrophy, implicating the involvement of 
OTX2 in pattern dystrophies.44 A different missense variant, p.Cys282Ser, was identified in OTX2 
in one patient in this study, and we cannot exclude that this variant may be disease-causing. 
Several heterozygous missense variants in RP1L1 have been associated with occult macular 
dystrophy, mainly in Asian families.45-47 Variant screening in the RP1L1 gene is complicated 
because the gene is highly polymorphic and shows a high degree of similarity with RP1,48 
therefore replication of the variant described in this study is warranted. 
Various variants in the BEST1 gene have been reported to be associated with autosomal 
dominant vitelliform macular dystrophies.49 Most of these variants are missense mutations 
and located within the first eight exons, whereas the p.Ser398Phe variant we report here is 
located in exon 9 of the gene. It is therefore unlikely that the p.Ser398Phe variant in BEST1 
identified in one AMD patient in this study is disease-causing.
Summarizing, we identified 12 potentially deleterious variants but of yet unknown clinical 
significance in genes associated with autosomal dominant macular dystrophies. It is unlikely 
that the variants in the BEST1, ELOVL4 and FCSN2 genes are disease-causing, but we cannot 
rule out the possibility that the variants in the PRDM13, IMPG1, PROM1, OTX2 and RP1L1 
genes might be disease-causing. Therefore one might consider to exclude patients carrying 
variants in genes associated with autosomal dominant macular dystrophies from clinical trials, 
in particular is the disease phenotype matches previously reported disease characteristics of 
these dystrophies. Other studies are needed to elucidate the potential pathogenicity of these 
novel variants.
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Susceptibility of development of age-related macular degeneration in heterozygous 
carriers of autosomal recessive macular dystrophies
Besides phenotypic similarities between AMD and macular dystrophies, it has been suggested 
that carriers of a single ABCA4 variant are at increased risk of developing AMD compared to 
noncarriers.50,51 In this study, we identified seven cases that carried a heterozygous ABCA4 
variant previously reported to be pathogenic, compared to only one control individual carrying 
a heterozygous pathogenic ABCA4 variant. However, the number of control individuals in this 
study was too small to draw conclusions. Larger studies are needed to evaluate the hypothesis 
that carriers of heterozygous variants associated with autosomal recessive macular dystrophies 
might be at increased risk for AMD development. 
Clinical implications 
It is increasingly important to correctly diagnose patients with macular degeneration with 
respect to inclusion in clinical trials and for future treatment. For both dry AMD and macular 
dystrophies no curative treatment is available in clinical routine yet, though multiple clinical 
trials are ongoing.4 To achieve a favorable outcome of clinical trials, selection of those 
patients who will most likely benefit from the treatment is essential. While treatment is still in 
development, for some macular diseases lifestyle interventions are recommended, including 
dietary changes or nutritional supplementation. Results of the Age-Related Eye Disease Study 
2 (AREDS2) indicate that oral supplementation of antioxidants (lutein, zeaxanthin, vitamins C 
and E) and zinc reduces the risk of progression to advanced AMD in patients with nonadvanced 
AMD or unilateral advanced AMD.52 Furthermore, high dietary intake of antioxidants and fish 
consumption can reduce the risk of advanced AMD among people with a high genetic risk of 
AMD.53 Contrarily, patients with Stargardt disease are recommended to limit vitamin A and 
beta-carotene intake, as they cannot metabolize vitamin A properly due to ABCA4 protein 
impairment.54 Low dietary intake of vitamin A in patients with Stargardt disease has been 
associated with better visual acuity compared to those with higher vitamin A intake.55 These 
different nutritional interventions between macular diseases underline the importance of 
proper diagnosis of AMD and AMD-mimicking dystrophies. 
Concluding, for clinical trials and future therapies for AMD it is important to identify those 
patients that will benefit most likely from the treatment and exclude AMD-mimicking 
dystrophies. Detailed phenotyping is necessary for distinguishing different macular diseases, 
and multimodal imaging can be useful. Despite modern imaging technologies, however, it can 
be difficult to clinically differentiate AMD from AMD-mimicking dystrophies. Genetic screening 
of genes involved in AMD-mimicking dystrophies can aid in establishing an accurate diagnosis. 
Based on the findings of this study, genetic screening of the PRPH2 gene is recommended 
because of the significant clinical overlap between CACD and AMD. 
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8GENOTYPE-PHENOTYPE CORRELATIONS 
OF LOW FREQUENCY GENETIC VARIANTS IN THE 
COMPLEMENT SYSTEM IN RENAL DISEASE AND 
AGE-RELATED MACULAR DEGENERATION
216
CHAPTER 8
ABSTRACT
Genetic alterations in the complement system have been linked to a variety of diseases, 
including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and age-
related macular degeneration (AMD). We performed sequence analysis of the complement 
genes CFH, CFI, and C3 in 866 renal diseases patients (aHUS/C3G) and 697 AMD patients. 
Genotype-phenotype correlations between the disease groups identified a higher frequency of 
protein-altering alleles in SCR20 of FH, and in the serine protease domain of FI in aHUS/C3G 
patients. In AMD a higher frequency of protein-altering alleles was observed in SCR3, SCR5 
and SCR7 of FH, the FI SRCR domain, and the MG3 domain of C3. Our data underscore the 
importance of the N-terminal SCRs of FH in C3b regulation in AMD, and the specificity with 
which the C-terminal SCRs of FH interact with the glomerular endothelium. Alterations in the 
SRCR domain of FI are likely to affect expression and thus overall activity, while FI changes 
related to renal disease are involved in structural elements around the active site. Alterations 
located in the MG3 domain of C3 in AMD patients may hamper regulation of C3. We observed 
a substantial overlap of variants between aHUS/C3G and AMD, however, there is a distinct 
clustering of variants within specific domains.
KEY WORDS
Atypical hemolytic uremic syndrome, C3 glomerulopathy, Age-related macular degeneration, 
Complement system, Alternative pathway
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INTRODUCTION
The complement system is part of the innate immune system which balances host protection 
and immune defense. The complement system can be activated via three pathways: the 
classical, lectin and alternative pathways, which converge at the step of cleavage of the central 
component C3 into C3a and C3b. C3b bound to activated factor B (Bb) forms the alternative 
pathway C3 convertase (C3bBb), which cleaves and activates more C3 molecules, thereby 
amplifying the cascade. When the C3 convertase binds additional C3b molecules, the C5 
convertase is formed (C3bBbC3b), which cleaves C5 into C5a and C5b. C5b interacts with C6, 
C7, C8 and multiple C9 molecules forming the membrane attack complex (C5b-9). Regulators, 
such as factor H (FH) and membrane cofactor protein (MCP; CD46), can inhibit complement 
activation by accelerating the decay of the C3 convertases or by acting as a cofactor for factor 
I (FI).1
Deregulation of the complement system, specifically the alternative pathway, has been 
implicated in a variety of diseases. Remarkably, protein-altering variants in genes of the 
complement system have been associated with very different clinical outcomes: atypical 
hemolytic uremic syndrome (aHUS; MIM# 235400), C3 glomerulopathy (C3G; or dense deposit 
disease [DDD]), and age-related macular degeneration (AMD; MIM# 603075).2,3 
aHUS is a rare acute disorder characterized by acute renal failure, thrombocytopenia, and 
microangiopathic hemolytic anemia. It is estimated that genetic variants in the complement 
factor H (CFH), complement factor I (CFI), complement C3 (C3), complement factor B (CFB), 
CD46 molecule (CD46), thrombomodulin (THBD), and diacylglycerol kinase epsilon (DGKE) 
genes, the presence of genomic rearrangement in the CFH/CFH-related (CFHR) gene cluster, 
and autoantibodies to FH account for 60% of all aHUS cases.4-6 
C3G is another rare renal illness, which is characterized by C3 deposition in the glomeruli 
of the kidney and can lead to renal failure. C3G pathogenesis is linked to the presence of 
autoantibodies that stabilize the alternative pathway and classical pathway C3 convertases 
(C3Nef and C4Nef). Genetic aberrations in the CFH, CFI, C3, CD46, CFHR5 genes, genomic 
rearrangements in the CFH/CFHR gene cluster, and anti-FH autoantibodies genes have been 
described in 20% of C3G patients.6-8
AMD, in contrast to aHUS and C3G, is a common disease in which gradual visual impairment 
occurs at older age due to degeneration of the central retina. The disease is characterized by 
the disruption of normal retinal pigment epithelium (RPE) function through the accumulation 
of waste products, called drusen, between Bruch’s membrane and the RPE. A combination of 
multiple genetic and environmental factors contribute to the pathogenesis of AMD. More than 
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a third of the disease-associated genetic variants reside in or near genes of the complement 
system: CFH, CFI, C3, complement C2 (C2)/CFB, complement C9 (C9), and vitronectin (VTN).9 In 
addition, rare protein-altering variants in the CFH, CFI, C3 and C9 genes have been associated 
with AMD.9,10. 
A number of low frequency protein-altering variants have been described to cause both aHUS/
C3G and AMD, such as the p.Arg53His and p.Arg1210Cys variants in CFH,11,12 p.Gly119Arg 
and p.Gly287Arg in CFI13,14 and p.Lys155Gln and p.Arg161Trp in C3.10,15,16 A pathophysiologic 
explanation on how the same mutation, in different patients, can lead to a different disease 
is not available.1 It has been suggested that the final disease outcome is determined by the 
individual’s overall genetic risk to each of these diseases, and is influenced by environmental 
factors.17 
However, a clustering of variants in certain protein domains in the different diseases has 
been described, supporting the existence of a genotype-phenotype correlation.18. In C3, the 
p.Arg161Trp variant is located in the MG2 domain and is present in 4-16% of aHUS patients.19,20 
A particularly prominent hotspot for aHUS mutations is located within the C-terminal short 
consensus repeat (SCR) (15-20) domains of FH, and is considered typical for this disease. Such 
clustering of variants in FH was not observed for C3G patients.21 In AMD, an enrichment of 
protein-altering variants has been reported in the N-terminal and C-terminal SCR domains 
of FH, and in the serine protease domain of FI.1,22,23 However, a systematic evaluation and 
comparison of genetic aberrations between the renal diseases (aHUS/C3G) and AMD has 
not yet been performed. Such analysis could provide a more in depth insight into genotype-
phenotype correlations for these diseases, and could considerably enhance our understanding 
of complement deregulation in human disease. 
In this study, we describe genetic variants identified in the CFH, CFI, and C3 genes in large 
patient cohorts consisting of 866 renal disease (aHUS/C3G) patients and 697 AMD patients, 
and provide a comprehensive genotype-phenotype correlation analyses between these disease 
groups. 
MATERIALS AND METHODS
Cohort description
The AMD cohort consisted of 697 individuals who were recruited as part of the European Genetic 
Database (EUGENDA) between December 2005 and June 2014. Only individuals affected by 
AMD were included in this study. To diagnose AMD, retinal images were evaluated according 
to the Cologne Image Reading Center (CIRCL) protocol. In short, AMD was characterized 
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as the presence of pigmentary changes together with at least 10 small drusen (<63 µm) 
or the presence of intermediate (63-124 µm) to large drusen (≥125 µm diameter) near the 
macula. Furthermore, late AMD was defined as either subfoveal geographic atrophy (GA) or 
choroidal neovascularization (CNV) in at least one eye. Written informed consent was obtained 
from all participants. The study was approved by the local ethics committees on Research 
Involving Human Subjects, and conducted according to the Declaration of Helsinki.
The aHUS/C3G cohort consisted of 886 patients that were referred to the Radboud university 
medical center for genetic screening between 2007 and 2015 to confirm the clinical diagnosis 
of aHUS or C3 glomerulopathy. The diagnosis of aHUS was defined as a presence of hemolytic 
anemia, thrombocytopenia and acute renal failure, that was not preceded with infection 
with Shiga toxin producing E. coli.6 C3G diagnosis was defined as active glomerulonephritis 
combined with predominantly C3 absent or marginal immunoglobulin deposition in renal 
biopsy 24. Most of the patients (around 70%) in this cohort were diagnosed with aHUS. However, 
in some of the cases the clinical diagnosis of aHUS or C3G was unclear, and therefore a genetic 
screening was requested as part of their clinical care.. 
Genetic screening
In this study we focused on the complement genes associated with both aHUS/C3G and AMD, 
which includes the CFH (HGNC:4883, MIM# 134370), CFI (HGNC:5394, MIM# 217030), and C3 
(HGNC:1318, MIM# 120700) genes 4,5,9,22. 
Genetic analysis was performed for the aHUS/C3G and AMD cohorts using DNA isolated from 
peripheral blood leucocytes using standard procedures. For the AMD cohort, whole-exome 
sequencing (WES) of 697 unrelated individuals was performed. WES capture and variant calling 
was obtained through the Nimblegen SeqCap EZ Exome v2 kit by paired-end sequencing on a 
Illumina HiSeq sequencer using TruSeq V3 chemistry as described in detail elsewhere (Corominas 
et al, manuscript submitted). WES data of the AMD cohort was filtered to select coding non-
synonymous and canonical splice-site variants in CFH (NM_00186.3), CFI (NM_00204.3), and C3 
(NM_000064.3). The mean coverage (and minimum to maximum range) for CFH, CFI, and C3 
were 135X (32-495), 124X (44-356), and 32X (2-137), respectively (Figure S1). 
Strict quality filters were set to obtain true positive hits including minimum read depth (n>20), 
variant reads (>10) and at least 20% should be variation reads. Variants identified in CFH were 
confirmed by Sanger sequencing due to the high similarities between CFH and the CHFR1-
4 genes. For the aHUS/C3G cohort, genetic analysis was performed by amplification of the 
coding regions and splice junctions of the CFH (NM_00186.3), CFI (NM_00204.3), and C3 
(NM_000064.3) by PCR, followed by Sanger sequencing or next-generation sequencing on an 
Ion torrent semiconductor (minimum coverage 40X).
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Only low frequency and rare variants (minor allele frequency <5%) based on the ExAC 
database25 were taken into account. Variants were considered aHUS/C3G- or AMD-specific 
when found only in the aHUS/C3G or AMD cohorts analyzed in this study and in literature. 
Reported odds-ratios for genetic variants in AMD were recently published by the International 
AMD Genomics Consortium.9,10 Annotation of the variants, including minor allele frequency of 
the ExAC database, were obtained using ANNOVAR.26 
Statistical analysis
Statistical analyses were done using SPSS Software for Windows version 22.0 (Fisher exact, 
2-sided, weighted by number). We calculated if there was a higher percentage of alleles within 
a specific protein domain of FH, FI, or C3 in aHUS/C3G compared to AMD, and vice versa. 
P-values <0.05 were considered as significant.
Protein structure analysis
Protein domains that carried a significantly higher percentage of alleles in aHUS/C3G or AMD 
were analyzed in more depth to determine the potential effect of the variants mapping to these 
domains. Variants were mapped on the available molecular structures of the C3b-miniFH-FI 
protein complex (PDB 5O32 27). Protein structures were retrieved from the protein data bank 
(PDB, www.rcsb.org)28 using YASARA.29 . 
Literature search
We performed a literature search to review low frequency coding non-synonymous and 
canonical splice-site variants in CFH, CFI, and C3 previously reported in aHUS, C3G and AMD. 
Moreover, variants were extracted from the Factor H aHUS Mutation Database (http://www.fh-
hus.org/), and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/).
RESULTS
Genetic variants identified in aHUS/C3G and AMD patients
We screened 886 aHUS/C3G patients and 697 AMD patients for low frequency variants in the 
coding and splice-site regions of CFH, CFI, and C3. In total, we identified 505 low frequency 
alleles in CFH, CFI, and C3, of which 379 were found in aHUS/C3G and 126 were found in AMD. 
In aHUS/C3G patients, we identified 225 heterozygous and 7 homozygous carriers of variants 
in CFH, 46 heterozygous and 2 homozygous carriers of variants in CFI, and 88 heterozygous 
carriers and 1 homozygous carrier of variants in C3. All 126 variants identified in AMD patients 
were heterozygous, of which 55 were found in CFH, 31 in CFI and 40 in C3. (Table S1).
221
GENOTYPE-PHENOTYPE CORRELATIONS IN RENAL DISEASE AND AMD
The 505 alleles represent 121 unique low frequency variants, of which 51 are novel and 70 were 
previously reported in literature (Table S2). Of the 51 novel variants identified, 8 variants in 
CFH (n=4), CFI (n=2), and C3 (n=2) lead to a premature stop, frameshift or abolished splice site, 
thereby leading to loss of protein function. The remaining 43 novel variants lead to missense 
alterations or to an in-frame insertion (Table S3). 
CFH contained the largest number of unique low frequency variants (n=64). Two-third of these 
variants were aHUS/C3G- (24/64) or AMD-specific (17/64), and one third was found in both 
patients groups (23/64). (Figure 1; Table S3). Three of the low frequency variants (p.Gln950His, 
p.Asn1050Tyr, p.Gln1143Glu) identified in CFH in aHUS/C3G patients, were previously reported 
to have a protective effect for AMD.10 The p.Gln950His variant was detected in 15 aHUS/C3G 
patients; the p.Asn1050Tyr variant was detected in 21 aHUS/C3G patients; and the p.Gln1143Glu 
variant was detected in 9 aHUS/C3G patients 
In CFI, a total of 25 unique low frequency variants was identified of which the majority were 
found in both patient groups (15/25). Only 4 (4/25) variants were specific for aHUS/C3G and 6 
(6/25) variants were exclusively found in AMD (Figure 1; Table S3). 
A total of 32 unique low frequency variants was identified in C3. These variants were evenly 
distributed between aHUS/C3G-specific variants (13/32), AMD-specific variants (9/32) and both 
phenotypes (10/32) (Figure 1; Table S3).
Genotype-phenotype correlations in aHUS/C3G and AMD
To determine genotype-phenotype correlations, we calculated if there was a higher percentage 
of alleles within a specific protein domain of FH, FI, or C3 in aHUS/C3G compared to AMD, and 
vice versa. We observed a higher frequency of protein-altering alleles in the SCR20 domain 
of FH and in the serine protease domain of FI in aHUS/C3G compared to AMD. In AMD we 
observed a higher frequency of protein-altering alleles in the SCR3, SCR5 and SCR7 domains 
of FH, the SRCR domain of FI, and the MG3 domain of C3 (Table 1) compared to aHUS/C3G. 
For FH we calculated the cumulative effect for the alleles found in the domains involved in 
cofactor activity, which include SCR1-4 at the N-terminus and SCR19-20 at the C-terminus of 
the protein. We observed a burden of alleles in the SCR19-20 domains at the C-terminus for 
aHUS/C3G (21.3% versus 3.6% in AMD), and a burden in the SCR1-4 domains at the N-terminus 
for AMD (20.0% versus 4.6% in aHUS/C3G)(Table S3). 
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Figure 1: Genetic variants identified in 886 aHUS/C3G patients and 697 AMD patients. Colors represent 
the phenotype in which the variants were identified: green (both in aHUS/C3G and AMD), orange (aHUS/
C3G only), blue (AMD only) or green^ (with circumflex)(protective for AMD but found recurrently in aHUS/
C3G). Protein domains that carried a significantly higher percentage of alleles in aHUS/C3G or AMD are 
colored gray. Protein interaction sites are reported underneath the domains with dotted lines. CFA = 
cofactor activity; DAA = decay-accelerating activity; CRP = C-reactive protein.
We next mapped the specific mutated amino acids found in the domains that differ significantly 
in allele frequency between aHUS/C3G and AMD on the available molecular structures of the 
C3b-FH-FI complex. These include the SCR3 and SCR20 domains of FH, the SRCR and serine 
protease domains of FI, and the MG3 domain of C3 in 5O32 (Figure 2). FH SCR5 and SCR7 we 
not mapped since there is no available protein structure. Figure 3 shows a detailed view of the 
residues that are altered in the SCR3 domain of FH (Figure 3a and b) and the SP domain of 
FI (Figure 3c and d) in the 5O32 complex, together with the amino acids of interacting protein 
partners that are in close proximity to the altered residues. 
Based on the mapping of the variants on the C3b-FH-FI protein complex, several observations 
can be made. Amino acids affected by aHUS/C3G variants in the SCR20 domain of FH do not 
interact directly with C3b (Figure 2). Amino acids affected by AMD variants in the SCR3 domain 
are located at the interface of FH with C3b and with FI (Figure 2). The residue Arg166 of SCR3, 
mutated in AMD, is located at the interface with the SP domain of FI as well as with CUB 
domain of C3b (Figure 2 and 3a). Other amino acids altered in AMD (Arg175, Ala173, His191, 
Asp187 and Ser193) are located at the interface with the C3b molecule. (Figure 3b). 
Variants affecting residues in the SP domain of FI appear to have different effects on FI binding 
and FI activity. Residues Arg406 and Lys441, affected by genetic variants identified in aHUS/
C3G and AMD, make contacts with Glu123 and Asn136 of FH, respectively (Figure 3c). The 
residues Pro553 and Glu548, affected by genetic variants identified in aHUS/C3G and AMD, are 
located in one of the activation loops in proximity to the FI active site (Figure 3d). The AMD-
associated variants affecting the SRCR domain of FI, are not located at the interface with C3b 
or FH (Figure 2).
aHUS /C3G and AMD variants found in literature
To compare the results of our study to previously reported variants, we compiled a list of low 
frequency variants found in literature for aHUS, C3G and AMD (Table S4). We identified an 
additional 441 unique variants resulting an amino acid change or splice site in CFH (n=236), 
CFI (n=104), and C3 (n=101). These variants were found in aHUS/C3G (n=212), AMD (n=189) and 
both phenotypes (n=40)(Table S5).
224
CHAPTER 8
Table 1: Allelic distribution of CFH, CFI and C3 variants identified in 886 aHUS/C3G patients and 697 
AMD patients. 
Gene Domain aHUS/C3G AMD p-value aHUS/C3G vs AMD
C
FH
N-terminus 1 (0.4%) 1 (1.8%) 0.340
SCR1 6 (2.5%) 3 (5.5%) 0.377
SCR2 0 (0%) 0 (0%) 1.000
SCR3 2 (0.8%) 8 (14.5%) 3.20E-05
SCR4 3 (1.3%) 0 (0%) 1.000
SCR5 0 (0%) 5 (9.1%) 1.97E-04
SCR6 1 (0.4%) 0 (0%) 1.000
SCR7 2 (0.8%) 5 (9.1%) 0.003
SCR8 0 (0%) 1 (1.8%) 0.187
SCR9 13 (5.4%) 1 (1.8%) 0.480
SCR10 1 (0.4%) 0 (0%) 1.000
SCR11 2 (0.8%) 2 (3.6%) 0.160
SCR12 2 (0.8%) 0 (0%) 1.000
SCR13 0 (0%) 1 (1.8%) 0.187
SCR14 8 (3.3%) 1 (1.8%) 1.000
SCR15 19 (7.9%) 1 (1.8%) 0.139
SCR16 20 (8.4%) 8 (14.5%) 0.199
SCR17 31 (13%) 2 (3.6%) 1.000
SCR18 77 (32.2%) 14 (25.5%) 0.419
SCR19 11 (4.6%) 0 (0%) 0.228
SCR20 40 (16.7%) 2 (3.6%) 0.010
N-terminus (SCR1-4) 11 (4.6%) 11 (20.0%) 5.20E-04
C-terminus (SCR19-20) 51 (21.3%) 2 (3.6%) 1.44E-03
Total CFH 239 55  
C
FI
N-terminus 0 (0%) 1 (3.2%) 0.383
FIMAC 1 (2.0%) 0 (0%) 1.000
SRCR 7 (14.0%) 15 (48.4%) 1.60E-03
LA1 3 (6.0%) 3 (9.7%) 0.670
LA2 6 (12.0%) 2 (6.5%) 0.704
Linker region 1 (2.0%) 1 (3.2%) 1.000
SP 32 (64.0%) 9 (29.0%) 2.96E-03
Total CFI 50 31  
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Table 1 (continued)
Gene Domain aHUS/C3G AMD p-value aHUS/C3G vs AMD
C
3
MG1 4 (4.4%) 3 (7.5%) 0.675
MG2 45 (50.0%) 21 (52.5%) 0.850
MG3 0 (0%) 5 (12.5%) 2.30E-03
MG4 0 (0%) 0 (0%) 1.000
MG5 9 (10.0%) 1 (2.5%) 0.174
MG6a 4 (4.4%) 0 (0%) 0.311
LNK 4 (4.4%) 1 (2.5%) 1.000
ANA 0 (0%) 0 (0%) 1.000
MG6b 4 (4.4%) 1 (2.5%) 1.000
MG7 2 (2.2%) 0 (0%) 1.000
CUB 0 (0%) 0 (0%) 1.000
TED 8 (8.9%) 0 (0%) 0.106
MG8 2 (2.2%) 0 (0%) 1.000
CTC 4 (4.4%) 6 (15.0%) 0.068
Total C3 90 40  
Percentage of variant alleles identified with significant p-values in bold.
DISCUSSION
In aHUS/C3G patients we observed a higher frequency of protein-altering alleles in the 
C-terminal SCR20 domain of FH and in the SP domain of FI (Figure 1). In AMD patients an 
increased frequency of protein-altering alleles was observed in the N-terminal SCR domains 
of FH, specifically domains SCR3, SCR5, and SCR7, in addition to the SRCR domain of FI, and 
the MG3 domain of C3.
Complement factor H
The SCR20 domain of FH, which is thought to interact with both C3b, C-reactive protein and 
endothelial cells, harbors significantly more aHUS/C3G associated genetic variants. Amino 
acids affected by genetic variants in this domain do not interact directly with C3b (Figure 2), 
but are likely to mediate FH attachment to the cell surface. Reduced binding to C3b and C3d 
was previously observed for variants p.Val1197Ala and p.Arg1210Cys in CFH (Table S3), which 
may be explained by the role of these residues in the overall structure of the FH C-terminus. 
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Interestingly, like SCR20, SCR19 of FH is also described to be important for interaction with the 
thioester-containing domain (TED) domain of C3b and C3d, and for cell surface interactions. 
Although the prevalence of aHUS/C3G variants in SCR19 was not significant in this study, no 
AMD variants were found by us in this domain. Only variant CFH p.Gln1143Glu, protective for 
AMD,9,10 was detected (Table S3), indicating the importance of genetic changes in this domain 
for the pathogenesis of renal disease. Since phenotype-specific prevalence of genetic variants 
in the TED domain of C3 for renal disease was not discovered by us or described in literature 
(Table S3; Table S4), the disease-specificity of C-terminal FH variants may lay within the 
interactions with the endothelium. 
In AMD patients, genetic variants were more prevalent in the N-terminal region of the protein. 
Available co-crystallization structures show that SCR3 is located at the interface of FH with 
C3b and with FI (Figure 2). The residue Arg166 of SCR3, mutated in AMD, is located at the 
interface with the serine protease domain of FI as well as with the CUB domain of C3b (Figure 
2 and 3a). Other amino acids altered in AMD (Arg175, Ala173, His191, Asp187 and Ser193) are 
located at the interface with C3b molecule. (Figure 3b). 
Our results are comparable to the variants found in literature. The variants more prevalent in 
aHUS/C3G are grouped at the C-terminal SCR19-20 domains of FH (52/148), while the AMD 
variants grouped in the first four SCR domains of CFH (28/74) (Table S4). Previously, over 60% 
of the aHUS-associated FH mutations were reported at the C-terminus.21 Variants in this region 
interfere with heparin binding, binding of C3b and C3d, and result in reduced cell-surface 
interaction.30,31 The low frequency variants reported in AMD are located at the N-terminus of 
FH and decrease cofactor activity for the FI-mediated cleavage of C3b.12,22
The C-terminus of FH is a hotspot for genetic variants in renal diseases, but not AMD, and is 
essential in endothelial binding of FH.32 Interestingly, the retinal Bruch’s membrane differs 
from the renal glomerular basement membrane in GAG binding sites.33 It is hypothesized that 
not FH but Factor H Like 1 (FHL1), the short form of FH (SCR1-7), is involved in the pathogenesis 
of AMD. FHL-1 has the same regulatory functions as FH, but due to its size only this FH form 
can diffuse into the Bruch’s membrane and drusen in the eye.34,35 This may explain why the 
genetic alterations at the C-terminus of FH, which is not present in FHL-1, are less prevalent 
in AMD than in renal disease. Consistently, the SCR19–20 region of FH localizes to GAGs in the 
glomeruli.33 
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FI
SRCR
AMD
FI
SP
aHUS/C3G
FH
SCR3
AMD
FH 
SCR20
aHUS/C3G
C3 
MG3
AMD
Factor H
SCR1-4
C3b
Factor I
Factor H
SCR19-20
Figure 2: Location of protein domains containing a higher percentage of alleles in aHUS/C3G or AMD 
on the structure of the C3b-FH-FI complex. Three-dimensional structure of C3b (gray) in complex with FI 
(cyan) and FH construct (purple) containing FH SCR1-4 and SCR19-20. Surfaces of fragments of C3b (233-
348), FI (119-188, 340-570) and FH (166-193, 1169-1215) carrying missense changes in domains, which 
contain a significantly higher percentage of alleles in aHUS/C3G or AMD, are shown in red. The figure is 
generated based on the PDB 5O32 27, using YASARA Version 17.8.15.29. 
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Arg175
His191
Ser193
Asp187
Ala173
Lys441
Arg448
Arg406
 Asn136
Glu123
Pro553
Ile340
Glu548
His380
Asp429
Ser525
A B
C D
Phe482
Glu211
Ser181
Gln183
Arg166
Ser361
Ser1305
Glu479
Figure 3: Localization of altered residues on the interface of C3b, FH and FI in proteins domains 
containing a higher percentage of alleles in aHUS/C3G or AMD. Fragments of the three dimensional 
structure of C3b (gray), FI (cyan) and FH construct (purple) are shown. The residues altered in the SCR3 
domain of FH (A and B) and the SP domain of FI (C and D) are shown. Residues that were found mutated 
in AMD only (yellow), aHUS/C3G (red) or both phenotypes (orange) are indicated, as well as amino acids 
of interacting partners that are in close proximity of the mutated residues (A, B, C). Important structural 
elements of FI are indicated in green: the charged loop 435-448 (C); the activation loop 548-553 and the 
catalytic triad (H380, D429, S525) (D). The figure is generated based on the PDB 5O32 27, using YASARA 
Version 17.8.15.29
Overall, C3b interactions with glomerular endothelium in the kidney may be more important 
than the interaction with the endothelium in the retina for maintaining the tissue homeostasis. 
Furthermore, our data underscore the importance of N-terminal region of FH in C3b regulation 
in AMD.
Three variants in CFH (c.2850G>T, p.Gln950His; c.3148A>T, p.Asn1050Tyr; c.3427C>G, 
p.Gln1143Glu) were reported as protective for AMD.10 CFH p.Gln950His, residing in SCR16, 
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is associated with disease risk for aHUS with moderate effect on cofactor function 36. CFH 
p.Asn1050Tyr, in SCR18, is a polymorphism reported various times in aHUS without functional 
analyses.37-39 No information is available on CFH p.Gln1143Glu and its association with aHUS/
C3G. The protective mechanisms of these variants in AMD remain to be elucidated. 
Complement factor I
In this study we observed that genetic changes in the SP domain of FI are more prevalent in 
aHUS/C3G than in AMD patients. The SP domain, together with the FIMAC domain, contains 
the binding sites important for C3b and C4b degradation 40,41. Variants found in the SP domain 
could interfere with proper cofactor activity . Residues Arg406 and Lys441 in the SP domain 
make contacts with Glu123 and Asn136 of FH, respectively (Figure 3c). Interestingly, a CFI 
variant affecting Arg448, found in AMD, is located in close proximity to these residues, within 
the charged loop (435-448) that is important in interaction with various C3b regulators (Figure 
3c).27 The CFI residues Pro553 and Glu548 are located in one of the activation loops in proximity 
to the FI active site (Figure 3d),42 while Ile340 at the N-terminus of the light chain plays a role 
in stabilizing of the oxyanion hole.27 The residue Tyr459 is a part of the hydrophobic patch, which 
is important in heavy chain/light chain contact of FI.27
Furthermore, we observed a clustering of alleles in the SRCR domain in AMD patients. None 
of the variants are located at the interface with C3b or FH. However, FI serum levels of AMD 
individuals carrying low frequency variants in the SRCR domain were reported as reduced 
(Table S3; Table S4), thus leading to overall impaired ability to degrade and inactivate C3b. 
In literature, the majority of variants were identified in the FI membrane-attack complex (FIMAC) 
(4/24 and 10/62), SRCR (5/24 and 12/62) and serine protease (SP) (10/24 and 23/62) domains 
for both aHUS/C3G and AMD. Previously, a burden of genetic variants was found in the light 
catalytic chain, the SP domain of FI for aHUS/C3G patients,40,41 and for AMD 1,43. However, we 
observe an enrichment of genetic variants in the SRCR domain of FI. It should be noted that 
rare genetic variant p.Gly119Arg, which confers high risk for AMD, also resides in SRCR of FI.14 
Thus, the FI genetic changes in AMD, which are more prevalent in the SRCR domain, are likely 
to affect the FI expression and thus overall activity, while FI changes more prevalent in renal 
disease are mostly involved in structural elements around the active site.
Complement component 3
In this study, an increased number of variants were found in the MG3 domain of C3 in AMD 
patients (Table S3; Table S4). There are no interactions known for the MG3 domain in C3b, 
including that with FB or complement inhibitors.44,45 However, MG3 is located at the predicted 
interface between C3b and C3 in the C3bBb-C3 enzyme-substrate complex. Genetic alterations 
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in MG3 may thus result in changes at this interface and in more efficient C3 activation by 
C3 convertase.46 The AMD variants affecting residues in the MG3 domain may thus affect the 
overall domain structure and the rates of C3 secretion and/or activation into C3b.
 
In literature, the majority of variants were identified in the TED domain for both aHUS/C3G 
(22/40) and AMD (14/53)(Table S4). For aHUS it was previously reported that the majority of 
variants reside in the TED, MG2 and MG5 domains of C3.16 The majority of aHUS/C3G variants 
were identified in the TED (8.9%) and MG2 (50%) domains. For AMD, we did not identify any 
variants in the TED domain, but the majority of variants identified resided in MG2 (52.5%) as 
well. Interestingly, rare genetic variant p.Lys155Gln, reported to confer risk for AMD, resides 
in the MG2 domain.
In conclusion, our data underscore the importance of the N-terminus of FH in C3b regulation 
in AMD, and of the FH C-terminus in renal disease. Alterations in the SRCR domain of FI 
(prevalent in AMD) are likely to affect expression and thus overall FH activity, while FI changes 
related to renal disease are involved in structural elements around the active site. For C3, 
AMD alterations located the MG3 domain may alter C3 secretion and/or activation into C3b. 
We observed a substantial overlap in variants between aHUS/C3G and AMD, however there is a 
distinct clustering of variants within specific domains.
 Depending on the location of the variant, the genetic variants follow a distinctive genotype–
phenotype correlation. Some genetic variants are associated with aHUS, C3G and AMD 
but individuals carrying these risk variants only present phenotypic characteristics of one 
disorder.17,47 It is likely not one specific variant that results in the manifestation of aHUS, C3G, or 
AMD, but a combination of rare and common disease specific risk variants and environmental 
factors will lead to the manifestation of either an eye or renal phenotype. 
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SUPPLEMENTARY INFORMATION
Table S1: Number of alleles found in this study. Total number of alleles identified in aHUS/C3G and 
AMD patients (heterozygous/homozygous)
Alleles in aHUS/C3G patients (het/hom) Alleles in AMD patients (het/hom)
CFH 239 (225/7) 55 (55/0)
CFI 50 (46/2) 31 (31/0)
C3 90 (88/1) 40 (40/0)
total 379 (359/10) 126 (126/0)
Table S2: Number of low frequency variants found in this study. Total number of genetic variants 
identified in aHUS/C3G and AMD patients (number of novel variants).
aHUS/C3G specific variants 
(novel)
AMD specific variants 
(novel)
aHUS/C3G and AMD variants 
(novel)
CFH 24 (15) 17 (8) 23 (1)
CFI 4 (4) 6 (2) 15 (1)
C3 13 (11) 9 (8) 10 (1)
total 41 (30) 32 (18) 48 (3)
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Table S5: Number of unique variants identified in literature.
CFH aHUS/C3G AMD aHUS/C3G and AMD CFI
aHUS/
C3G AMD
aHUS/C3G 
and AMD
N-terminus 0 0 0 N-terminus 0 1 0
SCR1 8 6 1 FIMAC 4 10 2
SCR2 7 5 2 SRCR 5 12 1
SCR3 4 11 1 LA1 2 6 0
SCR4 4 6 2 LA2 0 4 1
SCR5 0 4 0 Linkerregion 3 6 1
SCR6 2 5 2 SP 10 23 13
SCR7 5 3 1
SCR8 5 4 0
C3 aHUS/C3G AMD
aHUS/C3G 
and AMDSCR9 4 2 0
SCR10 7 6 1 N-terminus 0 0 0
SCR11 6 2 0 MG1 3 1 0
SCR12 3 3 1 MG2 2 1 0
SCR13 6 1 0 MG3 2 5 0
SCR14 8 2 0 MG4 0 1 1
SCR15 13 2 0 MG5 2 3 0
SCR16 5 3 1 MG6a 2 2 0
SCR17 7 3 0 LNK 1 4 1
SCR18 2 3 0 ANA 0 4 1
SCR19 20 0 1 αNT 1 0 1
SCR20 32 3 1 MG6b 0 0 0
MG7 1 3 0
CUB 0 0 0
TED 22 14 2
MG8 2 8 1
CTC 2 7 1
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Figure S1: Mean depth of coverage per gene of the AMD cohort. Mean coverage per domain of the AMD 
cohort with minimum and maximum coverage per complement genes CFH, CFI, and C3 in the whole 
exome sequencing samples. 
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9WHOLE-EXOME SEQUENCING 
IN AGE-RELATED MACULAR DEGENERATION 
IDENTIFIES RARE PROTEIN-ALTERING 
VARIANTS IN COL8A1, A COMPONENT OF 
BRUCH’S MEMBRANE
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CHAPTER 9
ABSTRACT
Purpose: Genome-wide association studies and targeted sequencing studies of candidate 
genes have identified common and rare variants that are associated with age-related macular 
degeneration (AMD). Whole-exome sequencing (WES) studies allow a more comprehensive 
analysis of rare, coding variants across all genes of the genome, and will contribute to a better 
understanding of the underlying disease mechanisms. To date, the number of WES studies in 
AMD case-control cohorts is still scarce and sample sizes are limited. To scrutinize the role of 
rare protein-altering variants in AMD etiology, we performed the largest WES study in AMD to 
date, in a large European cohort consisting of 1,125 AMD cases and 1,361 controls. 
Design: Genome-wide single-variant and gene-based association analyses of WES data.
Participants: 1,125 AMD cases and 1,361 controls.
Method: rare variants association analysis based on gene-based CMC burden test.
Main outcome measures: Genetic variants associated with AMD. 
Results: In this study, we detected a disease burden of rare protein-altering variants in the 
COL8A1 gene (p=7.07x10-05). The COL8A1 burden is explained by 14 rare protein-altering 
variants spread across the protein, which are found more often in cases (22/2,250 alleles, 1.0%) 
than in controls (11/2,722 alleles, 0.4%). The association of rare variants in the COL8A1 gene is 
independent of the common intergenic variant (rs140647181) near the COL8A1 gene, previously 
associated with AMD. We demonstrate that COL8A1 localizes at Bruch’s membrane, which has 
a key role in AMD pathogenesis. 
Conclusions: This study supports a role for protein-altering variants in the COL8A1 gene in 
AMD pathogenesis, and suggests that the previously observed association of the common 
intergenic variant is driven by effects on COL8A1. In this study we for the first time demonstrate 
the presence of COL8A1 in Bruch’s membrane, further supporting the role of COL8A1 variants 
in AMD pathogenesis. Protein-altering variants in COL8A1 may alter the integrity of Bruch’s 
membrane, contributing to the accumulation of drusen and the development of AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss 
among persons above age 50 years in the developed world.1,2 The disease is characterized by 
progressive damage to the retinal pigment epithelium (RPE) and photoreceptors in the macula, 
ultimately leading to visual impairment and blindness. In the early stages of AMD a spectrum 
of changes occur, including hypo- and hyperpigmentations of the retina and the formation 
of extracellular deposits (drusen) in Bruch’s membrane.2 These drusen increase in size and 
number during the intermediate stages. Two types of AMD can develop in the end stage of 
the disease. Geographic atrophy (GA), also referred to as the dry form, is characterized by 
RPE cell atrophy, causing photoreceptor cell death. Choroidal neovascularization (CNV), also 
called the wet form, is characterized by the formation of new blood vessels, leading to leakage, 
hemorrhages and sudden loss of vision.
AMD is a multifactorial disease influenced by a variety of environmental factors, including 
age, smoking history or sunlight exposure during working life.3,4 There is a large genetic 
component in AMD etiology, with an estimated heritability between 46% to 71%.5 Initially, 
genetic studies in AMD mainly focused on common variants in the population through genome-
wide association studies (GWAS) using single nucleotide polymorphism (SNP) microarrays.6–9 
These studies identified genetic variants in or near genes belonging to four main pathways, 
including the complement system, lipoprotein metabolism, angiogenesis and extracellular 
matrix remodeling. However, most common genetic variants identified by GWAS are located in 
non-coding or intergenic regions, and subsequently it is not always apparent which gene near 
the top-associated SNP is the causative gene.
Involvement of genes in a disease can be further established by identification of functionally 
relevant variants in the coding regions, which are often rare in the population with a minor 
allele frequency (MAF) ranging from 0.01% to 1%.8 Thus, several targeted sequencing studies 
focused on the discovery of rare variants in genes located within AMD loci. In these studies, 
rare variants were identified in Complement Factor H (CFH), Complement Factor I (CFI), 
Complement C3 (C3) and Complement C9 (C9)10–14 that are independently associated with AMD. 
Recently, a GWAS performed by the International AMD Genomics Consortium (IAMDGC) using 
an exome array enriched with rare variants identified 52 risk-associated variants at 34 genomic 
loci. Of these 52 variants, seven variants were rare and 45 were common variants.8
Testing the association of individual rare variants in single-variant analyses can be challenging, 
since very large sample sizes are needed to obtain sufficient power.15 Instead of testing each 
variant individually, aggregation tests can evaluate the cumulative effects of multiple genetic 
variants within a gene, leading to an increased study power.16 Sequence analysis of the 
290
CHAPTER 9
coding regions of 681 genes within AMD-associated loci in 1,676 AMD cases and 745 controls 
identified a higher burden of rare variants in CFI in cases (7.8%) than in controls (2.3%).12,17,18 
Furthermore, evaluation of the cumulative effect of rare protein-altering variants, using exome 
array data by the IAMDGC, identified a significant burden in four AMD-associated genes: CFH, 
CFI, Tissue Inhibitor of Metalloproteinases 3 (TIMP3) and Solute Carrier Family 16 Member 8 
(SLC16A8).8 A limitation of these studies is that either rare variants in a limited set of genes12 
or a limited number of rare variants across the genome8 were tested.
Whole-exome sequencing (WES) studies allow a more comprehensive association analysis of 
coding variants across all genes of the genome with complex traits and diseases.19 To date, 
the number of WES studies in AMD case-control cohorts is still scarce and sample sizes are 
limited. Gene-based analysis using WES of 213 neovascular AMD cases and 1,553 healthy 
controls from East Asian populations showed association of a variant in Ubiquitin Protein 
Ligase E3D (UBE3D) with AMD.20 More recently, WES of 39 individuals with bilateral CNV with 
low genetic risk scores and 36 unaffected controls with high genetic risk, did not det ect any 
genes that reached genome-wide significance in a gene-based analysis.21
The main goal of the present study is the identification of rare protein-altering variants that 
are associated with AMD. To achieve this goal, we performed WES in a large European cohort 
consisting of 1,125 cases and 1,361 controls to scrutinize the role of coding variants across the 
human genome in AMD etiology.
MATERIALS AND METHODS
Study population
A cohort of 2,516 individuals of European ancestry (1,493 females and 1,023 males with a mean 
age of 79 years) was recruited from the European Genetic Database (EUGENDA, n=799) and the 
Rotterdam Study (n=1,717).
From EUGENDA (www.eugenda.org), 667 AMD cases and 132 healthy controls were evaluated 
for this study. Inclusion of individuals took place between December 2005 and June 2014. All 
participants underwent clinical evaluation by a retinal specialist and were graded for AMD 
according to the Cologne Image Reading Center (CIRCL) protocol.22 Fundus photographs and 
spectral domain optical coherence tomograms were used to classify AMD by the presence 
of pigmentary changes together with at least 10 small drusen (<63 µm) or the presence of 
intermediate (63-124 µm) or large drusen (≥125 µm diameter) in the Early Treatment Diabetic 
Retinopathy Study (ETDRS) grid. Furthermore, late AMD was defined as either AMD with 
subfoveal geographic atrophy (GA) or choroidal neovascularization (CNV) in at least one eye. 
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Control individuals were included in the study when they exhibited no signs of AMD in either 
eye and were at least 65 years of age at inclusion.
The design of the Rotterdam Study has been described previously in detail.23,24 This prospective, 
population-based follow-up study that started in 1990 and has follow-up visits every five years. 
For this analysis, we included a total of 470 AMD cases and 1,247 controls from the Rotterdam 
Study I sub-cohort aged 55 years and older with WES data. All participants underwent after 
pupillary dilation, fundus photography of the macula using a 35° film fundus camera (Topcon 
TRV-50VT; Topcon Optical Company). For the last two follow-up visits a Topcon digital 35° 
color fundus camera (Topcon TRC 50EX with a Sony DXC-950P digital camera; 0.44 megapixel, 
Minato, Japan) was used. Fundus photos were graded according to the Rotterdam Classification 
which is based on the Wisconsin age-related maculopathy grading system25 (WARMGS) and the 
modified International Classification System.26 Cases were participants with early or late AMD, 
which is at least soft distinct drusen (≥63 µm) in combination with hypo- or hyper-pigmentary 
changes or soft indistinct drusen (≥ 125 µm) or reticular drusen. Controls were participants 
above 65 years with no signs of AMD or above 75 years of age with hard or soft distinct drusen 
(≥63 µm) or pigmentary abnormalities. 
In both cohorts, both eyes of all participants were graded separately by experienced graders, 
who were under the supervision of senior retinal specialists. The worst affected eye was used 
to classify the individual. Written informed consent was obtained from all participants. The 
study was approved by the local ethics committees on Research Involving Human Subjects of 
the participating centers, and all procedures were conducted according to the Declaration of 
Helsinki principles. The Rotterdam Study has been approved by the Medical Ethics Committee 
of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study).
WES capture and variant calling
Genomic DNA of all participants was isolated from blood samples according to standard 
procedures. DNA was fragmented into 200-400 bp fragments and the exome library was prepared 
on a Caliper Sciclone NGS workstation (Caliper Life Science, Hopkinton, MA). The exome was 
captured with the Nimblegen SeqCap EZ Exome v2.0 44Mb kit (Roche Nimblegen, Inc., Madison, 
WI), covering 329,028 exons and 710 miRNAs. Paired-end sequencing was performed on two 
Illumina HiSeq2000 sequencer using Illumina TruSeq V3 chemistry (Illumina, Inc., San Diego, 
CA). High quality reads were mapped to the UCSC hg19 reference genome using the Burrows-
Wheeler alignment tool27. Variant calling was performed by GATK HaplotypeCaller, following 
the GATK best practice guidelines [https://software.broadinstitute.org/gatk]. SNVs and indels 
were filtered separately using GATKs Variant-Quality Score Recalibration (VQSR) module. 
Variants with a VQSLOD score lower than -7.2 were removed. Variant annotation was done 
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using ANNOVAR28 and an in-house pipeline developed by the Department of Human Genetics of 
the Radboud University Medical Center29. Functional effects of variants were predicted by three 
different prediction algorithms: SIFT30, PolyPhen-231 and CADD32 (threshold of deleteriousness 
for CADD ≥ 20). In addition, conservation of candidate variants was estimated by PhyloP 
(threshold for deleteriousness ≥ 2.7) and Grantham (threshold for deleteriousness ≥ 80).
Data quality control
Stringent quality control steps were performed with PLINK v1.0733 in order to exclude those 
positions that had high chances to be false positives. Variants were removed according to 
the following criteria: i) genotypes with a missing rate higher than 5% of individuals and ii) 
common variants (MAF>0.05) that were not in Hardy-Weinberg equilibrium (HWE) in controls. 
After these quality control steps, a total of 744,022 variants were available for analysis. Subject-
level quality control was carried out, excluding individuals with a call rate < 95% or an extreme 
inbreeding coefficient (cutoff ± 0.12).34 Pairwise identity by descent (IBD) was calculated to 
confirm the lack of relatedness among all samples (PI-HAT<0.25). A multi-dimensional scaling 
(MDS) was performed with PLINK v1.07 to obtain the principal components, which were used to 
confirm that all individuals were clustered as European samples and to correct for population 
stratification (Figure S1; available at www.aaojournal.org). After all quality controls, a cohort of 
1,125 AMD cases and 1,361 controls was selected for association analyses.
Statistical analyses
A single variant association test was carried out with RAREMETALWORKER (http://genome.
sph.umich.edu/wiki/RAREMETALWORKER) using a linear mixed model. This software 
performs a score-statistics based rare-variant association analysis, providing single-variant 
results and a variance-covariance matrix. Linkage disequilibrium (LD) relationships between 
markers within 1 Mb are stored in the covariance matrix to perform the gene-level analyses. 
Analysis was performed using an additive model controlling for age, sex, clinic and the first 
four components. Genome-wide significance levels used for single-variant analysis were 
defined based on Bonferroni correction (p-value ≤ 5x10-08).
By definition, single-variant analyses have limited power to detect rare variant associations, 
especially for limited sample sizes. Association power was increased by evaluating the 
accumulated association of multiple rare exonic variants within each gene.35 Gene-based tests 
were carried out by RAREMETAL36 using the summary statistics and LD matrices generated in 
the single-variant analysis. Three different methods were used: the CMC_counts and Variable 
Thresholds (VT) tests, which are burden tests that assume all alleles to influence the association 
in the same direction, and the SKAT test, which evaluates risk and protective alleles in order 
to maximize power. A subset of 308,784 rare protein-altering variants (MAF<0.05) were used 
in the analysis, to avoid that the major presence of non-protein-altering variants (435,238) 
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would dilute the disease burden due to deleterious variants. We selected rare variants that 
alter amino-acid residues (non-synonymous variants), truncate proteins (nonsense and stop-
gain variants) or affect RNA splicing (variants affecting the invariate splice donor and splice 
acceptor sites). 
First we focused on the 34 previously reported AMD loci and we applied a Bonferroni-corrected 
significance threshold based on the 619 genes located within 500 kb of the top-associated SNP 
in each of the AMD loci (according to 8) and carrying at least one rare protein-altering variant 
(p-value < 0.05/619 = 8.07x10-05). Haploview37 was used to reconstruct the region of interest to 
validate that the rare COL8A1 variants belong to different haplotype blocks than the common 
risk variant rs140647181 identified in a previous single-variant test8. In a secondary analysis, we 
extended the search of rare variant disease burden to all genes across the genome, applying a 
Bonferroni-corrected significance threshold of 0.05/17,596 = 2.84x10-06. Quantile-quantile plots 
of p-values from single-variant analysis and gene-based tests were generated to discard any 
batch effect or population substructure.
Characterization of phenotypic features of COL8A1 variant carriers
Phenotypic characterization was performed including participants from the Rotterdam Study. 
AMD features were based on the eye with the most severe phenotype. Glaucoma related 
features are the mean of both eyes at the last visit during follow-up. Refraction was based 
on the mean spherical equivalent of both eyes at the last visit during follow-up, or the last 
visit before cataract extraction. Statistical significance was tested with an independent sample 
t-test for continuous variables, a chi-squared or Fisher’s exact test for dichotomous variables, 
and a Mann-Whitney U test for drusen area, due to its non-normal distribution. All tests 
performed were two sided. 
Mouse retina staining 
Eyes from P60 C57BL/6J wild-type mice were enucleated and embedded in Tissue-Tek® 
O.C.T. Compound (Sakura Finetek 4583). Seven micrometer sections were dried for 1 h at room 
temperature. Using the hydrophobic PAP pen (Sigma-Aldrich Z377821-1EA), a circle was drawn 
surrounding the sections. Retinas were then incubated for 20 min in PBS containing 0.05% 
Tween (MERCK, 8.22184.0500) and 0.05% Triton X-100 (Sigma Aldrich, 9002-93-1) at room 
temperature. After blocking in 0.1% ovoalbumin (Applichem, A4344,0250), 0.5% fish gelatine 
(Sigma-Aldrich, G7041-100G) and 5% bovine serum albumin (Sigma Aldrich, A7906-100G) 
in PBS for 30 min, primary antibodies were added and incubated overnight at 4°C. Primary 
antibodies used included rabbit polyclonal anti collagen type VIII alpha 1 (1:50, Sigma-Aldrich, 
#HPA053107) and rat monoclonal Laminin beta-1 (1:50, ThermoFisher Scientific, MA5-14657). 
Retinas were washed 4 x 5 min in PBS, incubated with the goat anti-rabbit Alexa 568 (1:500, Life 
technologies, A11006) and goat anti-rat Alexa 488 secondary antibody (1:500, Life technologies, 
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A11006) for 45 min at room temperature (dilution 1:500 in blocking solution). Nuclei staining 
with 4’,6-diamidino-2-phenylindole (1:8000, ITK, #0100-20) was combined with the secondary 
antibody incubation. Sections were then washed 4 x 5 min in PBS, rinsed in MilliQ-purified 
water and mounted in Prolong Gold anti-fade reagent (Life technologies, P36930). Imaging was 
performed using a Zeiss Z1 Imager. All images were taken at the same intensity. An image with 
ZEN software was created to obtain TIFF or JPEG files.
RESULTS
Whole exome sequencing
We performed WES on 2,516 unrelated individuals (1,125 cases and 1,361 controls), obtaining 
an average of 2,8 billion bases per individual and a mean coverage of 63X. After variant calling 
and recalibration, a total of 759,450 variants were identified, being 754,503 single nucleotide 
variants (SNVs) and 4,947 insertions or deletions (indels). Of the complete set of variants, 7.6% 
(57,571) were common variants and the remaining 92.4% (701,879) were classified as rare 
variants with a MAF <0.05. Genotype data obtained from WES were checked for concordance 
with the genotype data of a customized Illumina exome array,8 available for a subset of the 
study population (n=1,330). Variants genotyped by both WES and exome array (n=80,779) had 
a concordance rate of >99%, demonstrating the high quality of our sequencing data and high 
accuracy of our genotype calling.
Single variant and gene-based association analyses
We first performed a genome-wide single-variant analysis using the WES data of 1,125 AMD 
cases and 1,361 controls of European ancestry. Common variants were included in order to 
identify the association signals obtained from these variants. Results confirmed association of 
variants in the CFH and Age-Related Maculopathy Susceptibility 2 (ARMS2) genes with AMD in 
this cohort.8 Two common coding variants in CFH (rs1061170 [p = 4.24x10-11] and rs1061147 [p 
= 3.30x10-10]) and one common variant in ARMS2 (rs10490924 [p = 1.89x10-09]) were associated 
with AMD above the threshold of genome-wide significance (p-value ≤ 5x10-08; see Figure S2 
and Figure S3 available at www.aaojournal.org). 
Subsequently, we evaluated the burden of rare protein-altering variants in genes at previously 
identified AMD loci using gene-based burden tests. For this analysis 619 genes were selected 
that are within 500 kb of the top-associated SNP at 34 AMD loci identified in a recent GWAS8 
(Table S1; available at www.aaojournal.org). A CMC burden test (applying genomic control λ = 
0.940) showed a significant disease burden in the COL8A1 gene (p = 7.07x10-05) (Figure 1).
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Figure 1. Manhattan plot of gene-based analysis for disease burden, testing protein-altering variants 
in 18,215 genes using the CMC test. The blue line indicates the significance threshold (p-value < 0.05/619 
= 8.07x10-05) for testing 619 genes located in or near AMD-associated loci. The COL8A1 gene reaches 
the significance threshold, and is depicted in blue. The red line indicates the genome-wide significant 
threshold (p-value < 0.05/17,596 = 2.84x10-06) for genes outside the AMD-associated loci. The KBTBD12 and 
ZNF787 genes do not reach genome-wide significance, and are depicted in red. Bonferroni correction was 
applied to both significance thresholds.
We then expanded the burden analysis to protein-altering variants across the genome. The 
CMC burden test (applying genomic control λ = 1.057) showed a suggestive association in the 
KBTBD12 (p = 3.50x10-06) and ZNF787 genes (p = 2.89x10-05), but these associations did not 
reach the genome-wide significance level (Figure 1). The signal at the KBTBD12 gene did reach 
the genome-wide significance threshold when the SKAT test was applied (p = 4.45x10-07). In both 
tests, the association signal was mainly driven by the effect of one rare variant (rs148151101; 
p-value = 1.52x10-06). However, this particular variant in KBTBD12 was not associated with AMD 
in an exome array analysis in a cohort of 16,144 AMD cases and 17,832 controls of European 
ancestry by the IAMDGC (p = 0.387).8
Rare variant burden in the COL8A1 gene
We next determined whether the rare variant burden in COL8A1 is independent of the previously 
identified AMD-associated common variant (rs140647181) near the COL8A1 gene8. This 
common variant is intergenic, located 560 kb downstream of DCBLD2 and 177 kb upstream of 
COL8A1. To evaluate the independence between both signals, we reconstructed the haplotype 
blocks at the COL8A1 locus. Several recombination events between the rare protein-altering 
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variants in the COL8A1 gene and rs140647181 were observed (Figure 2). These results support 
that the rare variant burden observed in this study is independent of the common intergenic 
variant previously associated with AMD. 
Figure 2. Haploblock structure of the genomic region encompassing the COL8A1 gene and the AMD-
associated SNP rs140647181 located 177 kb upstream of COL8A1 (chr3:99,153,858-99,657,922). A 
Haploview plot was generated based on common SNVs extracted from the 1000 Genomes Phase 3 dataset. 
In black are depicted the most likely haploblocks in this region. This haplotype block distribution shows 
that coding variants identified in the COL8A1 gene (indicated with an asterisk, *) are not located in the 
same haplotype block as rs140647181.
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The COL8A1 burden is explained by 14 rare protein-altering variants spread across the protein 
(Figure 3), which are found more often in cases (22/2,250 alleles, 1.0%) than in controls (11/2,722 
alleles, 0.4%) (Table 1). Six variants, including one nonsense variant (p.G414*) and 5 missense 
variants (p.M70T, p.A96V, p.E520K, p.G711E, p.M744I), were identified only in cases but not in 
controls, and 5 additional variants (p.R225Q, p.A250V, p.R362Q, p.G695D, p.L741F) were found 
at a higher frequency in cases than in controls. The nonsense variant p.G414* is predicted 
to lead to a premature termination in the COL1 domain, or may cause nonsense-mediated 
decay of the COL8A1 mRNA. Two missense variants (p.G695D and p.G711E) are predicted to 
be deleterious with all conservation and pathogenicity tests used, and have a CADD score ≥20, 
which classifies them among the top 0.75% most deleterious mutations that are found in the 
human genome (Table 1). The two missense variants p.G695D and p.G711E affect two highly 
conserved amino acid residues in the non-collagenous 1 (NC1) domain (Figure 3).
Figure 3. Location and conservation of protein-coding variants in COL8A1. (A) Location of rare protein-
altering variants identified in AMD cases and controls in the different COL8A1 domains: triple-helical 
region (COL1), non-collagenous domain 1 (NC1) and 2 (NC2). Variants detected only in control individuals 
are depicted in gray. (B) Alignment of COL8A1 protein sequences of different species. Boxed missense 
variants identified in AMD patients, predicted to be deleterious in all conservation and pathogenicity tests 
(Table 1), affect highly conserved glycine residues in the NC1 domain.
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Table 2. Comparison of phenotypic features between carriers and non-carriers of COL8A1 variants.
Protein change COL8A1 variant  and AMD
COL8A1 variant, 
no AMD
No COL8A1 variant 
and AMD
 (N=16) (N=11) (N= 450)
Age at last visit 79.6 (SD 6.3) 82.5 (SD 7.9) 80.0 (SD 6.5)
Spherical Equivalent -0.37 (SD 1.86)* 1.14 (SD 1.83) 1.26 (SD 2.29)*
Mild myopia (-3 to -6D, %) 3/16 (19%) 1/11 (9%) 23/437 (5%)
Severe myopia (<= -6D, %) 0/16 (0%) 0/11 (0%) 2/437 (0%)
Corneal curvature, mm 7.72 (SD 0.32) 7.58 (SD 0.26) 7.70 (SD 0.26)
IOP, mmHg 13.8 (SD 3.0) 14.3 (SD 2.8) 13.9 (SD 3.3)
VCDR 0.36 (SD 0.18) 0.37 (SD 0.24) 0.32 (SD 0.18)
Subtype of AMD, number 3 GA, 0 CNV, 0 Mixed, 
13 Early
- 29 GA, 21 CNV, 21 
Mixed, 379 Early
Drusen area in grid, median 2% (range 0-37%) 0% (range 0-2%) 2% (range 0-75%)
Presence of hyperpigmentation, % 14/16 (88%) 1/11 (9%) 287/450 (64%)
Presence of reticular drusen, % 0/16 (0%) 0/11 (0%) 27/450 (6%)
Presence of drusen outside grid, % 10/16 (63%) 7/11 (64%) not available
* p=0.005 independent samples t-test (2-tailed) between AMD cases carrying a COL8A1 variant (N=16) 
and AMD cases without variants in COL8A1 (N=437), t-value=2.81 degrees of freedom=451. IOP: 
intraocular pressure. VCDR: vertical cup-disc ratio. GA: geographic atrophy (dry AMD). CNV: choroidal 
neovascularization (wet AMD). Mixed AMD: GA and CNV. 
Phenotypic features of COL8A1 variant carriers
We examined the effect of the COL8A1 variants on the AMD phenotype in participants from the 
Rotterdam Study only, because it is a population-based cohort study without prior selection 
on phenotype. This group consists of 16 AMD cases carrying a COL8A1 variant, 11 individuals 
carrying a COL8A1 variant without AMD, and 450 AMD cases without a COL8A1 variant 
(Table 2). Features of early AMD were not significantly different between COL8A1 carriers 
and non-carriers with AMD, although COL8A1 carriers had a somewhat higher proportion 
of hyper-pigmentary changes (p = 0.062). No statistically significant differences were found 
for glaucoma-related features such as intraocular pressure (IOP) and vertical cup-disc ratio 
(VCDR). The groups differed significantly in spherical equivalent; COL8A1 carriers being more 
myopic (p=0.005). However, there was no significant difference in the proportion of mild and 
severe myopia. 
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Localization of COL8A1 to Bruch’s membrane
Localization of COL8A1 in the retina has not yet been described in the literature. In order to 
assess whether COL8A1 is localized at Bruch’s membrane, the main AMD disease site, we 
performed immunohistochemistry on retinas of wild-type C57BL/6J adult mice. Laminin Beta-
1 (LAMB1) was used as a marker for Bruch’s membrane.38 The co-immunostaining of LAMB1 
and COL8A1 robustly demonstrated that both proteins localize at Bruch’s membrane (Figure 
4). In addition, COL8A1 showed some expression in the photoreceptor layer, being most evident 
at the outer plexiform layer (OPL), the synaptic region between the photoreceptor cells and 
the inner nuclear layer cells. To exclude that the staining was due to background staining 
derived from the use of secondary antibodies, we performed the same procedure without 
adding primary antibody (Figure S4; available at www.aaojournal.org). This confirmed that the 
COL8A1 and LAMB1 staining observed at Bruch’s membrane is due to the primary antibody. 
DISCUSSION
In this study we aimed to scrutinize the role of rare protein-altering variants in AMD etiology 
using WES. By focusing on rare and functionally relevant variants in the coding regions, we 
sought to determine the causality of genes in the disease. Since most top SNPs identified in 
GWAS studies for AMD are in non-coding or intergenic regions,8 it is not always apparent which 
gene near the top-associated SNP is the causative gene. In this study, WES analysis in 1,125 
AMD patients and 1,361 controls revealed a significant burden of rare protein-altering variants 
in the COL8A1 gene in AMD. The COL8A1 burden is explained by 14 rare protein-altering 
variants spread across the protein, which are found more often in cases (22/2,250 alleles, 1.0%) 
than in controls (11/2,722 alleles, 0.4%). The association of rare variants in the COL8A1 gene 
is independent of the common AMD-associated intergenic variant rs140647181, located 560 
kb downstream of DCBLD2 and 177 kb upstream of COL8A1.8 No rare-variant burden was 
observed in the DCBLD2 gene, nor in other genes at the same AMD locus. Taken together, 
these findings support that the previously observed association of the common intergenic 
variant rs140647181 is driven by effects on COL8A1 rather than other genes at the locus. 
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Figure 4. Immunodetection of COL8A1 in mouse retinas. (A) The localization of COL8A1 (in red) was 
studied on P90 retinas derived from wild-type C57BL/6J mice. Laminin Beta-1 (LAMB1, in green) was 
used as a Bruch’s membrane marker. COL8A1 co-localizes with LAMB1 at Bruch’s membrane. COL8A1 
staining also showed a weaker signal in other layers of the retina. (B) Magnifications of the outer region of 
the retina, where the co-localization between LAMB1 and COL8A1 can be appreciated. DAPI (in blue) was 
used to stain cell nuclei. BM: Bruch’s membrane; RPE: retinal pigment epithelium; OS: outer segments; 
IS: inner segments; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: 
inner plexiform layer and GCL: ganglion cell layer.
COL8A1 encodes one of the two alpha chains of collagen type VIII, which is a major component 
of ocular basement membranes.39 Several studies have investigated the association between 
alterations in genes encoding the two subunits of collagen VIII (COL8A1 and COL8A2) 
and ocular abnormalities such as myopic choroidal neovascularization, anterior segment 
dysgenesis and thin corneal stroma.40–43 Although several studies postulated a role for COL8A1 
in ocular basement membranes, so far no published data confirmed the localization of COL8A1 
in Bruch’s membrane. There are several lines of evidence to support that Bruch’s membrane 
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plays a crucial role in AMD. Due to its location, Bruch’s membrane is intensively involved in 
the exchange of numerous biomolecules, nutrients and waste products between the RPE and 
the choroidal capillary bed.44 A disturbed integrity or stability of Bruch’s membrane can lead 
to accumulation of these products in drusen, or can weaken the physical barrier against the 
invasion of new blood vessels into the retina.45 In this study, we demonstrate for the first time 
the presence of COL8A1 in Bruch’s membrane, further supporting the role of COL8A1 variants 
in AMD pathogenesis.46 
Protein-altering variants in COL8A1 may lead to structural alterations in Bruch’s membrane, 
which can be responsible for the development of AMD.41 Interestingly, we describe 14 rare 
protein-altering variants in COL8A1, including one nonsense variant (p.G414*), and two 
deleterious missense variants (p.G695D and p.G711E) that affect highly conserved residues in 
the C-terminal NC1 domain. The NC1 domain mediates proper folding of the protein and the 
assembly of collagen VIII and X into polygonal lattices.47–49 Therefore, these COL8A1 variants may 
lead to an aberrantly folded protein, impairing transport of the protein to Bruch’s membrane, 
or altering Bruch’s membrane integrity or stability. Consequently, this may contribute to the 
development of early AMD. In our study, we observe a higher proportion of hyper-pigmentary 
changes in AMD patients carrying COL8A1 variants, albeit non-significant. Larger patient 
populations are needed to validate this finding. Previous studies have implicated COL8A1 in 
retinal angiogenesis by mediating proliferation and migration of endothelial cells,41 suggesting 
that COL8A1 variants could contribute to the development of neovascularization in late AMD. 
Interestingly, COL8A1 variants seem to contribute to refractive error, although the contribution 
to severe myopic errors was insignificant. 
The findings described here need to be interpreted in light of several strengths and limitations. 
We demonstrated that WES with relatively large cohorts is an efficient strategy to detect 
burden in AMD-associated genes. Previous studies that detected disease burden in AMD 
were focused on predefined gene-sets using targeted sequencing12 or predefined variant-
sets using exome arrays,8 while our study performed a comprehensive exome-wide search 
for rare variants using WES. The main advantage of performing WES is that it enables the 
identification of all rare variants present in coding regions across the genome, allowing a more 
comprehensive evaluation of the disease burden than other approaches based on a limited set 
of genes or variants. An AMD disease burden has been previously described in CFH, CFI, TIMP3 
and SLC16A8,8,12 but these findings were not confirmed in our study. The reason may lie in the 
fact that despite having a relatively large cohort, our study may not have sufficient power to 
detect these associations. In the study by Fritsche et al., a larger cohort was used consisting of 
16,144 AMD cases and 17,832 controls.8 However, the majority of the COL8A1 variants (11/14) 
identified by WES in our study were not present on the exome array that was used by Fritsche 
et al., which may explain why a COL8A1 disease burden was not observed in that study.8 In 
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addition, differences in study designs and populations, case definition, geographical origin, 
statistical tests used or correction for confounding factors may explain the different results 
observed among these studies. 
In conclusion, we performed the largest exome-wide sequence analysis of rare protein-altering 
variants in AMD to date, and detected a disease burden in the COL8A1 gene. A common 
intergenic variant near this gene was previously associated with AMD risk.7,8 but no protein-
altering variants within the gene have been described in AMD so far. This work supports a 
role for protein-altering variants in COL8A1 gene in AMD pathogenesis, and suggests that 
the previously observed association of the common intergenic variant is driven by effects on 
COL8A1. In this study we for the first time demonstrate the presence of COL8A1 in Bruch’s 
membrane, further supporting the role of COL8A1 variants in AMD pathogenesis. Protein-
altering variants in COL8A1 may alter the integrity of Bruch’s membrane, contributing to the 
accumulation of drusen and the development of AMD. This study shows that WES provides 
a fruitful approach for gene and variant identification in complex disorders, such as AMD. 
Collaborative efforts among the scientific community are needed to perform even larger 
exome- or genome-wide sequencing studies,50 which will further increase our understanding 
of the genetic architecture and disease mechanisms of AMD.
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SUPPLEMENTARY INFORMATION
Figure S1. Multidimensional scaling analysis. The pair-wise genetic distances was used to identify 
relationships between our study cohort and the HapMap populations. The first two components were 
plotted in this figure.
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Figure S2. Manhattan plot for single-variant analysis. The association results of each variant (depicted in 
dots) are plotted against the genomic position. Significant variants after Bonferroni correction are depicted 
in green.
Figure S3. QQ-plot for single-variant analysis. The observed p-values [-log10(p-value)] from the single-
variant association analysis for all variants (red dots). The identity (lack of association) is depicted with a 
black line, together with the 95% confidence interval (grey shadow). The observed p-values are corrected 
by genomic control using ‐ of 0.990.
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Figure S4. Assessment of the background signal derived from the secondary antibodies. (A) Assessment 
of the goat anti-rabbit Alexa 568 (in red) and goat anti-rat Alexa 488 (in green) staining on P90 retinas 
derived from wild-type C57BL/6J mice. No signal was detected in the red channel (secondary antibody 
used to detect COL8A1). However, some signal in the outer segment of the photoreceptors was detected in 
the green channel (secondary antibody against LAMB1), but not at the Bruch’s membrane. Therefore, the 
signal at the outer segment is due to the secondary antibodies and therefore it was considered background. 
(B) Magnifications of the region of interest. DAPI (in blue) was used to stain the nuclei of the different cells. 
BM: Bruch’s membrane; RPE: retinal pigment epithelium; OS: outer segment; IS: inner segment; ONL: 
outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer and 
GCL: ganglion cell layer.
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Table S1. List of 619 genes carrying rare protein-altering variants that are located within AMD-
associated regions.
Gene ID Chr Start bp End bp Strand
KCNT2 1 196194909 196578355 -1
CFH 1 196621008 196716634 1
CFHR3 1 196743925 196763203 1
CFHR1 1 196788887 196801319 1
CFHR2 1 196788898 196928356 1
CFHR4 1 196819371 196888102 1
CFHR5 1 196946667 196978804 1
F13B 1 197008321 197036397 -1
ASPM 1 197053258 197115824 -1
ZBTB41 1 197122810 197169672 -1
CRB1 1 197170592 197447585 1
DENND1B 1 197473878 197744826 -1
IRS1 2 227596033 227664475 -1
RHBDD1 2 227700297 227863931 1
COL4A4 2 227867427 228028829 -1
COL4A3 2 228029281 228179508 1
MFF 2 228189867 228222550 1
TM4SF20 2 228226872 228246711 -1
AGFG1 2 228336868 228425930 1
C2orf83 2 228474806 228498036 -1
SLC19A3 2 228549926 228582728 -1
PRICKLE2 3 64079543 64431152 -1
ADAMTS9 3 64501333 64673676 -1
DCBLD2 3 98514785 98620533 -1
COL8A1 3 99357319 99518070 1
FILIP1L 3 99548985 99833357 -1
TBC1D23 3 99979844 100044095 1
NIT2 3 100053545 100075710 1
TOMM70A 3 100082275 100120242 -1
LNP1 3 100120037 100175163 1
TMEM45A 3 100211463 100296288 1
COL25A1 4 109731877 110223813 -1
SEC24B 4 110354928 110462052 1
CCDC109B 4 110481361 110609874 1
CASP6 4 110609785 110624739 -1
PLA2G12A 4 110631145 110651233 -1
CFI 4 110661852 110723335 -1
GAR1 4 110736666 110745893 1
RRH 4 110749150 110765760 1
LRIT3 4 110769358 110793471 1
EGF 4 110834040 110933422 1
ELOVL6 4 110967002 111120355 -1
RAI14 5 34656342 34832732 1
TTC23L 5 34838938 34899561 1
RAD1 5 34905369 34919094 -1
BRIX1 5 34915481 34926101 1
DNAJC21 5 34929698 34959069 1
AGXT2 5 34998206 35048198 -1
PRLR 5 35048861 35230794 -1
SPEF2 5 35617946 35814713 1
IL7R 5 35852797 35879705 1
CAPSL 5 35904397 35938881 -1
UGT3A1 5 35951112 36001130 -1
UGT3A2 5 36035119 36071460 -1
LMBRD2 5 36098514 36152063 -1
SKP2 5 36152091 36184421 1
RANBP3L 5 36248536 36302216 -1
OSMR 5 38845960 38945698 1
RICTOR 5 38938021 39074510 -1
FYB 5 39105338 39274630 -1
C9 5 39284364 39424970 -1
DAB2 5 39371780 39462402 -1
ZNF318 6 43274872 43337216 -1
ABCC10 6 43395104 43418168 1
DLK2 6 43418090 43424370 -1
TJAP1 6 43445261 43474294 1
LRRC73 6 43474707 43478424 -1
POLR1C 6 43477440 43497323 1
YIPF3 6 43479565 43484728 -1
XPO5 6 43490072 43543812 -1
POLH 6 43543887 43586701 1
GTPBP2 6 43573053 43596899 -1
MAD2L1BP 6 43597277 43608689 1
RSPH9 6 43612783 43640336 1
MRPS18A 6 43639040 43655528 -1
VEGFA 6 43737921 43754224 1
C6orf223 6 43968317 43973695 1
MRPL14 6 44081194 44095194 -1
TMEM63B 6 44094651 44123256 1
CAPN11 6 44126548 44152139 1
SLC29A1 6 44187242 44201888 1
HSP90AB1 6 44214824 44221620 1
SLC35B2 6 44221833 44225291 -1
NFKBIE 6 44225903 44233500 -1
TMEM151B 6 44238203 44275243 1
TCTE1 6 44246480 44265458 -1
AARS2 6 44267391 44281063 -1
SPATS1 6 44310397 44344904 1
CYP3A43 7 99425636 99463718 1
OR2AE1 7 99473610 99474680 -1
TRIM4 7 99474581 99517223 -1
GJC3 7 99520892 99527243 -1
AZGP1 7 99564343 99573780 -1
ZKSCAN1 7 99613204 99639312 1
ZSCAN21 7 99647390 99662661 1
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ZNF3 7 99661656 99680171 -1
COPS6 7 99686577 99689823 1
MCM7 7 99690351 99699563 -1
AP4M1 7 99699172 99707968 1
TAF6 7 99704693 99717464 -1
CNPY4 7 99717236 99723134 1
MBLAC1 7 99724317 99726118 1
C7orf43 7 99752043 99756338 -1
GAL3ST4 7 99756867 99766373 -1
GPC2 7 99767229 99774995 -1
STAG3 7 99775186 99819111 1
GATS 7 99798276 99869837 -1
PVRIG 7 99815864 99819113 1
SPDYE3 7 99905325 99919819 1
PILRB 7 99933737 99965356 1
PILRA 7 99965153 99997719 1
ZCWPW1 7 99998449 100026615 -1
MEPCE 7 100026413 100031741 1
PPP1R35 7 100032905 100034188 -1
C7orf61 7 100054238 100061894 -1
TSC22D4 7 100060982 100076902 -1
NYAP1 7 100081550 100092422 1
AGFG2 7 100136834 100165842 1
LRCH4 7 100169855 100183776 -1
SAP25 7 100169855 100171270 -1
FBXO24 7 100181605 100198740 1
PCOLCE 7 100199800 100205798 1
MOSPD3 7 100209725 100213007 1
TFR2 7 100218039 100240402 -1
ACTL6B 7 100240720 100254084 -1
GNB2 7 100271154 100276797 1
GIGYF1 7 100277130 100287071 -1
POP7 7 100303676 100305118 1
EPO 7 100318423 100321323 1
ZAN 7 100331249 100395419 1
EPHB4 7 100400187 100425121 -1
SLC12A9 7 100424442 100464631 1
TRIP6 7 100464760 100471076 1
SRRT 7 100472733 100486285 1
UFSP1 7 100486346 100487339 -1
ACHE 7 100487615 100494594 -1
LHFPL3 7 103969104 104549001 1
SRPK2 7 104751151 105039755 -1
PUS7 7 105080108 105162714 -1
RINT1 7 105172532 105208124 1
ATXN7L1 7 105245514 105517050 -1
PEBP4 8 22570769 22857513 -1
RHOBTB2 8 22844930 22877712 1
TNFRSF10B 8 22877646 22926692 -1
TNFRSF10C 8 22941868 22974950 1
TNFRSF10D 8 22993101 23021543 -1
TNFRSF10A 8 23047965 23082639 -1
CHMP7 8 23101150 23119512 1
R3HCC1 8 23127633 23153792 1
LOXL2 8 23154702 23282841 -1
ENTPD4 8 23243296 23315208 -1
SLC25A37 8 23386318 23432976 1
NKX2-6 8 23559964 23564111 -1
SMC5 9 72873937 72969804 1
KLF9 9 72999503 73029540 -1
TRPM3 9 73143979 74061820 -1
RORB 9 77112281 77308093 1
GABBR2 9 101050391 101471479 -1
ANKS6 9 101493611 101559247 -1
GALNT12 9 101569981 101612363 1
COL15A1 9 101705461 101833069 1
TGFBR1 9 101866320 101916474 1
ALG2 9 101978708 101984238 -1
SEC61B 9 101984346 101992897 1
OR13F1 9 107266455 107267547 1
OR13C4 9 107288534 107289490 -1
OR13C3 9 107298030 107299137 -1
OR13C8 9 107331449 107332411 1
OR13C5 9 107360650 107361788 -1
OR13C2 9 107366924 107367951 -1
OR13C9 9 107379529 107380485 -1
OR13D1 9 107456660 107457766 1
NIPSNAP3A 9 107509969 107522403 1
NIPSNAP3B 9 107526438 107539738 1
ABCA1 9 107543283 107690518 -1
SLC44A1 9 108006903 108201452 1
KIAA1217 10 23983675 24836772 1
ARHGAP21 10 24872538 25012597 -1
PRTFDC1 10 25137536 25241533 -1
ENKUR 10 25270908 25305089 -1
THNSL1 10 25305587 25315593 1
GPR158 10 25463991 25891155 1
NSMCE4A 10 123716603 123734732 -1
TACC2 10 123748689 124014060 1
BTBD16 10 124030821 124097677 1
PLEKHA1 10 124134212 124191867 1
ARMS2 10 124214169 124216868 1
HTRA1 10 124221041 124274424 1
DMBT1 10 124320181 124403252 1
C10orf120 10 124457225 124459338 -1
CUZD1 10 124591665 124639146 -1
FAM24B 10 124608594 124639157 -1
FAM24A 10 124670217 124672627 1
C10orf88 10 124690419 124713919 -1
OR10A7 12 55614809 55615759 1
OR6C74 12 55640982 55642086 1
OR6C6 12 55688072 55689016 -1
OR6C1 12 55714346 55715408 1
OR6C3 12 55725485 55726420 1
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OR6C75 12 55758895 55759833 1
OR6C65 12 55794214 55795289 1
OR6C76 12 55820038 55820976 1
OR6C2 12 55845998 55846936 1
OR6C70 12 55862984 55863922 -1
OR6C68 12 55886147 55887100 1
OR6C4 12 55944983 55946028 1
OR10P1 12 56030644 56031638 1
METTL7B 12 56075330 56078395 1
ITGA7 12 56078352 56109827 -1
BLOC1S1 12 56109820 56113871 1
RDH5 12 56114151 56118489 1
CD63 12 56119107 56123491 -1
GDF11 12 56137064 56150911 1
SARNP 12 56146247 56211540 -1
ORMDL2 12 56211703 56215663 1
DNAJC14 12 56214744 56224608 -1
MMP19 12 56229217 56236750 -1
WIBG 12 56295197 56326402 -1
DGKA 12 56321103 56347811 1
PMEL 12 56347889 56367101 -1
CDK2 12 56360553 56366568 1
RAB5B 12 56367697 56388490 1
SUOX 12 56390964 56400425 1
IKZF4 12 56401443 56432219 1
RPS26 12 56435637 56438116 1
ERBB3 12 56473641 56497289 1
PA2G4 12 56498103 56507691 1
ZC3H10 12 56511943 56516278 1
ESYT1 12 56512034 56538455 1
MYL6B 12 56546040 56553431 1
MYL6 12 56551945 56557280 1
SMARCC2 12 56556767 56583351 -1
RNF41 12 56598285 56615717 -1
NABP2 12 56615799 56623638 1
SLC39A5 12 56623833 56631630 1
ANKRD52 12 56631591 56652175 -1
COQ10A 12 56660642 56664750 1
CS 12 56665483 56694176 -1
CNPY2 12 56703626 56710120 -1
PAN2 12 56710007 56727837 -1
FAM216A 12 110906169 110928190 1
VPS29 12 110928902 110939922 -1
RAD9B 12 110939460 110969891 1
PPTC7 12 110969120 111021125 -1
TCTN1 12 111051832 111087235 1
HVCN1 12 111065646 111142755 -1
PPP1CC 12 111157485 111180744 -1
CCDC63 12 111284573 111345339 1
MYL2 12 111348623 111358526 -1
CUX2 12 111471828 111788358 1
FAM109A 12 111798455 111806925 -1
SH2B3 12 111843752 111889427 1
ATXN2 12 111890018 112037480 -1
BRAP 12 112079950 112123790 -1
ACAD10 12 112123857 112194903 1
ALDH2 12 112204691 112247782 1
MAPKAPK5 12 112279782 112334343 1
TMEM116 12 112369086 112450970 -1
ERP29 12 112451120 112461255 1
NAA25 12 112464500 112546826 -1
TRAFD1 12 112563305 112591407 1
HECTD4 12 112597992 112819896 -1
RPL6 12 112842994 112856642 -1
PTPN11 12 112856155 112947717 1
RPH3A 12 113008184 113336686 1
OAS1 12 113344582 113369990 1
OAS3 12 113376157 113411054 1
OAS2 12 113416200 113449528 1
DTX1 12 113494514 113535833 1
ALOX5AP 13 31309645 31338556 1
TEX26 13 31506840 31549639 1
HSPH1 13 31710762 31736525 -1
B3GALTL 13 31774073 31906413 1
RXFP2 13 32313674 32377009 1
ZFYVE26 14 68194091 68283307 -1
RAD51B 14 68286496 69196935 1
ZFP36L1 14 69254377 69263190 -1
ACTN1 14 69340860 69446157 -1
DCAF5 14 69517598 69619867 -1
ALDH1A2 15 58245622 58790065 -1
AQP9 15 58430368 58478110 1
LIPC 15 58702768 58861151 1
ADAM10 15 58887403 59042177 -1
FAM63B 15 59063391 59154099 1
SLTM 15 59171244 59225852 -1
OGFOD1 16 56485402 56513012 1
BBS2 16 56500748 56554195 -1
MT4 16 56598961 56602869 1
MT3 16 56622986 56625000 1
MT1E 16 56659387 56661024 1
MT1M 16 56666145 56667898 1
MT1B 16 56685811 56687116 1
MT1F 16 56691606 56694610 1
MT1G 16 56700643 56701977 -1
MT1H 16 56703726 56705041 1
MT1X 16 56716336 56718108 1
NUP93 16 56764017 56878797 1
SLC12A3 16 56899119 56949762 1
HERPUD1 16 56965960 56977798 1
CETP 16 56995762 57017757 1
NLRC5 16 57023397 57117443 1
CPNE2 16 57126449 57181878 1
FAM192A 16 57186378 57220028 -1
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RSPRY1 16 57220049 57274387 1
ARL2BP 16 57279010 57287516 1
PLLP 16 57290004 57318599 -1
CCL22 16 57392684 57400102 1
CX3CL1 16 57406370 57418960 1
CCL17 16 57438679 57449974 1
CIAPIN1 16 57462081 57481440 -1
COQ9 16 57481337 57495187 1
POLR2C 16 57496299 57505922 1
DOK4 16 57505863 57521239 -1
MLKL 16 74705753 74734858 -1
FA2H 16 74746853 74808729 -1
WDR59 16 74907468 75034071 -1
ZNRF1 16 75032928 75144892 1
LDHD 16 75145758 75150669 -1
ZFP1 16 75182390 75206134 1
CTRB2 16 75237994 75241083 -1
CTRB1 16 75252898 75258822 1
BCAR1 16 75262928 75301951 -1
CFDP1 16 75327596 75467383 -1
TMEM170A 16 75476952 75499395 -1
CHST6 16 75510949 75529282 -1
CHST5 16 75562433 75569145 -1
TMEM231 16 75572015 75590184 -1
GABARAPL2 16 75600249 75611779 1
ADAT1 16 75630879 75657198 -1
KARS 16 75661622 75682541 -1
TERF2IP 16 75681684 75795770 1
NOS2 17 26083792 26127525 -1
NLK 17 26368763 26523407 1
TMEM97 17 26646121 26655707 1
IFT20 17 26655352 26662515 -1
TNFAIP1 17 26662628 26674035 1
TMEM199 17 26684604 26708716 1
VTN 17 26691290 26700110 -1
SEBOX 17 26691290 26692265 -1
SARM1 17 26691378 26728065 1
SLC46A1 17 26721661 26734215 -1
SLC13A2 17 26800311 26824799 1
FOXN1 17 26833261 26865914 1
UNC119 17 26873725 26879686 -1
PIGS 17 26880401 26898890 -1
ALDOC 17 26900133 26904282 -1
SPAG5 17 26904588 26926297 -1
SGK494 17 26934982 26941218 -1
KIAA0100 17 26941458 26972472 -1
SDF2 17 26975374 26989207 -1
SUPT6H 17 26989109 27029697 1
PROCA1 17 27030215 27038872 -1
RAB34 17 27041299 27045447 -1
RPL23A 17 27046411 27051377 1
TLCD1 17 27051366 27054953 -1
NEK8 17 27052915 27070473 1
TRAF4 17 27071002 27077974 1
FAM222B 17 27082996 27182250 -1
ERAL1 17 27181956 27188085 1
FLOT2 17 27206353 27224697 -1
DHRS13 17 27224799 27230089 -1
PHF12 17 27232268 27278789 -1
BAIAP2 17 79008948 79091232 1
AATK 17 79091095 79139877 -1
ENTHD2 17 79202077 79212891 -1
SLC38A10 17 79218800 79269347 -1
TMEM105 17 79285074 79304474 -1
BAHCC1 17 79369275 79440126 1
ACTG1 17 79476997 79490873 -1
FSCN2 17 79495422 79504156 1
C17orf70 17 79506911 79520987 -1
NPLOC4 17 79523913 79615495 -1
TSPAN10 17 79604197 79615779 1
PDE6G 17 79617489 79630142 -1
OXLD1 17 79632066 79633665 -1
CCDC137 17 79633394 79640934 1
ARL16 17 79648204 79650954 -1
HGS 17 79650356 79670168 1
MRPL12 17 79670387 79674556 1
SLC25A10 17 79670401 79687569 1
GCGR 17 79762008 79771889 1
FAM195B 17 79780287 79791178 -1
PPP1R27 17 79791368 79792926 -1
P4HB 17 79801035 79818570 -1
ARHGDIA 17 79825597 79829282 -1
ALYREF 17 79845713 79849462 -1
ANAPC11 17 79848666 79858867 1
NPB 17 79858621 79860781 1
PCYT2 17 79858841 79869340 -1
SIRT7 17 79869815 79879199 -1
MAFG 17 79876146 79885590 -1
PYCR1 17 79890260 79900288 -1
MYADML2 17 79897521 79905109 -1
NOTUM 17 79910388 79919716 -1
ASPSCR1 17 79934683 79975282 1
STRA13 17 79976578 79981983 -1
LRRC45 17 79981178 79989027 1
RAC3 17 79989500 79992080 1
DCXR 17 79993012 79995608 -1
RFNG 17 80005778 80009707 -1
GPS1 17 80008567 80015346 1
DUS1L 17 80015382 80023763 -1
FASN 17 80036214 80056208 -1
CCDC57 17 80059336 80170706 -1
SLC16A3 17 80186273 80219005 1
CDC34 19 531714 542097 1
GZMM 19 544034 549919 1
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BSG 19 571297 583493 1
HCN2 19 589893 617159 1
POLRMT 19 617223 633597 -1
FGF22 19 639879 643703 1
RNF126 19 647526 663277 -1
FSTL3 19 676392 683385 1
PRSS57 19 685521 695460 -1
PALM 19 708953 748329 1
PTBP1 19 797075 812327 1
AZU1 19 825097 832017 1
PRTN3 19 840963 848175 1
ELANE 19 851014 856242 1
CFD 19 859453 863453 1
MED16 19 867962 893218 -1
R3HDM4 19 896503 913240 -1
KISS1R 19 917287 921015 1
ARID3A 19 925781 975939 1
WDR18 19 983174 994569 1
GRIN3B 19 1000418 1009731 1
CNN2 19 1026298 1039068 1
ABCA7 19 1040102 1065571 1
HMHA1 19 1065922 1086627 1
POLR2E 19 1086594 1095598 -1
GPX4 19 1103936 1106787 1
SBNO2 19 1107636 1174282 -1
STK11 19 1189406 1228428 1
C19orf26 19 1228286 1238026 -1
ATP5D 19 1241749 1244824 1
MIDN 19 1248552 1259142 1
CIRBP 19 1259384 1274879 1
C19orf24 19 1275026 1279248 1
MUM1 19 1285890 1378430 1
EFNA2 19 1286153 1301430 1
NDUFS7 19 1383526 1395583 1
GAMT 19 1397091 1401569 -1
DAZAP1 19 1407568 1435719 1
RPS15 19 1438358 1440583 1
APC2 19 1446300 1473243 1
C19orf25 19 1461142 1479555 -1
PCSK4 19 1481427 1490751 -1
REEP6 19 1491165 1497926 1
ADAMTSL5 19 1505017 1513603 -1
PTPRS 19 5158506 5340814 -1
ZNRF4 19 5455426 5456867 1
SAFB2 19 5587010 5624057 -1
SAFB 19 5623046 5668489 1
C19orf70 19 5678432 5680907 -1
HSD11B1L 19 5680615 5688533 1
LONP1 19 5691845 5720583 -1
CATSPERD 19 5720688 5778745 1
PRR22 19 5782971 5784776 -1
DUS3L 19 5784843 5791249 -1
NRTN 19 5823813 5828335 1
FUT6 19 5830621 5839742 -1
FUT3 19 5842899 5851485 -1
FUT5 19 5865837 5903798 -1
NDUFA11 19 5891287 5904017 -1
VMAC 19 5904869 5910864 1
CAPS 19 5911718 5915888 1
RANBP3 19 5916150 5978153 -1
RFX2 19 5993175 6199583 -1
ACSBG2 19 6135258 6193112 1
MLLT1 19 6212966 6279959 -1
ACER1 19 6306153 6333640 -1
CLPP 19 6361463 6368919 1
ALKBH7 19 6372444 6375042 1
GTF2F1 19 6379580 6393992 -1
KHSRP 19 6413359 6424805 -1
SLC25A41 19 6426048 6433790 -1
SLC25A23 19 6436090 6465214 -1
CRB3 19 6463788 6467232 1
DENND1C 19 6467218 6482568 -1
TUBB4A 19 6494330 6502859 -1
TNFSF9 19 6531010 6535931 1
CD70 19 6583194 6604114 -1
TNFSF14 19 6663148 6670599 -1
C3 19 6677715 6730573 -1
GPR108 19 6729925 6737614 -1
TRIP10 19 6737936 6751537 1
SH2D3A 19 6752171 6767599 -1
VAV1 19 6772725 6857377 1
MBD3L5 19 7030589 7033022 1
MBD3L3 19 7056220 7058651 -1
ZNF557 19 7069455 7087979 1
INSR 19 7112266 7294045 -1
ZNF285 19 44886459 44905774 -1
ZNF229 19 44921685 44952766 -1
ZNF180 19 44979854 45004576 -1
CEACAM20 19 45005729 45033811 -1
PVR 19 45147098 45166850 1
CEACAM19 19 45165545 45187631 1
CEACAM16 19 45202421 45213986 1
BCL3 19 45250962 45263301 1
CBLC 19 45281126 45303891 1
BCAM 19 45312328 45324673 1
PVRL2 19 45349432 45392485 1
TOMM40 19 45393826 45406946 1
APOE 19 45409011 45412650 1
APOC1 19 45417504 45422606 1
APOC4 19 45445495 45452820 1
APOC2 19 45449243 45452822 1
CLPTM1 19 45457842 45496599 1
RELB 19 45504688 45541452 1
CLASRP 19 45542298 45574214 1
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ZNF296 19 45574758 45579846 -1
GEMIN7 19 45582453 45594782 1
MARK4 19 45582546 45808541 1
NKPD1 19 45653008 45663408 -1
TRAPPC6A 19 45666186 45681495 -1
BLOC1S3 19 45682003 45685059 1
EXOC3L2 19 45715879 45737469 -1
CKM 19 45809672 45826235 -1
KLC3 19 45836692 45854778 1
ERCC2 19 45853095 45874176 -1
PPP1R13L 19 45882892 45909607 -1
CD3EAP 19 45909467 45914024 1
ERCC1 19 45910591 45982086 -1
FOSB 19 45971253 45978437 1
RTN2 19 45988547 46000319 -1
PPM1N 19 45992035 46005768 1
VASP 19 46009837 46030241 1
OPA3 19 46030685 46105470 -1
GPR4 19 46093022 46105466 -1
EML2 19 46110252 46148887 -1
GIPR 19 46171502 46186982 1
QPCTL 19 46195741 46207247 1
FBXO46 19 46213887 46234162 -1
SIX5 19 46268043 46272484 -1
DMPK 19 46272975 46285810 -1
DMWD 19 46286205 46296060 -1
RSPH6A 19 46298968 46318577 -1
SPINT3 20 44141101 44144264 -1
WFDC6 20 44162835 44168134 -1
EPPIN 20 44165625 44176391 -1
WFDC8 20 44179792 44207965 -1
WFDC9 20 44236578 44259907 -1
WFDC10A 20 44258165 44259835 1
WFDC11 20 44277202 44298909 -1
WFDC10B 20 44313292 44333658 -1
WFDC13 20 44330655 44337456 1
SPINT4 20 44350990 44354469 1
WFDC3 20 44376583 44420571 -1
DNTTIP1 20 44420576 44440066 1
UBE2C 20 44441215 44445596 1
TNNC2 20 44451853 44462384 -1
SNX21 20 44462449 44471914 1
ACOT8 20 44470360 44486045 -1
ZSWIM3 20 44486256 44507761 1
ZSWIM1 20 44509866 44513905 1
SPATA25 20 44515128 44516274 -1
NEURL2 20 44517264 44519926 -1
CTSA 20 44518783 44527459 1
PLTP 20 44527399 44540794 -1
PCIF1 20 44563267 44576662 1
ZNF335 20 44577292 44600833 -1
MMP9 20 44637547 44645200 1
SLC12A5 20 44650356 44688784 1
NCOA5 20 44689624 44718591 -1
CD40 20 44746911 44758502 1
CDH22 20 44802372 44937137 -1
SLC35C2 20 44978167 44993043 -1
ELMO2 20 44994688 45061704 -1
ZNF334 20 45129701 45142198 -1
CTCFL 20 56071035 56100708 -1
PCK1 20 56136136 56141513 1
ZBP1 20 56178902 56195632 -1
PMEPA1 20 56223448 56286592 -1
C20orf85 20 56725960 56736206 1
ANKRD60 20 56793551 56803709 -1
RAB22A 20 56884752 56942563 1
VAPB 20 56964178 57026157 1
APCDD1L 20 57034157 57090187 -1
C22orf42 22 32544993 32555309 -1
RFPL2 22 32586422 32600718 -1
SLC5A4 22 32614465 32651328 -1
RFPL3 22 32750872 32757148 1
BPIFC 22 32809834 32860471 -1
FBXO7 22 32870663 32894818 1
SYN3 22 32908539 33454358 -1
TIMP3 22 33197687 33259030 1
ELFN2 22 37764000 37823505 -1
MFNG 22 37865101 37882439 -1
CARD10 22 37886400 37915549 -1
CDC42EP1 22 37956454 37965412 1
LGALS2 22 37966255 37978623 -1
GGA1 22 38004481 38029571 1
SH3BP1 22 38030661 38062939 1
PDXP 22 38054734 38062941 1
LGALS1 22 38071615 38075813 1
NOL12 22 38077680 38170137 1
TRIOBP 22 38093011 38172563 1
H1F0 22 38201114 38203442 1
GCAT 22 38203912 38213183 1
GALR3 22 38219389 38221502 1
ANKRD54 22 38226862 38245334 -1
EIF3L 22 38244875 38285414 1
MICALL1 22 38301664 38338829 1
C22orf23 22 38339528 38349676 -1
POLR2F 22 38348614 38437922 1
SOX10 22 38366693 38383429 -1
PICK1 22 38452318 38471708 1
SLC16A8 22 38474141 38480100 -1
BAIAP2L2 22 38480896 38506677 -1
PLA2G6 22 38507502 38601697 -1
MAFF 22 38597889 38612518 1
TMEM184B 22 38615298 38669040 -1
CSNK1E 22 38686697 38794527 -1
KCNJ4 22 38822332 38851205 -1
313
WES IDENTIFIES PROTEIN-ALTERING RARE VARIANTS IN COL8A1
KDELR3 22 38864067 38879452 1
DDX17 22 38879445 38903665 -1
DMC1 22 38914954 38966291 -1
FAM227A 22 38974125 39052634 -1
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The general aim of this thesis was to elucidate the role of rare genetic variants in the 
pathogenesis of age-related macular degeneration (AMD). We set out to identify novel genetic 
causes of AMD, and to understand the effect of identified rare genetic variants on the disease 
mechanisms. The following section elaborates on the primary findings of this thesis, places 
these findings in a broader perspective, and discusses the clinical and scientific relevance. 
RARE VERSUS COMMON GENETIC VARIANTS
Studying rare genetic variants in complex traits has advantages and challenges when compared 
to studying common genetic variants.1,2 First, studying rare variants requires different study 
designs compared to common variants. In addition, rare variants seem to contribute only a 
small proportion of the disease risk of complex disease compared to common variants. On the 
other hand, the effect of common variants is usually subtle and not always apparent, while rare 
coding variants may result in clear functional consequences. Moreover, rare variants can have 
very large effect sizes on the disease risk opposed to common variants, which usually have 
relatively small effects. Finally, the frequency of rare variants can considerably vary among 
populations.
Rare variant study designs
Implicating rare genetic variants in disease pathogenesis requires immense sample sizes 
or specific study designs. Examples of study designs that can be utilized to find rare variant 
associations include: sampling extreme phenotypes, using population isolates or sub-
populations, performing targeted sequencing or studying families.3,4 
Extreme phenotype sampling is applicable in quantitative traits and focuses on extreme 
presentations at the tails of the phenotypic distribution. While this technique may boost the 
statistical power, it is sensitive to sampling bias and outcomes may be difficult to reflect on the 
general population.4,5 A recent study6 used extreme phenotype groups, based on a cumulative 
risk score, to identify associations outside the regions known to be associated with risk for 
AMD. 
The use of population isolates in rare variant association studies is based on the concept that 
they have a reduced genetic diversity. Disease-causing rare variants may therefore be found 
at higher frequencies within these groups compared to the general population.4 For example, 
sequencing of Amish individuals identified a population-specific, risk-conferring variant in 
CFH.7 
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A study design performing targeted sequencing of genes or pathways of interest allows for a 
reduction in time and costs. A reduced gene set provides increased accuracy, allows larger 
samples sizes to be analyzed and requires a smaller DNA input.8 Targeted sequencing of 
candidate genes led to the identification of rare genetic variants in C3 and CFI.9-11 
A study design using families relies on the occurrence of disease-causing variants at high 
frequency in affected family members compared to unaffected individuals, or affected families 
compared to the general population.4 In chapter 2 and 3 we used families with multiple 
individuals affected by AMD to identify rare genetic variants, which we replicated in a case-
control cohort.
Contribution of common versus rare variants to complex disease
Common variants are estimated to be the major contributor to disease risk in complex 
disorders. Park and colleagues12 showed that variants involved in complex diseases are skewed 
towards MAF >20%, rather than low frequency (MAF <5%) variants.12 It has been suggested that 
rare variants (MAF <1%) can explain a portion of the disease heritability in complex diseases. 
Genetic studies performed to date in AMD suggest that common variants have a much larger 
contribution to disease risk than low frequency variants. The 52 independently associated 
variants reported by the International AMD Genomics Consortium explain 27.2% of the disease 
variability, which included a 1.4% contribution from seven rare variants. Additional large 
studies using targeted sequencing, exome sequencing or whole genome sequencing may 
expand our knowledge on the contribution of rare variants to AMD pathogenesis. The samples 
size required to properly determine the impact of rare variants on disease risk was estimated 
at over 25,000 patients.13
Functional effect of common versus rare variants
Common variants in complex disorders are commonly identified through genome-wide 
association studies (GWAS). The index (tag) SNP tags multiple SNPs within the same haplotype 
block, and is in high linkage disequilibrium (LD) with those other SNPs. The index SNPs is 
often non-coding and the functional effect is not always apparant.14 Moreover, due to the high 
linkage disequilibrium of the index SNPs with other SNPs in the same haplotype block, the 
index SNP does not necessarily need to be the causative variant. Determining the functional 
effect of common variants on the disease mechanisms can therefore be challenging. 
On the other hand, rare coding variants may result in clear functional consequences, critically 
changing the amino acid, or leading to a premature stop in the protein. An example of a rare 
variant with a clear functional effect is CFH p.Arg1210Cys. This variant is one of the strongest 
rare genetic risk factors in AMD.9,13 Human serum albumin binds to the mutant cysteine, 
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interfering with FH’s ability to bind with ligands and abolishing all other FH functional domains. 
As a result the variant results in a partial FH deficiency.15,16 
Effect sizes of common versus rare variants
In complex diseases, an inverse relation exists between the odds ratio and the frequency of 
a genetic variant in the population (Figure 1).12 Variants like CFH rs570618 (in high linkage 
disequilibrium with CFH p.Tyr402His), ARMS2 rs3750846 (in high linkage disequilibrium with 
ARMS2 p.Ala69Ser), and protective CFH variants rs10922109, are unique examples of common 
variants with relatively large effect sizes (OR>2, or in the case of protective variant OR<0.5). 
These variants plot in the lower right corner of Figure 1 and are effectively identified by GWAS.
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Figure 1: Frequency and effect-size of AMD associated variants. Odds ratio (OR; y-axis) and minor allele 
frequency (MAF; x-axis) with MAF based on control individuals without AMD. The filled diamonds represent 
52 independently associated rare and common variants found in 34 loci as published by Fritsche et al.,13 
(supplementary table 4). The outlined diamonds represent 23 rare variants in CFH, CFI¸C3, and C9 that 
reached P<0.05 as reviewed in Chapter 1B17 (supplementary table 1). Variants CFH p.Arg1210Cys, CFI 
p.Gly119Arg, C9 p.Pro167Ser and C3 p.Lys155Gln (in bold) are shown both as filled and outlined diamonds. 
Protective ORs are transformed (1/OR) and depicted in orange.
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Rare variants with small effect sizes plot in the left lower corner of Figure 1. These type 
of variants are difficult to detect and require large sample sizes to reach genome-wide 
significance. Rare variants with a large effect size, like CFH p.Arg1210Cys and CFH p.Arg53Cys, 
(upper left corner of Figure 1), behave like highly penetrant Mendelian mutations, and are 
often found clustering in subpopulations or families. A challenge when studying rare variants, 
however, is that the effect size can only be estimated if the variant is identified in a sufficient 
amount of cases and controls to calculate the odds ratio. For rare variants identified in only a 
small number of cases or families, the effect size cannot accurately be calculated, making it 
difficult to provide an accurate risk assessment to carriers of such rare variants. 
Distribution of rare variants among populations
Allele frequencies can exhibit large diversity among populations. While most common variants 
are shared worldwide, rare variants have the tendency to cluster in specific populations or 
families. For example, the p.Arg1210Cys variant in CFH was first reported in a case-control 
study from the United States18. While some studies could replicate the finding9,13,15, other 
Caucasian studies 11,19-21 and Asian studies 22,23 were unable to replicate its strong association. 
Such population-specific rare variants in particular tend to have a strong functional effect.24 
In chapter 5 we describe the distribution of risk-associated rare genetic variants identified 
by the International AMD Genomic Consortium.13 We observed that the frequency of two of 
the variants (CFH rs121913059 and rs35292876 [p.Arg1210Cys]) show a different distribution 
among populations. However, all variants in the study had comparable risk estimates across 
the geographical regions. 
The occurrence of population-specific variations has implications for genetic counseling and 
carrier screening in both diagnostic and research settings. For example, carriers of specific 
rare genetic variants in the complement genes that increase complement activation may 
benefit more from complement inhibiting therapy than those who do not carry such variants25. 
Personalized treatment aiming at complement-activating rare variants in clinical trials may 
only be applicable to specific populations where these variants are sufficiently common.
FAMILY STUDIES TO IDENTIFY RARE GENETIC VARIANTS IN AMD
In this thesis we used family studies to identify rare genetic variants associated with AMD. A 
challenge that we encountered when studying rare variants in families, is that rare variants 
do not segregate with the disease. We observed an earlier age at symptom onset, and 
higher prevalence of a positive family history in individuals carrying rare genetic variants. 
Recommendations are provided on how family studies can be performed to identify additional 
rare variants. 
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Rare genetic variants identified in families with AMD
Family studies have shown a higher prevalence of AMD characteristics among relatives of 
AMD patients than in control families.26-30 The genetic risk of families with multiple affected 
individuals can largely be explained by a clustering of common risk variants in these families.27 
In families, for which common variants cannot explain the high burden of disease, the 
heritability is thought to lie within rare variants with large effect sizes.31 These rare variants 
can be difficult to detect in case-control studies due to their rare frequency, appearance in only 
a few families, or occurrence in specific populations.7,32,33 Recently, a number of studies using 
WES have successfully identified novel rare genetic variants by analyzing multiple affected 
individuals of large AMD families (Table 1).7,25,32-37 
We observed rare variants CFI p.Gly119Arg, C9 p.Pro167Ser and C3 p.Lys155Gln, which were 
previously implicated in AMD pathogenesis,9-11,20 in five of 22 families affected by AMD (chapter 
2 and 3). Although these variants aggregated within these families, they did not segregate 
completely with the disease phenotype (Chapter 2). Our observations show that rare variants 
found in large case-control studies are also observed in AMD families, but that these variants 
are not necessarily inherited in a dominant Mendelian inheritance pattern. Additional factors, 
like common variants and environmental factors may explain why one individual develops AMD 
while his/her siblings carrying the same rare variants do not. In a case-control setting, carriers 
of CFI p.Gly119Arg, C9 p.Pro167Ser and C3 p.Lys155Gln did show an earlier age at symptom 
onset. Furthermore, individuals carrying one of these rare variants reported a positive family 
history for AMD more often than patients with AMD who did not. 
In chapter 3 we screened the same 22 families for additional rare variants residing in 
complement genes CFH, CFI C3, and C9. We identified six new rare variants, namely CFH 
p.Ser193Leu, CFH p.Arg175Gln, CFI p.Pro553Ser, CFI p.Leu131Arg, C9 p.Arg118Trp, and C3 
p.Arg161Trp. These rare variants were found more often in affected than unaffected individuals, 
both in the families and the case-control cohort, but again the variants did not show perfect 
segregation with the disease phenotype in families affected by AMD.
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Considerations for unbiased approaches to identify rare variants in AMD families
In chapters 2 and 3 we focused on rare variants in genes that were previously associated with 
AMD. As a next step, the families could be used to identify rare variants in genes not yet known 
to be associated with AMD, using unbiased approaches. An approach that could be used is to 
search for variants that are shared among siblings. However, siblings naturally share a great 
number of genetic variants. Searching for variants shared among the affected siblings in an 
unbiased fashion will therefore result in large list of overlapping genetic variants.4,38 
Inclusion of one or more unaffected siblings can drastically narrow down the number of 
candidate variants by excluding variants shared with the unaffected sibling(s). However, it is 
of great importance that the unaffected individual is of similar age, or preferable older, than 
its affected siblings due to the large contribution of age on disease onset. If the unaffected 
individuals within a family affected by AMD are younger, chances are the individual will still 
develop AMD, and he/she can therefore not be considered a proper control. Increasing the 
number of affected and unaffected individuals in the analysis will reduce the probability of co-
segregation by chance.38 The families used in chapters 2 and 3 are densely affected by AMD, 
meaning that at least three siblings were diagnosed with AMD. 
A more powerful approach would be the use of multiple generation families, however, for age-
related diseases obtaining such families is difficult. Moreover, since rare genetic variants do 
not necessarily segregate with the disease in the family, filtering for variants shared among 
affected siblings, and not present in unaffected siblings, may unintentionally remove disease-
associated variants.
Testing for rare variants associations in AMD families
Rather than searching for variants that segregate in families, association designs can be 
used to identify rare disease-associated variants in families. Families are more genetically 
homogeneous compared to the general population. Therefore, an increased occurrence of 
disease-associated rare variants can be expected in affected family members. 
Using burden tests or variance component tests on a family dataset may successfully detect 
genetic associations. Numerous rare variant association methods for family-based samples 
have been published, each designed with a specific inheritance pattern and study design 
in mind.46 For example, some analyses are restricted to quantitative traits47-49 instead of 
dichotomous (binary) traits like AMD. Others strictly perform linkage analyses without further 
association analyses,50-52 or require parent-child information.39,48 Furthermore, assumptions 
such as complex or monogenic inheritance and common or rare disease frequency should be 
taken into account. Examples of rare variant based tests for complex disorders are provided in 
Table 2. 
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Table 2: Rare variant based tests for complex and dichotomous traits in families.
Methods Test Study design Source
RV-TDT: Rare variant 
transmission disequilibrium 
Transmission 
disequilibrium 
test (TDT)
Parent-child trio; 
Requires affected and 
unaffected individuals
He et al.,39 2014
GEE-KM: generalized 
estimating equations-based 
kernel association 
Burden, C-alpha Requires a large 
dataset of sib-pairs; 
prospective data can  
be included
Wang et al.,40 2013
PedCMC: pedigree  
Combined Multivariate  
and Collapsing
Burden Protective and 
deleterious variants  
are collapsed together
Zhu & Xiong,41 2012
PedGene: gene-level  
kernel and burden association 
tests with disease status  
for pedigree data
Burden, C-alpha Requires affected and 
unaffected individuals
Schaid et al.,42 2013
FARVAT: family-based  
rare variant association test
Burden, C-alpha, 
SKAT-O
Introduction of SKAT-O 
allows analysis of rare 
variants with different 
directions
Choi et al.,43 2014
Rare-variant association  
test based on identical by 
decent (IBD) sharing
Burden and variance-
component 
Uses alleles shared 
identical by descent  
nd requires a large 
dataset of sib-pairs 
Epstein et al.,44 
2015
mFARVAT: multivariate  
family-based rare variant 
association tool
Burden, SKAT-O Can include both 
homogeneous and 
heterogeneous 
approaches
Wang et al.,45 2016
Wang and colleagues46 compared a number of rare variant based tests for dichotomous traits, 
and reported FARVAT and PedGene to be the most efficient methods when examining families. 
Ultimately, FARVAT was recommended as it was most computational efficient and could 
incorporate SKAT-O statistics. However, these results were obtained using extended families 
consisting of 10 individuals and across three generations.43 In case of smaller families, like our 
dataset, one should combine both family and case-control data,53 add weighted common and 
rare genetic variants, and combine it with the SKAT-O algorithm.
WHOLE EXOME SEQUENCING AND IMPLICATIONS OF FINDING ‘A RARE 
VARIANT’
In this thesis we used whole-exome sequencing (WES) to detect rare genetic variants in AMD 
patients and control individuals for all chapters, except chapter 5. In rare variant studies, the 
far majority of variants detected by sequencing are rare or seen in only one individual.54,55 It can 
be difficult to assess if these rare variants are harmful or benign based on association with the 
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disease alone. There are numerous approaches at different experimental levels to assess the 
pathogenicity of rare variants. In this section a number of strategies on assessing the disease 
causality of rare variants are discussed.
Exome quality and annotation
Correct interpretation of data starts with a high quality dataset. Quality of the dataset should 
be guarded in the data analysis pipeline and subsequent quality control steps. Data analysis 
consists of base calling, read alignment, variant calling and annotation.56 Base calling is the 
initial step in which the nucleotides are identified within a single read. The quality of the calling 
is dependent on sample quality and if samples are uncontaminated. During read alignment 
the short DNA strands (50-400 base pairs) are compared to a reference as a puzzle. The larger 
the size of the strands, the more reliably can they be aligned to the reference. The problem 
is that some parts of the genome are highly repetitive or similar.57 The exome enrichment kit 
(Nimblegen SeqCap EZ Exome v2.0 44Mb kit) used for the studies in this thesis, captures 60 to 
90 basepairs per probe, which could lead to mismapping or low coverage in repetitive regions. 
Sanger sequencing can be used to validate if the variants are correctly called. 
Furthermore, exome kits may vary in the number of genes that are effectively captured, number 
of reads mapped back to the reference genome, number of duplicate ‘pair’ reads, and ability 
to capture variations.57 Quality control checks the number of variants per individual, fraction 
of variant sites and the ratio of transition and transversion. Variant calling quality depends on 
the depth of coverage across the exome, for which the recommended minimum is 20X at 80-
95% of the exome.58 For chapter 2, 3, and 6 we confirmed all identified WES variants by Sanger 
sequencing. In chapter 4, 7 and 8 we used a minimum number of (variant) reads, and for 
chapter 9 we report a mean coverage of 63X. During the last step, annotation, and functional 
effects of variants are added by tools like ANNOVAR.59
Variant interpretation
The power of rare variant analyses can be improved if the functional variants could be separated 
from the those without a functional effect. One way of predicting the functional effect of a 
variant is through ‘in silico’ prediction software (Table 3). 
These algorithms, based on conservation, structural information or amino acid physic-
chemical properties, estimate the likelihood of variant to be harmful. For the CFI gene these 
prediction algorithms seem well equipped. A correlation is seen between the prediction score 
(PolyPhen2) and Factor I (FI) serum levels. Variants predicted to be pathogenic generally have 
low FI levels, and these low serum FI levels strongly increase the risk of developing advanced 
AMD.67 Unfortunately, these algorithms are not always reliable, as can been seen for two 
genetic variants that are strongly associated with AMD. CFH p.Arg1210Cys and C3 p.Lys155Gln 
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are variants that are both predicted to be tolerated and benign by SIFT60 and PolyPhen61. 
Functional assays, however, show that CFH p.Arg1210Cys results in a partial FH deficiency, 
and C3 p.Lys155Gln results in reduced binding to FH and cleavage of C3b.9,10,15,18,20
Table 3: Most used software to predict the effect of genetic variants on protein function.
Abbreviation Software name Description Source
SIFT Sorting Inolerant 
From Tolerant
Predicts whether an amino acid 
substitution affects protein function 
based on the degree of conservation 
of amino acids in a sequence 
alignment.
Kumar et al.,60 2009
PolyPhen2 Polymorphism 
Phenotyping version 
2
Predicts the possible impact of 
an amino acid substitution on the 
structure and function of a human 
protein.
Adzhubei et al.,61 
2013 
PhyloP Phylogenetic 
P-values
Gives an estimation of the 
evolutionary conservation at individual 
alignment sites
Siepel et al.,62 2006
Grantham Grantham Predicts the distance between two 
amino acids at an evolutionary level
Grantham63 1974 
GERP++ Genomic 
Evolutionary Rate 
Profiling version 2
Consists of two programs, 
gerpcol and gerpelem. The first 
estimates constraints introduced by 
substitutions for each column of the 
alignment; the second then identifies 
constrained elements that occur.
Davydov et al.,64 2010
CADD Combined 
Annotation 
Dependent 
Depletion
A tool that combines multiple 
annotations into one value by 
contrasting variants using prediction 
and conservation tools.
Kircher et al.,65 2014
A complete list of prediction software is summarized by Richards et al., 66 2015.
The American College of Medical Genetics and Genomics published guidelines for the 
interpretation of genetic variants in Mendelian disorders. However, these guidelines are 
generally not applicable for common complex disorders like AMD. Terms like pathogenic and 
likely pathogenic are usually not informative in complex disorders; more accurate proof comes 
from statistical (association) analyses that implicate a genetic variant in the disease. It is 
recommended to describe the variants that are linked to the disorder as ‘risk alleles’.66
Association analyses of rare variants
When performing a large number of tests in association studies, the expected number 
of findings that cross the significance threshold of 0.05 will be considerable. Therefore, 
analyses with large number of variables should implement a correction for multiple testing. 
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Implementing such corrections, like Bonferonni or False Discovery Rate, can help reduce 
the number of false positive findings, but could consequently increase the number of false 
negative findings.68 Effective strategies to analyze rare variants is to group them based on 
gene association, location in the genome, or functional characteristics in a gene-based burden 
or variance-component test.4 In this way, correction can be applied to the number of genes 
interrogated instead of the number of variants. 
In this thesis, WES was performed in a case-control cohort consisting of 2486 individuals. First 
we performed a single variant analyses, and could confirm the previously described common 
variants in CFH and ARMS2 (Chapter 9). Single variant analysis had insufficient power to detect 
association with individual rare variants. Therefore, we next used gene-based burden tests, 
which accumulate the association of multiple rare variants per gene, to improve detection 
power. We used the combined multivariate and collapsing (CMC) method.69 This method 
‘collapses’ variants in a gene by recoding the variant status as present or absent. This binary 
recoding is done for rare and common variants separately. The model then evaluates the joint 
effect of the variants. This allowed us to observe a disease burden for the COL8A1 gene. The 
disease burden was explained by 14 rare protein-altering variants in COL8A1 which were found 
more often in cases (1.0%) than control individuals (0.4%). Unlike predefined gene-sets or 
variant-sets,10,13 we were able to detect exome-wide rare variants. Unfortunately, our study did 
not have sufficient power to confirm the disease burden of previously reported genes (CFH, CFI, 
TIMP3 and SLC16A8).13 
Adding genetic data of additional family members or other cohorts to the dataset may 
increase the power to detect association, but could potentially be outweighed by problems 
of heterogeneity in disease state, environmental differences, or even aberrations in allele 
frequency between populations.3 In chapter 9 we combined our WES case-control dataset 
with that of the Rotterdam Study.72,73 Both datasets were generated using the same exome 
enrichment kit, and to avoid discrepancies in calling between the two datasets we performed 
joint genotyping and recalibration of the files before quality control and annotation. In chapter 
3 we added family members to a case-control cohort in a binominal distribution model, while 
correcting for the shared genetic variation between the siblings. This allowed us to combine 
the two datasets and increase our sample size without creating an ascertainment bias.
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Table 4: Different strategies of providing evidence to implicate genetic variants to disease phenotype. 
Level Class Type
Gene level
 
Genetic Gene: within a gene an excess of genetic variants are found 
predominantly in cases compared to controls.
Experimental Protein interactions: the protein interacts with other proteins 
previously implicated in the disease of interest (genetically or 
biochemically). Biochemical function: the protein performs a function 
shared with other known genes in the disease of interest, or consistent 
with the phenotype. Expression: the gene is expressed in tissues 
relevant to the disease of interest and/or is altered in expression in 
patients who have the disease. Gene disruption: the gene/ protein 
function is altered in individuals carrying candidate mutations. Model 
systems: animal or cell-culture models with a similarly disrupted copy 
of the affected gene show a phenotype similar to the human disease. 
Rescue: the cellular phenotype in patient-derived cells can be rescued 
by addition of the wild-type gene product.
Variant 
level
 
 
Genetic Association: the variant is significantly enriched in cases compared to 
controls. Segregation: the variant is co-inherited with disease status 
within affected families. Population frequency: the variant is found 
at a higher frequency in study cohort compared to large population 
cohorts with similar ancestry to patients (consistent with the proposed 
inheritance model and disease prevalence).
Bioinformatic Conservation: the site of the variant displays evolutionary conservation 
consistent with deleterious effects of sequence changes at that 
location (like SIFT60). Predicted effect: variant is found at a location 
within the protein predicted to cause functional disruption (like 
PolyPhen261).
Experimental Gene disruption: the variant significantly alters levels, splicing or 
normal biochemical function of the protein of the affected gene (in 
patient cells or in vitro model). Phenotype recapitulation: introduction 
of the variant into a cell line or animal model results in a phenotype 
that is consistent with the disease. Rescue: the cellular phenotype in 
patient-derived cells or model organisms can be rescued by addition of 
wild-type gene product or specific knockdown of the variant allele.
Table adapted from 66,70,71.
For complex disorders, large case-control studies are required to find a genetic association, in 
particular for rare variants. In smaller studies functional characterization of non-synonymous 
variants may help to assess causality of variants, and provide evidence that the gene is 
essential in a specific biological mechanism (Table 4). The bottle neck, however, of performing 
functional tests (in vitro or in vivo) is, that the experiments can require extensive hands-on 
work and time.68 Table 5 summarizes the rare genetic variants identified in the CFH gene, for 
which functional work was performed and the association was evaluated in the largest available 
AMD cohort.13,17 
Only a few genetic variants are linked to the pathogenesis of AMD with strong genetic and 
functional evidence. There are also variants that are significantly enriched in AMD cases or 
controls individuals, but for which no functional evidence has been provided, and vice versa. 
This makes it difficult to interpret their effect on the disease pathogenesis. When generation 
of additional genetic evidence is not possible, for example due to a limited sample size or 
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when a variant is very rare, functional experiments can provide additional evidence on whether 
variants have an effect on the protein. 
New sequencing methods are under development and are referred to as third-generation 
sequencing. These methods allow the detection of a single molecules, and optimized long-
range sequencing.74 These types of approaches will especially be useful for sequencing highly 
similar regions like CFH and CFH-related genes, or regions that have low coverage in current 
WES datasets, like CFB/C2.
Table 5: Genetic variants in CFH for which functional analyses were performed
Evidence Variant in CFH Genetic association Functional implications (reviewed in 17)
Genetic and 
function
 p.Arg53Cys OR 22.54; p=0.001 No effect on FH serum levels, but reduced binding affinity, DAA and CA.
 p.Arg53His OR 13.39; p=0.01 Low C3 serum level, reduced binding affinity, DAA and CA.
 p.Arg1210Cys OR 20.28; p=8.91E-24 No effect on CA, but reduced binding affinity and in a partial FH deficiency
Genetic
 p.Gln950His OR 0.72; p=0.003
No effect on FH serum levels, does not affect 
CA and normal hemolytic activity. Slightly 
increased lysis in hemolytic assay.
 p.Asn1050Tyr OR 0.36; p=5.92E-44 Abnormal C3 but normal FH levels in serum
Function
 p.Arg127His not significant Reduced FH serum levels and impaired protein secretion.
 p.Val609Ile not significant Affects FH expression and resulted in decreased alternative pathway activity
No effect
 p.Gln400Lys not significant No or only mild effect on plasma concentrations of FH, C3 and FB
 p.Ser890Ile not significant
No effect on FH serum levels, does not affect 
binding affinity or CA and normal hemolytic 
activity. 
p. Thr956Met not significant No effect on FH or C3 plasma levels, no effect on expression or lysis.
 p.Val1007Leu not significant No effect on FH plasma levels, normal binding affinity and CA .
 p.Gly1194Asp not significant Normal serum levels for FH, FI and C3, slightly increased hemolytic lysis.
Genetic variants reported in multiple AMD case-control studies and available odds-ratio as reported 
Fritsche et al.,13 2016.. Abbreviations: CA = co-factor activity; DAA = decay accelerating activity
THE COMPLEMENT SYSTEM AND AMD
There are several lines of evidence to support a role of the complement system in the 
pathogenesis of AMD, both genetically13 and functionally on the level of the retina, RPE and 
choroid.75,76 In this thesis we used different functional measures of the complement system 
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to assess the impact of genetic variants on function. Furthermore, we performed genotype-
phenotype correlation analyses between the location of an amino acid change in the protein 
for different complement-related disorders. In addition, we described a distinct macular 
phenotype in individuals carrying rare genetic variants in a complement gene.
Measuring the activity of the complement system in AMD
The complement system is an elaborate and intricately regulated network of interacting 
proteins that activate or inhibit each other, stabilize or cleave components to enhance 
or attenuate activity. Complement activation can be defined in several ways. One could 
measure the overall activity of the complement system by determining the total membrane 
attack complex (MAC) formation. However, formation of the terminal complex is not the only 
relevant functional outcome of complement system activity. Upstream is the C3 convertase 
that determines to what extent the initial trigger is amplified. Convertase-mediated cleavage 
of C3 releases C3a and induces a conformational change in the remaining fragment, named 
C3b. C3b fulfils different roles, including complement activation through tick-over, to driving 
the amplification loop, mediating phagocytosis and initiating the generation of the terminal 
pathway. C3b can be processed by components of the regulators of complement activation 
family (RCA) into iC3b (C3dg and C3f), and binding of the RCA to C3b also provides a binding 
site for FI to inactivate C3.77 Over-activation or dysregulation of the complement system can be 
determined by measuring one or multiple of these components within the cascade. 
Inactivation of C3 eventually leads to the components C3dg and C3f. C3dg can be further 
digested releasing C3g and C3d. The C3d/C3 ratio has proven to be a sensitive marker of 
complement activation, correcting for the individual variation in C3 levels.78 In chapter 2 we 
used the C3d/C3 ratio as a measure of complement activation. 
In the presence of FH and FI, the C3 alpha chain is cleaved into three fragments (alpha 68- 
46- and 43 kDa). These fragments can be visualized on a protein gel by using fluorescently 
labeled C3b on serum samples. The intensity of the 43kDa fragment (in relation to the alpha 
chain) can be used to assess cofactor activity efficacy. In chapter 3, we assessed complement 
activity by measuring C3b degradation in the presence complement inhibitors with or without 
rare variants.
Systemic complement activation can be measured in serum or plasma, derived from whole 
blood samples.79-81 In chapter 3 and 9 enzyme-linked immunosorbent assays to detect the levels 
of soluble proteins FH, FI, C3 and C9 or the terminal complement complex were used. Another 
outcome measure to assess the effectiveness of the complement system is to determine if it 
can lyse foreign cells (chapter 9). Erythrocytes are non-nucleated cell that lyse relatively easy 
when exposed to a sensitized antibody. The released hemoglobin level in the supernatants 
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are used as an outcome measure of lysis. On the other hand, lysis of nucleated cells is more 
challenging as these cells actively shed MAC. Using a cell line, like ARPE-19 cells we used in 
chapter 8, cell lysis can be measured via lactate dehydrogenase release and apoptosis. 
It is hypothesized that local complement activation, rather than systemic activation, is of 
importance in AMD development. Local complement activation in the eye is usually determined 
by histological studies of ocular tissues from AMD patients.76,82,83 To date, only one study 
measured local complement activation using aqueous humor of AMD patients.84 The study 
showed a local increase of activation products Ba and C3a in neovascular AMD patients 
compared to control individuals. The up-regulation of activation products Ba and C3a was not 
significantly associated with AMD in systemic plasma levels, although a correlation was found 
between local and systemic activation products.84 It is likely that the complement regulatory 
system of the eye is regulated separately from circulation. For example, membrane attack 
complex (MAC) deposits accumulate in the aging choriocapillaris, but its accumulation is not 
observed in other organs. The increased accumulation may cause thinning and degeneration of 
the choriocapillaris, which would then fail to remove cellular debris and allow drusen to form.85 
Further research is needed to elucidate the relation between local and systemic complement 
activation, although this is hampered by the difficultly of obtaining ocular tissue and fluid.
The effect of genetic variants in complement genes
It is important to understand the functional effect of genetic variants on the protein to assess 
relevance and causality. Knowing the relevance of a variant can optimize prediction of disease 
onset, help design preventative measures, allow early detection, and specify treatment options.
Complement factor H and complement factor I
In chapter 3 we performed functional analyses to assess the effect of rare genetic variants in 
the CFH and CFI genes on the function of complement regulators FH and FI, respectively. For 
FH no aberrations in serum levels were observed compared in carriers compared to noncarrier 
individuals. In previous studies serum concentrations in carriers of rare CFH variants were 
found to reduced or normal compared to a reference.86,87 This indicates that not all rare variants 
in CFH lead to lower FH levels, and that there are two types of mutations. Type 1 mutations cause 
low protein levels as a result of misfolding or degradation, whereas type 2 mutations result in 
reduced functionality with normal protein levels. For FI we observed a median reduction in 
serum levels for carriers of rare variants in CFI (p.Gly119Arg and CFI p.Leu131Arg). A recent 
study demonstrated that a large number of rare CFI variants are type 1 mutations, resulting in 
lower FI levels.67 
We also measured the C3b degradation ability for individuals carrying CFH or CFI variants, and 
observed that carriers of rare variants in CFH and CFI had a lower capacity to degrade C3b 
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compared to noncarriers. FH serum levels remained stable, suggesting that CFH variants affect 
complement activation independent of FH serum levels by its inability to properly serve as a 
cofactor in the cleavage of C3b to inactive C3b. This finding might be explained by the variants’ 
location at the N-terminus, where a C3b-binding site is located. For FI it was previously shown 
that both expression and secretion of mutant FI protein were reduced compared with wild-type 
protein, and that it were the lower FI levels that led to reduced C3b degradation.11 
Complement component 9
For many variants in complement genes, functional data is already available, scattered 
throughout literature and organized in chapter 1B. Unfortunately, there is little known for 
complement component C9. Therefore, we evaluated the functional effect of rare variants 
identified in C9 in chapter 4. We identified elevated C9 serum levels for carriers of rare 
variants in the C9 gene (p.Met45Leu, p.Phe62Ser, p.Pro167Ser and p.Ala529Thr). However, 
no increase in serum concentration for the terminating complement complex between 
carriers and noncarriers was observed. The MAC is dependent on the incorporation of C9. We 
hypothesized that elevated levels of C9 lead to enhanced MAC deposition and damage to the 
retinal cells. However, we could not detect any increase in C9-dependent lytic activity of patient 
sera. More surprisingly, the p.Phe62Ser and p.Pro167Ser mutant proteins caused decreased 
lysis, which was contrary to our expectations. We did note a tendency of the p.Pro167Ser 
mutant protein to spontaneously aggregate and an increased polymerization of p.Phe62Ser 
and p.Pro167Ser mutant proteins. Future experiments need to be performed to evaluate the 
role of C9 p.Pro167Ser in AMD pathogenesis, for example, by determining the effect of protein 
aggregates on cells by measuring stress-related markers or by visualizing C9 expression on 
Western blot to see if polymerization of the protein occurs intracellular or extracellular.
Phenotypes of AMD patients carrying complement variants
Genetic variants in the CFH gene result in a specific AMD phenotype.19,88-91 Initially, it was 
observed that the common risk variant p.Tyr402His associated with the AMD subtype cuticular 
drusen.89,90 Later, also rare genetic variants in CFH were described to show distinct phenotypic 
features, including increased drusen and appearance of cuticular drusen.19,91
Ferrara and colleagues characterized 143 individuals based on fundus images, of which half 
(n=62) carried the rare variant CFH p.Arg1210Cys. For these individuals it was reported that 
carriers of the CFH p.Arg1210Cys variant had high macular drusen scores and were more 
likely to have advanced AMD compared than those without the variant.88 It should be noted that 
the noncarrier group contained more individuals without AMD, namely 28.4% (23/81), than the 
carrier group with 4.8% (3/62). 
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In chapter 6 we compared phenotypical characteristics of 51 carriers of rare CFH variants with 
102 age-matched noncarriers. Both groups consisted solely of individuals affected by AMD. 
For CFH carriers we observed an increased number of drusen around the macula and nasal 
to the optic disc. In addition, an association with the presence of crystalline or calcified drusen 
was found for CFH carriers. Presence of this type of drusen increases the risk of developing 
geographic atrophy.92,93 CFH carriers may develop geographic atrophy more often compared 
to choroidal neovascularization, as we observed for rare variant carriers of CFI, C3, and C9 
variants in chapter 2. Unfortunately, the sample size of this study was too small to draw 
definitive conclusions on the association of rare variants and particular AMD subtypes. 
Based on the findings we and others88 reported it is unlikely that carriers can be discriminated 
from noncarriers based solely on phenotypical characteristics. Other patient characteristics, 
like an early age at onset of symptoms, presence of cuticular drusen, and a positive family 
history for AMD can aid ophthalmologists to select patients for genetic screening.18,19,33,36,88,94 
Complement variants in AMD and renal disorders
Dysregulation of the complement system has been associated with very different clinical 
outcomes. This group of disorders, known as ‘complementopathies’, is characterized by over-
activation of the complement system. Inhibition of the complement system in these diseases 
may halt or reverse the disease process. Examples of complementopathies include paroxysmal 
nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), atypical hemolytic uremic 
syndrome (aHUS), and C3 glomerulopathy (C3G).95 It was recently suggested that AMD should 
also be classified as a complementopathy.96
 We focused on protein-altering variants in complement genes that are reported to cause AMD 
but also renal diseases aHUS and C3G.97,98 aHUS and C3G are rare disorders resulting in acute 
and lethal renal failure. Furthermore, aHUS manifests at an earlier age (90% of the patients 
is younger than 55)99 than advanced AMD, which is most often observed in individuals above 
the age of 65.100 It is interesting how such different disorders in age of onset, tissue type and 
lethality can both result from genetic alterations in the complement system.
The location of a variant can influence the properties of a given protein, which can be visualized 
and predicted from a three dimensional structure. Amino acid changes can have an effect on 
activity, aggregation, stability, binding, assembly or arrangement of the protein domains.101 In 
AMD, an enrichment of protein-altering variants has been reported in the N-terminal (SCR1-
4) and C-terminal (SCR19-20) short consensus repeats (SCR) domains of FH, in the serine 
protease domain of FI, and in the MG1 and MG2 domains of C3.17,102 Each of these domains is 
involved in co-factor activity mediated cleavage of C3b by FH and FI. Variants in these domains 
could therefore interfere with proper complement regulation. In chapter 8 we observed an 
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increased number of protein-altering variants in the SCR3, SCR5 and SCR7 domains of FH, 
the scavenger receptor cysteine-rich (SRCR) domain of FI, and the MG3 domain of C3 in AMD 
patients compared to aHUS and C3G. For aHUS and C3G patients we observed an increased 
number of variants in the C-terminus of FH, and in the serine protease domain of FI.
FH domains SCR 3, 5 and 7 are part of both the full length FH and the alternatively spliced factor 
H-like protein 1 (FHL-1). FHL-1 has the same functions as FH as it can bind C3b, interact with 
FI, and bind to Bruch’s membrane using the glycosaminoglycans binding site located in SCR7. 
However, FHL-1 can, due to its small size, regulate complement within Bruch’s membrane 
and drusen.103-106 We confirm that variants in the first domains of FH (up to SCR7) play a more 
important role in AMD pathogenesis, while the C-terminus is more important in renal disorders. 
The SRCR domain in FI does not contain any known interaction sites with cofactors, however, 
FI serum levels of AMD individuals carrying low frequency variants in the SRCR domain were 
reported as reduced. These reduced levels consequently impair normal FI function.11,25,107 The 
serine protease domain (together with the FIMAC domain) contains the binding sites important 
for C3b and C4b degradation108,109. Variants found in the serine protease domain could interfere 
with proper cofactor activity as the domain cannot be stabilized for proteolytic activity. The MG3 
domain of C3 is the only domain in the β-ring that undergoes rearrangement during conversion 
from C3 to C3c. Variants in this domain could possibly interfere with this rearrangement.
Genetic alterations in the complement system have been linked to aHUS, C3G, and AMD. 
However, individuals with rare or low frequency variants in the complement system present 
phenotypic characteristics of only one disorder.15,16 There are a number of hypotheses that 
could explain this observation. First, it is possible that the genetic burden in the complement 
system is higher in aHUS compared to AMD.110 In chapter 8 we observed three times as many 
rare genetic variants in aHUS/C3G compared to AMD. Second, AMD associated variants are 
generally common, and many variants reside is genes other than CFH, CFI and C3.13 Therefore, 
AMD is a result of a combination of common and rare variants in many genes, and is not 
only attributed to rare variants in the complement systm. Third, a different distribution of 
variants was observed in protein domains involved in AMD compared to renal disorders, 
suggesting that a genotype-phenotype correlation exists, at least for some of the variants. 
Fourth, genetic predisposition is not always enough to develop aHUS or AMD, but can act to 
exacerbate other triggering events. For aHUS these triggers include pregnancy, infections, and 
immunosuppressive drugs.111 For AMD, oxidative stress in the retina may act as a local trigger, 
among others. 
Because of the clear involvement of the complement system in both diseases, complement-
targeting therapies are actively being developed. For aHUS, successful implementation of 
a complement-inhibiting drug, Eculizumab, has already been achieved. Before approval 
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of Eculizumab in 2013 for treatment of aHUS,112 patients had to undergo kidney and liver 
transplantation to normalize complement regulation. No complement inhibiting therapy is 
currently approved for AMD, but several clinical trials are ongoing to determine the effectiveness 
of these therapies.
COMPLEMENT INHIBITORS 
Numerous trials using complement inhibiting agents, including protease inhibitors, antibodies 
against complement components, complement regulators or inhibitors, and anaphylatoxin 
receptor antagonists are ongoing or have been performed in AMD. From a patients perspective, 
the most important outcome of a therapy is the maintenance of visual acuity at follow-up. In a 
clinical trial setting other parameters can be used as trial outcomes, including visual function, 
quality of life, prevention of AMD progression (non-advanced to advanced AMD), and lesion size 
of the geographic atrophy.113
Clinical trials with complement inhibitors so far have produced disappointing results in AMD 
(Table 6). Some trials ended early for not meeting the interim criteria, like AL-78898A, and 
others reported only minimal improvement in visual acuity, like Eculizumab. These initial 
results suggest that we have insufficient knowledge on what role the complement system 
plays in AMD development. Until we know more about the exact mechanism, we are unable to 
precisely determine which subgroup of patients would benefit, which component in the cascade 
we should target, at which stage of the disease patients should be treated, and whether local 
or systemic administration would be most effective.
Each AMD patient is different in genetic background, age at onset of disease symptoms, 
current AMD stage and burden of environmental factors. More importantly, deregulation of 
the complement system may not be the underlying cause for developing AMD in all patients. It 
should be noted that there is a great range in complement levels, and that these are influenced 
by many factors including age of the individual, BMI, smoking status, AMD stage and genetic 
variation.80,81,114-119
Most complement inhibitors developed for treatment of AMD-associated geographic atrophy 
focus on the alternative pathway of the complement system, like the C3 and C5 convertases 
(Table 6). An alternative to this strategy would be to focus on the complement regulators such 
as FI and FH instead. Synthesized or plasma derived FI or FH could be used to treat AMD 
patients that show deficiencies for complement regulators.120 Rare variants in the CFH and CFI 
gene can lead to reduced serum levels, and supplementation may be beneficial for these types 
of complement dysregulation.10,11,15,25,36,67,86,121 To support this view, a synthesized short form of 
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FH showed promising results in model organisms, and is also considered as treatment option 
in FH associated complement dysfunction such as AMD.122-125 
The MAHALO study126 is a phase II clinical trial with Lampalizumab, an antibody directed 
against complement factor D. In this study, a reduction of lesion growth and loss of visual 
acuity was observed. Sub-analysis suggested that the reduction in lesion growth was mainly 
driven by the strong reduction seen for a common CFI risk allele group. Moreover, the CFI risk 
allele was linked to reduced FI expression in liver tissue. Unfortunately, more recently Phase 
III results, showed no reduction of mean change in lesion size at the primary endpoint (table 
6). It therefore remains unclear whether carriers of this common CFI risk variant would benefit 
more from complement-inhibiting treatments. 
We estimate that 10-20% of all AMD patients carry rare variants in the CFH and CFI genes. 
In chapter 3 we report that carriers of rare CFH and CFI variants have an impaired ability to 
regulate complement activation. We hypothesize that these patients may benefit more from 
complement-inhibiting therapy than patients with AMD in general. Further research focused 
on the subgroup of AMD patients which are burden by rare genetic variants in CFH and CFI 
could help improve personalized treatment.
Clinical trials for dry AMD currently focus on patients with advanced geographic atrophy. 
The geographic atrophy results from a slow and gradual degeneration of retinal pigment 
epithelium and photoreceptor cells in the central retina. Once these lesions appear they lead 
to the complete loss of cell structure.127 Complement inhibiting trials currently aim to slow 
the lesion growth, and cannot restore the cell structure that has already been lost. However, 
atrophy formation is a complex process in which inflammation and cell stress play a role over 
a long period of time. Once the complement system is triggered, it acts through different 
mechanisms. Loss of retinal pigment epithelium and Bruch’s membrane function increases 
access of complement proteins to the outer neural retina. Impaired or reduced expression 
complement regulators leads to complement attack on retinal pigment epithelium cells and 
photoreceptors. An increase in anaphylatoxins, opsonization and MAC formation, together with 
increased presence of phagocytes, promotes further loss of photoreceptors and retinal pigment 
epithelium.128 Stopping any of these individual processes may therefore not be sufficient to halt 
GA progression. Possibly complement inhibition therapy would be more effective before the 
onset of atrophy, preventing the formation of atrophy in the first place.
Most trials inhibiting complement target local complement activation rather than systemic 
activation (Table 6).129 Local administration has several advantages, as it will not only prevent 
disruption of the systemic immune system, which increases susceptibility of infections, but 
it also has the advantage of direct administration to the affected tissue. Local administration 
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of the drug is done via intravitreal injection. Important in that regard is that it is essential 
that the drug has the ability to diffuse through the BM to be able to reach the retinal pigment 
epithelium, Bruch’s membrane and choroid.129 Ideally, invasive procedures like intravitreal 
injection sould be replaced by less invasive options like topical administration.
DIAGNOSTIC PERSPECTIVE
Given the impact on quality of life and the limited treatment options for AMD, there is 
considerable interest in predicting the effect of genetic variants on disease onset and 
progression. A predictive model would allow taking appropriate preventative steps and further 
aid personalized and precision medicine. 
A reliable risk model for AMD incorporates genetic markers in addition to environmental 
triggers, baseline phenotype and demographic information.131 The best performing models 
to predict AMD progression include AMD risk genes, smoking status, body mass index, and 
baseline AMD phenotype.132-134 These data are relatively easy to obtain, in contrast to dietary 
factors, systemic biomarkers and complement measurements, which often need extensive 
laboratory workup or complex questionnaires. The models should include information on 
common genetic variants associated with AMD. 
Such genetic information can be obtained using a targeted sequencing assay. With such an 
assay, single common and rare variants, next to the complete sequencing of a set of genes, 
such as genes causing AMD-mimicking macular dystrophies and AMD-associated complement 
genes, can be analyzed simultaneously. This genetic test would enable the detection of patients 
with AMD-mimicking macular dystrophies, which can be clinically challenging to differentiate 
from AMD (chapter 7). The contribution of rare complement variants in a prediction model is 
limited due to their low population frequency, but they are informative for variant- or gene-
specific treatment.132 Seddon and colleagues135 recently published such a risk calculator that 
allows clinicians to enter patient specific genetic and environmental information to calculate 
a risk score. This risk calculator includes eight common genetic variants and two rare genetic 
variants (CFH p.Arg1210Cys and C3 p.Lys155Gln), along with information on age, sex, education, 
BMI, smoking status and macular phenotype.
Evaluating the effect of novel rare variants will be challenging, even if these variants reside in 
genes associated with AMD. Looking up the minor allele frequency in large population databases 
(like ExAC or gnomAD),54 and consulting functional information from public databases can help 
assess the impact of an identified variant. Ultimately, incorporation of biological information 
into a clinically useful risk model is required to properly assess the impact of a specific rare
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variant. In chapter 3 and 4 we performed functional analyses for a selected number variants 
found in CFH, CFI, C3, and C9. Systematical functional analyses of all variants identified in 
these genes will help interpret the consequences of rare coding variants on protein function. 
Functional analyses include measurements of circulating serum or plasma levels, or evaluating 
the effect of a variant in cell-based or animal models. For example, comparing systemic serum 
levels of variant carriers to a reference,67 cloning variants in vectors and expressing these in 
cell lines to assess altered activity, or injecting human mRNA in a zebrafish model to assess 
changes in vascular architecture in the eye as preformed previously.136 Other functional data 
that can be systematically integrated in a future prediction model include: gene expression, 
DNA methylation, proteomics, metabolomics, transcriptomics, or a complement-directed 
assay.
The commercial company 23andMe offers genetic testing including health reports on a variety 
of treatable and untreatable diseases. It was very recently announced that AMD will be added to 
the list of conditions for which can be screened.137 The test will screen for common variants CFH 
p.Tyr402His and ARMS2 Ala69Ser. Although these variants confer the highest common risk for 
AMD,13 they are insufficient to make a reliable prediction, especially when considering that 50 
other genetic variants have been also associated with AMD,13 including many with a protective 
effect. The first prediction model by Gold and collaegues138 tested variants in two genes, namely 
C2/CFB and CFH, and reported a correct prediction in 74% of the affected individuals and only 
56% of the controls. More recently132 it was shown that prediction tests became more reliable 
with a larger number of common genetic variants included. Furthermore, variables like age, 
smoking status, and BMI are essential for an accurate prediction. 23andMe’s health report 
will inform customers on their risk to develop disorder, an explanation of what the results 
mean, an overview of the condition, other factors that may influence risk, and suggests next 
steps. Keeping in mind that, at the moment, there is no preventative treatment for AMD other 
than to stop smoking and taking dietary supplements, there seems to be no harm (but also no 
significant advantage) in direct-to-consumer screening currently as offered by 23andMe. 
In this thesis, we described the identification of number of rare genetic variants residing in 
the complement system, extracellular matrix and inherited macular dystrophy genes using 
case-control and family-based analyses. These methods were effective to identify novel rare 
genetic variants, but ultimately supportive information from biological experiments is required 
to properly assess the impact of specific rare variants. Systematical functional analyses of 
rare genetic variants within a gene of interest will help interpret the consequences of rare 
coding variants on protein function in general. Functional analyses in combination with 
genetic information should be integrated in a diagnostic setting to reliably asses rare variant 
implications. Rare genetic variants have functional consequences that help us understand the 
underlying disease mechanisms. A better understanding of the disease mechanism as a whole 
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is needed to optimize treatment options. Knowing which role rare genetic variants play may 
therefore help us answer the questions whom to treat, what the drug should target, and how 
the drug should be administered. 
347
GENERAL DISCUSSION
REFERENCES
1. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 
2009;461(7265):747-753.
2. Gibson G. Rare and Common Variants: Twenty arguments. Nature reviews Genetics. 2011;13(2):135-
145.
3. Bomba L, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common 
disease. Genome Biology. 2017;18:77.
4. Auer PL, Lettre G. Rare variant association studies: considerations, challenges and opportunities. 
Genome Medicine. 2015;7(1):16.
5. Kosmicki JA, Churchhouse CL, Rivas MA, Neale BM. Discovery of rare variants for complex 
phenotypes. Human genetics. 2016;135(6):625-634.
6. Sardell RJ, Bailey JN, Courtenay MD, et al. Whole exome sequencing of extreme age-related 
macular degeneration phenotypes. Molecular vision. 2016;22:1062-1076.
7. Hoffman JD, Cooke Bailey JN, D’Aoust L, et al. Rare complement factor H variant associated with 
age-related macular degeneration in the Amish. Investigative ophthalmology & visual science. 
2014;55(7):4455-4460.
8. Lin X, Tang W, Ahmad S, et al. Applications of targeted gene capture and next-generation sequencing 
technologies in studies of human deafness and other genetic disabilities. Hearing research. 
2012;288(0):10.1016/j.heares.2012.1001.1004.
9. Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in complement 3 associated 
with age-related macular degeneration. Nat Genet. 2013;45(11):1375-1379.
10. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of 
advanced age-related macular degeneration. Nat Genet. 2013;45(11):1366-1370.
11. van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of 
age-related macular degeneration. Nature genetics. 2013;45(7):813-817.
12. Park J-H, Gail MH, Weinberg CR, et al. Distribution of allele frequencies and effect sizes and their 
interrelationships for common genetic susceptibility variants. Proceedings of the National Academy 
of Sciences of the United States of America. 2011;108(44):18026-18031.
13. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular 
degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134-143.
14. Tak YG, Farnham PJ. Making sense of GWAS: using epigenomics and genome engineering to 
understand the functional relevance of SNPs in non-coding regions of the human genome. 
Epigenetics & Chromatin. 2015;8:57.
15. Recalde S, Tortajada A, Subias M, et al. Molecular Basis of Factor H R1210C Association with Ocular 
and Renal Diseases. Journal of the American Society of Nephrology : JASN. 2016;27(5):1305-1311.
16. Martinez-Barricarte R, Pianetti G, Gautard R, et al. The Complement Factor H R1210C Mutation 
Is Associated With Atypical Hemolytic Uremic Syndrome. Journal of the American Society of 
Nephrology : JASN. 2008;19(3):639-646.
348
CHAPTER 10
17. Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular 
degeneration: A review of rare genetic variants and implications for personalized treatment. 
Molecular immunology. 2017;84:65-76.
18. Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of 
age-related macular degeneration. Nat Genet. 2011;43(12):1232-1236.
19. Duvvari MR, Saksens NT, van de Ven JP, et al. Analysis of rare variants in the CFH gene in patients with 
the cuticular drusen subtype of age-related macular degeneration. Molecular vision. 2015;21:285-
292.
20. Helgason H, Sulem P, Duvvari MR, et al. A rare nonsynonymous sequence variant in C3 is associated 
with high risk of age-related macular degeneration. Nat Genet. 2013;45(11):1371-1374.
21. Saksens NT, Geerlings MJ, Bakker B, et al. Rare Genetic Variants Associated With Development of 
Age-Related Macular Degeneration. JAMA ophthalmology. 2016;134(3):287-293.
22. Miyake M, Saito M, Yamashiro K, Sekiryu T, Yoshimura N. Complement factor H R1210C among 
Japanese patients with age-related macular degeneration. Japanese journal of ophthalmology. 
2015;59(5):273-278.
23. Shen SK, Liu XQ, Lu F, Yang ZL, Shi Y. [Association study between age-related macular degeneration 
and R1210C mutation of CFH gene in Chinese population]. Zhonghua yi xue yi chuan xue za zhi = 
Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2012;29(5):570-572.
24. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 
2015;526(7571):68-74.
25. Geerlings MJ, Kremlitzka M, Bakker B, et al. The Functional Effect of Rare Variants in Complement 
Genes on C3b Degradation in Patients With Age-Related Macular Degeneration. JAMA ophthalmology. 
2017;135(1):39-46.
26. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. American 
journal of ophthalmology. 1997;123(2):199-206.
27. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related 
maculopathy. Population-based familial aggregation study. Archives of ophthalmology (Chicago, Ill : 
1960). 1998;116(12):1646-1651.
28. Shahid H, Khan JC, Cipriani V, et al. Age-related macular degeneration: the importance of family 
history as a risk factor. The British journal of ophthalmology. 2012;96(3):427-431.
29. Saksens NT, Kersten E, Groenewoud JM, et al. Clinical characteristics of familial and sporadic age-
related macular degeneration: differences and similarities. Investigative ophthalmology & visual 
science. 2014;55(11):7085-7092.
30. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. American 
journal of ophthalmology. 1995;120(6):757-766.
31. Sobrin L, Maller JB, Neale BM, et al. Genetic profile for five common variants associated with age-
related macular degeneration in densely affected families: a novel analytic approach. European 
journal of human genetics : EJHG. 2010;18(4):496-501.
349
GENERAL DISCUSSION
32. Pras E, Kristal D, Shoshany N, et al. Rare genetic variants in Tunisian Jewish patients suffering from 
age-related macular degeneration. Journal of medical genetics. 2015;52(7):484-492.
33. Yu Y, Triebwasser MP, Wong EK, et al. Whole-exome sequencing identifies rare, functional CFH 
variants in families with macular degeneration. Human molecular genetics. 2014;23(19):5283-5293.
34. Ratnapriya R, Zhan X, Fariss RN, et al. Rare and common variants in extracellular matrix gene Fibrillin 
2 (FBN2) are associated with macular degeneration. Human molecular genetics. 2014;23(21):5827-
5837.
35. Duvvari MR, van de Ven JP, Geerlings MJ, et al. Whole Exome Sequencing in Patients with the 
Cuticular Drusen Subtype of Age-Related Macular Degeneration. PloS one. 2016;11(3):e0152047.
36. Wagner EK, Raychaudhuri S, Villalonga MB, et al. Mapping rare, deleterious mutations in Factor H: 
Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Scientific 
reports. 2016;6:31531.
37. Saksens N, Kersten E, Groenewoud JM, et al. Clinical characteristics of familial and sporadic age-
related macular degeneration: differences and similarities. Investigative ophthalmology & visual 
science. 2014;9:14-14659.
38. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-
genome sequencing. Nature reviews Genetics. 2010;11(6):415-425.
39. He Z, O’Roak BJ, Smith JD, et al. Rare-variant extensions of the transmission disequilibrium test: 
application to autism exome sequence data. American journal of human genetics. 2014;94(1):33-46.
40. Wang X, Lee S, Zhu X, Redline S, Lin X. GEE-based SNP set association test for continuous and 
discrete traits in family-based association studies. Genet Epidemiol. 2013;37(8):778-786.
41. Zhu Y, Xiong M. Family-based association studies for next-generation sequencing. American journal 
of human genetics. 2012;90(6):1028-1045.
42. Schaid DJ, McDonnell SK, Sinnwell JP, Thibodeau SN. Multiple genetic variant association testing 
by collapsing and kernel methods with pedigree or population structured data. Genet Epidemiol. 
2013;37(5):409-418.
43. Choi S, Lee S, Cichon S, et al. FARVAT: a family-based rare variant association test. Bioinformatics 
(Oxford, England). 2014;30(22):3197-3205.
44. Epstein Michael P, Duncan R, Ware Erin B, et al. A Statistical Approach for Rare-Variant Association 
Testing in Affected Sibships. American journal of human genetics. 2015;96(4):543-554.
45. Wang L, Lee S, Gim J, et al. Family-based Rare Variant Association Analysis: a Fast and Efficient 
Method of Multivariate Phenotype Association Analysis. Genetic epidemiology. 2016;40(6):502-511.
46. Wang L, Choi S, Lee S, Park T, Won S. Comparing family-based rare variant association tests for 
dichotomous phenotypes. BMC proceedings. 2016;10(Suppl 7):181-186.
47. Chen H, Meigs JB, Dupuis J. Sequence kernel association test for quantitative traits in family 
samples. Genet Epidemiol. 2013;37(2):196-204.
48. Jiang Y, Conneely KN, Epstein MP. Flexible and robust methods for rare-variant testing of quantitative 
traits in trios and nuclear families. Genet Epidemiol. 2014;38(6):542-551.
350
CHAPTER 10
49. Fang S, Sha Q, Zhang S. Two adaptive weighting methods to test for rare variant associations in 
family-based designs. Genet Epidemiol. 2012;36(5):499-507.
50. Li B, Wang GT, Leal SM. Generation of sequence-based data for pedigree-segregating Mendelian or 
Complex traits. Bioinformatics (Oxford, England). 2015;31(22):3706-3708.
51. Wang GT, Zhang D, Li B, Dai H, Leal SM. Collapsed haplotype pattern method for linkage analysis 
of next-generation sequence data. European journal of human genetics : EJHG. 2015;23(12):1739-
1743.
52. De G, Yip WK, Ionita-Laza I, Laird N. Rare variant analysis for family-based design. PloS one. 
2013;8(1):e48495.
53. Lin PL, Tsai WY, Chung RH. A combined association test for rare variants using family and case-
control data. BMC proceedings. 2016;10(Suppl 7):215-219.
54. Lek M, Karczewski K, Minikel E, et al. Analysis of protein-coding genetic variation in 60,706 humans. 
bioRxiv. 2015.
55. The UKKC. The UK10K project identifies rare variants in health and disease. Nature. 
2015;526(7571):82-90.
56. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation 
sequencing. Genetics in medicine : official journal of the American College of Medical Genetics. 
2013;15(9):733-747.
57. Sulonen A-M, Ellonen P, Almusa H, et al. Comparison of solution-based exome capture methods for 
next generation sequencing. Genome Biology. 2011;12(9):R94-R94.
58. Do R, Kathiresan S, Abecasis GR. Exome sequencing and complex disease: practical aspects of rare 
variant association studies. Human molecular genetics. 2012;21(R1):R1-R9.
59. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-
throughput sequencing data. Nucleic Acids Res. 2010;38(16):3.
60. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein 
function using the SIFT algorithm. Nature protocols. 2009;4(7):1073-1081.
61. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations 
using PolyPhen-2. Current protocols in human genetics / editorial board, Jonathan L Haines [et al]. 
2013;Chapter 7:Unit7.20.
62. Siepel A, Pollard KS, Haussler D. New methods for detecting lineage-specific selection. Proceedings 
of the 10th annual international conference on Research in Computational Molecular Biology; 2006; 
Venice, Italy.
63. Grantham R. Amino Acid Difference Formula to Help Explain Protein Evolution. Science (New York, 
NY). 1974;185(4154):862-864.
64. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of 
the human genome to be under selective constraint using GERP++. PLoS computational biology. 
2010;6(12):e1001025.
65. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for 
estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-315.
351
GENERAL DISCUSSION
66. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: 
a joint consensus recommendation of the American College of Medical Genetics and Genomics and 
the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
67. Kavanagh D, Yu Y, Schramm EC, et al. Rare genetic variants in the CFI gene are associated with 
advanced age-related macular degeneration and commonly result in reduced serum factor I levels. 
Human molecular genetics. 2015;24(13):3861-3870.
68. Ezewudo M, Zwick ME. Evaluating rare variants in complex disorders using next-generation 
sequencing. Current psychiatry reports. 2013;15(4):349.
69. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: 
application to analysis of sequence data. Am J Hum Genet. 2008;83.
70. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence 
variants in human disease. Nature. 2014;508(7497):469-476.
71. Manolio TA, Fowler DM, Starita LM, et al. Bedside Back to Bench: Building Bridges between Basic 
and Clinical Genomic Research. Cell. 2017;169(1):6-12.
72. Hofman A, Brusselle GG, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design 
update. European journal of epidemiology. 2015;30(8):661-708.
73. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design 
update. European journal of epidemiology. 2013;28(11):889-926.
74. Munroe DJ, Harris TJR. Third-generation sequencing fireworks at Marco Island. Nat Biotech. 
2010;28(5):426-428.
75. Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and 
degenerative diseases. European Journal of Pharmacology. 2016;787(Supplement C):94-104.
76. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging 
and age-related macular degeneration: hypothesis re-visited. Progress in retinal and eye research. 
2010;29(2):95-112.
77. Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 – The “Swiss 
Army Knife” of innate immunity and host defense. Immunological reviews. 2016;274(1):33-58.
78. Nürnberger W, Bhakdi S. Plasma C3d/C3 quotient as a parameter for in vivo complement activation. 
Journal of Immunological Methods. 1984;74(1):87-91.
79. Lechner J, Chen M, Hogg RE, et al. Higher plasma levels of complement C3a, C4a and C5a increase 
the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement 
activation in AMD. Immunity & ageing : I & A. 2016;13:4.
80. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. Plasma complement 
components and activation fragments: associations with age-related macular degeneration 
genotypes and phenotypes. Investigative ophthalmology & visual science. 2009;50(12):5818-5827.
81. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular 
degeneration. PloS one. 2008;3(7):e2593.
352
CHAPTER 10
82. Keenan TD, Toso M, Pappas C, Nichols L, Bishop PN, Hageman GS. Assessment of Proteins Associated 
With Complement Activation and Inflammation in Maculae of Human Donors Homozygous Risk at 
Chromosome 1 CFH-to-F13B. Investigative ophthalmology & visual science. 2015;56(8):4870-4879.
83. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous 
for the age-related macular degeneration risk-conferring variant of complement factor H have 
elevated levels of CRP in the choroid. Proceedings of the National Academy of Sciences of the United 
States of America. 2006;103(46):17456-17461.
84. Schick T, Steinhauer M, Aslanidis A, et al. Local complement activation in aqueous humor in patients 
with age-related macular degeneration. Eye (London, England). 2017;31(5):810-813.
85. Mullins RF, Warwick AN, Sohn EH, Lotery AJ. From compliment to insult: genetics of the 
complement system in physiology and disease in the human retina. Human molecular genetics. 
2017;26(R1):R51-R57.
86. Triebwasser MP, Roberson ED, Yu Y, et al. Rare Variants in the Functional Domains of Complement 
Factor H Are Associated With Age-Related Macular Degeneration. Investigative ophthalmology & 
visual science. 2015;56(11):6873-6878.
87. Mohlin FC, Nilsson SC, Levart TK, et al. Functional characterization of two novel non-synonymous 
alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome 
patients. Molecular immunology. 2015;65(2):367-376.
88. Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare Genetic 
Variant in Age-Related Macular Degeneration. JAMA ophthalmology. 2015;133(7):785-791.
89. Grassi MA, Folk JC, Scheetz TE, Taylor CM, Sheffield VC, Stone EM. Complement factor H 
polymorphism p.Tyr402His and cuticular Drusen. Archives of ophthalmology (Chicago, Ill : 1960). 
2007;125(1):93-97.
90. Boon CJ, Klevering BJ, Hoyng CB, et al. Basal laminar drusen caused by compound heterozygous 
variants in the CFH gene. American journal of human genetics. 2008;82(2):516-523.
91. van de Ven JP, Boon CJ, Fauser S, et al. Clinical evaluation of 3 families with basal laminar drusen 
caused by novel mutations in the complement factor H gene. Archives of ophthalmology (Chicago, Ill 
: 1960). 2012;130(8):1038-1047.
92. Oishi A, Thiele S, Nadal J, et al. Prevalence, Natural Course, and Prognostic Role of Refractile 
Drusen in Age-Related Macular Degeneration. Investigative ophthalmology & visual science. 
2017;58(4):2198-2206.
93. Suzuki M, Curcio CA, Mullins RF, Spaide RF. REFRACTILE DRUSEN: Clinical Imaging and Candidate 
Histology. Retina (Philadelphia, Pa). 2015;35(5):859-865.
94. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH 
haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular 
degeneration. Nat Genet. 2006;38(10):1173-1177.
95. Baines AC, Brodsky RA. Complementopathies. Blood reviews. 2017;31(4):213-223.
96. Kijlstra A, Berendschot TT. Age-related macular degeneration: a complementopathy? Ophthalmic 
Res. 2015;54(2):64-73.
353
GENERAL DISCUSSION
97. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular 
degeneration. Science (New York, NY). 2005;308(5720):385-389.
98. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic 
uremic syndrome. Kidney Int. 1998;53(4):836-844.
99. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic 
and familial aHUS and their impact on clinical phenotype. Clinical journal of the American Society of 
Nephrology : CJASN. 2010;5(10):1844-1859.
100. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of Age-Related Macular Degeneration in 
Europe: The Past and the Future. Ophthalmology. 2017.
101. Bhattacharya R, Rose PW, Burley SK, Prlić A. Impact of genetic variation on three dimensional 
structure and function of proteins. PloS one. 2017;12(3):e0171355.
102. Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights 
from Contemporary Genetics. Annual review of pathology. 2016.
103. Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of factor H-like 
protein 1 as the predominant complement regulator in Bruch’s membrane: implications for age-
related macular degeneration. Journal of immunology (Baltimore, Md : 1950). 2014;193(10):4962-
4970.
104. Clark SJ, Ridge LA, Herbert AP, et al. Tissue-specific host recognition by complement factor H is 
mediated by differential activities of its glycosaminoglycan-binding regions. Journal of immunology 
(Baltimore, Md : 1950). 2013;190(5):2049-2057.
105. Langford-Smith A, Keenan TDL, Clark SJ, Bishop PN, Day AJ. The Role of Complement in Age-
Related Macular Degeneration: Heparan Sulphate, a ZIP Code for Complement Factor H? Journal 
of Innate Immunity. 2014;6(4):407-416.
106. Langford-Smith A, Day AJ, Bishop PN, Clark SJ. Complementing the Sugar Code: Role of GAGs and 
Sialic Acid in Complement Regulation. Frontiers in immunology. 2015;6:25.
107. Kavanagh D, Pappworth IY, Anderson H, et al. Factor I autoantibodies in patients with atypical 
hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clinical journal of the 
American Society of Nephrology : CJASN. 2012;7(3):417-426.
108. Nilsson SC, Nita I, Mansson L, et al. Analysis of binding sites on complement factor I that are 
required for its activity. The Journal of biological chemistry. 2010;285(9):6235-6245.
109. Sanchez-Gallego JI, Groeneveld TW, Krentz S, Nilsson SC, Villoutreix BO, Blom AM. Analysis of 
binding sites on complement factor I using artificial N-linked glycosylation. The Journal of biological 
chemistry. 2012;287(17):13572-13583.
110. Richards A, Kavanagh D, Atkinson JP. Inherited Complement Regulatory Protein Deficiency 
Predisposes to Human Disease in Acute Injury and Chronic Inflammatory StatesThe Examples of 
Vascular Damage in Atypical Hemolytic Uremic Syndrome and Debris Accumulation in Age‐Related 
Macular Degeneration. Advances in Immunology. Vol 96: Academic Press; 2007:141-177.
111. Rodriguez de Cordoba S. aHUS: a disorder with many risk factors. Blood. 2010;115(2):158-160.
354
CHAPTER 10
112. Reuter S, Heitplatz B, Pavenstadt H, Suwelack B. Successful long-term treatment of TMA with 
eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation. 
Transplantation. 2013;96(10):e74-76.
113. Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular 
degeneration. The Cochrane database of systematic reviews. 2014(1):Cd009300.
114. Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement in 
humans and age-related macular degeneration. Human molecular genetics. 2010;19(1):209-215.
115. Paun CC, Lechanteur YT, Groenewoud JM, et al. A Novel Complotype Combination Associates 
with Age-Related Macular Degeneration and High Complement Activation Levels in vivo. Scientific 
reports. 2016;6:26568.
116. Ristau T, Paun C, Ersoy L, et al. Impact of the common genetic associations of age-related macular 
degeneration upon systemic complement component C3d levels. PloS one. 2014;9(3):e93459.
117. Smailhodzic D, Klaver CC, Klevering BJ, et al. Risk alleles in CFH and ARMS2 are independently 
associated with systemic complement activation in age-related macular degeneration. 
Ophthalmology. 2012;119(2):339-346.
118. Lechanteur YTE. Complement activation levels are related to disease stage in age-related macular 
degeneration. Radboud Repository, Radboud University Nijmegen; 2016.
119. Lechanteur Y, Schick T, Groenewoud J, et al. Levels of Complement Activation Differ Between Stages 
of Age-related Macular Degeneration. Investigative ophthalmology & visual science. 2015;56(7):787-
787.
120. Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC. Treatment with human 
complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. 
Kidney Int. 2010;78(3):279-286.
121. Lay E, Nutland S, Smith JE, et al. Complotype affects the extent of down-regulation by Factor I of the 
C3b feedback cycle in vitro. Clinical and experimental immunology. 2015;181(2):314-322.
122. Nichols E-M, Barbour TD, Pappworth IY, et al. An extended mini-complement factor H molecule 
ameliorates experimental C3 glomerulopathy. Kidney International. 2015;88(6):1314-1322.
123. Hebecker M, Alba-Dominguez M, Roumenina LT, et al. An engineered construct combining 
complement regulatory and surface-recognition domains represents a minimal-size functional 
factor H. Journal of immunology (Baltimore, Md : 1950). 2013;191(2):912-921.
124. Schmidt CQ, Bai H, Lin Z, et al. Rational engineering of a minimized immune inhibitor with unique 
triple-targeting properties. Journal of immunology (Baltimore, Md : 1950). 2013;190(11):5712-5721.
125. Schmidt CQ, Harder MJ, Nichols E-M, et al. Selectivity of C3-opsonin targeted complement inhibitors: 
A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria 
patients. Immunobiology. 2016;221(4):503-511.
126. Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway 
reduces geographic atrophy progression secondary to age-related macular degeneration. Science 
translational medicine. 2017;9(395).
355
GENERAL DISCUSSION
127. Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related 
macular degeneration: current challenges and future prospects. Clinical ophthalmology (Auckland, 
NZ). 2015;9:2159-2174.
128. Bradley DT, Zipfel PF, Hughes AE. Complement in age-related macular degeneration: a focus on 
function. Eye. 2011;25(6):683-693.
129. Clark SJ, Bishop PN. The eye as a complement dysregulation hotspot. Seminars in Immunopathology. 
2017.
130. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with 
eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. 
Ophthalmology. 2014;121(3):693-701.
131. Cooke Bailey JN, Hoffman JD, Sardell RJ, Scott WK, Pericak-Vance MA, Haines JL. The Application 
of Genetic Risk Scores in Age-Related Macular Degeneration: A Review. Journal of clinical medicine. 
2016;5(3):31.
132. Buitendijk GH, Rochtchina E, Myers C, et al. Prediction of age-related macular degeneration in the 
general population: the Three Continent AMD Consortium. Ophthalmology. 2013;120(12):2644-2655.
133. Chen Y, Zeng J, Zhao C, et al. Assessing susceptibility to age-related macular degeneration 
with genetic markers and environmental factors. Archives of ophthalmology (Chicago, Ill : 1960). 
2011;129(3):344-351.
134. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-
related macular degeneration using demographic, environmental, genetic, and ocular factors. 
Ophthalmology. 2011;118(11):2203-2211.
135. Seddon JM, Silver RE, Kwong M, Rosner B. Risk Prediction for Progression of Macular Degeneration: 
10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. 
Investigative ophthalmology & visual science. 2015;56(4):2192-2202.
136. Tan PL, Garrett ME, Willer JR, et al. Systematic Functional Testing of Rare Variants: Contributions 
of CFI to Age-Related Macular DegenerationFunctional Rare Variants in CFI Contribute to AMD. 
Investigative ophthalmology & visual science. 2017;58(3):1570-1576.
137. 23andMe. Learn More About 23andMe’s New Genetic Health Risk Reports. [Blog]. 2017; https://
blog.23andme.com/health-traits/learn-23andmes-new-genetic-health-risk-reports/.
138. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) 
genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458-462.

11
SUMMARY
SAMENVATTING
LIST OF PUBLICATIONS
CURRICULUM VITAE
DANKWOORD
358
CHAPTER 11
359
SUMMARY - SAMENVATTING - PUBLICATIONS - CV - DANKWOORD
SUMMARY
Age-related macular degeneration (AMD) is a disease affecting the central retina as result of a 
complex interaction of environmental and genetic risk factors. AMD is the most common cause 
of irreversible vision loss in the Western world. It was previously hypothesized that a common 
disease, like AMD, would be caused by common genetic variants. However, after uncovering 19 
loci associated with the disease, a large fraction of the heritability remained unexplained. Rare 
genetic variants, defined as genetic changes with a minor allele frequency below 1% in the 
population, can have large effects on disease and were proposed to account for the ‘missing’ 
heritability. The aim of this thesis is to further elucidate the role of rare genetic variants in 
AMD pathogenesis. We hypothesize that a proportion of the missing heritability in AMD can be 
explained by rare highly penetrant variants. We aim to identify novel genetic causes of AMD, 
and to understand their role in the disease mechanism of AMD.
In chapter 2 we reported the identification of rare genetic variants CFI p.Gly119Arg, C9 
p.Pro167Ser, and C3 p.Lys155Gln, which were previously associated with AMD, in 22 densely 
affected AMD families. Despite the strong association with AMD in case control association 
analyses, these rare variants did not segregate with the disease phenotype in our families. The 
presence of one of these rare variants was associated with a higher familial occurrence, as 
more than half of all patients who carried such a rare variant reported a positive family history 
for AMD. Clinically, the initial onset of symptoms in carriers of these rare variants occurred an 
average of six years earlier than in non-carriers. In addition, these genetic rare variants were 
more prevalent among patients with advanced AMD and geographic atrophy than in patients 
with neovascular AMD. Our finding emphasized the importance of counseling patients and 
family members to increase awareness and enable early detection of the disease.
In chapter 3 we continued our analysis into the 22 families we described in chapter 2 in 
search for additional rare variants in complement genes CFH, CFI, C3, and C9. We identified 
6 additional rare genetic variants. Although the identified variants were associated with AMD 
disease status and highly prevalent within these families, perfect segregation with the disease 
phenotype was not observed. By analyzing the effect of rare variants on protein expression, we 
found that carriers of CFH and C3 variants have normal serum FH concentration, CFI carriers 
(p.Gly119Arg and p.Ser193Leu) have reduced FI serum concentration, and C9 p.Pro167Ser 
carriers have increased C9 serum concentration. Furthermore, serum samples from carriers 
of rare variants in CFH and CFI revealed a diminished ability to degrade C3b, suggesting that 
the variants result in impaired complement regulation. We hypothesize that carriers of rare 
variants in CFH and CFI are less able to inhibit complement activation and may therefore 
benefit more from complement-inhibiting therapy than AMD patients in general. 
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In chapter 4 we evaluated the functional effect of seven rare variants in C9 identified in our AMD 
cohort. We identified elevated C9 serum levels for carriers of rare variants in C9 (p.Met45Leu, 
p.Phe62Ser, p.Pro167Ser and p.Ala529Thr), however no increase in serum concentration 
for the terminating complement complex between carriers and noncarriers was observed. 
Formation of the membrane attack complex (MAC) depends on the incorporation of C9. We 
assumed elevated concentrations lead to enhanced MAC deposition and damage to retinal 
cells. However, we could not detect any increase in C9-dependent lytic activity of patient sera. 
More surprisingly, the p.Phe62Ser and Pro167Ser variants caused decreased lysis which was 
contradictory to our expectations. We did note increased polymerization for p.Phe62Ser and a 
tendency of the p.Pro167Ser mutant to spontaneously aggregate. Future research is needed to 
evaluate the role of C9 p.Pro167Ser in AMD pathogenesis. 
In chapter 5 we explored the geographical occurance of seven rare genetic variants that 
were reported to be independently associated with AMD by the International AMD Genomics 
Consortium. We observed that two rare AMD-associated variants in the CFH gene (rs121913059 
[p.Arg1210Cys] and rs35292876) deviated in allele frequency among different geographical 
regions. As expected, risk estimates of each of the seven rare variants were comparable 
across geographical regions. Our findings emphasize that personalized treatment aimed at 
rare variants with functional effects may only be applicable to specific populations where these 
variants are sufficiently common.
In chapter 6 we compared the phenotypical characteristics of patients with AMD carrying a 
rare variant in the CFH gene to those without such a rare variant. We observed an increased 
number of drusen deposition in rare variant carriers, around the macula and nasal to the optic 
disc. Furthermore, rare variant carriers were graded more often as late atrophic AMD (57.1%) 
than noncarriers (28.1%). These phenotypical characteristics could guide ophthalmologists 
in selecting genetic tests. When limiting the analyzed variants to those that were confirmed 
to be pathogenic by case-control or functional studies, the associations between rare variant 
carriers and phenotypical characteristics became more pronounced. This emphasizes the 
importance of confirming the clinical significance of rare genetic variants.
In chapter 7 we aimed to evaluate the occurrence of AMD-mimicking dystrophies in our cohort 
of 183 cases diagnosed with intermediate or late geographic atrophy AMD. Using whole exome 
sequencing we evaluated rare genetic variants found in 19 genes associated with autosomal 
dominant and recessive macular degenerations mimicking AMD. A mutation in PRPH2 was 
identified (c.424C>T, p.Arg142Trp) in three individuals. This mutation is reported to be causal 
for central areolar choroidal dystrophy (CACD). Phenotypically there are strong similarities 
between CACD and AMD and based on images alone these patients can be easily overlooked 
and misdiagnosed. It is increasingly important to correctly diagnose patients with macular 
361
SUMMARY - SAMENVATTING - PUBLICATIONS - CV - DANKWOORD
degeneration with respect to inclusion in clinical trials and for future treatment. Based on our 
results genetic screening of the PRPH2 gene is recommended to exclude AMD-mimicking 
dystrophies.
In chapter 8 we compared the low frequency variants found in complement genes CFH, CFI, 
and C3 for 866 renal diseases patients, diagnosed with atypical hemolytic uremic syndrome 
(aHUS) or C3 glomerulopathy (C3G), and 697 AMD patients. Analyzing the domains in which 
low frequency variants cluster, combined with structural information, can help assess 
which domains are of functional importance. Such insight may help understand the way in 
which complement activation is responsible for two seemingly different disease phenotypes. 
Genotype-phenotype correlations between the disease groups identified a higher frequency 
of protein-altering variants in SCR20 of FH and in the serine protease domain of FI for aHUS/
C3G patients. For AMD, the N-terminus of FH, especially the SCR3, SCR5 and SCR7 domains, 
contained more protein altering variants, in addition to the SRCR domain in FI, and MG3 
domain of C3. For FH, our findings corroborate existing data that shows that FH interacts with 
the glomerular endothelium via the C-terminus while the N-terminus of FH is involved in C3b 
regulation in AMD. Alterations in FI’s SRCR domain are likely to affect expression and thus 
overall activity, while FI changes related to renal disease are involved in structural elements 
around the active site. For C3, alterations located the MG domains that interact with FH may 
hamper breakdown of C3. We observed a significant overlap in variants between aHUS/C3G 
and AMD, however there is a distinct clustering of variants within specific domains.
In chapter 9 we analyzed whole-exome sequencing information of 1125 AMD cases and 1361 
controls. Using single variant analysis we confirmed the association of common variants 
in CFH and ARMS2. Furthermore, we used gene-based burden tests called combined 
multivariate and collapsing (CMC), which accumulates the association from multiple rare 
variants per gene. Using CMC, we observed a disease burden for the COL8A1 gene driven by 
14 rare protein altering variants. Staining of mice retina demonstrated that COL8A1 localizes 
at Bruch’s membrane and is slightly expressed in the outer plexiform layer of the retina. Our 
findings suggest that protein-altering variants in COL8A1 could alter the integrity of Bruch’s 
membrane, thereby contributing to the accumulation of drusen and the development of AMD.
In conclusion, evaluating the effect of novel rare variants is challenging, even if these variants 
reside in genes previously associated with AMD. In this thesis, we described the identification 
of number of rare genetic variants residing in the complement system extracellular matrix and 
AMD-mimicking macular dystrophy genes using case-control and familial-based analyses. 
These methods were effective to identify novel rare genetic variants but ultimately supportive 
information from biological experiments was required to properly assess the impact of a 
specific rare variant. Systematical functional analyses of rare genetic variants within a gene 
of interest will help interpreting the consequences of rare coding variants on protein function 
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in general. Rare genetic variants have functional implications that help us understand the 
underlying disease mechanisms. A better understanding of the disease mechanisms as a 
whole is needed to optimize treatment options. Knowing which role rare genetic variants play 
may therefore help us answer the questions: whom to treat, what the drug should target and 
how the drug should be administered. 
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Leeftijdsgebonden maculadegeneratie (LMD) is een oogaandoening die de retina (beter bekend 
als het netvlies) aantast. Slijtage (degeneratie) van het netvlies kan leiden tot een verlies van 
gezichtsscherpte. LMD wordt veroorzaakt door een complexe interactie van omgevingsfactoren 
(zoals roken en voeding) en genetische risicofactoren. Deze ouderdomsziekte is de meest 
voorkomende oorzaak van verlies van het gezichtsvermogen in de westerse wereld. 
Voorheen werd gedacht dat een veel voorkomende ziekte als LMD alleen veroorzaakt kon 
worden door veelvoorkomende genetische varianten. Echter, na het ontdekken van 19 
genetische loci die betrokken zijn bij het ontstaan van de ziekte, kon toch een groot deel van 
de erfelijkheid niet worden verklaard. De hypothese werd daarom gesteld dat ook zeldzame 
genetische varianten de kans op het ontwikkelen van een veelvoorkomende ziekte kunnen 
vergroten. Een zeldzame variant wordt gedefinieerd als een genetische verandering met een 
allel frequentie lager dan 1%. Dit getal geeft aan hoe vaak een genetische verandering in een 
populatie voorkomt. Het doel van dit proefschrift is om verder te ontrafelen welke rol deze 
zeldzame genetische varianten spelen bij het ontstaan van LMD.  We denken dat een deel van 
de ontbrekende erfelijkheidsfactoren in LMD mogelijk verklaard kan worden door zeldzame 
varianten. Met dit proefschrift willen we de genetische oorzaken van LMD verder identificeren 
en hun rol in het ziektemechanisme van LMD beter begrijpen. 
In hoofdstuk 2 rapporteerden we de identificatie van zeldzame genetische varianten CFI 
p.Gly119Arg, C9 p.Pro167Ser en C3 p.Lys155Gln in 22 families waar bij meerdere familieleden 
LMD was vastgesteld. Al eerder was aangetoond dat deze genetische varianten een rol spelen 
bij het ontstaan van LMD. Met behulp van een patiënt-controle associatie analyse bevestigden 
we dat deze varianten inderdaad risico geven op het ontstaan van de ziekte. Echter, de varianten 
erfden in de families niet volledig over met de ziekte, ondanks de sterke associatie met LMD. 
De aanwezigheid van een zeldzame variant leek wel invloed te hebben op het voorkomen van 
LMD binnen deze families. Meer dan de helft van alle patiënten met een dergelijke zeldzame 
variant had een positieve familiegeschiedenis voor LMD. Klinisch gezien werden symptomen 
bij dragers van deze varianten gemiddeld zes jaar eerder opgemerkt dan bij niet-dragers. 
Daarbij kwamen deze genetisch varianten vaker voor bij patiënten met gevorderde LMD in 
combinatie met geografische atrofie (droge LMD) dan bij patiënten met neovasculaire (natte) 
LMD. Onze bevindingen benadrukken het belang van het op tijd inlichten van familieleden van 
LMD-patiënten over hun mogelijke risico op LMD. Zodoende kan men bij de familieleden het 
bewustzijn vergroten en vroege opsporing van de ziekte mogelijk te maken. 
In hoofdstuk 3 hebben we onze analyse van de 22 families uit hoofdstuk 2 doorgezet. We zijn op 
zoek gegaan naar andere zeldzame varianten in genen uit het complementsysteem (namelijk 
364
CHAPTER 11
CFH, CFI, C3 en C9). Het complementsysteem maakt onderdeel uit van het lichaamseigen 
afweer systeem. Binnen de families identificeerden we nog zes zeldzame genetische varianten 
in genen van het complementsysteem. Hoewel de geïdentificeerde varianten geassocieerd 
waren met LMD en veel voorkamen binnen deze families, werd geen perfecte overerving van 
de varianten met het ziektebeeld waargenomen. Door het effect van zeldzame varianten op 
eiwitniveau te analyseren, ontdekten we bij de dragers van CFH varianten normale serum FH-
concentraties. Voor CFI-dragers (p.Gly119Arg en p.Ser193Leu) vonden we een verminderde 
FI serumconcentratie en voor C9 p.Pro167Ser was de C9 serumconcentratie toegenomen. 
Bovendien toonden serummonsters van dragers van zeldzame varianten in CFH en CFI 
een verminderd vermogen om C3b af te breken. Dit suggereert dat de varianten resulteren 
in verminderde complementregulatie, dat wil zeggen dat de afweer tegen infecties en het 
opruimen van ziekmakende cellen verstoord is. We concluderen dat dragers van zeldzame 
varianten in CFI en CFH minder in staat zijn om dit mechanisme te remmen en daardoor 
waarschijnlijk meer baat zullen hebben bij complement remmende therapie dan LMD-
patiënten in het algemeen. 
In hoofdstuk 4 onderzochten we het effect van zeven zeldzame genetische varianten in het 
C9 gen op de functie van het C9 eiwit. In het complementsysteem vormt C9 met meerdere 
eiwitten een complex (genaamd het ‘membrane attack complex’ (MAC)) dat gaten kan boren in 
membranen van ziekmakende cellen om deze op die manier op te ruimen. In ons onderzoek 
toonden we verhoogde C9 serumwaarden aan bij dragers van zeldzame varianten in C9 
(p. Met45Leu, p. Phe62Ser, p.Pro167Ser en p.Ala529Thr). Er werd echter geen toename in 
serum concentratie waargenomen in de vorming van het MAC complex tussen dragers en 
niet-dragers. We veronderstelden dat verhoogde C9 concentraties zouden kunnen leiden tot 
verhoogde MAC vorming en uiteindelijk schade aan de netvliescellen. We konden echter geen 
toename van de C9 afhankelijke lytische activiteit (het boren van een gat) detecteren in cellen 
die werden blootgesteld aan serum van deze patiënten. De C9 p.Phe62Ser en p.Pro167Ser 
varianten veroorzaakten een verminderde lytische activiteit, wat tegengesteld was aan onze 
verwachtingen. We vonden een verhoogde polymerisatie voor p.Phe62Ser en de neiging van 
de p.Pro167Ser-variant om spontaan te aggregeren (misvouwen en klonteren). In de toekomst 
is aanvullend onderzoek nodig om de rol van C9 p.Pro167Ser in het ontstaan van LMD op te 
helderen. 
In hoofdstuk 5 hebben we onderzocht hoe vaak zeven zeldzame genetische varianten 
voorkomen in verschillende populaties. Voorheen was door het International LMD Genomics 
Consortium gerapporteerd dat deze zeven varianten geassocieerd zijn met LMD.  We zagen 
dat de allel frequenties van twee LMD-varianten in het CFH gen (rs121913059 [p. Arg1210Cys] 
en rs35292876) afweken tussen verschillende geografische regio’s. Zoals verwacht was het 
risico op LMD voor elk van deze zeven varianten vergelijkbaar binnen de geografische regio’s. 
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Onze bevindingen benadrukken dat het voorkomen van zeldzame varianten kan verschillen 
per populatie, en dat in de toekomst in andere populaties mogelijk nieuwe zeldzame varianten 
kunnen worden ontdekt. Ook zal  persoonsgerichte behandeling gericht tegen specifieke 
zeldzame varianten mogelijk alleen toegepast kunnen worden in populaties waar deze 
varianten vaak genoeg voorkomen. 
In hoofdstuk 6 hebben we de klinische kenmerken beschreven van patiënten met LMD met 
een zeldzame variant in het CFH gen. We hebben deze groep vergeleken met patiënten zonder 
een dergelijke zeldzame variant. Bij dragers van de zeldzame varianten zagen we een verhoogd 
aantal drusen (ophopingen van kalk, kristallen en afvalproducten) rond de macula en nasaal 
(neuszijde) van de oogzenuw. Bovendien hadden de dragers van zeldzame varianten vaker het 
eindstadium geografische atrofie (droge LMD;  57,1%) dan niet-dragers (28,1%). Wanneer er 
alleen gekeken werd naar dragers van varianten die de functie van het eiwit aantasten, dan 
waren deklinische kenmerken nog uitgesprokener. De klinische kenmerken van CFH dragers 
kunnen oogartsen helpen in het selecteren van patienten voor wie het aanvragen van een 
genetische test zinvol kan zijn. 
In hoofdstuk 7 wilden we het voorkomen van erfelijke macula dystrofieën bekijken die erg 
lijken op LMD. Dit hebben we gedaan in een groep met 183 LMD-patiënten met kenmerken van 
intermediair LMD of geografische atrofie (droge LMD). We maakten gebruik van whole exome 
sequencing, een techniek waarbij DNA snel uitgelezen kan worden. We evalueerden zeldzame 
genetische varianten uit 19 genen geassocieerd met autosomaal dominante en recessieve 
macula dystrofieën die op LMD kunnen lijken. Een mutatie in PRPH2 (c.424C> T, p. Arg142Trp) 
werd geïdentificeerd bij drie personen. Deze mutatie is verantwoordelijk voor het ontstaan van 
centrale areolaire choriodale dystrofie (CACD). De klinische kenmerken van CACD en LMD 
komen sterk overeen. Op basis van netvliesfoto’s kunnen deze patiënten gemakkelijk verkeerd 
worden gediagnosticeerd. Het wordt steeds belangrijker om patiënten met maculadegeneratie 
correct te diagnosticeren voor deelname aan klinische studies naar nieuwe behandelingen. 
Onze aanbeveling is om patiënten met droge LMD genetisch te testen voor het PRPH2-gen om 
op deze manier CACD uit te sluiten. 
In hoofdstuk 8 vergeleken we de varianten gevonden in complement genen CFH, CFI en C3 bij 
866 patiënten met nierziekten, gediagnosticeerd met atypisch hemolytisch uremisch syndroom 
(aHUS) of C3 glomerulopathie (C3G), en 697 LMD patiënten. De locatie waar een genetische 
variant zich bevindt bepaalt waar en welk effect deze heeft op het eiwit. Men kan ontrafelen 
hoe een eiwit werkt door vast te stellen welke delen (domeinen) van een eiwit functioneel 
worden aangetast door genetische varianten. Dergelijk inzicht kan helpen begrijpen hoe 
het complementsysteem verantwoordelijk is voor twee heel verschillende ziektebeelden. 
Bij patiënten met nierziekten werd een hogere frequentie van eiwit veranderende varianten 
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gevonden in SCR20 van FH en in het serine protease domein van FI. Voor patiënten met LMD 
bevatte de N-terminus van FH, in het bijzonder de SCR3, SCR5 en SCR7 domeinen, meer eiwit 
veranderende varianten, naast het SRCR domein in FI en MG3 domein van C3. Dit bevestigt 
eerder onderzoek dat aantoonde dat FH belangrijk is voor de binding aan het nier endotheel 
via de C-terminus, terwijl de N-terminus van FH betrokken is bij C3b-regulatie in het oog. 
Veranderingen in het SRCR domein van FI hebben waarschijnlijk invloed op de expressie en dus 
de algehele activiteit, terwijl nier-gerelateerde FI veranderingen betrokken zijn bij structurele 
elementen van het eiwit. Veranderingen in het MG3 domein van C3 kunnen de interactie met 
FH verstoren en de afbraak van C3b belemmeren. Samengenomen zagen we een grote overlap 
van varianten bij aHUS/C3G en LMD, maar was een duidelijke clustering van varianten binnen 
specifieke domeinen. 
In hoofdstuk 9 hebben we whole-exome sequencing informatie van 1125 LMD patiënten en 
1361 controles geanalyseerd met behulp van een ‘single variant’ analyse. Hiermee bevestigden 
we de associatie van veelvoorkomende varianten in CFH en ARMS2. Verder gebruikten we 
een ‘gene-based burdentest’, genaamd ‘combined multivariate and collapsing’ (CMC), die de 
associatie van meerdere zeldzame varianten per gen samenvoegt. Met behulp van de CMC test 
hebben we een ‘burden’ waargenomen voor het COL8A1 gen, veroorzaakt door 14 zeldzame 
varianten die het eiwit veranderen. Aankleuring van retina cellen van muizen toonde aan dat 
het COL8A1 eiwit zich in het membraan van Bruch bevindt. Onze bevindingen suggereren dat 
eiwit veranderende varianten in COL8A1 de werking van het membraan van Bruch kunnen 
veranderen, en daarmee bijdragen aan de ophoping van drusen en de ontwikkeling van LMD. 
In conclusie, een voorspelling doen over de werking van nieuw ontdekte genetische varianten 
is een uitdaging, zelfs als deze varianten voorkomen in genen die al eerder onderzocht zijn 
in relatie tot LMD. In dit proefschrift hebben we beschreven hoe we zeldzame genetische 
varianten hebben geïdentificeerd  in genen die een rol spelen in het afweersysteem, in de 
steunende weefselstructuur (de extracellulaire matrix), en in erfelijke macula dystrofieën. 
Uiteindelijk bleek aanvullende informatie vanuit biologische experimenten noodzakelijk om het 
effect van de genetische varianten goed te kunnen beoordelen. 
Inzicht in de functionele gevolgen van deze varianten helpt om het onderliggende 
ziektemechanisme te begrijpen. Een beter begrip van het ziektemechanisme is nodig om 
de behandelmogelijkheden te optimaliseren. Kennis over de rol van zeldzame genetische 
varianten kan ons helpen om in de toekomst effectievere behandelingen en persoonsgerichte 
zorg voor LMD te ontwikkelen.
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Na vier jaar van onderzoek en het schrijven van meerdere artikelen ben ik aangekomen aan 
(voorlopig) mijn laatste schrijfstuk. Het dankwoord, of met andere woorden, de paragraaf van 
een dissertatie die het meest gelezen wordt. Tijdens de afgelopen jaren zijn er veel mensen 
die ik heb leren kennen en waar ik mee heb mogen samenwerken. Graag wil ik een  aantal 
mensen in het bijzonder bedanken. Zoals het bij een wetenschappelijk artikel gaat staan de 
belangrijkste mensen zowel voor- als achteraan in de lijst van namen. Toch is het essentieel 
om niet te vergeten dat zonder de mensen ‘in het midden’ geen tekst geschreven had kunnen 
worden. Thank you all, I could not have done it without your help.
Anneke, ik wil jou bedanken voor de mooie kans die je mij geboden hebt door te kunnen 
promoveren op dit prachtige project. Ik heb zeer veel respect voor hoe jij alle ballen in de lucht 
weet te houden. Een dozijn promovendi en jij weet, met jouw brede kennis, substantieel bij te 
dragen aan alle projecten. Ook voor mijn project had je altijd meerdere ideeën en een duidelijk 
beeld over welke richting we op moesten. Jij wist altijd de door mij geschreven teksten net iets 
te veranderen en daarmeede juiste lading te geven. Daardoor kwam de boodschap van de tekst 
precies goed over. Ondanks jouw overvolle agenda had je tijd voor persoonlijke aandacht en 
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frustraties, zorgden jouw suggesties en opmerkingen ervoor dat het werk altijd  beter werd. 
Bedankt voor je kritische blik, openlijke directheid en helpende hand. Samen zijn we tot een 
aantal zeer mooie artikelen gekomen.
Carel, jouw perspectief op het doen van onderzoek was mij aan het begin van mijn project 
meteen helder, toen jij mij tijdens mijn sollicitatie vroeg: ‘Hoe zijn jouw bevindingen relevant 
voor de patiënt?’. Een logische vraag, maar één die soms door enthousiasme van ‘de 
wetenschapper’ voor nieuwe bevindingen uit het oog verloren wordt. Tijdens mijn project heb 
jij mij kritisch leren kijken naar klinisch onderzoek en benadrukt in gedachten leren te houden 
waar we het onderzoek voor doen. Jouw kenmerkende lach die regelmatig over de gang te 
horen is en jouw eeuwige enthousiasme voor nieuwe projecten zijn erg aanstekelijk. 
To my reading committee, Irma Joosten, Frans Cremers and Simon Clark, thank you for 
taking the time to appraise my thesis. I truly appreciate your rapid assessment.
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bioinformaticians: Arjen, Jordi and Marc. I’d like to thank you guys for your patience in 
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explaining me basic code and scripts. It has been a pleasure working with you. I wish you all 
the best in your new jobs. ^\(    ,    )/^
Bjorn, ik wil je bedanken voor al je hulp en geduld in het uitleggen alle lab-gerelateerde zaken. 
Na vier jaar samen gewerkt te hebben, waarvan een maand in Lund (Zweden), heb ik jou leren 
kennen als een hardwerkende, eerlijke en zeer sociale collega. Ik wens jou en Anne-Claire een 
mooie toekomst samen.
 
Dames van het secretariaat, Berna, Francis, Iris, Laura, en Mara ik heb erg veel respect hoe 
jullie ‘boven’ de afdeling draaiend weten te houden. Geen vraag is te lastig en elke afspraak 
kunnen we bij jullie laten plannen. Bedankt voor jullie onvoorwaardelijke hulp.
Promovendus bij de afdeling oogheelkunde ben je gelukkig niet alleen. Het is van onschatbare 
waarde om bij mede promovendi aan te kunnen kloppen voor hulp, een korte vraag, een koekje 
of om je verhaal kwijt te kunnen. Het is vooral belangrijk  om te weten dat je tijdens de lastige 
periodes van een promotie niet alleen bent. Als startende promovendus heb ik mij in kunnen 
lezen met het imponerende werk van John. Na de soepele verdediging van Dzenita wist ik 
wat ik kon verwachten; de lat lag hoog! Ramon, altijd vrolijk en tijd voor een praatje. Nicole, 
gedreven en toegewijd: bedankt voor je geduld tijdens het inwerken op ‘de familie dataset’. 
Mahesh, hardworking and modest, I wish you all the best in Washington. Yara, altijd integer en 
secuur ongeacht de tijdsdruk. Bedankt voor de altijd beschikbare helpende hand. Constantin, 
always full of creative ideas and with at least a dozen solutions at hand. I admire your view on 
the world: one full of possibilities. I am happy for you that fatherhood suits you so well. Shazia, 
how did you ever find the energy to do a second PhD? I admire your ever lasting motivation and 
positivity. Laura, guapa, ophthalmochica, I got to know you as a considerate and caring person. 
I love your sheer desire to live life to the fullest. I am happy that we became friends after the 
four years that we worked alongside each other. Dyon, als ik bij jou langs loop kan ik altijd 
rekenen op een  ‘yo, g!’ met een brede glimlach en een pak koekjes. Sanne, hardwerkend en 
eerlijk, ik weet zeker dat je het ‘RP1 verhaal’ tot een prachtig stuk zult vormen. Vivian, een echt 
beestfeest in vermomming met altijd een grapje paraat. Sarah, I am happy that I got to know 
you in the last months of my PhD as easy to talk to and eager to help. All the best of luck with 
‘CFH and CFI’. Erkin, full of jokes, good luck being the only male (non-clinical) PhD student, 
I know you’ll do great. Helaas heb ik niet de kans gehad om alle nieuwe promovendi Esmée, 
Tom, Susette en Anita goed te leren kennen maar ik wens jullie allemaal een mooi PhD traject. 
Het lijkt nog een eeuwigheid tot je verdediging, maar de tijd gaat sneller dan je denkt. Bedankt 
aan alle promovendi voor de leuke tijd samen!
Op zoek naar een nieuwe sportieve uitdaging heeft Roos mij overgehaald om mee te gaan 
naar kanopolo. Wat een geweldige sport, maar vooral wat een geweldige mensen! Ik heb me 
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vanaf training één volledig welkom gevoeld. Bram, Conrado, Danielle, Dirk, Elke, Eva, Hein 
(en Lein), Ineke, Koen, Sam, Sigi en Terence, ik verheug me nu al op komende toernooien, 
eskimoteer trainingen, spelletjesavonden en andere gelegenheden waarbij een biertje of 
wijntje niet misstaat.
Nigel, ik kan me nog goed herinneren hoe wij samen bij meneer Denissen zaten voor wiskunde. 
Sinds die tijd kan ik altijd ik rekenen op een grote glimlach, flauwe grappen en een serie van 
geanimeerde verhalen. Ik hoef maar te appen “Tijd voor een biertje?” en dan is het antwoord 
altijd: “Natuurlijk, waar?”. 
Tijdens één van onze scouting auto-rally’s is de naam ‘goldengirls’ ontstaan. Bij het horen 
van deze naam worden we soms raar aangekeken. Ik zie het echter als een mooi streven om 
samen zo oud te mogen worden en nog steeds hechte vrienden te zijn. Met jullie beland ik 
altijd in de meest bizarre situaties: van opgesloten zijn in parkeergarages tot verdwalentijdens 
nachtelijke tochten of rond scheuren door dorpen rondom Zwolle. Ik verwonder me soms over 
onze groepsdynamiek, zo verschillend als we zijn, maar samen zijn we een perfect team. Hilde, 
ik heb respect voor jouw sterke keuzes en manier van leven. Blijf alsjeblieft zo georganiseerd 
met liever tien planningen in de lucht dan 1 in de hand. Esmée, zo direct, nuchter en dapper als 
jij bent, zijn er maar weinig. Ga je dromen achterna maar vergeet je ons niet in Nieuw Zeeland? 
Paula, jij kletst ons de oren van ons hoofd maar ik ken zeer weinig mensen die zo heerlijk 
zichzelf durven zijn. Je hebt echt een hart van goud. Dames, dat we samen nog uit veel kamers 
mogen ontsnappen en in bizarre situaties terecht komen. 
Door een vraag naar koffie en luisterend oor zijn de Zwelgjes ontstaan. We hebben zowel de 
mooiste als slechtste momenten met elkaar gedeeld. Meiden bedankt voor de steun en goede 
adviezen. Als de gelegenheid zich weer voordoet draaien we dan samen een fles wijn open?
Freekje, ik vertel mensen soms grappend dat onze levens in elkaar gevlochten zijn. Zelfs nu je 
in Amerika woont met jouw lieve Martijn weet ik dingen eerder via onze mannen dan dat jij ze 
mij hebt kunnen vertellen. Ik mis jouw nuchtere kijk op zaken en gezelligheid tijdens een hapje 
en drankje. Tot snel! 
Nathalie, ik heb zeer veel respect voor jouw doorzettingsvermogen en kracht. Ik weet niet hoe 
je het doet om een promotie, opleiding, verhuizen, sporten en een sociaal leven bij te houden in 
de beschikbare uren van een dag. Jouw  openhartigheid, nuchterheid, loyaliteit, gecombineerd 
met een lichte chaos zorgen voor nooit een saai moment. 
Mijn paranimfen Roos en Eveline, ik kan niet in woorden uitdrukken hoe fijn ik het vind dat jullie 
tijdens mijn verdediging naast mij staan. Roos, ik heb bewondering voor jouw innovativiteit, 
enthousiasme en lef. Al zijn we samen op kantoor, op een polo veld of verdiept in een bordspel, 
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met jou is het altijd gezellig. Volg je dromen en fiets de wereld rond. Eef, mijn klinische 
wederhelft, wat hebben we samen veel gedeeld: van frustraties over de database tot verbazing 
over hoe zaken soms lopen. Het maakt niet uit wat het vraagstuk was, samen kwamen we er 
altijd uit, “we doen het wel zelf”. Ik ben blij dat ik altijd op jou kan vertrouwen.
Lieve Daan, Inge, Robbert, Karlijn, Almar, Karen, Ludo en Saskia, je schoonfamilie heb je 
natuurlijk niet voor het kiezen, maar bij jullie voelde ik mij vanaf het begin welkom. Ik ben blij 
dat we samen kunnen dansen, feesten en lachen.
Lieve Omi, Oma en Opa ik vind het erg fijn dat jullie bij mijn verdediging kunnen zijn. Na vandaag 
is onderzoek is nu echt klaar. Lieve Opa, nog voordat ik begon aan mijn promotie onderzoek 
vertelde jij mij over prikken die je in jouw oog moest krijgen. Tijdens de afgelopen jaren heen 
heb jij alle mogelijke ‘prikken’ gekregen. Ik ben erg blij dat deze medicatie voor jou helpt. Ik 
hoop dat ik jouw trots maak met dit drukwerk. 
Lieve Hannah, ik vind het soms jammer dat ik niet, net zoals jij, scheurend in de Suzie lekker 
één keer in de week bij papa en mama kan aanschuiven. Ik vind het mooi hoe zorgzaam jij bent, 
je bent een echte doorzetter en altijd in voor een feestje. Joeri, koning BBQ, vol humor en altijd 
in voor lekker eten of een borrel. Wat fijn dat je er dit jaar weer bij bent in Dienten.
Lieve Julia, soms zijn wij samen als water en vuur, stiekem denk ik dat dit komt omdat we in 
de meeste aspecten sterk op elkaar lijken. Gedreven, perfectionistisch en altijd het beste van 
jezelf en anderen verwachten. Jouw prachtige ontwerp is door iedereen te bewonderen op de 
kaft van dit proefschrift. 
Lieve Papa en Mama, bedankt voor jullie eeuwige steun in mijn ambitieuze loopbaankeuzes. 
Jullie hebben mij geleerd om door te zetten, mijn dromen achterna te gaan en mij nooit naar 
beneden te laten praten door anderen. Liefde voor uitgebreid koken, bakken en eten (het liefst 
in combinatie met een goed glas wijn) hebben jullie aan mij doorgegeven. Gezellig samen eten 
en drinken met goede vrienden en familie “zo moet het leven zijn”.
Allerliefste Erik, wie had gedacht dat ‘naar rechts swipen’ zo goed uit zou pakken? Jij hebt mij 
door de laatste stressvolle maanden heen geholpen met een luisterend oor en vele knuffels. 
Ik ben dankbaar dat ik mij nooit heb hoeven verantwoorden betreft mijn lange dagen of als het 
huishouden er even bij in schoot. Ik waardeer het enorm dat je blijft proberen mij te begrijpen 
als ik weer een verhaal afsteek over mijn onderzoek, zelfs als ik in mijn enthousiasme vergeet 
de termen uit te leggen. Stiekem weet ik dat ‘AMD’ voor jou nog steeds Arbo en Milieu Dienst 
betekend. Lieverd, eindelijk is het zo ver: het is tijd om onze rugzakken in te pakken!
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PHD PORTFOLIO
Maartje J. Geerlings
Department of Ophthalmology
Radboud Institute for Molecular Life Sciences
PhD period:     01-10-2013 to 01-10-2017
Promotors:       Prof. dr. Anneke I. den Hollander
                           Prof. dr. Carel B. Hoyng
Co-promotor:  Dr. Eiko K. de Jong
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
- Graduate Course
- Genetic Association workshop
- Opfriscursus statistiek voor promovendi
- Novel Therapies for Retinal dystrophies
- Genetic Epidemiology Course (MED-5E005)
- Scientific Integrity for PhD students
- The Art of Presenting Science
- Academic writing & how to write a medical scientific paper
- Intermediate & advanced workshop in UCSC
- Basiscursus Regelgeving en Organisatie voor Klinisch onderzoeker
- MBSR: Mindfulness Based Stress Reduction for PhD students
- Mindfulness: compassie
2014
2014
2014
2014
2014
2015
2015
2015/2016
2015
2016
2017
2017
2.00
1.75
1.00
0.30
7.00
1.00
1.50
3.20
0.40
1.25
2.00
1.50
b) Seminars & lectures
- RIMLS and other lectures (n=13)
- RIMLS Technical forms (n=3)
- Radboud Research Rounds (n=2)
- RIMLS PhD retreat* (n=4)
- Sensory Disease Meeting (weekly; 12 presentations*)
- Journal Club Human Genetics (weekly; 3 presentations*)
- Theme Discussion Human Genetics (weekly; 3 presentations*)
- Grant writing workshops and career development (n=4)
2013-2017
2014
2014-2017
2014-2017
2013-2017
2013-2016
2014-2017
2017
1.30
0.30
0.20
2.50
4.00
3.00
3.00
1.70
c) Symposia & congresses
- RIMLS New Frontiers Symposium (n=3)
- Refereeravonden Oogheelkunde (n=2)
- EUGENDA retreat & AMD-day *** (n=3)
- Dutch Ophthalmology PhD Students conference ** (n=3)
- Publieksavond Therapie in Zicht 
- Annual ARVO 2015 conference*
- Young researcher visioncamp#
- 6th International NOG-Symposium on AMD#
- ASHG 2016 conference#
- Nederlands Oogheelkunde Gezelschap (NOG): bijeenkomst*
2013-2015
2014-2015
2013-2017
2014-2017
2015
2015
2015
2015
2016
2017
3.00
0.20
1.50
2.00
0.10
1.75
1.25
1.00
1.50
0.50
TEACHING ACTIVITIES
d) Lecturing and Supervision of internships / other
- Mini-internship 3rd year medical students
- Mini-internship 1st year biomedical students
- Writing and distribution patient newsletter
- Information distribution to patients at the ’50plusBeurs’
2014
2014
2015
2015
1.30
1.00
0.50
0.50
TOTAL 55.0
* oral presentation; # poster presentation

